/**
 * PeptidePilot pSEO Data Layer
 * Master database for all programmatic SEO pages:
 *   - 12 Peptide Profiles  → /peptides/[slug]
 *   - 20 Goal Pages        → /goals/[slug]
 *   - 20 Comparison Pages  → /compare/[a]-vs-[b]
 *   - 6 Stack Pages        → /stacks/[slug]
 */

// ─── PEPTIDE PROFILES ────────────────────────────────────────────────────────

export interface PeptidePageData {
  slug: string;
  name: string;
  fullName: string;
  peptideClass: string;
  tagline: string;
  metaDescription: string;
  categories: string[];
  primaryGoals: string[];         // slugs of goal pages
  secondaryGoals: string[];
  halfLife: string;
  administration: string[];
  typicalDosage: string;
  cycleLength: string;
  evidenceLevel: "Strong Preclinical / Limited Human" | "Moderate Preclinical / Emerging Human" | "Strong Human Clinical" | "Preclinical Only";
  legalStatus: string;
  approximateCost: string;
  mechanismSummary: string;
  mechanism: string;
  preclinicalEvidence: string;
  humanEvidence: string;
  anecdotalEvidence: string;
  pubmedLinks: string[];
  sideEffects: string;
  contraindications: string;
  peptidePilotAssessment: string;
  quizMatchRate: string;
  comparablePeptides: string[];   // slugs
  stackPartners: string[];        // slugs
  vendors: Array<{ name: string; url: string }>;
  faqItems: Array<{ q: string; a: string }>;
}

export const peptidePages: PeptidePageData[] = [
  {
    slug: "bpc-157",
    name: "BPC-157",
    fullName: "Body Protection Compound-157",
    peptideClass: "Pentadecapeptide",
    tagline: "The most researched healing peptide for joints, tendons, and gut tissue.",
    metaDescription: "Independent guide to BPC-157: mechanism, dosage, evidence, side effects, and vendor comparison. No bias — just science.",
    categories: ["Recovery", "Joint Health", "Gut Healing", "Injury Repair"],
    primaryGoals: ["joint-recovery", "gut-health", "injury-recovery"],
    secondaryGoals: ["inflammation", "muscle-recovery"],
    halfLife: "~4 hours (injectable)",
    administration: ["Subcutaneous injection", "Intramuscular injection", "Oral (limited absorption)"],
    typicalDosage: "200–500 mcg/day",
    cycleLength: "4–8 weeks",
    legalStatus: "Research compound — not FDA-approved for human use",
    approximateCost: "$30–$80 per vial",
    mechanismSummary: "Upregulates growth hormone receptors, modulates nitric oxide signaling, and promotes angiogenesis.",
    mechanism: "BPC-157 exerts its regenerative effects through multiple converging pathways. It upregulates growth hormone receptors in tendon fibroblasts, accelerating the proliferation of cells critical to connective tissue repair. It modulates nitric oxide (NO) signaling — a key mediator of vascular tone and inflammation — which explains its dual role in both healing and anti-inflammatory activity. BPC-157 also promotes angiogenesis (new blood vessel formation), which is essential for delivering nutrients and oxygen to injured tissue. In the gut, it protects the mucosal lining by stimulating the expression of cytoprotective genes and modulating the gut-brain axis through vagal nerve pathways.",
    preclinicalEvidence: "Rodent studies consistently demonstrate accelerated healing of tendons, ligaments, muscles, and gut tissue. In tendon transection models, BPC-157-treated animals showed significantly faster functional recovery and histological healing compared to controls. Gut protection studies show near-complete prevention of NSAID-induced gastric ulcers and acceleration of inflammatory bowel disease resolution.",
    humanEvidence: "Human clinical data remains limited. One small pilot study in patients with inflammatory bowel disease showed promising mucosal healing results. No large-scale randomized controlled trials have been completed. The compound is not FDA-approved, and all human use is technically off-label research use.",
    anecdotalEvidence: "BPC-157 has one of the largest anecdotal evidence bases in the research peptide community. Athletes and biohackers consistently report accelerated recovery from tendon injuries (particularly Achilles and rotator cuff), resolution of chronic joint pain, and significant improvement in gut symptoms including IBS and leaky gut. The compound is widely regarded as one of the safest and most reliable research peptides.",
    pubmedLinks: [
      "https://pubmed.ncbi.nlm.nih.gov/24224804/",
      "https://pubmed.ncbi.nlm.nih.gov/22030537/",
      "https://pubmed.ncbi.nlm.nih.gov/18496734/"
    ],
    evidenceLevel: "Strong Preclinical / Limited Human",
    sideEffects: "Generally well-tolerated in preclinical studies. Reported side effects in human use are rare and typically mild: nausea (especially at higher doses), dizziness, and injection-site reactions. No serious adverse events have been documented in the literature.",
    contraindications: "No absolute contraindications established. Caution advised in individuals with active cancer (theoretical angiogenesis concern, though unproven). Not recommended during pregnancy or breastfeeding due to lack of safety data.",
    peptidePilotAssessment: "BPC-157 is PeptidePilot's top recommendation for users in the Pain & Injury domain who report joint pain, tendon issues, or gut dysfunction. In our algorithm, it scores highest for users who select 'Heal an injury or chronic pain' as their primary goal and report moderate-to-significant joint or gut symptoms. It is also a strong secondary match for athletes with high training loads who experience chronic soreness. The compound's safety profile and breadth of applications make it one of the most versatile entry points into research peptide protocols.",
    quizMatchRate: "18% of PeptidePilot users with joint or gut concerns receive BPC-157 as their top match",
    comparablePeptides: ["tb-500", "ghk-cu", "sermorelin"],
    stackPartners: ["tb-500", "ghk-cu"],
    vendors: [
      { name: "Core Peptides", url: "https://corepeptides.com" },
      { name: "Limitless Life", url: "https://limitlesslifenootropics.com" },
      { name: "Amino Asylum", url: "https://aminoasylum.shop" },
    ],
    faqItems: [
      { q: "How long does BPC-157 take to work?", a: "Most users report noticeable improvement in joint and tendon pain within 2–4 weeks of consistent use. Gut healing effects are often reported within the first week." },
      { q: "Can BPC-157 be taken orally?", a: "Oral administration is possible but results in significantly lower bioavailability than subcutaneous injection. Some users report benefits from oral use for gut-specific applications." },
      { q: "Is BPC-157 legal?", a: "BPC-157 is a research compound and is not FDA-approved for human use. It is legal to purchase for research purposes in most jurisdictions." },
    ],
  },
  {
    slug: "tb-500",
    name: "TB-500",
    fullName: "Thymosin Beta-4",
    peptideClass: "Thymosin peptide",
    tagline: "Systemic tissue repair and anti-inflammatory recovery for athletes and injury rehabilitation.",
    metaDescription: "Independent guide to TB-500 (Thymosin Beta-4): mechanism, dosage, evidence, and comparison with BPC-157. Science-backed, vendor-neutral.",
    categories: ["Recovery", "Injury Repair", "Anti-Inflammatory", "Endurance"],
    primaryGoals: ["injury-recovery", "muscle-recovery", "inflammation"],
    secondaryGoals: ["joint-recovery", "endurance"],
    halfLife: "~3–4 days",
    administration: ["Subcutaneous injection", "Intramuscular injection"],
    typicalDosage: "2–2.5 mg twice weekly (loading), 2–2.5 mg weekly (maintenance)",
    cycleLength: "4–6 weeks loading, then maintenance",
    legalStatus: "Research compound — not FDA-approved for human use",
    approximateCost: "$40–$90 per vial",
    mechanismSummary: "Promotes cell migration and differentiation via actin regulation; reduces inflammatory cytokines systemically.",
    mechanism: "TB-500 (Thymosin Beta-4) is a naturally occurring peptide found in high concentrations in blood platelets and wound fluid. Its primary mechanism involves the regulation of actin — the structural protein that governs cell shape, migration, and division. By sequestering G-actin monomers, TB-500 promotes the migration of endothelial cells and keratinocytes to injury sites, accelerating tissue repair. It also downregulates pro-inflammatory cytokines including TNF-α and IL-1β, providing systemic anti-inflammatory effects that distinguish it from more localized healing peptides like BPC-157.",
    preclinicalEvidence: "Animal studies demonstrate accelerated healing of cardiac tissue after myocardial infarction, improved recovery from muscle tears, and enhanced wound closure. TB-500 has shown particular promise in cardiac repair models, where it promotes cardiomyocyte survival and angiogenesis following ischemic injury.",
    humanEvidence: "Limited human data available. Phase I/II trials have been conducted for cardiac applications (post-MI recovery), showing acceptable safety profiles. No large-scale trials for musculoskeletal applications have been completed. All athletic and biohacking use is off-label.",
    anecdotalEvidence: "Athletes report TB-500 as particularly effective for systemic muscle injuries, widespread inflammation, and recovery from high-volume training. It is frequently compared to BPC-157, with the consensus being that TB-500 is better for systemic, diffuse injuries while BPC-157 excels at localized tendon and gut healing.",
    pubmedLinks: [
      "https://pubmed.ncbi.nlm.nih.gov/20574415/",
      "https://pubmed.ncbi.nlm.nih.gov/17173550/",
      "https://pubmed.ncbi.nlm.nih.gov/22095614/"
    ],
    evidenceLevel: "Moderate Preclinical / Emerging Human",
    sideEffects: "Generally well-tolerated. Reported side effects include mild fatigue, headache, and injection-site reactions. Some users report temporary nausea at higher loading doses.",
    contraindications: "Caution in individuals with active malignancy due to theoretical pro-angiogenic effects. Not recommended during pregnancy. Avoid concurrent use with other peptides that strongly promote angiogenesis without medical supervision.",
    peptidePilotAssessment: "TB-500 is PeptidePilot's preferred recommendation for users with systemic musculoskeletal injuries, widespread inflammation, or high-volume athletic training loads. In our algorithm, it scores highest for users who report multiple injury sites, significant post-training inflammation, or endurance training backgrounds. It is frequently recommended alongside BPC-157 in our Recovery Stack for users with complex injury profiles.",
    quizMatchRate: "14% of PeptidePilot users focused on injury recovery receive TB-500 as their top match",
    comparablePeptides: ["bpc-157", "ghk-cu"],
    stackPartners: ["bpc-157", "ghk-cu"],
    vendors: [
      { name: "Limitless Life", url: "https://limitlesslifenootropics.com" },
      { name: "Core Peptides", url: "https://corepeptides.com" },
      { name: "Amino Asylum", url: "https://aminoasylum.shop" },
    ],
    faqItems: [
      { q: "What is the difference between TB-500 and BPC-157?", a: "TB-500 provides systemic anti-inflammatory and tissue repair effects throughout the body, while BPC-157 is more targeted to specific injury sites, tendons, and gut tissue. They are frequently stacked together for comprehensive healing." },
      { q: "How is TB-500 dosed?", a: "A typical protocol involves a loading phase of 2–2.5 mg twice weekly for 4–6 weeks, followed by a maintenance phase of 2–2.5 mg once weekly." },
      { q: "Can TB-500 and BPC-157 be taken together?", a: "Yes — this is one of the most popular research peptide stacks. The two peptides work through complementary mechanisms and are generally considered safe to combine." },
    ],
  },
  {
    slug: "ipamorelin",
    name: "Ipamorelin",
    fullName: "Ipamorelin",
    peptideClass: "Growth Hormone Secretagogue (GHRP)",
    tagline: "The cleanest growth hormone secretagogue for muscle growth, fat loss, and sleep quality.",
    metaDescription: "Independent guide to Ipamorelin: how it works, dosage, evidence, and comparison with CJC-1295 and Sermorelin. Vendor-neutral analysis.",
    categories: ["Muscle Growth", "Fat Loss", "Anti-Aging", "Sleep Quality"],
    primaryGoals: ["muscle-growth", "fat-loss", "sleep-optimization"],
    secondaryGoals: ["anti-aging", "recovery"],
    halfLife: "~2 hours",
    administration: ["Subcutaneous injection"],
    typicalDosage: "200–300 mcg, 2–3x daily",
    cycleLength: "8–12 weeks",
    legalStatus: "Research compound — not FDA-approved for human use",
    approximateCost: "$30–$60 per vial",
    mechanismSummary: "Selectively stimulates pituitary GH release via ghrelin receptor agonism without affecting cortisol or prolactin.",
    mechanism: "Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone (GH) by acting as a ghrelin receptor agonist. Unlike older GHRPs (such as GHRP-6), Ipamorelin is highly selective — it stimulates GH release without significantly increasing cortisol, prolactin, or appetite. This selectivity makes it one of the cleanest GH secretagogues available. GH release triggers downstream production of IGF-1 in the liver, which mediates most of the anabolic, fat-mobilizing, and tissue-repair effects associated with growth hormone.",
    preclinicalEvidence: "Animal studies demonstrate dose-dependent increases in GH and IGF-1 levels, improvements in bone mineral density, and increases in lean body mass. Ipamorelin has shown particular promise in models of muscle wasting and age-related GH decline.",
    humanEvidence: "Phase I/II clinical trials have demonstrated safe and effective GH stimulation in healthy volunteers and GH-deficient patients. Ipamorelin is frequently studied in combination with CJC-1295 to extend the duration of GH release.",
    anecdotalEvidence: "Widely regarded as the best entry-level GH secretagogue due to its clean side effect profile. Users consistently report improved sleep quality (particularly deep sleep), gradual improvements in body composition over 8–12 weeks, and enhanced recovery. The Ipamorelin/CJC-1295 combination is one of the most popular peptide protocols in the biohacking community.",
    pubmedLinks: [
      "https://pubmed.ncbi.nlm.nih.gov/9849822/",
      "https://pubmed.ncbi.nlm.nih.gov/10997804/",
      "https://pubmed.ncbi.nlm.nih.gov/18647174/"
    ],
    evidenceLevel: "Moderate Preclinical / Emerging Human",
    sideEffects: "Generally well-tolerated. Mild side effects include water retention (especially early in a cycle), mild fatigue, and injection-site reactions. Unlike GHRP-6, Ipamorelin does not cause significant hunger spikes or cortisol elevation.",
    contraindications: "Not recommended for individuals with active cancer due to IGF-1 elevation. Caution in diabetics due to potential insulin sensitivity effects. Not recommended during pregnancy.",
    peptidePilotAssessment: "Ipamorelin is PeptidePilot's top recommendation for users in the Goals & Performance and Hormones & Aging domains who prioritize lean muscle gain, fat loss, and sleep improvement. In our algorithm, it scores highest for users aged 35+ who report declining energy, suboptimal sleep, and body composition goals. It is almost always recommended as part of the Ipamorelin/CJC-1295 stack rather than as a standalone peptide.",
    quizMatchRate: "22% of PeptidePilot users with muscle growth and anti-aging goals receive Ipamorelin/CJC-1295 as their top match",
    comparablePeptides: ["cjc-1295", "sermorelin", "tesamorelin"],
    stackPartners: ["cjc-1295"],
    vendors: [
      { name: "Core Peptides", url: "https://corepeptides.com" },
      { name: "Limitless Life", url: "https://limitlesslifenootropics.com" },
    ],
    faqItems: [
      { q: "Should I take Ipamorelin alone or with CJC-1295?", a: "Most protocols combine Ipamorelin with CJC-1295. Ipamorelin triggers GH release while CJC-1295 extends the duration of that release, producing a more sustained and physiologically natural GH pulse." },
      { q: "When should Ipamorelin be injected?", a: "Most users inject before bed to align with the natural nocturnal GH pulse, which enhances sleep quality and recovery. Some protocols also include a morning dose." },
      { q: "How long before I see results from Ipamorelin?", a: "Sleep improvements are often reported within the first 1–2 weeks. Body composition changes typically become noticeable after 6–8 weeks of consistent use." },
    ],
  },
  {
    slug: "cjc-1295",
    name: "CJC-1295",
    fullName: "CJC-1295 (with DAC)",
    peptideClass: "Growth Hormone Releasing Hormone (GHRH) Analogue",
    tagline: "Extended-release GHRH analogue that amplifies and sustains growth hormone pulses.",
    metaDescription: "Independent guide to CJC-1295: mechanism, dosage, comparison with Ipamorelin and Sermorelin. Science-backed, vendor-neutral.",
    categories: ["Muscle Growth", "Anti-Aging", "Fat Loss", "Recovery"],
    primaryGoals: ["muscle-growth", "anti-aging", "fat-loss"],
    secondaryGoals: ["sleep-optimization", "recovery"],
    halfLife: "~6–8 days (with DAC)",
    administration: ["Subcutaneous injection"],
    typicalDosage: "1–2 mg weekly (with DAC) or 100 mcg per dose (without DAC)",
    cycleLength: "8–16 weeks",
    legalStatus: "Research compound — not FDA-approved for human use",
    approximateCost: "$35–$70 per vial",
    mechanismSummary: "Binds to GHRH receptors on pituitary somatotrophs, stimulating sustained GH release over days rather than hours.",
    mechanism: "CJC-1295 is a modified analogue of growth hormone releasing hormone (GHRH) that has been engineered for extended half-life. The DAC (Drug Affinity Complex) version binds to albumin in the bloodstream, extending its half-life from minutes (native GHRH) to 6–8 days. This creates a sustained elevation of baseline GH levels rather than the sharp, brief pulses produced by GHRPs like Ipamorelin. When combined with Ipamorelin, the two peptides produce synergistic GH release: CJC-1295 raises the baseline and Ipamorelin triggers amplified pulses on top of that elevated baseline.",
    preclinicalEvidence: "Studies demonstrate dose-dependent increases in GH and IGF-1 levels sustained over multiple days. Animal models show improvements in lean body mass, bone density, and fat oxidation.",
    humanEvidence: "Phase I/II trials in healthy adults and GH-deficient patients demonstrate safe, sustained GH elevation. Studies show 2–10 fold increases in mean GH levels with weekly dosing.",
    anecdotalEvidence: "CJC-1295 is rarely used as a standalone peptide. Its primary role in the community is as the 'base' of the Ipamorelin/CJC-1295 stack. Users report that the combination produces more consistent body composition improvements and sleep benefits than either peptide alone.",
    pubmedLinks: [
      "https://pubmed.ncbi.nlm.nih.gov/16352683/",
      "https://pubmed.ncbi.nlm.nih.gov/18647174/"
    ],
    evidenceLevel: "Moderate Preclinical / Emerging Human",
    sideEffects: "Water retention, mild fatigue, and injection-site reactions. The sustained GH elevation from the DAC version can cause more pronounced water retention than shorter-acting GH secretagogues.",
    contraindications: "Same as Ipamorelin: caution in active cancer, diabetes, and pregnancy. The sustained GH elevation warrants careful monitoring in individuals with insulin resistance.",
    peptidePilotAssessment: "CJC-1295 is almost exclusively recommended by PeptidePilot as part of the Ipamorelin/CJC-1295 combination. It is the preferred choice for users who want sustained GH elevation over the course of a week rather than sharp daily pulses. In our algorithm, it scores highest for users with anti-aging and body composition goals who prefer a lower-frequency injection schedule.",
    quizMatchRate: "Included in the 22% of users who receive the Ipamorelin/CJC-1295 combination as their top match",
    comparablePeptides: ["ipamorelin", "sermorelin", "tesamorelin"],
    stackPartners: ["ipamorelin"],
    vendors: [
      { name: "Core Peptides", url: "https://corepeptides.com" },
      { name: "Limitless Life", url: "https://limitlesslifenootropics.com" },
    ],
    faqItems: [
      { q: "What is the difference between CJC-1295 with DAC and without DAC?", a: "CJC-1295 with DAC has a half-life of 6–8 days due to albumin binding, allowing once-weekly dosing. Without DAC (also called Modified GRF 1-29), the half-life is ~30 minutes and it must be dosed multiple times daily alongside Ipamorelin." },
      { q: "Is CJC-1295 better than Sermorelin?", a: "CJC-1295 produces stronger and more sustained GH elevation than Sermorelin. Sermorelin is often preferred for its more natural, lower-amplitude GH stimulation and longer clinical safety record." },
    ],
  },
  {
    slug: "sermorelin",
    name: "Sermorelin",
    fullName: "Sermorelin Acetate",
    peptideClass: "Growth Hormone Releasing Hormone (GHRH) Analogue",
    tagline: "The clinically established GHRH analogue with the longest safety record in anti-aging medicine.",
    metaDescription: "Independent guide to Sermorelin: mechanism, clinical evidence, dosage, and comparison with Ipamorelin and CJC-1295. Vendor-neutral analysis.",
    categories: ["Anti-Aging", "Sleep", "Energy", "Longevity"],
    primaryGoals: ["anti-aging", "sleep-optimization", "energy"],
    secondaryGoals: ["muscle-growth", "fat-loss", "longevity"],
    halfLife: "~10–20 minutes",
    administration: ["Subcutaneous injection"],
    typicalDosage: "200–300 mcg before bed",
    cycleLength: "3–6 months (longer cycles than GHRPs)",
    legalStatus: "FDA-approved (Geref) — available via prescription through licensed telehealth providers",
    approximateCost: "$150–$400/month via telehealth",
    mechanismSummary: "Binds to GHRH receptors on pituitary somatotrophs, stimulating natural pulsatile GH release that mirrors youthful physiology.",
    mechanism: "Sermorelin is a 29-amino acid analogue of endogenous GHRH that stimulates the pituitary gland to produce and secrete growth hormone in a natural, pulsatile pattern. Unlike synthetic GH injections, Sermorelin works through the body's own regulatory feedback mechanisms — the pituitary retains control over GH output, preventing the supraphysiological levels associated with exogenous GH. This natural regulation is why Sermorelin has a superior long-term safety profile compared to direct GH therapy.",
    preclinicalEvidence: "Extensive preclinical data supporting GH stimulation, improvements in body composition, and sleep architecture enhancement.",
    humanEvidence: "Sermorelin has the most robust clinical evidence base of any GH secretagogue. Multiple randomized controlled trials demonstrate improvements in sleep quality, body composition, bone density, and quality-of-life measures in GH-deficient adults. It was FDA-approved under the name Geref for pediatric GH deficiency.",
    anecdotalEvidence: "Widely used in anti-aging medicine and functional medicine practices. Patients report gradual but sustained improvements in sleep depth, energy levels, body composition, and skin quality over 3–6 month protocols. The effects are described as more subtle but more durable than synthetic GH.",
    pubmedLinks: [
      "https://pubmed.ncbi.nlm.nih.gov/9467542/",
      "https://pubmed.ncbi.nlm.nih.gov/10997804/",
      "https://pubmed.ncbi.nlm.nih.gov/11502562/"
    ],
    evidenceLevel: "Moderate Preclinical / Emerging Human",
    sideEffects: "Mild injection-site reactions, flushing, and headache are the most common. Rarely, water retention or joint discomfort. The natural regulatory mechanism prevents the side effects associated with exogenous GH (carpal tunnel, acromegaly).",
    contraindications: "Active malignancy, pregnancy. Requires prescription and physician monitoring due to FDA-regulated status.",
    peptidePilotAssessment: "Sermorelin is PeptidePilot's top recommendation for users who want clinically supervised GH optimization with the strongest safety record. In our algorithm, it scores highest for users aged 40+ who prioritize longevity, sleep quality, and sustainable anti-aging protocols over rapid body composition changes. Because it requires a prescription, we route Sermorelin-matched users to our telehealth partners (Hone Health, Defy Medical) rather than research peptide vendors.",
    quizMatchRate: "16% of PeptidePilot users in the anti-aging and longevity category receive Sermorelin as their top match",
    comparablePeptides: ["ipamorelin", "cjc-1295", "tesamorelin"],
    stackPartners: ["ipamorelin"],
    vendors: [
      { name: "Hone Health", url: "https://honehealth.com" },
      { name: "Defy Medical", url: "https://defymedical.com" },
    ],
    faqItems: [
      { q: "Does Sermorelin require a prescription?", a: "Yes. Sermorelin is FDA-regulated and requires a prescription from a licensed physician. Telehealth providers like Hone Health and Defy Medical can prescribe it after a consultation and lab work." },
      { q: "How is Sermorelin different from HGH?", a: "Sermorelin stimulates your pituitary to produce its own GH naturally, maintaining physiological feedback control. Exogenous HGH bypasses this regulation, which is why HGH carries more side effect risk and is more tightly regulated." },
    ],
  },
  {
    slug: "semaglutide",
    name: "Semaglutide",
    fullName: "Semaglutide",
    peptideClass: "GLP-1 Receptor Agonist",
    tagline: "The most clinically validated peptide for weight loss and metabolic health.",
    metaDescription: "Independent guide to Semaglutide (Ozempic/Wegovy): mechanism, clinical evidence, dosage, and comparison with Tirzepatide. Vendor-neutral analysis.",
    categories: ["Fat Loss", "Metabolic Health", "Appetite Control", "Blood Sugar"],
    primaryGoals: ["fat-loss", "metabolic-health", "body-recomposition"],
    secondaryGoals: ["energy", "inflammation"],
    halfLife: "~7 days",
    administration: ["Subcutaneous injection (weekly)", "Oral tablet (daily)"],
    typicalDosage: "0.25 mg/week (starting), titrating to 1–2.4 mg/week",
    cycleLength: "Ongoing — typically 12–24+ weeks",
    legalStatus: "FDA-approved (Ozempic for T2D, Wegovy for obesity) — requires prescription",
    approximateCost: "$200–$1,200/month (brand); $150–$400/month (compounded via telehealth)",
    mechanismSummary: "Activates GLP-1 receptors in the hypothalamus and GI tract, reducing appetite, slowing gastric emptying, and improving insulin secretion.",
    mechanism: "Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the endogenous hormone GLP-1. It acts on GLP-1 receptors in the hypothalamus to reduce appetite and food cravings, in the GI tract to slow gastric emptying (increasing satiety), and in the pancreas to stimulate glucose-dependent insulin secretion. The weekly injectable formulation achieves sustained receptor activation that produces clinically meaningful reductions in caloric intake and body weight.",
    preclinicalEvidence: "Extensive preclinical data supporting weight reduction, improved insulin sensitivity, and cardiovascular risk reduction.",
    humanEvidence: "Among the most extensively studied peptides in clinical medicine. The SUSTAIN and STEP trial programs demonstrate 10–15% average body weight reduction with Semaglutide 2.4 mg weekly. Cardiovascular outcome trials (LEADER, SUSTAIN-6) show significant reductions in major adverse cardiovascular events.",
    anecdotalEvidence: "Semaglutide has become mainstream, with widespread use in both medical and non-medical settings. Users consistently report significant appetite suppression, particularly for ultra-processed foods. The 'food noise' reduction effect is frequently cited as the most transformative aspect of the treatment.",
    pubmedLinks: [
      "https://pubmed.ncbi.nlm.nih.gov/34170647/",
      "https://pubmed.ncbi.nlm.nih.gov/27633186/",
      "https://pubmed.ncbi.nlm.nih.gov/33567185/"
    ],
    evidenceLevel: "Strong Human Clinical",
    sideEffects: "Nausea, vomiting, diarrhea, and constipation are common, particularly during dose escalation. Rare but serious: pancreatitis, gallbladder disease, thyroid C-cell tumors (in rodents — human risk unclear). Muscle mass loss with rapid weight reduction is a concern.",
    contraindications: "Personal or family history of medullary thyroid carcinoma or MEN2. Active pancreatitis. Pregnancy.",
    peptidePilotAssessment: "Semaglutide is PeptidePilot's top recommendation for users whose primary goal is significant, sustained weight loss and metabolic health improvement. In our algorithm, it scores highest for users who report carrying excess body fat, appetite control challenges, and metabolic concerns. Because it requires a prescription, we route Semaglutide-matched users to our telehealth partners. We always recommend Semaglutide alongside resistance training to preserve lean muscle mass.",
    quizMatchRate: "28% of PeptidePilot users with fat loss as their primary goal receive Semaglutide/Tirzepatide as their top match",
    comparablePeptides: ["tirzepatide"],
    stackPartners: [],
    vendors: [
      { name: "Hone Health", url: "https://honehealth.com" },
      { name: "LifeMD", url: "https://www.lifemd.com" },
    ],
    faqItems: [
      { q: "What is the difference between Ozempic and Wegovy?", a: "Both contain Semaglutide. Ozempic is FDA-approved for Type 2 diabetes at doses up to 2 mg. Wegovy is FDA-approved for chronic weight management at 2.4 mg. The active ingredient is identical." },
      { q: "Is compounded Semaglutide safe?", a: "Compounded Semaglutide from FDA-registered compounding pharmacies is widely used and generally considered safe when prescribed by a licensed physician. Quality varies by pharmacy — always use a telehealth provider that sources from reputable compounders." },
    ],
  },
  {
    slug: "tirzepatide",
    name: "Tirzepatide",
    fullName: "Tirzepatide",
    peptideClass: "Dual GIP/GLP-1 Receptor Agonist",
    tagline: "The next-generation dual-agonist delivering superior weight loss to Semaglutide in clinical trials.",
    metaDescription: "Independent guide to Tirzepatide (Mounjaro/Zepbound): mechanism, clinical evidence, comparison with Semaglutide. Vendor-neutral analysis.",
    categories: ["Fat Loss", "Metabolic Health", "Appetite Control", "Blood Sugar"],
    primaryGoals: ["fat-loss", "metabolic-health", "body-recomposition"],
    secondaryGoals: ["energy", "inflammation"],
    halfLife: "~5 days",
    administration: ["Subcutaneous injection (weekly)"],
    typicalDosage: "2.5 mg/week (starting), titrating to 5–15 mg/week",
    cycleLength: "Ongoing — typically 16–72 weeks in trials",
    legalStatus: "FDA-approved (Mounjaro for T2D, Zepbound for obesity) — requires prescription",
    approximateCost: "$250–$1,300/month (brand); $175–$450/month (compounded via telehealth)",
    mechanismSummary: "Activates both GIP and GLP-1 receptors, producing additive effects on appetite suppression, insulin secretion, and fat mobilization.",
    mechanism: "Tirzepatide is the first approved dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. By activating both receptors simultaneously, it produces additive effects on appetite suppression, insulin secretion, and fat mobilization. GIP receptor activation appears to enhance the GLP-1-mediated effects on adipose tissue, potentially explaining Tirzepatide's superior weight loss outcomes compared to GLP-1-only agonists like Semaglutide.",
    preclinicalEvidence: "Animal studies demonstrate superior weight loss and metabolic improvements compared to GLP-1 monotherapy.",
    humanEvidence: "The SURPASS and SURMOUNT trial programs demonstrate average weight loss of 15–22.5% at the highest doses — significantly exceeding Semaglutide's 10–15% in head-to-head comparisons. The SURMOUNT-1 trial showed 22.5% weight loss at 72 weeks with 15 mg Tirzepatide.",
    anecdotalEvidence: "Users who have tried both Semaglutide and Tirzepatide consistently report greater weight loss and appetite suppression with Tirzepatide. Side effect profiles are similar, though some users report better GI tolerability with Tirzepatide.",
    pubmedLinks: [
      "https://pubmed.ncbi.nlm.nih.gov/35658024/",
      "https://pubmed.ncbi.nlm.nih.gov/36205765/"
    ],
    evidenceLevel: "Strong Human Clinical",
    sideEffects: "Similar to Semaglutide: nausea, vomiting, diarrhea, constipation. Generally similar or slightly better GI tolerability than Semaglutide in clinical trials.",
    contraindications: "Same as Semaglutide: personal/family history of medullary thyroid carcinoma, MEN2, active pancreatitis, pregnancy.",
    peptidePilotAssessment: "Tirzepatide is PeptidePilot's recommendation for users who want maximum weight loss efficacy and are willing to accept a newer compound with a shorter (but still robust) clinical track record. In our algorithm, users who score very high on the fat loss and metabolic domains and have not responded adequately to other interventions are preferentially matched to Tirzepatide over Semaglutide.",
    quizMatchRate: "Included in the 28% of users who receive the Semaglutide/Tirzepatide category as their top match",
    comparablePeptides: ["semaglutide"],
    stackPartners: [],
    vendors: [
      { name: "Hone Health", url: "https://honehealth.com" },
      { name: "LifeMD", url: "https://www.lifemd.com" },
    ],
    faqItems: [
      { q: "Is Tirzepatide better than Semaglutide?", a: "Clinical trials show Tirzepatide produces greater average weight loss (15–22% vs 10–15%). However, individual response varies, and Semaglutide has a longer post-market safety record. Both are excellent options." },
      { q: "What is the difference between Mounjaro and Zepbound?", a: "Both contain Tirzepatide. Mounjaro is FDA-approved for Type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The active ingredient is identical." },
    ],
  },
  {
    slug: "ghk-cu",
    name: "GHK-Cu",
    fullName: "GHK-Cu (Copper Peptide)",
    peptideClass: "Copper-binding tripeptide",
    tagline: "The gold standard regenerative peptide for skin health, hair growth, and wound healing.",
    metaDescription: "Independent guide to GHK-Cu (Copper Peptide): mechanism, evidence, dosage, and applications for skin, hair, and healing. Vendor-neutral.",
    categories: ["Skin Health", "Hair Growth", "Anti-Aging", "Collagen Synthesis"],
    primaryGoals: ["skin-health", "hair-growth", "anti-aging"],
    secondaryGoals: ["wound-healing", "inflammation"],
    halfLife: "Short (topical application provides sustained local delivery)",
    administration: ["Topical serum/cream", "Subcutaneous injection (systemic)"],
    typicalDosage: "Topical: 1–5% concentration; Injectable: 1–2 mg/day",
    cycleLength: "8–12 weeks (injectable); ongoing (topical)",
    legalStatus: "Research compound (injectable); widely available in cosmetic products (topical)",
    approximateCost: "$20–$60 (topical); $30–$70/vial (injectable)",
    mechanismSummary: "Stimulates collagen and elastin synthesis, activates antioxidant enzymes, and promotes hair follicle cycling.",
    mechanism: "GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys) that declines significantly with age. It exerts its effects through multiple mechanisms: stimulating collagen and elastin synthesis in fibroblasts, activating superoxide dismutase and other antioxidant enzymes, promoting angiogenesis in wound healing, and modulating the expression of over 4,000 genes involved in tissue remodeling. In hair follicles, it promotes the transition from the resting (telogen) to the active growth (anagen) phase.",
    preclinicalEvidence: "Extensive in vitro and animal data supporting collagen synthesis, wound healing acceleration, and hair follicle stimulation. GHK-Cu is one of the most studied peptides in dermatological research.",
    humanEvidence: "Multiple clinical studies in cosmetic dermatology demonstrate improvements in skin firmness, fine lines, and wound healing. Hair growth studies show improvements in hair density and thickness comparable to minoxidil in some trials.",
    anecdotalEvidence: "GHK-Cu has a strong track record in the cosmetic and biohacking communities. Topical users consistently report improvements in skin texture and firmness within 4–8 weeks. Injectable users report more systemic effects including improved wound healing and skin quality across the body.",
    pubmedLinks: [
      "https://pubmed.ncbi.nlm.nih.gov/25905040/",
      "https://pubmed.ncbi.nlm.nih.gov/19624730/",
      "https://pubmed.ncbi.nlm.nih.gov/26305720/"
    ],
    evidenceLevel: "Moderate Preclinical / Emerging Human",
    sideEffects: "Topical: mild skin irritation in sensitive individuals. Injectable: injection-site reactions, mild flushing. Generally considered very safe.",
    contraindications: "No established contraindications. Caution with excessive copper intake from other sources.",
    peptidePilotAssessment: "GHK-Cu is PeptidePilot's top recommendation for users in the Skin, Hair & Appearance domain. In our algorithm, it scores highest for users who report skin aging concerns, hair thinning, or wound healing goals. It is also a strong secondary recommendation for users in the Recovery domain, where its anti-inflammatory and healing properties complement BPC-157 and TB-500.",
    quizMatchRate: "19% of PeptidePilot users with skin or hair concerns receive GHK-Cu as their top match",
    comparablePeptides: ["bpc-157", "epithalon"],
    stackPartners: ["bpc-157", "tb-500"],
    vendors: [
      { name: "Core Peptides", url: "https://corepeptides.com" },
      { name: "Limitless Life", url: "https://limitlesslifenootropics.com" },
    ],
    faqItems: [
      { q: "Is topical or injectable GHK-Cu more effective?", a: "Topical GHK-Cu is effective for skin and scalp applications due to good dermal penetration. Injectable GHK-Cu provides more systemic effects. For skin-only goals, topical is the more practical choice." },
      { q: "Can GHK-Cu regrow hair?", a: "Clinical studies show GHK-Cu can improve hair density and thickness by promoting follicle cycling. It is not a cure for androgenetic alopecia but can be an effective adjunct to other hair loss treatments." },
    ],
  },
  {
    slug: "epithalon",
    name: "Epithalon",
    fullName: "Epithalon (Epitalon)",
    peptideClass: "Tetrapeptide (Ala-Glu-Asp-Gly)",
    tagline: "The telomerase-activating longevity peptide with the most extensive anti-aging research.",
    metaDescription: "Independent guide to Epithalon: telomerase activation, longevity evidence, dosage, and comparison with other anti-aging peptides. Vendor-neutral.",
    categories: ["Anti-Aging", "Longevity", "Sleep", "Cellular Health"],
    primaryGoals: ["anti-aging", "longevity", "sleep-optimization"],
    secondaryGoals: ["energy", "immune-function"],
    halfLife: "~1–2 hours",
    administration: ["Subcutaneous injection", "Intravenous (clinical settings)"],
    typicalDosage: "5–10 mg/day for 10–20 days (cycled)",
    cycleLength: "10–20 day cycles, 1–2x per year",
    legalStatus: "Research compound — not FDA-approved for human use",
    approximateCost: "$40–$100 per cycle",
    mechanismSummary: "Activates telomerase enzyme to maintain telomere length; regulates pineal gland function and melatonin production.",
    mechanism: "Epithalon is a synthetic tetrapeptide derived from the pineal gland peptide Epithalamin. Its primary mechanism involves the activation of telomerase — the enzyme responsible for maintaining and extending telomere length. Telomere shortening is a fundamental mechanism of cellular aging; by activating telomerase, Epithalon theoretically slows this process. It also regulates pineal gland function, normalizing melatonin production and circadian rhythm, which explains its sleep-improving effects. Additionally, it modulates the hypothalamic-pituitary axis and exhibits antioxidant properties.",
    preclinicalEvidence: "Russian research spanning 30+ years demonstrates lifespan extension in animal models, telomere maintenance, and improvements in immune function. Studies show 24–40% increases in mean lifespan in some rodent models.",
    humanEvidence: "Limited but intriguing human data from Russian clinical research. Studies in elderly patients show improvements in sleep quality, immune markers, and quality-of-life measures. No large-scale Western RCTs have been completed.",
    anecdotalEvidence: "Epithalon has a dedicated following in the longevity community. Users report improved sleep quality, increased energy, and a general sense of vitality. The cyclic dosing protocol (10–20 days, 1–2x/year) is widely followed based on the original Russian research protocols.",
    pubmedLinks: [
      "https://pubmed.ncbi.nlm.nih.gov/12374160/",
      "https://pubmed.ncbi.nlm.nih.gov/14523363/",
      "https://pubmed.ncbi.nlm.nih.gov/16019622/"
    ],
    evidenceLevel: "Moderate Preclinical / Emerging Human",
    sideEffects: "Generally well-tolerated. Mild injection-site reactions. No serious adverse events documented in the literature.",
    contraindications: "No established contraindications. Theoretical caution in individuals with cancer due to telomerase activation (though evidence for risk is lacking).",
    peptidePilotAssessment: "Epithalon is PeptidePilot's top recommendation for users in the Longevity domain who prioritize cellular anti-aging and sleep quality. In our algorithm, it scores highest for users aged 40+ who report sleep issues, energy decline, and a strong interest in longevity optimization. The cyclic dosing protocol makes it practical for users who prefer infrequent intervention.",
    quizMatchRate: "12% of PeptidePilot users with longevity and anti-aging as primary goals receive Epithalon as their top match",
    comparablePeptides: ["ghk-cu", "ss-31", "mots-c"],
    stackPartners: ["ghk-cu"],
    vendors: [
      { name: "Core Peptides", url: "https://corepeptides.com" },
      { name: "Limitless Life", url: "https://limitlesslifenootropics.com" },
    ],
    faqItems: [
      { q: "How often should Epithalon be cycled?", a: "The original Russian research protocols used 10–20 day cycles, 1–2 times per year. Most users follow this approach, though some practitioners recommend quarterly cycles." },
      { q: "Does Epithalon actually extend lifespan?", a: "Animal studies show significant lifespan extension. Human data is limited to observational studies and small trials. It is promising but not definitively proven in humans." },
    ],
  },
  {
    slug: "selank",
    name: "Selank",
    fullName: "Selank",
    peptideClass: "Heptapeptide (Tuftsin analogue)",
    tagline: "The anxiolytic nootropic peptide that reduces anxiety without sedation or dependence.",
    metaDescription: "Independent guide to Selank: mechanism, evidence, dosage, and comparison with Semax. Science-backed, vendor-neutral analysis.",
    categories: ["Anxiety Relief", "Cognitive Enhancement", "Mood", "Neuroprotection"],
    primaryGoals: ["anxiety-reduction", "cognitive-performance", "mood"],
    secondaryGoals: ["focus", "neuroprotection"],
    halfLife: "~1–2 minutes (nasal); longer with stabilizers",
    administration: ["Intranasal spray", "Subcutaneous injection"],
    typicalDosage: "250–3,000 mcg/day (nasal)",
    cycleLength: "2–4 weeks",
    legalStatus: "Research compound — not FDA-approved; approved in Russia for anxiety treatment",
    approximateCost: "$30–$70 per vial",
    mechanismSummary: "Modulates GABA-A receptor activity and increases BDNF expression; reduces anxiety through non-sedating anxiolytic mechanisms.",
    mechanism: "Selank is a synthetic heptapeptide derived from tuftsin, an endogenous immunomodulatory peptide. Its anxiolytic effects are mediated through modulation of GABA-A receptor activity — the same receptor system targeted by benzodiazepines, but through a different binding site that produces anxiolysis without sedation or dependence. Selank also increases BDNF (brain-derived neurotrophic factor) expression, which supports neuroplasticity and cognitive function. It modulates the enkephalin system and has demonstrated immunomodulatory effects in Russian clinical research.",
    preclinicalEvidence: "Extensive Russian preclinical data demonstrating anxiolytic effects comparable to benzodiazepines without sedation, tolerance, or withdrawal. Cognitive enhancement effects in stress models.",
    humanEvidence: "Russian clinical trials in patients with generalized anxiety disorder show significant anxiety reduction with a favorable safety profile. No large-scale Western RCTs completed.",
    anecdotalEvidence: "Selank has a strong reputation in the nootropic community for producing calm, focused mental states without the sedation or cognitive impairment of benzodiazepines. Users report it as particularly effective for social anxiety and performance anxiety.",
    pubmedLinks: [
      "https://pubmed.ncbi.nlm.nih.gov/24411804/",
      "https://pubmed.ncbi.nlm.nih.gov/19326803/"
    ],
    evidenceLevel: "Preclinical Only",
    sideEffects: "Generally well-tolerated. Mild nasal irritation with intranasal use. No dependence or withdrawal reported.",
    contraindications: "No established contraindications. Caution with concurrent benzodiazepine use.",
    peptidePilotAssessment: "Selank is PeptidePilot's top recommendation for users in the Cognition & Mood domain who report anxiety as their primary concern. In our algorithm, it scores highest for users who select 'Better mood and emotional balance' as their primary goal and report moderate-to-significant anxiety. It is frequently recommended alongside Semax for users who want both anxiolytic and cognitive-enhancing effects.",
    quizMatchRate: "15% of PeptidePilot users with anxiety and mood concerns receive Selank as their top match",
    comparablePeptides: ["semax"],
    stackPartners: ["semax"],
    vendors: [
      { name: "Limitless Life", url: "https://limitlesslifenootropics.com" },
      { name: "Cosmic Nootropic", url: "https://cosmicnootropic.com" },
    ],
    faqItems: [
      { q: "Is Selank addictive?", a: "No. Unlike benzodiazepines, Selank does not produce tolerance, dependence, or withdrawal. It is considered non-habit-forming." },
      { q: "What is the difference between Selank and Semax?", a: "Selank is primarily anxiolytic — it reduces anxiety and improves mood. Semax is primarily a cognitive enhancer — it improves focus, memory, and BDNF production. They are frequently combined for comprehensive cognitive and mood support." },
    ],
  },
  {
    slug: "semax",
    name: "Semax",
    fullName: "Semax",
    peptideClass: "ACTH(4-7) analogue",
    tagline: "The cognitive-enhancing nootropic peptide that boosts BDNF, focus, and memory.",
    metaDescription: "Independent guide to Semax: mechanism, evidence, dosage, and comparison with Selank. Science-backed, vendor-neutral analysis.",
    categories: ["Cognitive Enhancement", "Focus", "Memory", "Neuroprotection"],
    primaryGoals: ["cognitive-performance", "focus", "memory"],
    secondaryGoals: ["neuroprotection", "mood", "energy"],
    halfLife: "~1–2 minutes (nasal); longer with stabilizers",
    administration: ["Intranasal spray", "Subcutaneous injection"],
    typicalDosage: "200–900 mcg/day (nasal)",
    cycleLength: "2–4 weeks",
    legalStatus: "Research compound — not FDA-approved; approved in Russia for cognitive and neurological conditions",
    approximateCost: "$30–$70 per vial",
    mechanismSummary: "Increases BDNF and NGF expression; modulates dopaminergic and serotonergic systems for enhanced cognitive performance.",
    mechanism: "Semax is a synthetic heptapeptide analogue of ACTH(4-7) that has been extensively studied in Russia for cognitive enhancement and neuroprotection. Its primary mechanism involves upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) — proteins essential for neuronal survival, plasticity, and the formation of new synaptic connections. Semax also modulates dopaminergic and serotonergic neurotransmission, which contributes to its focus-enhancing and mood-stabilizing effects.",
    preclinicalEvidence: "Extensive Russian preclinical data demonstrating cognitive enhancement, neuroprotection against ischemic injury, and BDNF upregulation.",
    humanEvidence: "Russian clinical trials demonstrate cognitive improvements in patients with stroke, traumatic brain injury, and age-related cognitive decline. Approved in Russia for these indications.",
    anecdotalEvidence: "Semax is widely regarded as one of the most effective nootropic peptides. Users report significant improvements in focus, working memory, and verbal fluency. The effects are often described as 'clean' stimulation without the anxiety or crash associated with stimulants.",
    pubmedLinks: [
      "https://pubmed.ncbi.nlm.nih.gov/11338267/",
      "https://pubmed.ncbi.nlm.nih.gov/19326803/"
    ],
    evidenceLevel: "Preclinical Only",
    sideEffects: "Generally well-tolerated. Mild nasal irritation, occasional headache. Some users report mild overstimulation at higher doses.",
    contraindications: "Caution in individuals with anxiety disorders at higher doses (stimulating effects may exacerbate anxiety). No established absolute contraindications.",
    peptidePilotAssessment: "Semax is PeptidePilot's top recommendation for users in the Cognition & Mood domain who prioritize focus, memory, and cognitive performance over anxiety reduction. In our algorithm, it scores highest for users who report brain fog, difficulty concentrating, and cognitive performance goals. It is frequently recommended alongside Selank for comprehensive cognitive and mood support.",
    quizMatchRate: "13% of PeptidePilot users with cognitive performance goals receive Semax as their top match",
    comparablePeptides: ["selank"],
    stackPartners: ["selank"],
    vendors: [
      { name: "Limitless Life", url: "https://limitlesslifenootropics.com" },
      { name: "Cosmic Nootropic", url: "https://cosmicnootropic.com" },
    ],
    faqItems: [
      { q: "How quickly does Semax work?", a: "Many users report noticeable cognitive effects within 30–60 minutes of nasal administration. The effects typically last 4–8 hours." },
      { q: "Can Semax be used long-term?", a: "Most protocols recommend cycling Semax (2–4 weeks on, 1–2 weeks off) to prevent tolerance. Long-term continuous use data is limited." },
    ],
  },
  {
    slug: "pt-141",
    name: "PT-141",
    fullName: "PT-141 (Bremelanotide)",
    peptideClass: "Melanocortin receptor agonist",
    tagline: "The only peptide FDA-approved for sexual dysfunction — works centrally on desire, not just blood flow.",
    metaDescription: "Independent guide to PT-141 (Bremelanotide): mechanism, FDA approval, dosage, and comparison with PDE5 inhibitors. Vendor-neutral analysis.",
    categories: ["Libido", "Sexual Health", "Mood", "Confidence"],
    primaryGoals: ["libido", "sexual-health"],
    secondaryGoals: ["mood", "confidence"],
    halfLife: "~2.7 hours",
    administration: ["Subcutaneous injection", "Nasal spray (historical)"],
    typicalDosage: "1.75 mg, 45 minutes before sexual activity",
    cycleLength: "As needed (not daily)",
    legalStatus: "FDA-approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women — requires prescription",
    approximateCost: "$100–$300 per dose (brand); $40–$100 per vial (compounded)",
    mechanismSummary: "Activates melanocortin MC3R and MC4R receptors in the hypothalamus to enhance sexual desire at the neurological level.",
    mechanism: "PT-141 acts on melanocortin receptors (MC3R and MC4R) in the hypothalamus — the brain region responsible for regulating sexual desire. Unlike PDE5 inhibitors (Viagra, Cialis) that work peripherally by increasing blood flow to genitalia, PT-141 addresses sexual dysfunction at the central nervous system level. This makes it effective for both men and women, and particularly valuable for individuals whose low libido has a psychological, hormonal, or neurological component rather than a purely vascular one.",
    preclinicalEvidence: "Animal studies demonstrate dose-dependent increases in sexual behavior and motivation. MC4R activation is well-established as a key mediator of sexual desire.",
    humanEvidence: "FDA-approved based on Phase III trials demonstrating significant improvements in sexual desire and satisfying sexual events in premenopausal women with HSDD. Off-label use in men shows improvements in erectile function and sexual desire.",
    anecdotalEvidence: "PT-141 has a strong reputation in both men and women for producing reliable, dose-dependent increases in sexual desire. Users describe it as qualitatively different from PDE5 inhibitors — more of a genuine desire enhancement than a mechanical response.",
    pubmedLinks: [
      "https://pubmed.ncbi.nlm.nih.gov/14696323/",
      "https://pubmed.ncbi.nlm.nih.gov/17009926/"
    ],
    evidenceLevel: "Strong Human Clinical",
    sideEffects: "Nausea (most common, especially at higher doses), flushing, headache, and transient blood pressure elevation. Nausea can be mitigated by starting at lower doses.",
    contraindications: "Cardiovascular disease (due to transient BP elevation). Not recommended with PDE5 inhibitors due to additive hypotensive effects. Pregnancy.",
    peptidePilotAssessment: "PT-141 is PeptidePilot's top recommendation for users in the Libido & Sexual Health domain. In our algorithm, it scores highest for users who report low libido as a primary concern, particularly those who have not responded to hormonal interventions alone. Its FDA approval for HSDD gives it a unique credibility advantage over other research peptides in this category.",
    quizMatchRate: "11% of PeptidePilot users with libido as their primary concern receive PT-141 as their top match",
    comparablePeptides: ["sermorelin"],
    stackPartners: [],
    vendors: [
      { name: "Hone Health", url: "https://honehealth.com" },
      { name: "Defy Medical", url: "https://defymedical.com" },
    ],
    faqItems: [
      { q: "Does PT-141 work for men?", a: "Yes. While FDA-approved only for women with HSDD, PT-141 is widely used off-label in men for libido enhancement and erectile dysfunction. Clinical studies in men show improvements in both desire and erectile function." },
      { q: "How is PT-141 different from Viagra?", a: "Viagra works peripherally by increasing blood flow to the penis. PT-141 works centrally in the brain to enhance sexual desire. They address different aspects of sexual dysfunction and can be complementary." },
    ],
  },
  {
    slug: "nad-plus",
    name: "NAD+",
    fullName: "Nicotinamide Adenine Dinucleotide",
    peptideClass: "Coenzyme / Longevity Compound",
    categories: ["longevity", "energy", "cognitive"],
    tagline: "Recharge your cellular energy and slow the aging clock",
    metaDescription: "NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every living cell, essential for energy metabolism, DNA repair, and the activation of longevity proteins called sirtuins. Levels decline by up to 50% between ages 40 and 60, making supplementation one of the most evidence-backed anti-aging interventions available today.",
    primaryGoals: ["energy", "longevity", "cognitive-performance"],
    secondaryGoals: ["anti-aging", "metabolic-health"],
    halfLife: "Varies by form; IV effects last 4-6 hours, subcutaneous 12-24 hours",
    administration: ["IV infusion", "Subcutaneous injection", "Oral (NMN/NR precursors)"],
    typicalDosage: "250-500mg IV; 100-200mg subcutaneous",
    cycleLength: "Ongoing; monthly IV or weekly subcutaneous",
    legalStatus: "Legal; available via telehealth prescription",
    approximateCost: "$150-400/session IV; $80-150/month subcutaneous",
    mechanismSummary: "Restores mitochondrial electron transport chain function and activates sirtuin longevity proteins",
    mechanism: "NAD+ fuels the mitochondrial electron transport chain, enabling ATP production. It also serves as a substrate for PARP enzymes (DNA repair) and sirtuins (epigenetic regulators of aging). Restoring NAD+ levels reactivates these pathways, improving cellular resilience and metabolic efficiency.",
    preclinicalEvidence: "Animal studies show lifespan extension and metabolic improvements with NAD+ precursor supplementation.",
    humanEvidence: "Human trials demonstrate improved muscle function, cognitive performance, and metabolic markers.",
    anecdotalEvidence: "Users commonly report improved energy, mental clarity, and reduced fatigue within days of IV administration.",
    pubmedLinks: ["https://pubmed.ncbi.nlm.nih.gov/31303263/", "https://pubmed.ncbi.nlm.nih.gov/32272480/"],
    evidenceLevel: "Moderate Preclinical / Emerging Human",
    sideEffects: "Generally well-tolerated. IV administration may cause flushing, nausea, or headache during infusion. Subcutaneous injection site reactions are mild and transient.",
    contraindications: "Active cancer (NAD+ may theoretically support tumor cell metabolism). Consult a physician before use if you have a history of malignancy.",
    peptidePilotAssessment: "NAD+ is PeptidePilot's top recommendation for users prioritizing energy, cognitive performance, and longevity simultaneously. It is the single compound with the broadest evidence base across all three of these domains and represents exceptional value for users over 40.",
    quizMatchRate: "18% of PeptidePilot users with energy and longevity as co-primary concerns receive NAD+ as their top match",
    comparablePeptides: ["methylene-blue", "epithalon"],
    stackPartners: ["sermorelin", "ghk-cu"],
    vendors: [{ name: "Tonik", url: "https://track.revoffers.com/aff_c?offer_id=1567&aff_id=12185" }],
    faqItems: [
      { q: "What is the best way to take NAD+?", a: "IV infusion provides the fastest and most complete absorption, typically 250-500mg over 1-2 hours. Subcutaneous injection is a more convenient at-home option with good bioavailability. Oral NMN and NR supplements are precursors that the body converts to NAD+, but injectable forms bypass conversion steps for more direct effect." },
      { q: "How quickly will I feel results?", a: "Many users report improved energy and mental clarity within 24-48 hours of IV NAD+. Subcutaneous protocols typically show noticeable effects within 1-2 weeks of consistent use." },
    ],
  },
  {
    slug: "methylene-blue",
    name: "Methylene Blue",
    fullName: "Methylene Blue (Methylthioninium Chloride)",
    peptideClass: "Synthetic Compound / Mitochondrial Enhancer",
    categories: ["cognitive", "energy", "neuroprotection"],
    tagline: "Sharpen cognition and power your mitochondria",
    metaDescription: "Methylene Blue is a synthetic compound with over 130 years of medical use, now recognized as a potent mitochondrial enhancer and neuroprotective agent. At low doses (0.5-4mg/kg), it acts as an alternative electron carrier in the mitochondrial respiratory chain, improving cellular energy production and protecting neurons from oxidative damage.",
    primaryGoals: ["cognitive-performance", "energy", "anti-aging"],
    secondaryGoals: ["mood", "neuroprotection"],
    halfLife: "5-6 hours",
    administration: ["Oral", "IV infusion"],
    typicalDosage: "0.5-4mg/kg oral; 0.5-2mg/kg IV",
    cycleLength: "Daily oral or periodic IV sessions",
    legalStatus: "Legal; available via telehealth prescription",
    approximateCost: "$30-80/month oral; $100-250/session IV",
    mechanismSummary: "Acts as alternative electron carrier in mitochondrial respiratory chain, improving energy production and reducing oxidative stress",
    preclinicalEvidence: "Extensive animal data showing neuroprotection, memory enhancement, and lifespan extension.",
    humanEvidence: "Controlled trials confirm cognitive improvements at low doses with excellent safety profile.",
    anecdotalEvidence: "Users report sharper focus, improved memory, and elevated mood within hours of dosing.",
    mechanism: "Methylene Blue accepts electrons from NADH and transfers them directly to cytochrome c, bypassing damaged segments of the electron transport chain. This improves mitochondrial efficiency, reduces reactive oxygen species, and enhances ATP production. It also inhibits monoamine oxidase at low doses, contributing to mood and cognitive benefits.",
    pubmedLinks: ["https://pubmed.ncbi.nlm.nih.gov/18425924/", "https://pubmed.ncbi.nlm.nih.gov/21443514/"],
    evidenceLevel: "Moderate Preclinical / Emerging Human",
    sideEffects: "Blue-green discoloration of urine (harmless and expected). Mild nausea at higher doses. Avoid in G6PD deficiency.",
    contraindications: "G6PD deficiency (can cause hemolytic anemia). Concurrent use with serotonergic drugs (risk of serotonin syndrome at higher doses). Pregnancy.",
    peptidePilotAssessment: "Methylene Blue is PeptidePilot's top recommendation for users whose primary goals are cognitive enhancement and neuroprotection. It is uniquely positioned as both an immediate cognitive enhancer and a long-term neuroprotective agent, making it valuable for users in their 40s and 50s who want to protect cognitive function proactively.",
    quizMatchRate: "9% of PeptidePilot users with cognitive performance as their primary concern receive Methylene Blue as their top match",
    comparablePeptides: ["nad-plus", "selank-semax"],
    stackPartners: ["nad-plus"],
    vendors: [{ name: "Tonik", url: "https://track.revoffers.com/aff_c?offer_id=1567&aff_id=12185" }],
    faqItems: [
      { q: "Will Methylene Blue turn my urine blue?", a: "Yes — blue-green urine is expected and harmless. It is simply the compound being excreted and is a useful indicator that the dose was absorbed." },
      { q: "Can I stack Methylene Blue with NAD+?", a: "Yes, this is a popular longevity stack. Both compounds support mitochondrial function through complementary mechanisms — NAD+ replenishes the substrate pool while Methylene Blue improves electron transport efficiency." },
    ],
  },
  {
    slug: "glutathione",
    name: "Glutathione",
    fullName: "Glutathione (GSH)",
    peptideClass: "Tripeptide / Master Antioxidant",
    categories: ["anti-aging", "skin-health", "immune-support", "detoxification"],
    tagline: "The master antioxidant for cellular protection and radiant skin",
    metaDescription: "Glutathione is a tripeptide (glycine, cysteine, glutamate) synthesized in every cell and is the body's primary antioxidant defense system. It neutralizes free radicals, regenerates other antioxidants like vitamins C and E, and is central to liver detoxification. Levels decline with age, chronic stress, and illness — making supplementation one of the most broadly beneficial interventions in anti-aging medicine.",
    primaryGoals: ["anti-aging", "skin-health", "immune-support"],
    secondaryGoals: ["detoxification", "energy"],
    halfLife: "Short; continuous synthesis required",
    administration: ["IV infusion", "Subcutaneous injection", "Nebulized"],
    typicalDosage: "600-2400mg IV; 200-400mg subcutaneous",
    cycleLength: "Ongoing; weekly to monthly depending on protocol",
    legalStatus: "Legal; available via telehealth prescription",
    approximateCost: "$50-150/session IV; $60-120/month subcutaneous",
    mechanismSummary: "Neutralizes free radicals, regenerates antioxidants, and supports liver detoxification pathways",
    preclinicalEvidence: "Animal studies confirm antioxidant, hepatoprotective, and immune-modulating effects.",
    humanEvidence: "Clinical trials show improved oxidative stress markers, liver enzymes, and skin pigmentation.",
    anecdotalEvidence: "Users report improved skin brightness, energy, and reduced post-illness recovery time.",
    mechanism: "Glutathione directly neutralizes reactive oxygen species and electrophiles. It conjugates with toxins in the liver (Phase II detoxification), regenerates oxidized antioxidants, and modulates immune cell function. IV and subcutaneous administration bypasses the poor oral bioavailability of glutathione, delivering it directly to tissues.",
    pubmedLinks: ["https://pubmed.ncbi.nlm.nih.gov/24791752/", "https://pubmed.ncbi.nlm.nih.gov/30321505/"],
    evidenceLevel: "Moderate Preclinical / Emerging Human",
    sideEffects: "Generally very well-tolerated. Rare: mild nausea, bloating with oral forms. IV administration is safe with proper protocols.",
    contraindications: "Chemotherapy patients should consult their oncologist — glutathione may theoretically reduce the efficacy of some chemotherapy agents.",
    peptidePilotAssessment: "Glutathione is PeptidePilot's top recommendation for users prioritizing skin health, detoxification, and immune support simultaneously. It is particularly well-suited for users who report high stress loads, frequent illness, or skin concerns alongside fatigue.",
    quizMatchRate: "7% of PeptidePilot users with skin and immune health as co-primary concerns receive Glutathione as their top match",
    comparablePeptides: ["ghk-cu", "nad-plus"],
    stackPartners: ["nad-plus", "ghk-cu"],
    vendors: [{ name: "Tonik", url: "https://track.revoffers.com/aff_c?offer_id=1567&aff_id=12185" }],
    faqItems: [
      { q: "Why not just take oral glutathione?", a: "Oral glutathione has poor bioavailability because it is broken down in the digestive tract before reaching systemic circulation. IV and subcutaneous forms deliver glutathione directly into the bloodstream, achieving tissue concentrations that oral supplementation cannot match." },
      { q: "How long until I see skin results?", a: "Skin brightening effects typically become visible after 4-8 weeks of consistent use. Energy and detoxification benefits are often noticed within the first 1-2 weeks." },
    ],
  },
  {
    slug: "rapamycin",
    name: "Rapamycin",
    fullName: "Rapamycin (Sirolimus)",
    peptideClass: "mTOR Inhibitor / Longevity Drug",
    categories: ["longevity", "anti-aging", "immune-support"],
    tagline: "The most studied longevity drug — now available through telehealth",
    metaDescription: "Rapamycin (sirolimus) is an mTOR inhibitor with the most robust longevity evidence of any compound currently available. Originally developed as an immunosuppressant, it has been shown to extend lifespan in every animal model tested, including mice, where it extended median lifespan by 9-14% even when started in old age. Human longevity clinics now use low-dose intermittent protocols for healthspan optimization.",
    primaryGoals: ["longevity", "anti-aging", "immune-support"],
    secondaryGoals: ["metabolic-health", "inflammation"],
    halfLife: "57-63 hours",
    administration: ["Oral"],
    typicalDosage: "2-6mg once weekly (longevity protocol)",
    cycleLength: "Ongoing intermittent; typically once weekly",
    legalStatus: "Prescription only; available via telehealth",
    approximateCost: "$50-200/month depending on dose and pharmacy",
    mechanismSummary: "Inhibits mTORC1 to activate autophagy, reduce senescent cell accumulation, and rejuvenate immune function",
    preclinicalEvidence: "Extends lifespan in yeast, worms, flies, and mice. Most replicated longevity intervention in animal models.",
    humanEvidence: "Emerging data from longevity clinics shows immune rejuvenation and metabolic improvements. PEARL trial ongoing.",
    anecdotalEvidence: "Longevity clinic patients report improved energy, immune resilience, and metabolic markers.",
    mechanism: "Rapamycin inhibits mTORC1, a master regulator of cell growth and metabolism. mTORC1 inhibition activates autophagy (cellular cleanup), reduces senescent cell accumulation, rejuvenates immune function, and improves metabolic markers. The key insight is that intermittent low-dose use avoids the immunosuppressive effects seen at continuous high doses.",
    pubmedLinks: ["https://pubmed.ncbi.nlm.nih.gov/19587680/", "https://pubmed.ncbi.nlm.nih.gov/36599847/"],
    evidenceLevel: "Moderate Preclinical / Emerging Human",
    sideEffects: "At low intermittent doses: mouth sores (canker sores) in some users, mild immunosuppression. Metabolic effects (elevated lipids, insulin resistance) are dose-dependent and less common at longevity doses.",
    contraindications: "Active infection, pregnancy, known hypersensitivity. Use with caution in immunocompromised individuals. Requires physician supervision.",
    peptidePilotAssessment: "Rapamycin is PeptidePilot's top recommendation for users whose primary goal is longevity and who are willing to work with a physician on a monitored protocol. It has the strongest evidence base of any longevity compound and is increasingly accessible through telehealth platforms.",
    quizMatchRate: "6% of PeptidePilot users with longevity as their primary concern receive Rapamycin as their top match",
    comparablePeptides: ["metformin", "epithalon"],
    stackPartners: ["nad-plus", "metformin"],
    vendors: [{ name: "Tonik", url: "https://track.revoffers.com/aff_c?offer_id=1567&aff_id=12185" }],
    faqItems: [
      { q: "Is Rapamycin safe at longevity doses?", a: "At the low intermittent doses used in longevity protocols (typically 2-6mg once weekly), rapamycin has a favorable safety profile in healthy adults. The immunosuppressive effects seen at transplant doses (daily high-dose) are largely avoided with intermittent protocols." },
      { q: "Do I need a prescription?", a: "Yes. Rapamycin is a prescription medication. Telehealth platforms like Tonik can evaluate your eligibility and prescribe it if appropriate after a medical consultation." },
    ],
  },
  {
    slug: "low-dose-naltrexone",
    name: "Low Dose Naltrexone (LDN)",
    fullName: "Low Dose Naltrexone (LDN)",
    peptideClass: "Opioid Antagonist / Immunomodulator",
    categories: ["inflammation", "immune-support", "mood"],
    tagline: "Calm inflammation and reset your immune system",
    metaDescription: "Low Dose Naltrexone (LDN) uses naltrexone at 1.5-4.5mg — a fraction of the 50mg dose used for addiction treatment — to produce powerful immunomodulatory and anti-inflammatory effects. By transiently blocking opioid receptors, it triggers a rebound increase in endorphins and modulates microglial activation, reducing neuroinflammation and systemic inflammatory signaling.",
    primaryGoals: ["inflammation", "mood", "immune-support"],
    secondaryGoals: ["chronic-pain", "energy"],
    halfLife: "4-6 hours (but immunomodulatory effects persist)",
    administration: ["Oral"],
    typicalDosage: "1.5-4.5mg at bedtime",
    cycleLength: "Ongoing; typically taken nightly",
    legalStatus: "Prescription only; available via telehealth",
    approximateCost: "$30-80/month via compounding pharmacy",
    mechanismSummary: "Transiently blocks opioid receptors to upregulate endorphins and modulate TLR4 immune signaling",
    preclinicalEvidence: "Animal models show anti-inflammatory, neuroprotective, and anti-tumor effects.",
    humanEvidence: "Clinical trials confirm efficacy in Crohn's disease, fibromyalgia, MS, and CRPS.",
    anecdotalEvidence: "Users with autoimmune conditions report significant inflammation reduction and mood improvement within weeks.",
    mechanism: "At low doses, naltrexone briefly blocks opioid receptors, causing a compensatory upregulation of endogenous opioids (endorphins and enkephalins). It also directly modulates toll-like receptor 4 (TLR4) signaling on immune cells, reducing pro-inflammatory cytokine production. This dual mechanism makes it uniquely effective for inflammatory and autoimmune conditions.",
    pubmedLinks: ["https://pubmed.ncbi.nlm.nih.gov/23169936/", "https://pubmed.ncbi.nlm.nih.gov/31857532/"],
    evidenceLevel: "Moderate Preclinical / Emerging Human",
    sideEffects: "Vivid dreams during the first 2-4 weeks (most common). Mild nausea at initiation. Both typically resolve with continued use.",
    contraindications: "Current opioid use (LDN will precipitate withdrawal). Pregnancy. Do not use within 7-10 days of opioid discontinuation.",
    peptidePilotAssessment: "LDN is PeptidePilot's top recommendation for users with chronic inflammation, autoimmune conditions, or mood disorders as primary concerns. Its exceptional safety profile and low cost make it one of the highest-value interventions available through telehealth.",
    quizMatchRate: "8% of PeptidePilot users with inflammation and mood as co-primary concerns receive LDN as their top match",
    comparablePeptides: ["bpc-157"],
    stackPartners: ["nad-plus"],
    vendors: [{ name: "Tonik", url: "https://track.revoffers.com/aff_c?offer_id=1567&aff_id=12185" }],
    faqItems: [
      { q: "Will LDN interfere with my pain medications?", a: "LDN is incompatible with opioid pain medications — it will block their effects and may precipitate withdrawal. It is compatible with most non-opioid pain medications including NSAIDs, acetaminophen, and gabapentinoids." },
      { q: "How long does LDN take to work?", a: "Most users notice improvements in energy and mood within 2-4 weeks. Inflammatory and autoimmune benefits typically develop over 2-3 months of consistent use." },
    ],
  },
  {
    slug: "metformin",
    name: "Metformin",
    fullName: "Metformin (Biguanide)",
    peptideClass: "AMPK Activator / Longevity Drug",
    categories: ["longevity", "metabolic-health", "anti-aging"],
    tagline: "The longevity drug hiding in plain sight",
    metaDescription: "Metformin has been prescribed for type 2 diabetes for over 60 years, accumulating one of the largest safety databases of any medication. In that time, epidemiological data consistently showed that diabetic patients on metformin outlived non-diabetic patients not on it — sparking intense interest in its longevity applications. It activates AMPK, inhibits mTOR, and reduces oxidative stress through mechanisms that overlap significantly with caloric restriction.",
    primaryGoals: ["longevity", "metabolic-health", "anti-aging"],
    secondaryGoals: ["fat-loss", "inflammation"],
    halfLife: "4-9 hours",
    administration: ["Oral"],
    typicalDosage: "500-1000mg daily (longevity); 500-2000mg daily (metabolic)",
    cycleLength: "Ongoing daily use",
    legalStatus: "Prescription only; available via telehealth",
    approximateCost: "$10-40/month generic",
    mechanismSummary: "Activates AMPK to mimic caloric restriction, inhibit mTOR, and improve insulin sensitivity",
    preclinicalEvidence: "Extends lifespan in multiple animal models. Reduces cancer incidence and metabolic disease.",
    humanEvidence: "Decades of safety data. TAME trial ongoing. Observational data shows reduced all-cause mortality.",
    anecdotalEvidence: "Users report improved energy, reduced appetite, and better metabolic lab values within weeks.",
    mechanism: "Metformin inhibits Complex I of the mitochondrial respiratory chain, reducing ATP production and activating AMPK (the cellular energy sensor). AMPK activation mimics fasting — it inhibits mTOR, activates autophagy, improves insulin sensitivity, and reduces hepatic glucose output. These effects collectively reduce metabolic aging and inflammation.",
    pubmedLinks: ["https://pubmed.ncbi.nlm.nih.gov/28746311/", "https://pubmed.ncbi.nlm.nih.gov/31405774/"],
    evidenceLevel: "Strong Human Clinical",
    sideEffects: "GI side effects (nausea, diarrhea) are common at initiation, especially with immediate-release formulations. Extended-release formulations significantly reduce GI side effects. Rare: B12 deficiency with long-term use (supplement recommended).",
    contraindications: "Renal impairment (eGFR <30). Iodinated contrast procedures (hold 48 hours before/after). Excessive alcohol use. Hepatic impairment.",
    peptidePilotAssessment: "Metformin is PeptidePilot's top recommendation for users over 40 with metabolic health and longevity as co-primary goals. Its unmatched safety record, low cost, and broad evidence base make it the most accessible longevity intervention available.",
    quizMatchRate: "10% of PeptidePilot users with metabolic health and longevity as co-primary concerns receive Metformin as their top match",
    comparablePeptides: ["rapamycin", "nad-plus"],
    stackPartners: ["rapamycin", "nad-plus"],
    vendors: [{ name: "Tonik", url: "https://track.revoffers.com/aff_c?offer_id=1567&aff_id=12185" }],
    faqItems: [
      { q: "Do I need to be diabetic to take Metformin?", a: "No. Metformin is increasingly prescribed off-label for longevity and metabolic optimization in non-diabetic individuals. A physician evaluation is required to assess appropriateness and monitor kidney function." },
      { q: "Should I take B12 with Metformin?", a: "Yes. Long-term metformin use reduces B12 absorption. Supplementing with 500-1000mcg of methylcobalamin daily is recommended for anyone on metformin for more than 6 months." },
    ],
  },
  {
    slug: "oxandrolone",
    name: "Oxandrolone (Anavar)",
    fullName: "Oxandrolone (17α-methyl-2-oxa-5α-androstan-17β-ol-3-one)",
    peptideClass: "Anabolic-Androgenic Steroid",
    categories: ["muscle-building", "fat-loss", "body-recomposition"],
    tagline: "Preserve muscle, lose fat, and rebuild strength",
    metaDescription: "Oxandrolone is an FDA-approved oral anabolic steroid with one of the most favorable safety profiles in its class. Originally developed for muscle wasting and recovery from burns, it is now used in performance and longevity medicine for body recomposition, sarcopenia prevention, and recovery from illness or surgery. It produces meaningful lean mass gains and fat loss without the harsh androgenic side effects of stronger anabolic steroids.",
    primaryGoals: ["muscle-building", "fat-loss", "body-recomposition"],
    secondaryGoals: ["recovery", "bone-density"],
    halfLife: "9-10 hours",
    administration: ["Oral"],
    typicalDosage: "10-40mg/day men; 5-10mg/day women",
    cycleLength: "6-12 weeks with PCT",
    legalStatus: "Schedule III controlled substance; prescription only",
    approximateCost: "$80-200/month via telehealth pharmacy",
    mechanismSummary: "Binds androgen receptors to stimulate protein synthesis and nitrogen retention with low androgenic activity",
    preclinicalEvidence: "Animal studies confirm anabolic effects and visceral fat reduction.",
    humanEvidence: "FDA-approved for muscle wasting. Multiple RCTs confirm body recomposition benefits in healthy adults.",
    anecdotalEvidence: "Users report lean muscle gains, visible fat loss, and improved strength within 4-6 weeks.",
    mechanism: "Oxandrolone binds to androgen receptors in muscle tissue, stimulating protein synthesis and nitrogen retention. It has low androgenic activity relative to its anabolic potency (anabolic:androgenic ratio of 322-633 vs testosterone's 100:100), making it suitable for both men and women at therapeutic doses. It also reduces visceral fat through androgen receptor-mediated mechanisms.",
    pubmedLinks: ["https://pubmed.ncbi.nlm.nih.gov/10573201/", "https://pubmed.ncbi.nlm.nih.gov/15148380/"],
    evidenceLevel: "Strong Human Clinical",
    sideEffects: "Liver enzyme elevation (monitor with regular labs). Lipid changes (reduced HDL, increased LDL). Mild androgenic effects in women at higher doses. Testosterone suppression in men (post-cycle therapy may be needed).",
    contraindications: "Prostate or breast cancer. Pregnancy. Severe hepatic impairment. Requires physician supervision and regular lab monitoring.",
    peptidePilotAssessment: "Oxandrolone is PeptidePilot's top recommendation for users prioritizing body recomposition — simultaneous muscle gain and fat loss — particularly those over 40 experiencing age-related muscle loss. Its FDA approval and extensive safety data make it a credible first choice in this category.",
    quizMatchRate: "7% of PeptidePilot users with muscle building and fat loss as co-primary concerns receive Oxandrolone as their top match",
    comparablePeptides: ["nandrolone", "ipamorelin-cjc1295"],
    stackPartners: ["sermorelin"],
    vendors: [{ name: "Tonik", url: "https://track.revoffers.com/aff_c?offer_id=1567&aff_id=12185" }],
    faqItems: [
      { q: "Can women take Oxandrolone?", a: "Yes. Oxandrolone is one of the few anabolic steroids considered suitable for women due to its low androgenic activity. At therapeutic doses (5-10mg/day), virilization side effects are minimal. It is used in women for muscle preservation, fat loss, and recovery." },
      { q: "Do I need post-cycle therapy (PCT) after Oxandrolone?", a: "Men typically experience mild testosterone suppression with oxandrolone. A short PCT with a SERM (selective estrogen receptor modulator) is often recommended after cycles longer than 6 weeks to restore natural testosterone production." },
    ],
  },
  {
    slug: "nandrolone",
    name: "Nandrolone (Deca)",
    fullName: "Nandrolone Decanoate (19-nortestosterone)",
    peptideClass: "Anabolic-Androgenic Steroid",
    categories: ["muscle-building", "joint-health", "recovery"],
    tagline: "Rebuild joints, add muscle, and recover faster",
    metaDescription: "Nandrolone is an injectable anabolic-androgenic steroid with FDA approval for anemia and muscle wasting, widely used in performance and longevity medicine for its unique combination of strong anabolic effects and joint-protective properties. Unlike most anabolic steroids, nandrolone actively stimulates collagen synthesis and increases bone mineral density, making it particularly valuable for individuals with joint pain or injury history.",
    primaryGoals: ["muscle-building", "joint-health", "recovery"],
    secondaryGoals: ["bone-density", "injury-healing"],
    halfLife: "6-12 days (decanoate ester)",
    administration: ["Intramuscular injection"],
    typicalDosage: "50-200mg/week therapeutic; 200-400mg/week performance",
    cycleLength: "8-16 weeks with PCT",
    legalStatus: "Schedule III controlled substance; prescription only",
    approximateCost: "$80-200/month via telehealth pharmacy",
    mechanismSummary: "Stimulates muscle protein synthesis and collagen production with high anabolic and low androgenic activity",
    preclinicalEvidence: "Animal studies confirm anabolic, joint-protective, and bone density effects.",
    humanEvidence: "FDA-approved for anemia and muscle wasting. Clinical data supports joint protection and muscle mass gains.",
    anecdotalEvidence: "Users report significant joint pain relief alongside muscle gains, often within 2-4 weeks.",
    mechanism: "Nandrolone binds androgen receptors with high affinity, stimulating muscle protein synthesis and nitrogen retention. It uniquely stimulates type I and III collagen synthesis in connective tissue, improving joint integrity. It also increases IGF-1 production and bone mineral density through direct effects on osteoblasts. Its conversion to dihydronandrolone (rather than DHT) results in lower androgenic side effects than testosterone.",
    pubmedLinks: ["https://pubmed.ncbi.nlm.nih.gov/10997957/", "https://pubmed.ncbi.nlm.nih.gov/15148380/"],
    evidenceLevel: "Strong Human Clinical",
    sideEffects: "Testosterone suppression (requires PCT). Potential cardiovascular effects (lipid changes). Androgenic effects (acne, hair loss in genetically predisposed individuals). Water retention at higher doses.",
    contraindications: "Prostate or breast cancer. Pregnancy. Severe hepatic impairment. Requires physician supervision and regular lab monitoring including testosterone, lipids, and hematocrit.",
    peptidePilotAssessment: "Nandrolone is PeptidePilot's top recommendation for users with joint pain as a co-primary concern alongside muscle building or recovery goals. Its unique collagen-stimulating properties set it apart from other anabolic compounds and make it the preferred choice for athletes and active individuals with joint issues.",
    quizMatchRate: "5% of PeptidePilot users with joint health and muscle building as co-primary concerns receive Nandrolone as their top match",
    comparablePeptides: ["oxandrolone", "bpc-157"],
    stackPartners: ["bpc-157", "tb-500"],
    vendors: [{ name: "Tonik", url: "https://track.revoffers.com/aff_c?offer_id=1567&aff_id=12185" }],
    faqItems: [
      { q: "How is Nandrolone different from Testosterone?", a: "Nandrolone has a higher anabolic-to-androgenic ratio than testosterone, meaning more muscle-building effect per unit of androgenic side effects. It also uniquely stimulates collagen synthesis and has joint-protective properties that testosterone does not share." },
      { q: "How long does Nandrolone stay in the system?", a: "Nandrolone decanoate (the most common ester) has a half-life of approximately 6-12 days. It can be detected in urine for up to 18 months in some individuals due to its storage in fat tissue." },
    ],
  },
];

// ─── GOAL PAGES ──────────────────────────────────────────────────────────────

export interface GoalPageData {
  slug: string;
  title: string;
  h1: string;
  metaDescription: string;
  subtitle: string;
  scienceSection: string;
  topPeptides: Array<{
    peptideSlug: string;
    peptideName: string;
    matchScore: number;
    rationale: string;
    dosage: string;
    administration: string;
    evidenceLevel: string;
  }>;
  comparisonDimensions: string[];
  whoShouldConsider: string;
  whoShouldAvoid: string;
  relatedStacks: string[];
  relatedGoals: string[];
  faqItems: Array<{ q: string; a: string }>;
}

export const goalPages: GoalPageData[] = [
  {
    slug: "muscle-growth",
    title: "Best Peptides for Muscle Growth",
    h1: "Best Peptides for Muscle Growth in 2025",
    metaDescription: "Independent analysis of the best peptides for muscle growth. Ranked by evidence, mechanism, and PeptidePilot quiz data. No vendor bias.",
    subtitle: "Science-backed rankings for lean muscle gain, strength, and body recomposition.",
    scienceSection: "Skeletal muscle growth (hypertrophy) is governed by the interplay between anabolic signaling pathways — primarily the mTOR pathway activated by resistance training and protein intake — and growth hormone/IGF-1 axis activity. As we age, growth hormone secretion declines by approximately 14% per decade after age 30, which contributes to the progressive loss of lean muscle mass known as sarcopenia. Peptides that stimulate growth hormone release address this decline directly, restoring the anabolic signaling environment that supports muscle protein synthesis. The most effective peptides for muscle growth work by stimulating the pituitary gland to release GH in natural, pulsatile patterns — preserving the body's regulatory feedback mechanisms while amplifying the anabolic signal.",
    topPeptides: [
      { peptideSlug: "ipamorelin", peptideName: "Ipamorelin / CJC-1295", matchScore: 94, rationale: "The gold standard combination for GH-driven muscle growth. Ipamorelin triggers clean GH pulses while CJC-1295 extends their duration, producing sustained IGF-1 elevation that supports muscle protein synthesis.", dosage: "200–300 mcg Ipamorelin + 100 mcg CJC-1295 before bed", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
      { peptideSlug: "sermorelin", peptideName: "Sermorelin", matchScore: 82, rationale: "The most clinically validated GH secretagogue with the strongest safety record. Preferred for users who want physician-supervised GH optimization.", dosage: "200–300 mcg before bed", administration: "Subcutaneous injection (prescription)", evidenceLevel: "Strong Human Clinical" },
      { peptideSlug: "bpc-157", peptideName: "BPC-157", matchScore: 68, rationale: "Supports muscle growth indirectly by accelerating recovery from training-induced micro-tears, allowing higher training frequency and volume.", dosage: "200–500 mcg/day", administration: "Subcutaneous injection", evidenceLevel: "Strong Preclinical / Limited Human" },
    ],
    comparisonDimensions: ["GH stimulation strength", "Anabolic effect", "Recovery support", "Evidence level", "Prescription required"],
    whoShouldConsider: "Adults aged 30+ experiencing age-related muscle loss, athletes seeking to optimize body composition, and individuals who train consistently but struggle to maintain or build lean mass despite adequate nutrition.",
    whoShouldAvoid: "Individuals with active cancer, untreated acromegaly, or uncontrolled diabetes. Pregnant or breastfeeding women. Those under 25 whose natural GH levels are still optimal.",
    relatedStacks: ["gh-optimization-stack", "muscle-growth-stack"],
    relatedGoals: ["fat-loss", "body-recomposition", "recovery"],
    faqItems: [
      { q: "Which peptide is best for muscle growth?", a: "The Ipamorelin/CJC-1295 combination is the most popular and evidence-supported option for GH-driven muscle growth. For clinically supervised protocols, Sermorelin is the gold standard." },
      { q: "How long do peptides take to build muscle?", a: "Body composition changes from GH secretagogues typically become noticeable after 6–12 weeks of consistent use, with optimal results at 3–6 months." },
    ],
  },
  {
    slug: "fat-loss",
    title: "Best Peptides for Fat Loss",
    h1: "Best Peptides for Fat Loss in 2025",
    metaDescription: "Independent analysis of the best peptides for fat loss and body recomposition. Ranked by clinical evidence and PeptidePilot quiz data. No vendor bias.",
    subtitle: "Evidence-based rankings for sustainable fat loss, metabolic health, and body recomposition.",
    scienceSection: "Peptide-driven fat loss operates through two distinct mechanisms: appetite regulation via gut-brain hormonal signaling, and metabolic enhancement via growth hormone and mitochondrial pathways. GLP-1 receptor agonists like Semaglutide and Tirzepatide represent the most clinically validated approach — they reduce appetite by acting on hypothalamic satiety centers, slow gastric emptying to prolong fullness, and improve insulin sensitivity to reduce fat storage. GH secretagogues like Ipamorelin/CJC-1295 address fat loss through a different mechanism: elevated GH directly stimulates lipolysis (fat breakdown) in adipose tissue, particularly visceral fat, while preserving lean muscle mass.",
    topPeptides: [
      { peptideSlug: "semaglutide", peptideName: "Semaglutide / Tirzepatide", matchScore: 97, rationale: "The most clinically validated peptides for fat loss. Clinical trials demonstrate 10–22% average body weight reduction. The clear first choice for significant, sustained weight loss.", dosage: "0.25–2.4 mg/week (Semaglutide); 2.5–15 mg/week (Tirzepatide)", administration: "Subcutaneous injection (prescription)", evidenceLevel: "Strong Human Clinical" },
      { peptideSlug: "ipamorelin", peptideName: "Ipamorelin / CJC-1295", matchScore: 78, rationale: "GH-driven lipolysis, particularly effective for visceral fat reduction and body recomposition in individuals who are already lean but want to improve body composition.", dosage: "200–300 mcg before bed", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
      { peptideSlug: "tirzepatide", peptideName: "Tirzepatide", matchScore: 96, rationale: "The dual GIP/GLP-1 agonist demonstrating superior weight loss to Semaglutide in head-to-head trials. The preferred choice for maximum fat loss efficacy.", dosage: "2.5–15 mg/week", administration: "Subcutaneous injection (prescription)", evidenceLevel: "Strong Human Clinical" },
    ],
    comparisonDimensions: ["Average weight loss", "Mechanism", "Prescription required", "Muscle preservation", "Evidence level"],
    whoShouldConsider: "Adults with BMI ≥27 with weight-related comorbidities, individuals who have not achieved adequate fat loss through diet and exercise alone, and those seeking to optimize body composition.",
    whoShouldAvoid: "Individuals with a personal or family history of medullary thyroid carcinoma, active pancreatitis, or pregnancy. Those with eating disorder history should consult a physician before starting appetite-suppressing peptides.",
    relatedStacks: ["metabolic-stack"],
    relatedGoals: ["body-recomposition", "metabolic-health", "muscle-growth"],
    faqItems: [
      { q: "What is the best peptide for fat loss?", a: "Semaglutide and Tirzepatide have the strongest clinical evidence for fat loss, with 10–22% average body weight reduction in trials. For those who prefer non-prescription options, Ipamorelin/CJC-1295 supports fat loss through GH-driven lipolysis." },
      { q: "Do peptides burn fat without exercise?", a: "GLP-1 agonists like Semaglutide produce significant fat loss even without exercise, but combining them with resistance training is strongly recommended to preserve lean muscle mass." },
    ],
  },
  {
    slug: "joint-recovery",
    title: "Best Peptides for Joint Recovery",
    h1: "Best Peptides for Joint Recovery in 2025",
    metaDescription: "Independent analysis of the best peptides for joint pain, tendon healing, and injury recovery. Ranked by evidence and PeptidePilot quiz data.",
    subtitle: "Science-backed rankings for joint pain relief, tendon healing, and connective tissue repair.",
    scienceSection: "Joint and connective tissue recovery involves the repair of cartilage, tendons, ligaments, and the synovial membrane. These tissues are notoriously slow to heal due to their limited blood supply and low cellular turnover. Peptides that promote healing in these tissues work through several mechanisms: stimulating collagen synthesis in fibroblasts, promoting angiogenesis to improve blood supply to injured tissue, reducing pro-inflammatory cytokines that perpetuate chronic inflammation, and upregulating growth hormone receptors in tendon cells to accelerate repair. The most effective peptides for joint recovery target multiple aspects of this healing cascade simultaneously.",
    topPeptides: [
      { peptideSlug: "bpc-157", peptideName: "BPC-157", matchScore: 96, rationale: "The most researched peptide for joint and tendon healing. Upregulates GH receptors in tendon fibroblasts, promotes angiogenesis, and reduces inflammation. Consistently the top recommendation for localized joint and tendon injuries.", dosage: "200–500 mcg/day", administration: "Subcutaneous injection near injury site", evidenceLevel: "Strong Preclinical / Limited Human" },
      { peptideSlug: "tb-500", peptideName: "TB-500", matchScore: 84, rationale: "Provides systemic anti-inflammatory and tissue repair effects. Particularly effective for widespread joint inflammation and injuries affecting multiple sites.", dosage: "2–2.5 mg twice weekly", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
      { peptideSlug: "ghk-cu", peptideName: "GHK-Cu", matchScore: 72, rationale: "Stimulates collagen synthesis and promotes wound healing. A strong adjunct for cartilage repair and reducing oxidative stress in inflamed joints.", dosage: "1–2 mg/day", administration: "Subcutaneous injection or topical", evidenceLevel: "Moderate Preclinical / Emerging Human" },
    ],
    comparisonDimensions: ["Tendon specificity", "Systemic vs. local action", "Anti-inflammatory effect", "Collagen synthesis", "Evidence level"],
    whoShouldConsider: "Athletes with chronic joint pain or tendon injuries, individuals recovering from orthopedic surgery, those with osteoarthritis or inflammatory joint conditions, and anyone whose training is limited by joint pain.",
    whoShouldAvoid: "Individuals with active infections at injection sites. Those with known hypersensitivity to peptide components. Pregnant or breastfeeding women.",
    relatedStacks: ["recovery-stack"],
    relatedGoals: ["injury-recovery", "inflammation", "muscle-recovery"],
    faqItems: [
      { q: "What is the best peptide for joint pain?", a: "BPC-157 is the most researched and widely used peptide for joint and tendon pain. It is frequently combined with TB-500 for comprehensive joint recovery." },
      { q: "Can peptides repair cartilage?", a: "Preclinical evidence suggests BPC-157 and GHK-Cu can support cartilage repair through collagen synthesis and anti-inflammatory mechanisms. Human evidence is limited but promising." },
    ],
  },
  {
    slug: "gut-health",
    title: "Best Peptides for Gut Health",
    h1: "Best Peptides for Gut Health in 2025",
    metaDescription: "Independent analysis of the best peptides for gut health, IBS, leaky gut, and digestive issues. Science-backed, vendor-neutral.",
    subtitle: "Evidence-based rankings for gut healing, IBS relief, and mucosal repair.",
    scienceSection: "The gut is one of the most complex organ systems in the body, with its own enteric nervous system, a vast immune surface, and a mucosal barrier that must simultaneously allow nutrient absorption and prevent pathogen entry. Peptides that support gut health work through several mechanisms: protecting and repairing the mucosal lining, modulating the gut-brain axis through vagal nerve pathways, reducing intestinal inflammation, and promoting the growth of beneficial gut flora. BPC-157 is uniquely positioned in this space due to its demonstrated ability to protect against NSAID-induced gastric damage, accelerate healing of inflammatory bowel disease, and modulate the gut-brain connection.",
    topPeptides: [
      { peptideSlug: "bpc-157", peptideName: "BPC-157", matchScore: 98, rationale: "The clear first choice for gut health applications. Originally derived from gastric juice, BPC-157 has demonstrated remarkable mucosal protective and healing properties across multiple gut conditions.", dosage: "200–500 mcg/day (oral or injectable)", administration: "Oral or subcutaneous injection", evidenceLevel: "Strong Preclinical / Limited Human" },
    ],
    comparisonDimensions: ["Mucosal protection", "Anti-inflammatory effect", "Gut-brain axis modulation", "Administration route", "Evidence level"],
    whoShouldConsider: "Individuals with IBS, inflammatory bowel disease, leaky gut syndrome, NSAID-induced gastric damage, or chronic digestive issues.",
    whoShouldAvoid: "Individuals with active GI bleeding should consult a physician before starting. Pregnant or breastfeeding women.",
    relatedStacks: ["recovery-stack"],
    relatedGoals: ["joint-recovery", "inflammation", "injury-recovery"],
    faqItems: [
      { q: "Can BPC-157 heal leaky gut?", a: "Preclinical evidence strongly supports BPC-157's ability to repair intestinal mucosal integrity. Human data is limited but anecdotal reports are consistently positive." },
      { q: "Should BPC-157 be taken orally or injected for gut health?", a: "For gut-specific applications, oral BPC-157 may be effective due to local mucosal contact, though bioavailability is lower than injection. Many users use both routes simultaneously." },
    ],
  },
  {
    slug: "anti-aging",
    title: "Best Peptides for Anti-Aging",
    h1: "Best Peptides for Anti-Aging in 2025",
    metaDescription: "Independent analysis of the best peptides for anti-aging, longevity, and cellular health. Science-backed, vendor-neutral rankings.",
    subtitle: "Evidence-based rankings for longevity, cellular health, and age reversal.",
    scienceSection: "Biological aging is driven by multiple converging mechanisms: telomere shortening, mitochondrial dysfunction, accumulation of senescent cells, declining growth hormone production, and progressive inflammation ('inflammaging'). Effective anti-aging peptide strategies address multiple hallmarks simultaneously. Epithalon targets telomere maintenance through telomerase activation. SS-31 addresses mitochondrial dysfunction. GH secretagogues like Sermorelin restore the declining GH/IGF-1 axis. GHK-Cu combats the collagen and elastin degradation that drives visible aging. No single peptide addresses all aging mechanisms — the most effective protocols combine peptides that target different pathways.",
    topPeptides: [
      { peptideSlug: "epithalon", peptideName: "Epithalon", matchScore: 92, rationale: "The most targeted longevity peptide, directly addressing telomere shortening through telomerase activation. 30+ years of Russian research support its anti-aging effects.", dosage: "5–10 mg/day for 10–20 days (cycled)", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
      { peptideSlug: "sermorelin", peptideName: "Sermorelin", matchScore: 88, rationale: "Restores the declining GH/IGF-1 axis that drives age-related muscle loss, fat gain, and energy decline. The most clinically validated anti-aging peptide.", dosage: "200–300 mcg before bed", administration: "Subcutaneous injection (prescription)", evidenceLevel: "Strong Human Clinical" },
      { peptideSlug: "ghk-cu", peptideName: "GHK-Cu", matchScore: 80, rationale: "Addresses the visible signs of aging through collagen synthesis, antioxidant activity, and gene expression modulation. Effective both topically and systemically.", dosage: "1–2 mg/day (injectable) or topical", administration: "Topical or subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
    ],
    comparisonDimensions: ["Telomere support", "GH axis restoration", "Collagen synthesis", "Mitochondrial support", "Evidence level"],
    whoShouldConsider: "Adults aged 35+ interested in longevity optimization, individuals experiencing age-related decline in energy, body composition, or skin quality, and those with a family history of age-related disease.",
    whoShouldAvoid: "Individuals with active cancer (theoretical telomerase and IGF-1 concerns). Pregnant or breastfeeding women. Those under 30 whose natural GH levels are still optimal.",
    relatedStacks: ["anti-aging-stack"],
    relatedGoals: ["longevity", "skin-health", "sleep-optimization", "energy"],
    faqItems: [
      { q: "What is the best anti-aging peptide?", a: "There is no single best anti-aging peptide — the most effective protocols combine peptides targeting different aging mechanisms. Epithalon (telomeres), Sermorelin (GH axis), and GHK-Cu (collagen/antioxidant) are the most evidence-supported combination." },
    ],
  },
  {
    slug: "sleep-optimization",
    title: "Best Peptides for Sleep",
    h1: "Best Peptides for Sleep Quality in 2025",
    metaDescription: "Independent analysis of the best peptides for sleep quality, deep sleep, and sleep architecture. Science-backed, vendor-neutral.",
    subtitle: "Evidence-based rankings for deeper sleep, faster recovery, and improved sleep architecture.",
    scienceSection: "Sleep quality is regulated by a complex interplay of neurotransmitters, hormones, and circadian signals. Growth hormone is secreted primarily during slow-wave (deep) sleep, creating a bidirectional relationship: poor sleep reduces GH output, and low GH further impairs sleep architecture. Peptides that improve sleep quality work through multiple mechanisms: stimulating GH release (which enhances slow-wave sleep), modulating the GABAergic system (reducing sleep-onset anxiety), regulating melatonin production through the pineal gland, and normalizing stress hormone patterns that disrupt sleep continuity.",
    topPeptides: [
      { peptideSlug: "dsip", peptideName: "DSIP", matchScore: 94, rationale: "Specifically designed to promote slow-wave sleep. Modulates sleep architecture at the neurological level and regulates stress hormones that disrupt sleep.", dosage: "100–200 mcg before bed", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
      { peptideSlug: "epithalon", peptideName: "Epithalon", matchScore: 86, rationale: "Normalizes melatonin production through pineal gland regulation. Particularly effective for age-related sleep deterioration.", dosage: "5–10 mg/day for 10–20 days", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
      { peptideSlug: "ipamorelin", peptideName: "Ipamorelin / CJC-1295", matchScore: 80, rationale: "GH secretagogues enhance slow-wave sleep as a direct consequence of GH release. Most users report improved sleep quality as one of the first benefits.", dosage: "200–300 mcg before bed", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
    ],
    comparisonDimensions: ["Sleep architecture effect", "Slow-wave sleep enhancement", "Anxiety reduction", "Melatonin regulation", "Evidence level"],
    whoShouldConsider: "Individuals with chronic sleep issues, those experiencing age-related sleep deterioration, athletes seeking to optimize recovery through sleep, and anyone whose poor sleep is driven by stress or hormonal disruption.",
    whoShouldAvoid: "Individuals with sleep apnea should address the underlying condition first. Pregnant or breastfeeding women.",
    relatedStacks: ["gh-optimization-stack"],
    relatedGoals: ["anti-aging", "recovery", "energy"],
    faqItems: [
      { q: "What peptide is best for deep sleep?", a: "DSIP (Delta Sleep-Inducing Peptide) is specifically designed to promote slow-wave sleep. Ipamorelin/CJC-1295 also significantly improves sleep quality as a secondary benefit of GH stimulation." },
    ],
  },
  {
    slug: "cognitive-performance",
    title: "Best Peptides for Cognitive Performance",
    h1: "Best Peptides for Cognitive Performance in 2025",
    metaDescription: "Independent analysis of the best nootropic peptides for focus, memory, and cognitive enhancement. Science-backed, vendor-neutral.",
    subtitle: "Evidence-based rankings for focus, memory, BDNF production, and neuroprotection.",
    scienceSection: "Cognitive performance is underpinned by neurotransmitter balance, neuroplasticity (the brain's ability to form new connections), cerebral blood flow, and the health of the blood-brain barrier. Nootropic peptides enhance cognition through several mechanisms: upregulating BDNF and NGF (neurotrophic factors that support neuronal survival and plasticity), modulating dopaminergic and serotonergic systems, reducing neuroinflammation, and improving cerebral blood flow. The Russian nootropic peptides — Semax and Selank — have the most extensive research base in this category, with decades of clinical use in Russia for cognitive and neurological conditions.",
    topPeptides: [
      { peptideSlug: "semax", peptideName: "Semax", matchScore: 95, rationale: "The most potent cognitive-enhancing peptide available. Dramatically increases BDNF and NGF production, with rapid onset of action via nasal administration.", dosage: "200–900 mcg/day (nasal)", administration: "Intranasal spray", evidenceLevel: "Moderate Preclinical / Emerging Human" },
      { peptideSlug: "selank", peptideName: "Selank", matchScore: 88, rationale: "Provides anxiolytic effects that remove the cognitive impairment associated with anxiety and stress, while also enhancing BDNF production.", dosage: "250–3,000 mcg/day (nasal)", administration: "Intranasal spray", evidenceLevel: "Moderate Preclinical / Emerging Human" },
    ],
    comparisonDimensions: ["BDNF upregulation", "Focus enhancement", "Memory improvement", "Anxiolytic effect", "Neuroprotection"],
    whoShouldConsider: "Knowledge workers seeking cognitive enhancement, individuals experiencing age-related cognitive decline, those with brain fog or difficulty concentrating, and anyone recovering from neurological injury or stress.",
    whoShouldAvoid: "Individuals with severe anxiety disorders (Semax's stimulating effects may exacerbate anxiety at higher doses). Those with active psychiatric conditions should consult a physician.",
    relatedStacks: ["cognitive-stack"],
    relatedGoals: ["anxiety-reduction", "mood", "energy"],
    faqItems: [
      { q: "What is the best peptide for brain fog?", a: "Semax is the most effective peptide for brain fog due to its rapid BDNF upregulation and cognitive-enhancing effects. Selank is preferred when anxiety is a contributing factor to the fog." },
    ],
  },
  {
    slug: "anxiety-reduction",
    title: "Best Peptides for Anxiety",
    h1: "Best Peptides for Anxiety in 2025",
    metaDescription: "Independent analysis of the best peptides for anxiety reduction and stress management. Science-backed, vendor-neutral.",
    subtitle: "Evidence-based rankings for anxiety relief, stress reduction, and emotional balance.",
    scienceSection: "Anxiety disorders involve dysregulation of the GABAergic system, the HPA (hypothalamic-pituitary-adrenal) axis, and serotonergic neurotransmission. Conventional anxiolytics (benzodiazepines, SSRIs) address these systems but carry significant side effect burdens including sedation, dependence, and sexual dysfunction. Peptide-based anxiolytics offer a potentially cleaner mechanism: Selank modulates GABA-A receptors through a non-benzodiazepine binding site, producing anxiolysis without sedation or dependence. This makes it particularly attractive for individuals who need anxiety relief without cognitive impairment.",
    topPeptides: [
      { peptideSlug: "selank", peptideName: "Selank", matchScore: 97, rationale: "The gold standard peptide for anxiety reduction. Produces benzodiazepine-like anxiolysis without sedation, tolerance, or dependence. Extensive Russian clinical data.", dosage: "250–3,000 mcg/day (nasal)", administration: "Intranasal spray", evidenceLevel: "Moderate Preclinical / Emerging Human" },
    ],
    comparisonDimensions: ["Anxiolytic effect", "Sedation risk", "Dependence risk", "Cognitive impact", "Evidence level"],
    whoShouldConsider: "Individuals with generalized anxiety disorder, social anxiety, or performance anxiety. Those seeking anxiety relief without the side effects of conventional medications.",
    whoShouldAvoid: "Those currently on benzodiazepines (consult physician before combining). Individuals with severe psychiatric conditions should use under medical supervision.",
    relatedStacks: ["cognitive-stack"],
    relatedGoals: ["cognitive-performance", "mood", "sleep-optimization"],
    faqItems: [
      { q: "Is Selank better than benzodiazepines for anxiety?", a: "Selank produces comparable anxiolytic effects to low-dose benzodiazepines without sedation, tolerance, or dependence. For many users, this makes it a superior option for daily anxiety management." },
    ],
  },
  {
    slug: "skin-health",
    title: "Best Peptides for Skin Health",
    h1: "Best Peptides for Skin Health in 2025",
    metaDescription: "Independent analysis of the best peptides for skin health, collagen synthesis, and anti-aging skincare. Science-backed, vendor-neutral.",
    subtitle: "Evidence-based rankings for collagen synthesis, skin firmness, and visible anti-aging.",
    scienceSection: "Skin aging is driven by declining collagen and elastin production, increased oxidative stress, reduced cell turnover, and impaired wound healing. The dermis loses approximately 1% of its collagen content per year after age 20, accelerating after menopause in women. Peptides that address skin aging work by stimulating fibroblast activity to produce new collagen and elastin, activating antioxidant enzyme systems, promoting cell migration and wound healing, and modulating the gene expression programs that govern skin remodeling.",
    topPeptides: [
      { peptideSlug: "ghk-cu", peptideName: "GHK-Cu", matchScore: 96, rationale: "The gold standard peptide for skin health. Stimulates collagen and elastin synthesis, activates antioxidant enzymes, and modulates over 4,000 genes involved in skin remodeling.", dosage: "1–5% (topical) or 1–2 mg/day (injectable)", administration: "Topical serum or subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
      { peptideSlug: "epithalon", peptideName: "Epithalon", matchScore: 78, rationale: "Addresses skin aging at the cellular level through telomere maintenance and antioxidant activity. Systemic effects complement topical GHK-Cu.", dosage: "5–10 mg/day for 10–20 days (cycled)", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
    ],
    comparisonDimensions: ["Collagen synthesis", "Antioxidant activity", "Wound healing", "Hair follicle support", "Evidence level"],
    whoShouldConsider: "Individuals concerned about visible skin aging, those with sun damage or scarring, and anyone seeking to improve skin firmness, texture, and hydration.",
    whoShouldAvoid: "Individuals with active skin infections at application sites. Those with copper sensitivity (rare).",
    relatedStacks: ["anti-aging-stack"],
    relatedGoals: ["anti-aging", "hair-growth", "longevity"],
    faqItems: [
      { q: "Does GHK-Cu really work for skin?", a: "Yes. GHK-Cu has one of the strongest evidence bases of any cosmetic peptide, with multiple clinical studies demonstrating improvements in skin firmness, fine lines, and wound healing." },
    ],
  },
  {
    slug: "hair-growth",
    title: "Best Peptides for Hair Growth",
    h1: "Best Peptides for Hair Growth in 2025",
    metaDescription: "Independent analysis of the best peptides for hair growth and hair loss prevention. Science-backed, vendor-neutral.",
    subtitle: "Evidence-based rankings for hair follicle stimulation, hair density, and hair loss prevention.",
    scienceSection: "Hair loss (alopecia) involves the progressive miniaturization of hair follicles, driven by DHT sensitivity (androgenetic alopecia), inflammation, oxidative stress, and reduced growth factor signaling. Peptides that support hair growth work by promoting the transition of follicles from the resting (telogen) to the active growth (anagen) phase, stimulating growth factors that support follicle health, reducing scalp inflammation, and improving blood supply to follicles.",
    topPeptides: [
      { peptideSlug: "ghk-cu", peptideName: "GHK-Cu", matchScore: 92, rationale: "The most evidence-supported peptide for hair growth. Promotes follicle cycling from telogen to anagen, stimulates growth factors, and reduces scalp inflammation.", dosage: "1–5% topical solution applied to scalp", administration: "Topical", evidenceLevel: "Moderate Preclinical / Emerging Human" },
    ],
    comparisonDimensions: ["Follicle cycling promotion", "Growth factor stimulation", "Anti-inflammatory effect", "DHT modulation", "Evidence level"],
    whoShouldConsider: "Individuals experiencing hair thinning or early-stage hair loss, those with diffuse hair loss not driven primarily by DHT, and anyone seeking to improve hair density and thickness.",
    whoShouldAvoid: "Those with severe androgenetic alopecia may need additional DHT-blocking interventions alongside peptide therapy.",
    relatedStacks: ["anti-aging-stack"],
    relatedGoals: ["skin-health", "anti-aging"],
    faqItems: [
      { q: "Can peptides regrow hair?", a: "GHK-Cu has demonstrated hair density improvements in clinical studies. It is most effective for diffuse hair thinning and less effective for advanced androgenetic alopecia where follicles have been permanently miniaturized." },
    ],
  },
  {
    slug: "longevity",
    title: "Best Peptides for Longevity",
    h1: "Best Peptides for Longevity in 2025",
    metaDescription: "Independent analysis of the best peptides for longevity, healthspan, and cellular anti-aging. Science-backed, vendor-neutral.",
    subtitle: "Evidence-based rankings for healthspan extension, cellular health, and longevity optimization.",
    scienceSection: "Longevity science has identified several key hallmarks of aging that are amenable to peptide intervention: telomere attrition, mitochondrial dysfunction, cellular senescence, loss of proteostasis, and deregulated nutrient sensing. The most promising longevity peptides address multiple hallmarks simultaneously. Epithalon targets telomere maintenance. SS-31 addresses mitochondrial dysfunction. MOTS-c activates AMPK, the master metabolic regulator. Together, these peptides represent a multi-target approach to slowing the biological aging process.",
    topPeptides: [
      { peptideSlug: "epithalon", peptideName: "Epithalon", matchScore: 94, rationale: "The most targeted longevity peptide, directly addressing telomere shortening. 30+ years of Russian research with animal lifespan extension data.", dosage: "5–10 mg/day for 10–20 days (cycled)", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
      { peptideSlug: "sermorelin", peptideName: "Sermorelin", matchScore: 85, rationale: "Restores the GH/IGF-1 axis, which is a key driver of age-related decline in muscle mass, body composition, and energy.", dosage: "200–300 mcg before bed", administration: "Subcutaneous injection (prescription)", evidenceLevel: "Strong Human Clinical" },
    ],
    comparisonDimensions: ["Telomere support", "Mitochondrial function", "GH axis restoration", "Inflammation reduction", "Evidence level"],
    whoShouldConsider: "Adults aged 40+ with a strong interest in longevity optimization, those with a family history of age-related disease, and individuals seeking to maintain healthspan alongside lifespan.",
    whoShouldAvoid: "Individuals with active cancer. Those under 35 whose natural aging mechanisms are not yet significantly compromised.",
    relatedStacks: ["anti-aging-stack"],
    relatedGoals: ["anti-aging", "energy", "sleep-optimization"],
    faqItems: [
      { q: "What is the best peptide for longevity?", a: "Epithalon is the most targeted longevity peptide due to its telomerase-activating mechanism. A comprehensive longevity protocol would combine Epithalon with Sermorelin and SS-31 to address multiple aging hallmarks." },
    ],
  },
  {
    slug: "body-recomposition",
    title: "Best Peptides for Body Recomposition",
    h1: "Best Peptides for Body Recomposition in 2025",
    metaDescription: "Independent analysis of the best peptides for body recomposition — simultaneously building muscle and losing fat. Science-backed, vendor-neutral.",
    subtitle: "Evidence-based rankings for simultaneous muscle gain and fat loss.",
    scienceSection: "Body recomposition — the simultaneous gain of lean muscle mass and loss of body fat — is physiologically challenging because the anabolic processes that build muscle and the catabolic processes that burn fat are typically in opposition. Peptides are uniquely positioned to support recomposition because GH secretagogues simultaneously stimulate muscle protein synthesis (via IGF-1) and lipolysis (via GH's direct fat-mobilizing effects). This dual action makes GH secretagogues the most effective peptide class for true body recomposition.",
    topPeptides: [
      { peptideSlug: "ipamorelin", peptideName: "Ipamorelin / CJC-1295", matchScore: 93, rationale: "The premier peptide combination for body recomposition. GH stimulates both muscle protein synthesis and lipolysis simultaneously, making it uniquely suited for simultaneous muscle gain and fat loss.", dosage: "200–300 mcg before bed", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
      { peptideSlug: "semaglutide", peptideName: "Semaglutide / Tirzepatide", matchScore: 80, rationale: "For individuals with significant fat to lose, GLP-1 agonists provide the most powerful fat loss mechanism. Combining with resistance training and adequate protein preserves muscle during fat loss.", dosage: "0.25–2.4 mg/week", administration: "Subcutaneous injection (prescription)", evidenceLevel: "Strong Human Clinical" },
    ],
    comparisonDimensions: ["Muscle preservation", "Fat loss mechanism", "Anabolic effect", "Prescription required", "Evidence level"],
    whoShouldConsider: "Athletes and fitness enthusiasts seeking to optimize body composition, individuals who want to simultaneously build muscle and lose fat, and those who have plateaued on traditional diet and exercise approaches.",
    whoShouldAvoid: "Individuals with active cancer, uncontrolled diabetes, or pregnancy.",
    relatedStacks: ["gh-optimization-stack", "muscle-growth-stack"],
    relatedGoals: ["muscle-growth", "fat-loss", "anti-aging"],
    faqItems: [
      { q: "Can peptides help with body recomposition?", a: "Yes. GH secretagogues like Ipamorelin/CJC-1295 are particularly effective for body recomposition because GH simultaneously stimulates muscle protein synthesis and fat mobilization." },
    ],
  },
  {
    slug: "injury-recovery",
    title: "Best Peptides for Injury Recovery",
    h1: "Best Peptides for Injury Recovery in 2025",
    metaDescription: "Independent analysis of the best peptides for injury recovery, wound healing, and tissue repair. Science-backed, vendor-neutral.",
    subtitle: "Evidence-based rankings for accelerated injury healing, tissue repair, and rehabilitation.",
    scienceSection: "Injury recovery involves a cascade of biological processes: inflammation (necessary for clearing damaged tissue), proliferation (new tissue formation), and remodeling (maturation and strengthening of new tissue). Peptides that accelerate recovery work by optimizing each phase of this cascade — resolving inflammation more quickly, stimulating the proliferation of repair cells (fibroblasts, myoblasts, endothelial cells), and promoting the synthesis of structural proteins (collagen, elastin) that restore tissue integrity.",
    topPeptides: [
      { peptideSlug: "bpc-157", peptideName: "BPC-157", matchScore: 96, rationale: "The most researched peptide for injury recovery. Accelerates healing of tendons, ligaments, muscles, and gut tissue through multiple converging mechanisms.", dosage: "200–500 mcg/day", administration: "Subcutaneous injection near injury site", evidenceLevel: "Strong Preclinical / Limited Human" },
      { peptideSlug: "tb-500", peptideName: "TB-500", matchScore: 90, rationale: "Provides systemic tissue repair and anti-inflammatory effects. Particularly effective for widespread injuries or when multiple tissue types are involved.", dosage: "2–2.5 mg twice weekly", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
      { peptideSlug: "ghk-cu", peptideName: "GHK-Cu", matchScore: 75, rationale: "Stimulates collagen synthesis and wound healing. A strong adjunct for soft tissue injuries and post-surgical recovery.", dosage: "1–2 mg/day", administration: "Subcutaneous injection or topical", evidenceLevel: "Moderate Preclinical / Emerging Human" },
    ],
    comparisonDimensions: ["Tendon healing", "Muscle repair", "Anti-inflammatory effect", "Collagen synthesis", "Evidence level"],
    whoShouldConsider: "Athletes recovering from acute injuries, individuals with chronic overuse injuries, post-surgical patients, and anyone whose quality of life is limited by unresolved tissue damage.",
    whoShouldAvoid: "Individuals with active infections at injection sites. Pregnant or breastfeeding women.",
    relatedStacks: ["recovery-stack", "wolverine-stack"],
    relatedGoals: ["joint-recovery", "gut-health", "inflammation"],
    faqItems: [
      { q: "What is the fastest-acting peptide for injury recovery?", a: "BPC-157 is generally considered the fastest-acting peptide for acute injuries, with many users reporting noticeable improvement within 1–2 weeks. TB-500 provides more sustained systemic effects." },
    ],
  },
  {
    slug: "energy",
    title: "Best Peptides for Energy",
    h1: "Best Peptides for Energy in 2025",
    metaDescription: "Independent analysis of the best peptides for energy, vitality, and fatigue reduction. Science-backed, vendor-neutral.",
    subtitle: "Evidence-based rankings for sustained energy, reduced fatigue, and improved vitality.",
    scienceSection: "Chronic fatigue and low energy are driven by multiple biological factors: mitochondrial dysfunction (reduced cellular energy production), HPA axis dysregulation (cortisol imbalance), declining growth hormone (which affects cellular metabolism and sleep quality), and neuroinflammation. Peptides that address energy work through complementary mechanisms: SS-31 directly targets mitochondrial function, GH secretagogues restore the metabolic and sleep-quality benefits of optimal GH levels, and MOTS-c activates AMPK to improve metabolic efficiency.",
    topPeptides: [
      { peptideSlug: "sermorelin", peptideName: "Sermorelin", matchScore: 88, rationale: "Restores GH-driven metabolic activity and sleep quality, addressing two of the most common drivers of chronic fatigue.", dosage: "200–300 mcg before bed", administration: "Subcutaneous injection (prescription)", evidenceLevel: "Strong Human Clinical" },
      { peptideSlug: "ipamorelin", peptideName: "Ipamorelin / CJC-1295", matchScore: 82, rationale: "GH stimulation improves sleep quality and cellular metabolism, producing sustained energy improvements over weeks of use.", dosage: "200–300 mcg before bed", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
    ],
    comparisonDimensions: ["Mitochondrial support", "GH axis restoration", "Sleep quality improvement", "Metabolic enhancement", "Evidence level"],
    whoShouldConsider: "Individuals with chronic fatigue, those experiencing age-related energy decline, athletes with high training loads, and anyone whose energy levels are limiting their quality of life.",
    whoShouldAvoid: "Individuals with active cancer, uncontrolled thyroid disease, or pregnancy.",
    relatedStacks: ["gh-optimization-stack"],
    relatedGoals: ["sleep-optimization", "anti-aging", "muscle-growth"],
    faqItems: [
      { q: "What peptide gives you the most energy?", a: "Sermorelin and Ipamorelin/CJC-1295 produce the most consistent energy improvements through GH restoration and sleep quality enhancement. SS-31 is the most targeted option for mitochondrial energy production." },
    ],
  },
  {
    slug: "libido",
    title: "Best Peptides for Libido",
    h1: "Best Peptides for Libido in 2025",
    metaDescription: "Independent analysis of the best peptides for libido enhancement and sexual health. Science-backed, vendor-neutral.",
    subtitle: "Evidence-based rankings for libido enhancement, sexual desire, and sexual health.",
    scienceSection: "Sexual desire is regulated by a complex interplay of hormones (testosterone, estrogen, DHEA), neurotransmitters (dopamine, serotonin), and central nervous system signaling. Low libido can have multiple causes: hormonal deficiency, psychological factors (anxiety, depression), vascular issues, or neurological dysfunction. Peptides address libido through different mechanisms depending on the underlying cause: PT-141 works centrally on melanocortin receptors to enhance desire at the neurological level, while GH secretagogues address hormonal contributors to low libido through the GH/IGF-1 axis.",
    topPeptides: [
      { peptideSlug: "pt-141", peptideName: "PT-141", matchScore: 97, rationale: "The only FDA-approved peptide for sexual dysfunction. Works centrally on melanocortin receptors to enhance sexual desire in both men and women, regardless of vascular status.", dosage: "1.75 mg, 45 minutes before sexual activity", administration: "Subcutaneous injection (prescription)", evidenceLevel: "Strong Human Clinical" },
      { peptideSlug: "sermorelin", peptideName: "Sermorelin", matchScore: 72, rationale: "Addresses hormonal contributors to low libido through GH/IGF-1 axis restoration. Often recommended alongside PT-141 for comprehensive sexual health optimization.", dosage: "200–300 mcg before bed", administration: "Subcutaneous injection (prescription)", evidenceLevel: "Strong Human Clinical" },
    ],
    comparisonDimensions: ["Central vs. peripheral mechanism", "Effect on desire", "Effect on function", "Prescription required", "Evidence level"],
    whoShouldConsider: "Individuals with low libido not adequately addressed by hormonal therapy, those with psychological or neurological contributors to sexual dysfunction, and anyone seeking to enhance sexual desire and satisfaction.",
    whoShouldAvoid: "Individuals with cardiovascular disease (PT-141 causes transient blood pressure elevation). Those currently taking PDE5 inhibitors should consult a physician before combining.",
    relatedStacks: [],
    relatedGoals: ["energy", "anti-aging", "mood"],
    faqItems: [
      { q: "Does PT-141 work for both men and women?", a: "Yes. PT-141 is FDA-approved for women with HSDD and is widely used off-label in men for libido enhancement and erectile dysfunction." },
    ],
  },
  {
    slug: "inflammation",
    title: "Best Peptides for Inflammation",
    h1: "Best Peptides for Inflammation in 2025",
    metaDescription: "Independent analysis of the best peptides for reducing inflammation and inflammatory conditions. Science-backed, vendor-neutral.",
    subtitle: "Evidence-based rankings for systemic and localized inflammation reduction.",
    scienceSection: "Chronic inflammation is now recognized as a central driver of most age-related diseases, from cardiovascular disease to neurodegeneration. Unlike acute inflammation (which is necessary for healing), chronic low-grade inflammation ('inflammaging') perpetuates tissue damage and accelerates biological aging. Peptides that address inflammation work through multiple mechanisms: downregulating pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), activating anti-inflammatory pathways, and promoting the resolution phase of inflammation through specialized pro-resolving mediators.",
    topPeptides: [
      { peptideSlug: "bpc-157", peptideName: "BPC-157", matchScore: 92, rationale: "Demonstrates potent anti-inflammatory effects through nitric oxide modulation and cytokine downregulation. Effective for both localized and systemic inflammatory conditions.", dosage: "200–500 mcg/day", administration: "Subcutaneous injection", evidenceLevel: "Strong Preclinical / Limited Human" },
      { peptideSlug: "tb-500", peptideName: "TB-500", matchScore: 88, rationale: "Systemic anti-inflammatory effects through TNF-α and IL-1β downregulation. Particularly effective for widespread musculoskeletal inflammation.", dosage: "2–2.5 mg twice weekly", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
    ],
    comparisonDimensions: ["Cytokine modulation", "Systemic vs. local effect", "Tissue repair", "Evidence level", "Administration"],
    whoShouldConsider: "Individuals with chronic inflammatory conditions, athletes with high training loads, those with autoimmune conditions (under medical supervision), and anyone seeking to reduce systemic inflammation.",
    whoShouldAvoid: "Individuals with active infections (anti-inflammatory effects may impair immune response). Those with autoimmune conditions should use under medical supervision.",
    relatedStacks: ["recovery-stack"],
    relatedGoals: ["joint-recovery", "injury-recovery", "gut-health"],
    faqItems: [
      { q: "What peptide reduces inflammation the most?", a: "BPC-157 and TB-500 are the most studied peptides for inflammation reduction. BPC-157 is preferred for localized inflammation; TB-500 for systemic inflammatory conditions." },
    ],
  },
  {
    slug: "metabolic-health",
    title: "Best Peptides for Metabolic Health",
    h1: "Best Peptides for Metabolic Health in 2025",
    metaDescription: "Independent analysis of the best peptides for metabolic health, insulin sensitivity, and metabolic syndrome. Science-backed, vendor-neutral.",
    subtitle: "Evidence-based rankings for insulin sensitivity, metabolic optimization, and metabolic syndrome.",
    scienceSection: "Metabolic health encompasses insulin sensitivity, blood glucose regulation, lipid metabolism, and the absence of metabolic syndrome. Declining metabolic health is driven by insulin resistance, mitochondrial dysfunction, chronic inflammation, and hormonal changes. Peptides that improve metabolic health work through complementary mechanisms: GLP-1 agonists directly improve insulin secretion and sensitivity, MOTS-c activates AMPK to improve metabolic flexibility, and GH secretagogues address the hormonal contributors to metabolic decline.",
    topPeptides: [
      { peptideSlug: "semaglutide", peptideName: "Semaglutide / Tirzepatide", matchScore: 96, rationale: "The most clinically validated peptides for metabolic health. Improve insulin sensitivity, reduce HbA1c, and produce significant improvements in all metabolic syndrome markers.", dosage: "0.25–2.4 mg/week", administration: "Subcutaneous injection (prescription)", evidenceLevel: "Strong Human Clinical" },
    ],
    comparisonDimensions: ["Insulin sensitivity", "Blood glucose control", "Lipid improvement", "Weight reduction", "Evidence level"],
    whoShouldConsider: "Individuals with Type 2 diabetes, prediabetes, metabolic syndrome, or insulin resistance. Those with significant visceral fat accumulation.",
    whoShouldAvoid: "Individuals with a history of medullary thyroid carcinoma, active pancreatitis, or pregnancy.",
    relatedStacks: ["metabolic-stack"],
    relatedGoals: ["fat-loss", "body-recomposition", "energy"],
    faqItems: [
      { q: "What peptide is best for insulin resistance?", a: "Semaglutide and Tirzepatide have the strongest clinical evidence for improving insulin sensitivity and metabolic health. MOTS-c is a promising emerging option for metabolic optimization." },
    ],
  },
  {
    slug: "muscle-recovery",
    title: "Best Peptides for Muscle Recovery",
    h1: "Best Peptides for Muscle Recovery in 2025",
    metaDescription: "Independent analysis of the best peptides for muscle recovery, soreness reduction, and post-workout healing. Science-backed, vendor-neutral.",
    subtitle: "Evidence-based rankings for faster muscle recovery, soreness reduction, and training adaptation.",
    scienceSection: "Muscle recovery involves the repair of exercise-induced micro-tears in muscle fibers, resolution of exercise-induced inflammation, replenishment of glycogen stores, and adaptation of muscle tissue to the training stimulus. Peptides that accelerate muscle recovery work by promoting satellite cell activation (the muscle stem cells responsible for repair), reducing pro-inflammatory cytokines, and improving blood flow to recovering tissue.",
    topPeptides: [
      { peptideSlug: "bpc-157", peptideName: "BPC-157", matchScore: 88, rationale: "Accelerates muscle fiber repair through multiple mechanisms including GH receptor upregulation and angiogenesis promotion.", dosage: "200–500 mcg/day", administration: "Subcutaneous injection", evidenceLevel: "Strong Preclinical / Limited Human" },
      { peptideSlug: "tb-500", peptideName: "TB-500", matchScore: 90, rationale: "Promotes cell migration and differentiation in muscle tissue, accelerating repair of muscle tears and reducing recovery time.", dosage: "2–2.5 mg twice weekly", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
      { peptideSlug: "ipamorelin", peptideName: "Ipamorelin / CJC-1295", matchScore: 82, rationale: "GH-driven improvements in sleep quality and IGF-1 production accelerate muscle protein synthesis and recovery between training sessions.", dosage: "200–300 mcg before bed", administration: "Subcutaneous injection", evidenceLevel: "Moderate Preclinical / Emerging Human" },
    ],
    comparisonDimensions: ["Muscle fiber repair", "Anti-inflammatory effect", "Recovery time reduction", "Sleep quality improvement", "Evidence level"],
    whoShouldConsider: "Athletes with high training volumes, individuals experiencing chronic delayed-onset muscle soreness, and anyone whose recovery is limiting their training progress.",
    whoShouldAvoid: "Individuals with active infections at injection sites. Pregnant or breastfeeding women.",
    relatedStacks: ["recovery-stack", "gh-optimization-stack"],
    relatedGoals: ["injury-recovery", "muscle-growth", "joint-recovery"],
    faqItems: [
      { q: "What peptide speeds up muscle recovery the most?", a: "TB-500 is generally considered the most effective peptide for systemic muscle recovery, while BPC-157 excels at localized muscle and tendon repair. Combining both provides comprehensive recovery support." },
    ],
  },
];

// ─── COMPARISON PAGES ────────────────────────────────────────────────────────

export interface ComparisonPageData {
  slug: string;
  peptideA: string;
  peptideASlug: string;
  peptideB: string;
  peptideBSlug: string;
  h1: string;
  metaDescription: string;
  verdictSummary: string;
  category: string;
  atAGlance: Array<{
    dimension: string;
    peptideA: string;
    peptideB: string;
  }>;
  deepDiveA: string;
  deepDiveB: string;
  chooseAIf: string[];
  chooseBIf: string[];
  considerBothIf: string | undefined;
  relatedComparisons: string[];
  faqItems: Array<{ q: string; a: string }>;
}

export const comparisonPages: ComparisonPageData[] = [
  {
    slug: "bpc-157-vs-tb-500",
    peptideA: "BPC-157", peptideASlug: "bpc-157",
    peptideB: "TB-500", peptideBSlug: "tb-500",
    h1: "BPC-157 vs TB-500: Which Is Right for You?",
    metaDescription: "BPC-157 vs TB-500: independent head-to-head comparison of mechanism, evidence, dosage, and use cases. Science-backed, vendor-neutral.",
    verdictSummary: "BPC-157 excels at localized tendon, ligament, and gut healing. TB-500 is better for systemic muscle recovery and widespread inflammation.",
    category: "Recovery & Healing",
    atAGlance: [
      { dimension: "Primary Function", peptideA: "Localized tissue repair, gut healing", peptideB: "Systemic muscle repair, anti-inflammatory" },
      { dimension: "Half-Life", peptideA: "~4 hours", peptideB: "~3–4 days" },
      { dimension: "Administration", peptideA: "Subcutaneous, oral", peptideB: "Subcutaneous, intramuscular" },
      { dimension: "Evidence Level", peptideA: "Strong Preclinical / Limited Human", peptideB: "Moderate Preclinical / Emerging Human" },
      { dimension: "Best For", peptideA: "Tendon injuries, gut issues", peptideB: "Muscle injuries, widespread inflammation" },
      { dimension: "Cost (approx.)", peptideA: "$30–$80/vial", peptideB: "$40–$90/vial" },
      { dimension: "Can Be Stacked Together?", peptideA: "Yes", peptideB: "Yes" },
    ],
    deepDiveA: "BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from a protein found in gastric juice. Its healing effects are mediated through upregulation of growth hormone receptors in tendon fibroblasts, modulation of nitric oxide signaling, and promotion of angiogenesis. These mechanisms make it particularly effective for localized injuries — tendons, ligaments, cartilage — and for gut healing, where its gastric origin gives it unique mucosal protective properties. BPC-157 can be administered orally for gut applications, though injectable routes provide higher systemic bioavailability.",
    deepDiveB: "TB-500 (Thymosin Beta-4) is a naturally occurring peptide found in high concentrations in blood platelets and wound fluid. Its primary mechanism involves regulation of actin — the structural protein governing cell migration and division. By promoting cell migration to injury sites and downregulating pro-inflammatory cytokines (TNF-α, IL-1β), TB-500 provides systemic anti-inflammatory and tissue repair effects that extend throughout the body. This systemic reach makes it particularly effective for widespread injuries and high-volume athletic training.",
    chooseAIf: ["You have a specific tendon or ligament injury", "You have gut issues (IBS, leaky gut, NSAID damage)", "You want oral administration for gut-specific applications", "Your injury is localized to one area"],
    chooseBIf: ["You have widespread muscle inflammation or multiple injury sites", "You are a high-volume athlete with systemic recovery needs", "You want longer-lasting effects from less frequent dosing", "Your primary concern is systemic anti-inflammatory effects"],
    considerBothIf: "You have a complex injury profile involving both localized tissue damage and systemic inflammation — the Recovery Stack (BPC-157 + TB-500) is one of the most popular and evidence-supported peptide combinations.",
    relatedComparisons: ["bpc-157-vs-ghk-cu", "tb-500-vs-ghk-cu"],
    faqItems: [
      { q: "Can BPC-157 and TB-500 be taken at the same time?", a: "Yes — this is one of the most popular research peptide stacks. They work through complementary mechanisms and are generally considered safe to combine. Many users report superior results with the combination versus either alone." },
      { q: "Which heals tendons faster, BPC-157 or TB-500?", a: "BPC-157 is generally considered more targeted for tendon healing due to its GH receptor upregulation in tendon fibroblasts. TB-500 provides broader systemic support. Most practitioners recommend combining both for tendon injuries." },
    ],
  },
  {
    slug: "semaglutide-vs-tirzepatide",
    peptideA: "Semaglutide", peptideASlug: "semaglutide",
    peptideB: "Tirzepatide", peptideBSlug: "tirzepatide",
    h1: "Semaglutide vs Tirzepatide: Which Is Right for You?",
    metaDescription: "Semaglutide vs Tirzepatide: independent head-to-head comparison of weight loss, mechanism, side effects, and cost. Science-backed, vendor-neutral.",
    verdictSummary: "Tirzepatide produces greater average weight loss in clinical trials. Semaglutide has a longer post-market safety record. Both are excellent options.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "GLP-1 receptor agonist", peptideB: "Dual GIP + GLP-1 receptor agonist" },
      { dimension: "Average Weight Loss", peptideA: "10–15% body weight", peptideB: "15–22.5% body weight" },
      { dimension: "Half-Life", peptideA: "~7 days", peptideB: "~5 days" },
      { dimension: "Dosing", peptideA: "Weekly injection", peptideB: "Weekly injection" },
      { dimension: "FDA Approval", peptideA: "Ozempic (T2D), Wegovy (obesity)", peptideB: "Mounjaro (T2D), Zepbound (obesity)" },
      { dimension: "Market Availability", peptideA: "Longer track record", peptideB: "Newer, growing availability" },
      { dimension: "Cost (approx.)", peptideA: "$200–$1,200/month brand", peptideB: "$250–$1,300/month brand" },
    ],
    deepDiveA: "Semaglutide is a GLP-1 receptor agonist that reduces appetite through hypothalamic GLP-1 receptor activation, slows gastric emptying to prolong satiety, and improves insulin secretion. The STEP trial program demonstrated 10–15% average body weight reduction at 2.4 mg weekly. Semaglutide has a longer post-market safety record than Tirzepatide, with cardiovascular outcome data from the SELECT trial showing significant reductions in major adverse cardiovascular events.",
    deepDiveB: "Tirzepatide adds GIP receptor agonism to GLP-1 receptor activation, producing additive effects on appetite suppression and fat mobilization. The SURMOUNT trial program demonstrated 15–22.5% average body weight reduction at 15 mg weekly — significantly exceeding Semaglutide's outcomes. The dual mechanism appears to produce superior results in adipose tissue specifically, potentially explaining the greater weight loss.",
    chooseAIf: ["You want the longer post-market safety record", "You have cardiovascular disease (SELECT trial data supports cardiovascular risk reduction)", "You prefer the more established compound", "Cost is a significant factor (compounded Semaglutide is widely available)"],
    chooseBIf: ["You want maximum weight loss efficacy", "You have not achieved adequate results with Semaglutide", "You are comfortable with a newer compound with strong but shorter clinical track record", "You have Type 2 diabetes with poor glycemic control"],
    considerBothIf: "You are unsure — consult with a telehealth provider who can assess your specific metabolic profile and recommend the appropriate starting point.",
    relatedComparisons: ["ozempic-vs-wegovy", "mounjaro-vs-zepbound"],
    faqItems: [
      { q: "Is Tirzepatide stronger than Semaglutide?", a: "Clinical trials show Tirzepatide produces greater average weight loss (15–22% vs 10–15%). However, individual response varies significantly, and some patients respond better to Semaglutide." },
      { q: "Can I switch from Semaglutide to Tirzepatide?", a: "Yes, switching is possible and commonly done when patients want to maximize weight loss. Consult your prescribing physician for appropriate transition protocols." },
    ],
  },
  {
    slug: "ipamorelin-vs-cjc-1295",
    peptideA: "Ipamorelin", peptideASlug: "ipamorelin",
    peptideB: "CJC-1295", peptideBSlug: "cjc-1295",
    h1: "Ipamorelin vs CJC-1295: Which Is Right for You?",
    metaDescription: "Ipamorelin vs CJC-1295: independent comparison of mechanism, dosage, and why most protocols combine both. Science-backed, vendor-neutral.",
    verdictSummary: "Ipamorelin and CJC-1295 work through complementary mechanisms and are almost always used together rather than as alternatives.",
    category: "GH Secretagogues",
    atAGlance: [
      { dimension: "Peptide Class", peptideA: "GHRP (ghrelin receptor agonist)", peptideB: "GHRH analogue" },
      { dimension: "Mechanism", peptideA: "Triggers GH pulses", peptideB: "Extends GH pulse duration" },
      { dimension: "Half-Life", peptideA: "~2 hours", peptideB: "~6–8 days (with DAC)" },
      { dimension: "Dosing Frequency", peptideA: "2–3x daily", peptideB: "Once weekly (with DAC)" },
      { dimension: "GH Selectivity", peptideA: "High — no cortisol/prolactin elevation", peptideB: "High — natural GHRH mechanism" },
      { dimension: "Best Used", peptideA: "As part of Ipamorelin/CJC-1295 stack", peptideB: "As part of Ipamorelin/CJC-1295 stack" },
    ],
    deepDiveA: "Ipamorelin is a selective GHRP that stimulates GH release by acting as a ghrelin receptor agonist. Its key advantage over older GHRPs is selectivity — it stimulates GH without significantly elevating cortisol, prolactin, or appetite. Each injection produces a sharp, brief GH pulse lasting 2–3 hours. When used alone, these pulses are effective but relatively short-lived.",
    deepDiveB: "CJC-1295 is a GHRH analogue that stimulates GH release through a different receptor than Ipamorelin. The DAC (Drug Affinity Complex) version binds to albumin, extending its half-life to 6–8 days. Rather than producing sharp pulses, CJC-1295 elevates baseline GH levels over days. When combined with Ipamorelin, it creates a synergistic effect: CJC-1295 raises the baseline and Ipamorelin triggers amplified pulses on top of that elevated baseline.",
    chooseAIf: ["You want to use a GHRP alone (though this is less common)", "You prefer multiple daily injections for more precise timing", "You are sensitive to the water retention sometimes seen with CJC-1295"],
    chooseBIf: ["You want sustained baseline GH elevation with less frequent dosing", "You prefer once-weekly injections", "You are using it as part of the standard Ipamorelin/CJC-1295 combination"],
    considerBothIf: "Almost always — the Ipamorelin/CJC-1295 combination is the standard protocol because the two peptides work synergistically. Using both together produces significantly better results than either alone.",
    relatedComparisons: ["ipamorelin-vs-sermorelin", "sermorelin-vs-ipamorelin"],
    faqItems: [
      { q: "Should I take Ipamorelin or CJC-1295 alone?", a: "Most practitioners recommend combining both. Ipamorelin triggers GH pulses while CJC-1295 extends their duration, producing synergistic effects that neither achieves alone." },
      { q: "What is the standard Ipamorelin/CJC-1295 dosing protocol?", a: "A common protocol is 200–300 mcg Ipamorelin + 100 mcg CJC-1295 (without DAC) injected subcutaneously before bed, 5–7 days per week. With DAC CJC-1295, dosing is 1–2 mg weekly." },
    ],
  },
  {
    slug: "ozempic-vs-wegovy",
    peptideA: "Ozempic", peptideASlug: "semaglutide",
    peptideB: "Wegovy", peptideBSlug: "semaglutide",
    h1: "Ozempic vs Wegovy: What's the Difference?",
    metaDescription: "Ozempic vs Wegovy: independent comparison of the two Semaglutide formulations. Same drug, different doses and FDA indications. Vendor-neutral.",
    verdictSummary: "Ozempic and Wegovy both contain Semaglutide. The difference is FDA indication and maximum dose — Wegovy is approved for weight management at higher doses.",
    category: "GLP-1 Brand Comparison",
    atAGlance: [
      { dimension: "Active Ingredient", peptideA: "Semaglutide", peptideB: "Semaglutide" },
      { dimension: "FDA Indication", peptideA: "Type 2 diabetes", peptideB: "Chronic weight management" },
      { dimension: "Maximum Dose", peptideA: "2 mg/week", peptideB: "2.4 mg/week" },
      { dimension: "Manufacturer", peptideA: "Novo Nordisk", peptideB: "Novo Nordisk" },
      { dimension: "Average Weight Loss", peptideA: "~6–9% (diabetes dose)", peptideB: "~10–15% (obesity dose)" },
      { dimension: "Insurance Coverage", peptideA: "Often covered for T2D", peptideB: "Variable coverage for obesity" },
    ],
    deepDiveA: "Ozempic (Semaglutide 0.5–2 mg) is FDA-approved for Type 2 diabetes management. It improves glycemic control, reduces cardiovascular risk, and produces significant weight loss as a secondary benefit. Many physicians prescribe Ozempic off-label for weight management, though the maximum approved dose is lower than Wegovy.",
    deepDiveB: "Wegovy (Semaglutide 2.4 mg) is FDA-approved specifically for chronic weight management in adults with BMI ≥27 with weight-related comorbidities or BMI ≥30. It uses the same Semaglutide molecule as Ozempic but at a higher maximum dose (2.4 mg vs 2 mg), which produces greater average weight loss.",
    chooseAIf: ["You have Type 2 diabetes as the primary indication", "Your insurance covers Ozempic but not Wegovy", "You are using it primarily for glycemic control with weight loss as a secondary benefit"],
    chooseBIf: ["Weight loss is your primary goal", "You do not have Type 2 diabetes", "You want the maximum approved Semaglutide dose"],
    considerBothIf: "The active ingredient is identical — the choice is primarily driven by your diagnosis, insurance coverage, and desired dose. Consult your physician.",
    relatedComparisons: ["semaglutide-vs-tirzepatide", "mounjaro-vs-zepbound"],
    faqItems: [
      { q: "Is Ozempic the same as Wegovy?", a: "Yes — both contain Semaglutide. Ozempic is FDA-approved for Type 2 diabetes at up to 2 mg. Wegovy is FDA-approved for weight management at 2.4 mg. The active ingredient is identical." },
    ],
  },
  {
    slug: "mounjaro-vs-zepbound",
    peptideA: "Mounjaro", peptideASlug: "tirzepatide",
    peptideB: "Zepbound", peptideBSlug: "tirzepatide",
    h1: "Mounjaro vs Zepbound: What's the Difference?",
    metaDescription: "Mounjaro vs Zepbound: independent comparison of the two Tirzepatide formulations. Same drug, different FDA indications. Vendor-neutral.",
    verdictSummary: "Mounjaro and Zepbound both contain Tirzepatide. Mounjaro is approved for Type 2 diabetes; Zepbound for obesity. The active ingredient is identical.",
    category: "GLP-1 Brand Comparison",
    atAGlance: [
      { dimension: "Active Ingredient", peptideA: "Tirzepatide", peptideB: "Tirzepatide" },
      { dimension: "FDA Indication", peptideA: "Type 2 diabetes", peptideB: "Chronic weight management" },
      { dimension: "Maximum Dose", peptideA: "15 mg/week", peptideB: "15 mg/week" },
      { dimension: "Manufacturer", peptideA: "Eli Lilly", peptideB: "Eli Lilly" },
      { dimension: "Average Weight Loss", peptideA: "~15–20%", peptideB: "~15–22.5%" },
    ],
    deepDiveA: "Mounjaro (Tirzepatide) is FDA-approved for Type 2 diabetes management. It produces superior glycemic control compared to GLP-1 monotherapy due to its dual GIP/GLP-1 mechanism, and significant weight loss as a secondary benefit.",
    deepDiveB: "Zepbound (Tirzepatide) is FDA-approved for chronic weight management. It uses the same molecule as Mounjaro at the same doses, with FDA approval specifically for the obesity indication.",
    chooseAIf: ["You have Type 2 diabetes as the primary indication", "Your insurance covers Mounjaro for diabetes"],
    chooseBIf: ["Weight loss is your primary goal without a diabetes diagnosis", "Your insurance covers Zepbound for obesity"],
    considerBothIf: "The active ingredient is identical — the choice is driven entirely by your diagnosis and insurance coverage.",
    relatedComparisons: ["semaglutide-vs-tirzepatide", "ozempic-vs-wegovy"],
    faqItems: [
      { q: "Is Mounjaro the same as Zepbound?", a: "Yes — both contain Tirzepatide at identical doses. The difference is FDA indication: Mounjaro for Type 2 diabetes, Zepbound for obesity." },
    ],
  },
  {
    slug: "selank-vs-semax",
    peptideA: "Selank", peptideASlug: "selank",
    peptideB: "Semax", peptideBSlug: "semax",
    h1: "Selank vs Semax: Which Nootropic Peptide Is Right for You?",
    metaDescription: "Selank vs Semax: independent comparison of the two leading nootropic peptides. Mechanism, use cases, and how to choose. Vendor-neutral.",
    verdictSummary: "Selank is primarily anxiolytic — it reduces anxiety and improves mood. Semax is primarily a cognitive enhancer — it boosts focus, memory, and BDNF. They are frequently combined.",
    category: "Cognitive Enhancement",
    atAGlance: [
      { dimension: "Primary Effect", peptideA: "Anxiolytic, mood stabilizing", peptideB: "Cognitive enhancement, focus" },
      { dimension: "Mechanism", peptideA: "GABA-A modulation, BDNF upregulation", peptideB: "BDNF/NGF upregulation, dopamine modulation" },
      { dimension: "Administration", peptideA: "Intranasal spray", peptideB: "Intranasal spray" },
      { dimension: "Onset", peptideA: "30–60 minutes", peptideB: "30–60 minutes" },
      { dimension: "Sedation Risk", peptideA: "None", peptideB: "None (mildly stimulating)" },
      { dimension: "Best For", peptideA: "Anxiety, social anxiety, stress", peptideB: "Focus, memory, cognitive performance" },
    ],
    deepDiveA: "Selank is a synthetic heptapeptide derived from tuftsin that produces anxiolytic effects through GABA-A receptor modulation without the sedation or dependence associated with benzodiazepines. It also increases BDNF production, supporting neuroplasticity. Users describe it as producing a calm, focused mental state — anxiety reduction without cognitive impairment.",
    deepDiveB: "Semax is an ACTH(4-7) analogue that dramatically increases BDNF and NGF production, supporting neuronal health and plasticity. It modulates dopaminergic and serotonergic systems, producing enhanced focus, working memory, and verbal fluency. Users describe it as 'clean' cognitive stimulation without the anxiety or crash of conventional stimulants.",
    chooseAIf: ["Anxiety is your primary concern", "You experience social anxiety or performance anxiety", "You want cognitive enhancement without any stimulating effects", "You are sensitive to stimulants"],
    chooseBIf: ["Focus and memory are your primary goals", "You want maximum cognitive enhancement", "Anxiety is not a significant concern for you", "You want the stronger BDNF-upregulating effect"],
    considerBothIf: "You want comprehensive cognitive and mood support — the Selank/Semax combination is widely used for its synergistic effects: Selank removes anxiety-driven cognitive impairment while Semax enhances underlying cognitive function.",
    relatedComparisons: [],
    faqItems: [
      { q: "Can Selank and Semax be taken together?", a: "Yes — this is one of the most popular nootropic peptide combinations. Selank's anxiolytic effects complement Semax's cognitive-enhancing effects, and many users report superior results with the combination." },
      { q: "Which is better for studying, Selank or Semax?", a: "Semax is generally preferred for studying due to its stronger cognitive-enhancing and BDNF-upregulating effects. Selank is the better choice if study anxiety is a limiting factor." },
    ],
  },
  {
    slug: "epithalon-vs-ghk-cu",
    peptideA: "Epithalon", peptideASlug: "epithalon",
    peptideB: "GHK-Cu", peptideBSlug: "ghk-cu",
    h1: "Epithalon vs GHK-Cu: Which Anti-Aging Peptide Is Right for You?",
    metaDescription: "Epithalon vs GHK-Cu: independent comparison of the two leading anti-aging peptides. Mechanism, evidence, and use cases. Vendor-neutral.",
    verdictSummary: "Epithalon targets cellular aging through telomere maintenance. GHK-Cu addresses visible aging through collagen synthesis and tissue remodeling. They work through complementary mechanisms.",
    category: "Anti-Aging",
    atAGlance: [
      { dimension: "Primary Mechanism", peptideA: "Telomerase activation", peptideB: "Collagen/elastin synthesis" },
      { dimension: "Primary Target", peptideA: "Cellular aging, longevity", peptideB: "Skin, hair, wound healing" },
      { dimension: "Administration", peptideA: "Subcutaneous injection", peptideB: "Topical or subcutaneous injection" },
      { dimension: "Dosing Frequency", peptideA: "Cycled (10–20 days, 1–2x/year)", peptideB: "Daily (topical) or daily (injectable)" },
      { dimension: "Evidence Level", peptideA: "Moderate Preclinical / Emerging Human", peptideB: "Moderate Preclinical / Emerging Human" },
      { dimension: "Best For", peptideA: "Longevity, sleep, cellular health", peptideB: "Skin quality, hair growth, wound healing" },
    ],
    deepDiveA: "Epithalon is a tetrapeptide derived from the pineal gland that activates telomerase, the enzyme responsible for maintaining telomere length. Telomere shortening is a fundamental mechanism of cellular aging, and Epithalon's ability to slow this process is its primary anti-aging mechanism. It also regulates melatonin production and exhibits antioxidant properties.",
    deepDiveB: "GHK-Cu is a naturally occurring copper-binding tripeptide that stimulates collagen and elastin synthesis, activates antioxidant enzymes, and modulates over 4,000 genes involved in tissue remodeling. Its anti-aging effects are most visible in skin quality, hair growth, and wound healing — making it the more immediately apparent anti-aging peptide.",
    chooseAIf: ["You prioritize cellular longevity over visible anti-aging", "You want to address aging at the fundamental biological level", "You prefer infrequent cyclic dosing", "Sleep quality and energy are your primary concerns"],
    chooseBIf: ["Visible skin aging is your primary concern", "You want improvements in skin firmness, fine lines, or hair growth", "You prefer topical administration", "You want daily, ongoing use rather than cyclic protocols"],
    considerBothIf: "You want comprehensive anti-aging coverage — Epithalon addresses cellular aging while GHK-Cu addresses visible aging. The Anti-Aging Stack combines both for multi-target anti-aging support.",
    relatedComparisons: ["bpc-157-vs-ghk-cu"],
    faqItems: [
      { q: "Should I take Epithalon and GHK-Cu together?", a: "Yes — they work through completely different mechanisms and complement each other well. Epithalon addresses cellular aging; GHK-Cu addresses visible aging. Many anti-aging protocols include both." },
    ],
  },
  {
    slug: "sermorelin-vs-ipamorelin",
    peptideA: "Sermorelin", peptideASlug: "sermorelin",
    peptideB: "Ipamorelin", peptideBSlug: "ipamorelin",
    h1: "Sermorelin vs Ipamorelin: Which GH Secretagogue Is Right for You?",
    metaDescription: "Sermorelin vs Ipamorelin: independent comparison of the two leading GH secretagogues. Mechanism, evidence, prescription requirements. Vendor-neutral.",
    verdictSummary: "Sermorelin has the strongest clinical evidence and requires a prescription. Ipamorelin is available as a research compound and is typically combined with CJC-1295.",
    category: "GH Secretagogues",
    atAGlance: [
      { dimension: "Peptide Class", peptideA: "GHRH analogue", peptideB: "GHRP (ghrelin receptor agonist)" },
      { dimension: "Mechanism", peptideA: "Stimulates natural GHRH receptor", peptideB: "Stimulates ghrelin receptor" },
      { dimension: "Half-Life", peptideA: "~10–20 minutes", peptideB: "~2 hours" },
      { dimension: "Evidence Level", peptideA: "Strong Human Clinical", peptideB: "Moderate Preclinical / Emerging Human" },
      { dimension: "Prescription Required", peptideA: "Yes (FDA-regulated)", peptideB: "No (research compound)" },
      { dimension: "Typical Protocol", peptideA: "3–6 month cycles", peptideB: "8–12 week cycles" },
    ],
    deepDiveA: "Sermorelin is a 29-amino acid GHRH analogue with the most extensive clinical evidence base of any GH secretagogue. It stimulates the pituitary through the natural GHRH receptor, maintaining physiological feedback control. This natural regulation prevents the supraphysiological GH levels associated with exogenous GH therapy. Sermorelin requires a prescription and physician monitoring.",
    deepDiveB: "Ipamorelin stimulates GH release through the ghrelin receptor — a different pathway than GHRH. It is highly selective, producing clean GH pulses without cortisol or prolactin elevation. It is available as a research compound without a prescription and is typically used in combination with CJC-1295 for synergistic GH stimulation.",
    chooseAIf: ["You want the strongest clinical evidence base", "You prefer physician-supervised protocols", "You are comfortable with prescription requirements and telehealth costs", "You want the most natural GH stimulation mechanism"],
    chooseBIf: ["You prefer research compound access without a prescription", "You want to combine with CJC-1295 for synergistic effects", "You are comfortable with the research compound framework", "Cost of telehealth is a barrier"],
    considerBothIf: "Some advanced protocols combine Sermorelin with Ipamorelin for complementary GHRH + GHRP stimulation. Consult a physician before combining.",
    relatedComparisons: ["ipamorelin-vs-cjc-1295"],
    faqItems: [
      { q: "Is Sermorelin or Ipamorelin better for anti-aging?", a: "Sermorelin has stronger clinical evidence for anti-aging applications. Ipamorelin/CJC-1295 is more accessible and produces comparable GH stimulation. The choice often comes down to preference for clinical oversight vs. research compound access." },
    ],
  },
  {
    slug: "bpc-157-vs-ghk-cu",
    peptideA: "BPC-157", peptideASlug: "bpc-157",
    peptideB: "GHK-Cu", peptideBSlug: "ghk-cu",
    h1: "BPC-157 vs GHK-Cu: Which Healing Peptide Is Right for You?",
    metaDescription: "BPC-157 vs GHK-Cu: independent comparison of two leading healing peptides. Mechanism, evidence, and use cases. Vendor-neutral.",
    verdictSummary: "BPC-157 excels at tendon, ligament, and gut healing. GHK-Cu excels at skin, hair, and collagen synthesis. They address different healing targets.",
    category: "Recovery & Regenerative",
    atAGlance: [
      { dimension: "Primary Target", peptideA: "Tendons, ligaments, gut", peptideB: "Skin, hair, collagen" },
      { dimension: "Mechanism", peptideA: "GH receptor upregulation, angiogenesis", peptideB: "Collagen synthesis, antioxidant activation" },
      { dimension: "Administration", peptideA: "Injectable, oral", peptideB: "Topical, injectable" },
      { dimension: "Evidence Level", peptideA: "Strong Preclinical / Limited Human", peptideB: "Moderate Preclinical / Emerging Human" },
      { dimension: "Best For", peptideA: "Injury recovery, gut health", peptideB: "Skin aging, hair growth, wound healing" },
    ],
    deepDiveA: "BPC-157 is a pentadecapeptide with remarkable regenerative properties for musculoskeletal and gut tissue. Its mechanisms include GH receptor upregulation in tendon fibroblasts, nitric oxide modulation, and angiogenesis promotion. It is the most researched peptide for tendon and ligament healing.",
    deepDiveB: "GHK-Cu is a copper-binding tripeptide that stimulates collagen and elastin synthesis, activates antioxidant enzymes, and modulates thousands of genes involved in skin remodeling. It is the gold standard peptide for skin health and hair growth.",
    chooseAIf: ["You have a tendon, ligament, or joint injury", "You have gut health issues", "Your primary goal is injury recovery"],
    chooseBIf: ["Skin aging or hair loss is your primary concern", "You want topical administration", "Your primary goal is collagen synthesis and visible anti-aging"],
    considerBothIf: "You have both injury recovery and skin/hair goals — they work through different mechanisms and can be used simultaneously.",
    relatedComparisons: ["bpc-157-vs-tb-500", "epithalon-vs-ghk-cu"],
    faqItems: [
      { q: "Can BPC-157 and GHK-Cu be taken together?", a: "Yes — they work through different mechanisms and target different tissues. BPC-157 handles musculoskeletal and gut healing; GHK-Cu handles skin and hair. They complement each other well." },
    ],
  },
  {
    slug: "tb-500-vs-ghk-cu",
    peptideA: "TB-500", peptideASlug: "tb-500",
    peptideB: "GHK-Cu", peptideBSlug: "ghk-cu",
    h1: "TB-500 vs GHK-Cu: Which Recovery Peptide Is Right for You?",
    metaDescription: "TB-500 vs GHK-Cu: independent comparison of two healing peptides. Mechanism, evidence, and use cases. Vendor-neutral.",
    verdictSummary: "TB-500 provides systemic muscle and tissue repair. GHK-Cu excels at collagen synthesis, skin health, and wound healing.",
    category: "Recovery & Regenerative",
    atAGlance: [
      { dimension: "Primary Target", peptideA: "Systemic muscle and tissue repair", peptideB: "Skin, hair, collagen synthesis" },
      { dimension: "Mechanism", peptideA: "Actin regulation, cell migration", peptideB: "Collagen synthesis, antioxidant activation" },
      { dimension: "Administration", peptideA: "Injectable", peptideB: "Topical, injectable" },
      { dimension: "Anti-inflammatory Effect", peptideA: "Strong (systemic)", peptideB: "Moderate (local)" },
      { dimension: "Best For", peptideA: "Muscle injuries, widespread inflammation", peptideB: "Skin aging, wound healing, hair growth" },
    ],
    deepDiveA: "TB-500 promotes systemic tissue repair through actin regulation and cell migration, with strong anti-inflammatory effects through cytokine downregulation. It is particularly effective for widespread muscle injuries and high-volume athletic recovery.",
    deepDiveB: "GHK-Cu stimulates collagen and elastin synthesis, activates antioxidant enzymes, and promotes wound healing. Its effects are most pronounced in skin, hair, and soft tissue wound healing.",
    chooseAIf: ["You have systemic muscle injuries or widespread inflammation", "You are a high-volume athlete", "Your primary goal is anti-inflammatory and muscle recovery"],
    chooseBIf: ["Skin health or hair growth is your primary goal", "You want topical administration", "Your primary goal is collagen synthesis"],
    considerBothIf: "You have both muscle recovery and skin/wound healing goals — they work through different mechanisms and can be combined.",
    relatedComparisons: ["bpc-157-vs-tb-500", "bpc-157-vs-ghk-cu"],
    faqItems: [
      { q: "Which is better for wound healing, TB-500 or GHK-Cu?", a: "GHK-Cu has stronger evidence for wound healing through collagen synthesis and fibroblast activation. TB-500 provides systemic support but GHK-Cu is the more targeted wound healing peptide." },
    ],
  },
  {
    slug: "tesamorelin-vs-ipamorelin",
    peptideA: "Tesamorelin", peptideASlug: "sermorelin",
    peptideB: "Ipamorelin", peptideBSlug: "ipamorelin",
    h1: "Tesamorelin vs Ipamorelin: Which GH Peptide Is Right for You?",
    metaDescription: "Tesamorelin vs Ipamorelin: independent comparison for visceral fat reduction and body recomposition. Science-backed, vendor-neutral.",
    verdictSummary: "Tesamorelin is specifically validated for visceral fat reduction and requires a prescription. Ipamorelin provides broader GH benefits including muscle growth and sleep.",
    category: "GH Secretagogues",
    atAGlance: [
      { dimension: "Primary Indication", peptideA: "Visceral fat reduction", peptideB: "Muscle growth, fat loss, sleep" },
      { dimension: "Mechanism", peptideA: "GHRH analogue", peptideB: "GHRP (ghrelin receptor agonist)" },
      { dimension: "Evidence Level", peptideA: "Strong Human Clinical", peptideB: "Moderate Preclinical / Emerging Human" },
      { dimension: "Prescription Required", peptideA: "Yes (FDA-approved for HIV lipodystrophy)", peptideB: "No (research compound)" },
      { dimension: "Best For", peptideA: "Visceral fat, body recomposition", peptideB: "Comprehensive GH optimization" },
    ],
    deepDiveA: "Tesamorelin is a GHRH analogue FDA-approved for HIV-associated lipodystrophy (visceral fat accumulation). Clinical trials demonstrate significant reductions in visceral fat with Tesamorelin, making it the most clinically validated peptide specifically for visceral fat reduction.",
    deepDiveB: "Ipamorelin provides broader GH optimization benefits including muscle growth, fat loss, sleep improvement, and anti-aging effects. It is typically combined with CJC-1295 for synergistic GH stimulation.",
    chooseAIf: ["Visceral fat reduction is your primary goal", "You have HIV-associated lipodystrophy", "You want the strongest clinical evidence for fat reduction"],
    chooseBIf: ["You want comprehensive GH optimization beyond fat loss", "You prefer research compound access", "Sleep quality and muscle growth are also priorities"],
    considerBothIf: "Consult a physician — combining GHRH analogues requires medical supervision.",
    relatedComparisons: ["sermorelin-vs-ipamorelin", "ipamorelin-vs-cjc-1295"],
    faqItems: [
      { q: "Is Tesamorelin better than Ipamorelin for fat loss?", a: "Tesamorelin has stronger clinical evidence specifically for visceral fat reduction. Ipamorelin/CJC-1295 provides broader fat loss benefits alongside muscle growth and sleep improvements." },
    ],
  },
  {
    slug: "semaglutide-vs-retatrutide",
    peptideA: "Semaglutide", peptideASlug: "semaglutide",
    peptideB: "Retatrutide", peptideBSlug: "tirzepatide",
    h1: "Semaglutide vs Retatrutide: The Next Generation of Weight Loss Peptides",
    metaDescription: "Semaglutide vs Retatrutide: independent comparison of GLP-1 monotherapy vs triple agonist. Evidence, weight loss outcomes, and availability. Vendor-neutral.",
    verdictSummary: "Semaglutide is FDA-approved and widely available. Retatrutide is a triple agonist (GLP-1/GIP/glucagon) in Phase III trials showing superior weight loss.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "GLP-1 receptor agonist", peptideB: "Triple agonist: GLP-1 + GIP + glucagon" },
      { dimension: "Average Weight Loss", peptideA: "10–15%", peptideB: "~24% (Phase II data)" },
      { dimension: "FDA Status", peptideA: "Approved (Ozempic/Wegovy)", peptideB: "Phase III trials (not yet approved)" },
      { dimension: "Availability", peptideA: "Widely available via prescription", peptideB: "Clinical trials only (as of 2025)" },
    ],
    deepDiveA: "Semaglutide is the established standard of care for GLP-1-based weight management, with robust clinical evidence and widespread availability. It is the appropriate choice for anyone seeking evidence-based, physician-supervised weight management today.",
    deepDiveB: "Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase II data shows approximately 24% body weight reduction — exceeding both Semaglutide and Tirzepatide. It is currently in Phase III trials and not yet FDA-approved.",
    chooseAIf: ["You want an FDA-approved, widely available treatment", "You need to start treatment now", "You want the most established safety record"],
    chooseBIf: ["You are willing to wait for a potentially more effective option", "You qualify for and are interested in clinical trial participation", "Maximum weight loss efficacy is your primary criterion"],
    considerBothIf: "Start with Semaglutide or Tirzepatide now. Retatrutide may become available in 2026–2027 and could be considered as a future option.",
    relatedComparisons: ["semaglutide-vs-tirzepatide"],
    faqItems: [
      { q: "When will Retatrutide be available?", a: "Retatrutide is currently in Phase III clinical trials. FDA approval is anticipated in 2026–2027 if trials are successful." },
    ],
  },
  {
    slug: "aod-9604-vs-semaglutide",
    peptideA: "AOD-9604", peptideASlug: "semaglutide",
    peptideB: "Semaglutide", peptideBSlug: "semaglutide",
    h1: "AOD-9604 vs Semaglutide: Which Weight Loss Peptide Is Right for You?",
    metaDescription: "AOD-9604 vs Semaglutide: independent comparison for fat loss. Mechanism, evidence, and use cases. Vendor-neutral.",
    verdictSummary: "Semaglutide has vastly stronger clinical evidence for weight loss. AOD-9604 is a research compound with limited human data.",
    category: "Weight Loss",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "GH fragment — stimulates lipolysis", peptideB: "GLP-1 receptor agonist — appetite suppression" },
      { dimension: "Evidence Level", peptideA: "Preclinical Only", peptideB: "Strong Human Clinical" },
      { dimension: "Average Weight Loss", peptideA: "Limited human data", peptideB: "10–15% body weight" },
      { dimension: "Prescription Required", peptideA: "No (research compound)", peptideB: "Yes" },
      { dimension: "Appetite Suppression", peptideA: "Minimal", peptideB: "Strong" },
    ],
    deepDiveA: "AOD-9604 is a modified fragment of human growth hormone (hGH) that stimulates lipolysis (fat breakdown) without the anabolic effects of full GH. Animal studies show fat reduction, but human clinical trials have not demonstrated significant weight loss. It failed to meet primary endpoints in Phase III trials for obesity.",
    deepDiveB: "Semaglutide has the most robust clinical evidence base of any weight loss peptide, with 10–15% average body weight reduction in large-scale randomized controlled trials.",
    chooseAIf: ["You are specifically researching GH fragment mechanisms", "You want a non-prescription option (with the understanding that evidence is very limited)"],
    chooseBIf: ["Weight loss is your primary goal and you want proven results", "You are willing to use a prescription medication", "Clinical evidence is important to you"],
    considerBothIf: "The evidence strongly favors Semaglutide for weight loss. AOD-9604 is not recommended as a primary weight loss intervention based on current evidence.",
    relatedComparisons: ["semaglutide-vs-tirzepatide"],
    faqItems: [
      { q: "Does AOD-9604 work for weight loss?", a: "Animal studies show fat reduction, but AOD-9604 failed to demonstrate significant weight loss in human clinical trials. Semaglutide has vastly stronger evidence for human weight loss." },
    ],
  },
  {
    slug: "cjc-1295-vs-ghrp-6",
    peptideA: "CJC-1295", peptideASlug: "cjc-1295",
    peptideB: "GHRP-6", peptideBSlug: "ipamorelin",
    h1: "CJC-1295 vs GHRP-6: Which GH Peptide Combination Is Right for You?",
    metaDescription: "CJC-1295 vs GHRP-6: independent comparison of GHRH analogue vs older GHRP. Mechanism, side effects, and why Ipamorelin has largely replaced GHRP-6. Vendor-neutral.",
    verdictSummary: "CJC-1295 is a GHRH analogue; GHRP-6 is an older GHRP. Ipamorelin has largely replaced GHRP-6 due to its cleaner side effect profile.",
    category: "GH Secretagogues",
    atAGlance: [
      { dimension: "Peptide Class", peptideA: "GHRH analogue", peptideB: "GHRP (older generation)" },
      { dimension: "Mechanism", peptideA: "GHRH receptor stimulation", peptideB: "Ghrelin receptor agonism" },
      { dimension: "Cortisol Elevation", peptideA: "None", peptideB: "Significant" },
      { dimension: "Appetite Stimulation", peptideA: "None", peptideB: "Strong (hunger spikes)" },
      { dimension: "Modern Preference", peptideA: "Widely used", peptideB: "Largely replaced by Ipamorelin" },
    ],
    deepDiveA: "CJC-1295 is a modern GHRH analogue that stimulates GH release through the natural GHRH receptor pathway without side effects on cortisol or appetite. It is the standard GHRH component of modern GH secretagogue protocols.",
    deepDiveB: "GHRP-6 is an older generation GHRP that stimulates GH release but also significantly elevates cortisol and prolactin, and causes strong hunger spikes. It has largely been replaced by Ipamorelin, which provides similar GH stimulation with a much cleaner side effect profile.",
    chooseAIf: ["You are building a modern GH secretagogue protocol (combine with Ipamorelin)"],
    chooseBIf: ["GHRP-6 is rarely preferred over Ipamorelin in modern protocols due to its inferior side effect profile"],
    considerBothIf: "Modern protocols use CJC-1295 + Ipamorelin rather than CJC-1295 + GHRP-6. GHRP-6 is primarily of historical interest.",
    relatedComparisons: ["ipamorelin-vs-cjc-1295", "sermorelin-vs-ipamorelin"],
    faqItems: [
      { q: "Is GHRP-6 still used?", a: "GHRP-6 has largely been replaced by Ipamorelin in modern protocols due to Ipamorelin's cleaner side effect profile (no cortisol elevation, no hunger spikes). GHRP-6 is primarily of historical interest." },
    ],
  },
  {
    slug: "pt-141-vs-kisspeptin",
    peptideA: "PT-141", peptideASlug: "pt-141",
    peptideB: "Kisspeptin", peptideBSlug: "pt-141",
    h1: "PT-141 vs Kisspeptin: Which Sexual Health Peptide Is Right for You?",
    metaDescription: "PT-141 vs Kisspeptin: independent comparison of two central-acting sexual health peptides. Mechanism, evidence, and use cases. Vendor-neutral.",
    verdictSummary: "PT-141 is FDA-approved for HSDD with strong evidence. Kisspeptin is an emerging research peptide with promising but limited human data.",
    category: "Sexual Health",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "Melanocortin receptor agonist (MC3R/MC4R)", peptideB: "Kisspeptin receptor agonist (KISS1R)" },
      { dimension: "FDA Status", peptideA: "Approved (Vyleesi for HSDD)", peptideB: "Research compound" },
      { dimension: "Evidence Level", peptideA: "Strong Human Clinical", peptideB: "Emerging Human" },
      { dimension: "Primary Effect", peptideA: "Sexual desire enhancement", peptideB: "LH/FSH stimulation, desire enhancement" },
      { dimension: "Prescription Required", peptideA: "Yes", peptideB: "No (research compound)" },
    ],
    deepDiveA: "PT-141 (Bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women and is widely used off-label in men. It acts on melanocortin receptors in the hypothalamus to enhance sexual desire at the neurological level, independent of vascular mechanisms.",
    deepDiveB: "Kisspeptin is an endogenous neuropeptide that regulates the HPG (hypothalamic-pituitary-gonadal) axis, stimulating LH and FSH release. Emerging research suggests it may enhance sexual desire and arousal through both hormonal and direct neurological mechanisms. Human data is promising but limited.",
    chooseAIf: ["You want FDA-approved treatment with strong clinical evidence", "You need physician-supervised treatment for HSDD", "You want the most established option"],
    chooseBIf: ["You are interested in emerging research and hormonal optimization", "You want to explore non-prescription options", "You are interested in HPG axis optimization alongside libido enhancement"],
    considerBothIf: "PT-141 is the appropriate first choice for sexual desire enhancement based on current evidence. Kisspeptin may be considered as an adjunct for hormonal optimization.",
    relatedComparisons: [],
    faqItems: [
      { q: "Is Kisspeptin better than PT-141?", a: "PT-141 has significantly stronger clinical evidence for sexual desire enhancement. Kisspeptin is promising but has limited human data. PT-141 is the appropriate first choice based on current evidence." },
    ],
  },
  {
    slug: "semaglutide-vs-liraglutide",
    peptideA: "Semaglutide", peptideASlug: "semaglutide",
    peptideB: "Liraglutide", peptideBSlug: "semaglutide",
    h1: "Semaglutide vs Liraglutide: Which GLP-1 Is Right for You?",
    metaDescription: "Semaglutide vs Liraglutide: independent comparison of two GLP-1 receptor agonists for weight loss. Evidence, dosing, and outcomes. Vendor-neutral.",
    verdictSummary: "Semaglutide produces greater weight loss than Liraglutide in head-to-head trials and requires only weekly rather than daily injections.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "Active Ingredient", peptideA: "Semaglutide", peptideB: "Liraglutide" },
      { dimension: "Dosing Frequency", peptideA: "Once weekly", peptideB: "Once daily" },
      { dimension: "Average Weight Loss", peptideA: "10–15%", peptideB: "5–8%" },
      { dimension: "FDA Approval", peptideA: "Ozempic (T2D), Wegovy (obesity)", peptideB: "Victoza (T2D), Saxenda (obesity)" },
      { dimension: "Convenience", peptideA: "Weekly injection", peptideB: "Daily injection" },
    ],
    deepDiveA: "Semaglutide is a second-generation GLP-1 receptor agonist with a 7-day half-life, enabling once-weekly dosing. Head-to-head trials (STEP 8) demonstrate significantly greater weight loss with Semaglutide compared to Liraglutide.",
    deepDiveB: "Liraglutide (Saxenda) was the first GLP-1 agonist approved for obesity and has a longer safety record. However, it requires daily injections and produces less weight loss than Semaglutide.",
    chooseAIf: ["You want greater weight loss efficacy", "You prefer weekly rather than daily injections", "You are starting a new GLP-1 protocol"],
    chooseBIf: ["You have been on Liraglutide and are tolerating it well", "Your physician recommends it for specific clinical reasons", "Insurance coverage favors Liraglutide"],
    considerBothIf: "Most new patients should start with Semaglutide given its superior efficacy and convenience. Liraglutide may be appropriate for patients already established on it.",
    relatedComparisons: ["semaglutide-vs-tirzepatide", "ozempic-vs-wegovy"],
    faqItems: [
      { q: "Should I switch from Liraglutide to Semaglutide?", a: "Semaglutide produces greater weight loss and requires less frequent injections. Many patients switch from Liraglutide to Semaglutide for these reasons. Consult your physician for appropriate transition protocols." },
    ],
  },
  {
    slug: "mots-c-vs-nad",
    peptideA: "MOTS-c", peptideASlug: "mots-c",
    peptideB: "NAD+", peptideBSlug: "epithalon",
    h1: "MOTS-c vs NAD+: Which Longevity Intervention Is Right for You?",
    metaDescription: "MOTS-c vs NAD+: independent comparison of two mitochondrial longevity interventions. Mechanism, evidence, and use cases. Vendor-neutral.",
    verdictSummary: "MOTS-c is a mitochondrial peptide that activates AMPK. NAD+ precursors (NMN, NR) restore NAD+ levels. They work through complementary mechanisms.",
    category: "Longevity",
    atAGlance: [
      { dimension: "Type", peptideA: "Mitochondrial-derived peptide", peptideB: "Coenzyme / NAD+ precursor" },
      { dimension: "Primary Mechanism", peptideA: "AMPK activation, metabolic regulation", peptideB: "NAD+ restoration, sirtuin activation" },
      { dimension: "Administration", peptideA: "Subcutaneous injection", peptideB: "Oral (NMN/NR) or IV (NAD+)" },
      { dimension: "Evidence Level", peptideA: "Preclinical / Early Human", peptideB: "Moderate Human (NMN/NR)" },
      { dimension: "Best For", peptideA: "Metabolic health, endurance, insulin sensitivity", peptideB: "Energy, DNA repair, sirtuin activation" },
    ],
    deepDiveA: "MOTS-c is a mitochondrial-derived peptide that activates AMPK — the master metabolic regulator — improving insulin sensitivity, fat oxidation, and metabolic flexibility. It is one of the most promising emerging longevity peptides.",
    deepDiveB: "NAD+ precursors (NMN, NR) restore declining NAD+ levels, activating sirtuins and PARP enzymes involved in DNA repair, energy metabolism, and cellular stress response. NAD+ decline is a well-established hallmark of aging.",
    chooseAIf: ["Metabolic health and insulin sensitivity are your primary concerns", "You want AMPK activation for metabolic optimization", "You prefer injectable peptide protocols"],
    chooseBIf: ["You want oral supplementation convenience", "DNA repair and sirtuin activation are your primary goals", "You want the more established longevity intervention"],
    considerBothIf: "MOTS-c and NAD+ precursors work through complementary mechanisms and are frequently combined in comprehensive longevity protocols.",
    relatedComparisons: ["epithalon-vs-ghk-cu"],
    faqItems: [
      { q: "Is MOTS-c better than NMN?", a: "They work through different mechanisms. MOTS-c activates AMPK for metabolic optimization; NMN restores NAD+ for sirtuin activation and DNA repair. They are complementary rather than competitive." },
    ],
  },

  // ── BATCH 3 EXPANSION: 51 additional comparisons ──────────────────────────

  {
    slug: "ozempic-vs-mounjaro",
    peptideA: "Ozempic", peptideASlug: "semaglutide",
    peptideB: "Mounjaro", peptideBSlug: "tirzepatide",
    h1: "Ozempic vs Mounjaro: Which GLP-1 Drug Is Right for You?",
    metaDescription: "Ozempic vs Mounjaro: independent head-to-head comparison of semaglutide and tirzepatide for weight loss and diabetes. Evidence-based, vendor-neutral.",
    verdictSummary: "Mounjaro (tirzepatide) produces greater average weight loss in clinical trials due to its dual GIP/GLP-1 mechanism. Ozempic (semaglutide) has a longer safety track record and broader insurance coverage.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "Drug Class", peptideA: "GLP-1 agonist", peptideB: "GIP + GLP-1 dual agonist" },
      { dimension: "Avg. Weight Loss", peptideA: "~15% body weight", peptideB: "~20-22% body weight" },
      { dimension: "FDA Approved", peptideA: "Diabetes + Obesity", peptideB: "Diabetes + Obesity" },
      { dimension: "Dosing", peptideA: "Once weekly", peptideB: "Once weekly" },
      { dimension: "Cost", peptideA: "~$900-$1,000/month", peptideB: "~$1,000-$1,100/month" },
    ],
    deepDiveA: "Ozempic (semaglutide) is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves insulin secretion. It has been on the market since 2017 with an extensive safety database across millions of patients.",
    deepDiveB: "Mounjaro (tirzepatide) activates both GIP and GLP-1 receptors, producing superior weight loss outcomes in the SURMOUNT trials. The dual mechanism appears to have additive effects on appetite suppression and metabolic improvement.",
    chooseAIf: ["You want the more established safety record", "Insurance coverage is a priority", "You have responded well to GLP-1 monotherapy previously"],
    chooseBIf: ["Maximum weight loss is your primary goal", "You have not responded adequately to GLP-1 monotherapy", "You want the most clinically studied dual agonist"],
    considerBothIf: "Both are appropriate first-line options for obesity treatment; the choice is often driven by insurance coverage and prescriber preference.",
    relatedComparisons: ["semaglutide-vs-tirzepatide", "ozempic-vs-wegovy", "wegovy-vs-mounjaro"],
    faqItems: [
      { q: "Is Mounjaro stronger than Ozempic?", a: "Clinical trials show tirzepatide produces greater average weight loss (~20-22% vs ~15%), but individual responses vary significantly." },
    ],
  },

  {
    slug: "ozempic-vs-saxenda",
    peptideA: "Ozempic", peptideASlug: "semaglutide",
    peptideB: "Saxenda", peptideBSlug: "liraglutide",
    h1: "Ozempic vs Saxenda: Comparing GLP-1 Weight Loss Options",
    metaDescription: "Ozempic vs Saxenda: independent comparison of semaglutide and liraglutide for weight loss. Efficacy, dosing, side effects, and cost. Vendor-neutral.",
    verdictSummary: "Ozempic (semaglutide) produces significantly greater weight loss than Saxenda (liraglutide) and requires only once-weekly dosing vs daily. Saxenda has a longer track record in obesity specifically.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "Active Compound", peptideA: "Semaglutide", peptideB: "Liraglutide" },
      { dimension: "Dosing Frequency", peptideA: "Once weekly", peptideB: "Once daily" },
      { dimension: "Avg. Weight Loss", peptideA: "~15% body weight", peptideB: "~8% body weight" },
      { dimension: "Administration", peptideA: "Subcutaneous injection", peptideB: "Subcutaneous injection" },
      { dimension: "Cost", peptideA: "~$900/month", peptideB: "~$1,300/month" },
    ],
    deepDiveA: "Semaglutide has a longer half-life than liraglutide, enabling once-weekly dosing. The STEP trials demonstrated ~15% average weight loss at the 2.4mg Wegovy dose, significantly outperforming liraglutide in head-to-head studies.",
    deepDiveB: "Liraglutide (Saxenda) was the first GLP-1 agonist approved specifically for obesity (2014). It requires daily injection but has a well-established safety profile and is often preferred when weekly injections are not tolerated.",
    chooseAIf: ["You want maximum weight loss efficacy", "Weekly dosing convenience is important", "Cost per unit of weight loss matters"],
    chooseBIf: ["Daily dosing flexibility is preferred", "You want the longest-established obesity-specific GLP-1", "You have had adverse reactions to semaglutide"],
    considerBothIf: undefined,
    relatedComparisons: ["ozempic-vs-mounjaro", "semaglutide-vs-liraglutide", "wegovy-vs-saxenda"],
    faqItems: [
      { q: "Is Ozempic better than Saxenda for weight loss?", a: "Clinical data consistently shows semaglutide produces approximately twice the weight loss of liraglutide. The STEP 8 trial directly comparing them found semaglutide superior." },
    ],
  },

  {
    slug: "wegovy-vs-mounjaro",
    peptideA: "Wegovy", peptideASlug: "semaglutide",
    peptideB: "Mounjaro", peptideBSlug: "tirzepatide",
    h1: "Wegovy vs Mounjaro: The Two Leading Weight Loss Drugs Compared",
    metaDescription: "Wegovy vs Mounjaro: independent comparison of semaglutide 2.4mg and tirzepatide for obesity treatment. Clinical evidence, side effects, and cost. Vendor-neutral.",
    verdictSummary: "Both are highly effective. Mounjaro produces greater average weight loss (~20-22% vs ~15%) but Wegovy has longer obesity-specific approval history. The choice often comes down to insurance and individual response.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "Active Compound", peptideA: "Semaglutide 2.4mg", peptideB: "Tirzepatide" },
      { dimension: "Mechanism", peptideA: "GLP-1 agonist", peptideB: "GIP + GLP-1 dual agonist" },
      { dimension: "Avg. Weight Loss", peptideA: "~15%", peptideB: "~20-22%" },
      { dimension: "FDA Obesity Approval", peptideA: "2021", peptideB: "2023 (Zepbound)" },
      { dimension: "Dosing", peptideA: "Once weekly", peptideB: "Once weekly" },
    ],
    deepDiveA: "Wegovy is the obesity-specific formulation of semaglutide at 2.4mg weekly. The STEP trials established it as a landmark obesity treatment with ~15% average weight loss and significant cardiometabolic benefits.",
    deepDiveB: "Mounjaro's obesity indication (Zepbound) was approved in 2023 after SURMOUNT trials showed ~20-22% weight loss. Its dual GIP/GLP-1 mechanism may explain superior efficacy vs GLP-1 monotherapy.",
    chooseAIf: ["Wegovy has better insurance coverage for you", "You prefer the longer obesity-specific track record", "You are sensitive to GIP receptor effects"],
    chooseBIf: ["Maximum weight loss is the priority", "You have not achieved adequate results on semaglutide", "Zepbound is covered by your insurance"],
    considerBothIf: "Both are excellent first-line options. Many clinicians start with Wegovy and escalate to Mounjaro if response is insufficient.",
    relatedComparisons: ["ozempic-vs-mounjaro", "mounjaro-vs-zepbound", "semaglutide-vs-tirzepatide"],
    faqItems: [
      { q: "Which causes more weight loss, Wegovy or Mounjaro?", a: "Clinical trials show Mounjaro (tirzepatide) produces greater average weight loss (~20-22%) compared to Wegovy (~15%), though individual results vary considerably." },
    ],
  },

  {
    slug: "wegovy-vs-saxenda",
    peptideA: "Wegovy", peptideASlug: "semaglutide",
    peptideB: "Saxenda", peptideBSlug: "liraglutide",
    h1: "Wegovy vs Saxenda: Which GLP-1 Obesity Drug Is More Effective?",
    metaDescription: "Wegovy vs Saxenda: independent comparison for obesity treatment. Efficacy, dosing frequency, side effects, and cost. Science-backed, vendor-neutral.",
    verdictSummary: "Wegovy (semaglutide 2.4mg) produces significantly greater weight loss (~15% vs ~8%) and requires only once-weekly dosing. Saxenda (liraglutide) has a longer obesity-specific track record.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "Active Compound", peptideA: "Semaglutide 2.4mg", peptideB: "Liraglutide 3mg" },
      { dimension: "Dosing", peptideA: "Once weekly", peptideB: "Once daily" },
      { dimension: "Avg. Weight Loss", peptideA: "~15%", peptideB: "~8%" },
      { dimension: "FDA Obesity Approval", peptideA: "2021", peptideB: "2014" },
    ],
    deepDiveA: "Wegovy's once-weekly dosing and superior efficacy have made it the preferred GLP-1 for obesity in most clinical guidelines. The STEP 8 trial directly comparing semaglutide to liraglutide showed semaglutide's clear superiority.",
    deepDiveB: "Saxenda (liraglutide 3mg) was the first daily GLP-1 approved for obesity. Despite lower efficacy than semaglutide, it remains a useful option for patients who cannot tolerate weekly injections or have insurance barriers to newer agents.",
    chooseAIf: ["You want the most effective GLP-1 option", "Weekly dosing is convenient for your lifestyle", "Cost per unit of weight loss is a consideration"],
    chooseBIf: ["Daily dosing flexibility is preferred", "You have had adverse reactions to semaglutide", "Saxenda is covered by your insurance and Wegovy is not"],
    considerBothIf: undefined,
    relatedComparisons: ["ozempic-vs-saxenda", "wegovy-vs-mounjaro", "semaglutide-vs-liraglutide"],
    faqItems: [
      { q: "Is Wegovy more effective than Saxenda?", a: "Yes. The STEP 8 trial directly comparing semaglutide 2.4mg to liraglutide 3mg showed semaglutide produced nearly twice the weight loss (~15% vs ~8%)." },
    ],
  },

  {
    slug: "tirzepatide-vs-retatrutide",
    peptideA: "Tirzepatide", peptideASlug: "tirzepatide",
    peptideB: "Retatrutide", peptideBSlug: "retatrutide",
    h1: "Tirzepatide vs Retatrutide: Dual vs Triple Agonist Compared",
    metaDescription: "Tirzepatide vs retatrutide: comparing the dual GIP/GLP-1 agonist to the triple GIP/GLP-1/glucagon agonist. Evidence, weight loss data, and availability. Vendor-neutral.",
    verdictSummary: "Retatrutide's triple agonism (GIP + GLP-1 + glucagon) produced ~24% weight loss in Phase 2 trials, potentially exceeding tirzepatide. However, retatrutide is not yet FDA approved as of 2025.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "GIP + GLP-1 dual agonist", peptideB: "GIP + GLP-1 + glucagon triple agonist" },
      { dimension: "FDA Status", peptideA: "Approved (2022)", peptideB: "Phase 3 trials (2025)" },
      { dimension: "Avg. Weight Loss", peptideA: "~20-22%", peptideB: "~24% (Phase 2)" },
      { dimension: "Availability", peptideA: "Prescription only", peptideB: "Research compound / clinical trials" },
    ],
    deepDiveA: "Tirzepatide is the most effective approved weight loss medication as of 2025. Its dual GIP/GLP-1 mechanism produces superior outcomes to GLP-1 monotherapy, with ~20-22% average weight loss in the SURMOUNT trials.",
    deepDiveB: "Retatrutide adds glucagon receptor agonism to the GIP/GLP-1 combination, potentially increasing energy expenditure in addition to appetite suppression. Phase 2 data showed ~24% weight loss, but Phase 3 data is still pending.",
    chooseAIf: ["You want an FDA-approved treatment available now", "You want the most clinically validated option", "Insurance coverage is important"],
    chooseBIf: ["You are interested in clinical trial participation", "You want the potentially most effective future option", "You are following emerging research closely"],
    considerBothIf: undefined,
    relatedComparisons: ["semaglutide-vs-tirzepatide", "semaglutide-vs-retatrutide", "ozempic-vs-mounjaro"],
    faqItems: [
      { q: "Is retatrutide better than tirzepatide?", a: "Phase 2 data suggests retatrutide may produce greater weight loss (~24% vs ~20-22%), but Phase 3 trials are ongoing and retatrutide is not yet FDA approved." },
    ],
  },

  {
    slug: "ozempic-vs-rybelsus",
    peptideA: "Ozempic", peptideASlug: "semaglutide",
    peptideB: "Rybelsus", peptideBSlug: "semaglutide",
    h1: "Ozempic vs Rybelsus: Injectable vs Oral Semaglutide Compared",
    metaDescription: "Ozempic vs Rybelsus: comparing injectable and oral semaglutide. Bioavailability, efficacy, dosing, and which is right for you. Independent, vendor-neutral.",
    verdictSummary: "Both contain semaglutide but differ in delivery. Ozempic (injectable) achieves higher bioavailability and greater weight loss. Rybelsus (oral) is more convenient but requires strict fasting protocols and produces less weight loss.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "Active Compound", peptideA: "Semaglutide", peptideB: "Semaglutide" },
      { dimension: "Route", peptideA: "Subcutaneous injection", peptideB: "Oral tablet" },
      { dimension: "Dosing Frequency", peptideA: "Once weekly", peptideB: "Once daily (fasting)" },
      { dimension: "Bioavailability", peptideA: "~89%", peptideB: "~1% (with SNAC absorption enhancer)" },
      { dimension: "Primary Indication", peptideA: "Type 2 diabetes + obesity", peptideB: "Type 2 diabetes" },
    ],
    deepDiveA: "Ozempic delivers semaglutide subcutaneously with near-complete bioavailability. Once-weekly dosing provides stable plasma levels and has demonstrated significant HbA1c reduction and weight loss in clinical trials.",
    deepDiveB: "Rybelsus uses the SNAC absorption enhancer to deliver oral semaglutide. It must be taken on an empty stomach with no more than 120ml of water, waiting 30 minutes before eating. Bioavailability is low but sufficient for glycemic control.",
    chooseAIf: ["Weight loss is a primary goal", "You prefer weekly over daily dosing", "You want maximum semaglutide bioavailability"],
    chooseBIf: ["You have needle phobia or injection anxiety", "Oral medication is strongly preferred", "Glycemic control is the primary goal (not weight loss)"],
    considerBothIf: undefined,
    relatedComparisons: ["ozempic-vs-wegovy", "semaglutide-vs-tirzepatide", "ozempic-vs-mounjaro"],
    faqItems: [
      { q: "Is Rybelsus as effective as Ozempic?", a: "No. Due to lower bioavailability, Rybelsus produces less weight loss than Ozempic. It is primarily indicated for glycemic control in type 2 diabetes, not obesity." },
    ],
  },

  {
    slug: "trulicity-vs-ozempic",
    peptideA: "Trulicity", peptideASlug: "semaglutide",
    peptideB: "Ozempic", peptideBSlug: "semaglutide",
    h1: "Trulicity vs Ozempic: Dulaglutide vs Semaglutide Compared",
    metaDescription: "Trulicity vs Ozempic: independent comparison of dulaglutide and semaglutide for type 2 diabetes and weight loss. Evidence, efficacy, and side effects. Vendor-neutral.",
    verdictSummary: "Ozempic (semaglutide) produces significantly greater weight loss and HbA1c reduction than Trulicity (dulaglutide) in head-to-head trials. Trulicity remains a reasonable option for patients who cannot tolerate semaglutide.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "Active Compound", peptideA: "Dulaglutide", peptideB: "Semaglutide" },
      { dimension: "Dosing", peptideA: "Once weekly", peptideB: "Once weekly" },
      { dimension: "Avg. Weight Loss", peptideA: "~3-5%", peptideB: "~6-15%" },
      { dimension: "HbA1c Reduction", peptideA: "~1.3-1.5%", peptideB: "~1.5-1.8%" },
    ],
    deepDiveA: "Trulicity (dulaglutide) is a once-weekly GLP-1 agonist approved for type 2 diabetes. It is well-tolerated and has cardiovascular outcome data (REWIND trial), but produces less weight loss than semaglutide.",
    deepDiveB: "Ozempic (semaglutide) consistently outperforms dulaglutide in head-to-head trials for both HbA1c reduction and weight loss. The SUSTAIN 7 trial directly comparing them showed semaglutide's superiority at both 0.5mg and 1mg doses.",
    chooseAIf: ["You have not tolerated semaglutide", "Trulicity is preferred by your insurer", "Modest weight loss is acceptable"],
    chooseBIf: ["Maximum HbA1c reduction is the goal", "Significant weight loss is desired", "You want the most clinically proven GLP-1 agonist"],
    considerBothIf: undefined,
    relatedComparisons: ["ozempic-vs-mounjaro", "semaglutide-vs-tirzepatide", "ozempic-vs-saxenda"],
    faqItems: [
      { q: "Which is better, Trulicity or Ozempic?", a: "Clinical trials consistently show Ozempic (semaglutide) produces greater HbA1c reduction and weight loss than Trulicity (dulaglutide). Ozempic is generally preferred when efficacy is the primary consideration." },
    ],
  },

  {
    slug: "victoza-vs-ozempic",
    peptideA: "Victoza", peptideASlug: "liraglutide",
    peptideB: "Ozempic", peptideBSlug: "semaglutide",
    h1: "Victoza vs Ozempic: Liraglutide vs Semaglutide for Diabetes",
    metaDescription: "Victoza vs Ozempic: independent comparison of liraglutide and semaglutide for type 2 diabetes. Efficacy, dosing, weight loss, and cardiovascular outcomes. Vendor-neutral.",
    verdictSummary: "Ozempic (semaglutide) produces greater HbA1c reduction and weight loss than Victoza (liraglutide) and requires only once-weekly dosing. Victoza has a longer track record and strong cardiovascular outcome data.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "Active Compound", peptideA: "Liraglutide 1.2-1.8mg", peptideB: "Semaglutide 0.5-1mg" },
      { dimension: "Dosing", peptideA: "Once daily", peptideB: "Once weekly" },
      { dimension: "Avg. Weight Loss", peptideA: "~3-4%", peptideB: "~5-6% (diabetes dose)" },
      { dimension: "CV Outcome Trial", peptideA: "LEADER (positive)", peptideB: "SUSTAIN-6 (positive)" },
    ],
    deepDiveA: "Victoza (liraglutide 1.2-1.8mg) was one of the first GLP-1 agonists widely adopted. The LEADER trial demonstrated significant cardiovascular risk reduction. It requires daily injection but is well-tolerated.",
    deepDiveB: "Ozempic's once-weekly dosing is a major convenience advantage. The SUSTAIN-6 trial showed cardiovascular benefit, and it consistently outperforms liraglutide in efficacy comparisons.",
    chooseAIf: ["Daily dosing flexibility is preferred", "You have used Victoza successfully before", "Victoza is better covered by your insurance"],
    chooseBIf: ["Weekly dosing convenience is important", "You want greater HbA1c reduction", "Weight loss is a secondary goal"],
    considerBothIf: undefined,
    relatedComparisons: ["ozempic-vs-saxenda", "semaglutide-vs-liraglutide", "ozempic-vs-mounjaro"],
    faqItems: [
      { q: "Should I switch from Victoza to Ozempic?", a: "Many patients switching from Victoza to Ozempic experience greater HbA1c reduction and weight loss with the added convenience of weekly dosing. Discuss with your prescriber." },
    ],
  },

  {
    slug: "ipamorelin-vs-sermorelin",
    peptideA: "Ipamorelin", peptideASlug: "ipamorelin",
    peptideB: "Sermorelin", peptideBSlug: "sermorelin",
    h1: "Ipamorelin vs Sermorelin: Which GH Secretagogue Is Better?",
    metaDescription: "Ipamorelin vs sermorelin: independent comparison of two growth hormone secretagogues. Mechanism, pulse quality, side effects, and clinical use. Vendor-neutral.",
    verdictSummary: "Ipamorelin produces cleaner, more selective GH pulses with fewer side effects. Sermorelin mimics the natural GHRH mechanism more closely and has more clinical data. Both are effective; the choice depends on your protocol goals.",
    category: "Growth Hormone",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "GHRP (ghrelin mimetic)", peptideB: "GHRH analogue" },
      { dimension: "GH Pulse Quality", peptideA: "Clean, selective, no cortisol spike", peptideB: "Physiological GHRH-like pulse" },
      { dimension: "Half-Life", peptideA: "~2 hours", peptideB: "~10-20 minutes" },
      { dimension: "Side Effects", peptideA: "Minimal (mild hunger)", peptideB: "Flushing, headache possible" },
      { dimension: "Clinical Data", peptideA: "Preclinical + limited human", peptideB: "More human clinical data" },
    ],
    deepDiveA: "Ipamorelin is a selective GHRP that stimulates GH release without significantly raising cortisol or prolactin — a key advantage over older GHRPs like GHRP-6. It produces clean, pulsatile GH release ideal for anti-aging and body composition protocols.",
    deepDiveB: "Sermorelin is a GHRH analogue that stimulates the pituitary to produce GH through the natural GHRH pathway. It has more human clinical data and is often prescribed off-label for adult GH deficiency.",
    chooseAIf: ["You want minimal side effects", "Cortisol and prolactin elevation is a concern", "You are stacking with a GHRH peptide like CJC-1295"],
    chooseBIf: ["You want more clinical data behind your protocol", "GHRH-pathway stimulation is preferred", "You want a standalone GH secretagogue"],
    considerBothIf: "Ipamorelin + sermorelin is a popular combination that stimulates GH through two complementary pathways (GHRP + GHRH), producing synergistic GH release.",
    relatedComparisons: ["ipamorelin-vs-cjc-1295", "sermorelin-vs-ipamorelin", "tesamorelin-vs-ipamorelin"],
    faqItems: [
      { q: "Can I take ipamorelin and sermorelin together?", a: "Yes. Combining a GHRP (ipamorelin) with a GHRH analogue (sermorelin) produces synergistic GH release. This combination is commonly used in anti-aging and body composition protocols." },
    ],
  },

  {
    slug: "cjc-1295-vs-sermorelin",
    peptideA: "CJC-1295", peptideASlug: "cjc-1295",
    peptideB: "Sermorelin", peptideBSlug: "sermorelin",
    h1: "CJC-1295 vs Sermorelin: GHRH Analogues Compared",
    metaDescription: "CJC-1295 vs sermorelin: independent comparison of two GHRH analogues. Half-life, GH pulse characteristics, and clinical use. Vendor-neutral.",
    verdictSummary: "CJC-1295 has a dramatically longer half-life (days vs minutes) due to its DAC modification, producing sustained GH elevation. Sermorelin produces more physiological pulsatile GH release. The choice depends on whether you want sustained or pulsatile GH.",
    category: "Growth Hormone",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "GHRH analogue with DAC", peptideB: "GHRH analogue (1-29 fragment)" },
      { dimension: "Half-Life", peptideA: "~6-8 days (with DAC)", peptideB: "~10-20 minutes" },
      { dimension: "GH Pattern", peptideA: "Sustained elevation", peptideB: "Pulsatile (physiological)" },
      { dimension: "Dosing Frequency", peptideA: "1-2x per week", peptideB: "Daily" },
    ],
    deepDiveA: "CJC-1295 with DAC binds to albumin in the bloodstream, extending its half-life to 6-8 days. This produces sustained GH and IGF-1 elevation, which is effective for body composition but less physiological than pulsatile release.",
    deepDiveB: "Sermorelin closely mimics natural GHRH, producing pulsatile GH release that follows the body's natural rhythm. Daily dosing is required but the physiological pattern may be preferable for long-term use.",
    chooseAIf: ["Convenience of 1-2x weekly dosing is important", "Sustained IGF-1 elevation is the goal", "You are stacking with a GHRP like ipamorelin"],
    chooseBIf: ["Physiological pulsatile GH release is preferred", "Long-term use with minimal receptor desensitization is the goal", "Daily injection is acceptable"],
    considerBothIf: undefined,
    relatedComparisons: ["ipamorelin-vs-cjc-1295", "ipamorelin-vs-sermorelin", "tesamorelin-vs-sermorelin"],
    faqItems: [
      { q: "Is CJC-1295 stronger than sermorelin?", a: "CJC-1295 with DAC produces more sustained GH and IGF-1 elevation due to its longer half-life. Whether this is 'stronger' depends on your goals — sustained elevation vs physiological pulsatile release." },
    ],
  },

  {
    slug: "ghrp-6-vs-ghrp-2",
    peptideA: "GHRP-6", peptideASlug: "ghrp-6",
    peptideB: "GHRP-2", peptideBSlug: "ghrp-2",
    h1: "GHRP-6 vs GHRP-2: Which Growth Hormone Releasing Peptide Is Better?",
    metaDescription: "GHRP-6 vs GHRP-2: independent comparison of two first-generation GHRPs. GH release potency, hunger side effects, cortisol elevation, and use cases. Vendor-neutral.",
    verdictSummary: "GHRP-2 produces stronger GH release than GHRP-6 but also causes greater cortisol and prolactin elevation. GHRP-6 causes more pronounced hunger. Both have been largely superseded by ipamorelin for most protocols.",
    category: "Growth Hormone",
    atAGlance: [
      { dimension: "GH Release Potency", peptideA: "Moderate", peptideB: "Strong" },
      { dimension: "Cortisol Elevation", peptideA: "Moderate", peptideB: "Higher" },
      { dimension: "Prolactin Elevation", peptideA: "Moderate", peptideB: "Higher" },
      { dimension: "Hunger Side Effect", peptideA: "Pronounced", peptideB: "Moderate" },
      { dimension: "Typical Dose", peptideA: "100-300 mcg", peptideB: "100-300 mcg" },
    ],
    deepDiveA: "GHRP-6 was one of the first synthetic GHRPs studied. It produces significant GH release but also causes pronounced hunger (ghrelin-mediated), which can be a side effect or benefit depending on goals. Cortisol elevation is moderate.",
    deepDiveB: "GHRP-2 produces stronger GH release than GHRP-6 but with greater cortisol and prolactin elevation. It is often considered more potent but with a less favorable side effect profile compared to newer GHRPs like ipamorelin.",
    chooseAIf: ["Appetite stimulation is a desired effect (e.g., in underweight individuals)", "You want a well-studied first-generation GHRP", "Cost is a primary consideration"],
    chooseBIf: ["Maximum GH release is the priority", "Appetite stimulation is not desired", "You are using it short-term for a specific protocol"],
    considerBothIf: undefined,
    relatedComparisons: ["ipamorelin-vs-ghrp-6", "ipamorelin-vs-ghrp-2", "cjc-1295-vs-ghrp-6"],
    faqItems: [
      { q: "Which is better, GHRP-6 or GHRP-2?", a: "GHRP-2 produces stronger GH release but with more side effects (cortisol, prolactin, hunger). Most modern protocols prefer ipamorelin over both due to its cleaner side effect profile." },
    ],
  },

  {
    slug: "ipamorelin-vs-ghrp-6",
    peptideA: "Ipamorelin", peptideASlug: "ipamorelin",
    peptideB: "GHRP-6", peptideBSlug: "ghrp-6",
    h1: "Ipamorelin vs GHRP-6: Modern vs Classic GHRP Compared",
    metaDescription: "Ipamorelin vs GHRP-6: independent comparison of a selective modern GHRP against the classic first-generation GHRP. Side effects, GH release, and clinical preference. Vendor-neutral.",
    verdictSummary: "Ipamorelin is the clear choice for most modern protocols. It produces selective GH release without cortisol or prolactin elevation, and without the pronounced hunger of GHRP-6. GHRP-6 may be preferred when appetite stimulation is desired.",
    category: "Growth Hormone",
    atAGlance: [
      { dimension: "Selectivity", peptideA: "Highly selective for GH", peptideB: "Less selective" },
      { dimension: "Cortisol Elevation", peptideA: "Minimal", peptideB: "Moderate" },
      { dimension: "Hunger Side Effect", peptideA: "Mild", peptideB: "Pronounced" },
      { dimension: "GH Release", peptideA: "Moderate, clean pulse", peptideB: "Strong but less clean" },
    ],
    deepDiveA: "Ipamorelin's selectivity for GH release without cortisol or prolactin elevation makes it the preferred GHRP in most modern anti-aging and body composition protocols. It is typically combined with a GHRH analogue like CJC-1295.",
    deepDiveB: "GHRP-6 is a first-generation GHRP with a well-established research history. Its pronounced hunger side effect (via ghrelin pathway) can be useful for individuals trying to increase caloric intake, such as those recovering from illness.",
    chooseAIf: ["You want the cleanest GH release with minimal side effects", "Cortisol management is important", "You are on a long-term anti-aging protocol"],
    chooseBIf: ["Appetite stimulation is a desired goal", "You are recovering from illness or surgery and need to increase food intake", "Cost is a primary consideration"],
    considerBothIf: undefined,
    relatedComparisons: ["ipamorelin-vs-cjc-1295", "ghrp-6-vs-ghrp-2", "ipamorelin-vs-sermorelin"],
    faqItems: [
      { q: "Why do most people prefer ipamorelin over GHRP-6?", a: "Ipamorelin produces selective GH release without the cortisol elevation, prolactin elevation, or pronounced hunger associated with GHRP-6. For most goals, ipamorelin offers a cleaner side effect profile." },
    ],
  },

  {
    slug: "ipamorelin-vs-ghrp-2",
    peptideA: "Ipamorelin", peptideASlug: "ipamorelin",
    peptideB: "GHRP-2", peptideBSlug: "ghrp-2",
    h1: "Ipamorelin vs GHRP-2: Selective vs Potent GHRP Compared",
    metaDescription: "Ipamorelin vs GHRP-2: independent comparison. Ipamorelin offers selective GH release; GHRP-2 offers stronger release with more side effects. Which is right for your protocol? Vendor-neutral.",
    verdictSummary: "Ipamorelin is preferred for long-term protocols due to its selective GH release and minimal side effects. GHRP-2 may be chosen when maximum GH stimulation is needed short-term, accepting higher cortisol and prolactin.",
    category: "Growth Hormone",
    atAGlance: [
      { dimension: "GH Release Potency", peptideA: "Moderate", peptideB: "Strong" },
      { dimension: "Cortisol Elevation", peptideA: "Minimal", peptideB: "Significant" },
      { dimension: "Prolactin Elevation", peptideA: "Minimal", peptideB: "Significant" },
      { dimension: "Long-Term Suitability", peptideA: "Excellent", peptideB: "Moderate (due to side effects)" },
    ],
    deepDiveA: "Ipamorelin's selectivity makes it ideal for long-term protocols. It does not desensitize GH receptors as rapidly as older GHRPs and does not produce the hormonal side effects that complicate extended GHRP-2 use.",
    deepDiveB: "GHRP-2 produces stronger acute GH release than ipamorelin, which may be advantageous for short-term protocols focused on maximum GH stimulation. However, cortisol and prolactin elevation limit its suitability for extended use.",
    chooseAIf: ["Long-term protocol safety is the priority", "You want minimal hormonal side effects", "You are stacking with a GHRH analogue"],
    chooseBIf: ["Maximum short-term GH stimulation is needed", "You are using it for a brief, intensive protocol", "You are monitoring cortisol and prolactin closely"],
    considerBothIf: undefined,
    relatedComparisons: ["ipamorelin-vs-ghrp-6", "ghrp-6-vs-ghrp-2", "ipamorelin-vs-cjc-1295"],
    faqItems: [
      { q: "Is GHRP-2 stronger than ipamorelin?", a: "GHRP-2 produces stronger acute GH release, but with greater cortisol and prolactin elevation. For most long-term protocols, ipamorelin's cleaner profile makes it the preferred choice." },
    ],
  },

  {
    slug: "hexarelin-vs-ipamorelin",
    peptideA: "Hexarelin", peptideASlug: "hexarelin",
    peptideB: "Ipamorelin", peptideBSlug: "ipamorelin",
    h1: "Hexarelin vs Ipamorelin: The Most Potent GHRP vs the Cleanest",
    metaDescription: "Hexarelin vs ipamorelin: comparing the most potent GHRP against the most selective. GH release, side effects, desensitization, and clinical use. Vendor-neutral.",
    verdictSummary: "Hexarelin is the most potent GHRP but causes significant receptor desensitization and cortisol/prolactin elevation. Ipamorelin is less potent but far more suitable for sustained protocols due to its selectivity.",
    category: "Growth Hormone",
    atAGlance: [
      { dimension: "GH Release Potency", peptideA: "Highest among GHRPs", peptideB: "Moderate" },
      { dimension: "Receptor Desensitization", peptideA: "Significant (rapid)", peptideB: "Minimal" },
      { dimension: "Cortisol Elevation", peptideA: "Significant", peptideB: "Minimal" },
      { dimension: "Long-Term Suitability", peptideA: "Poor (desensitization)", peptideB: "Excellent" },
    ],
    deepDiveA: "Hexarelin produces the strongest acute GH release of any GHRP, but this comes at the cost of rapid receptor desensitization, making it unsuitable for continuous long-term use. It is sometimes used in short cycles for maximum GH stimulation.",
    deepDiveB: "Ipamorelin's selectivity and minimal receptor desensitization make it the gold standard for sustained GH optimization protocols. It is the most commonly recommended GHRP for anti-aging and body composition.",
    chooseAIf: ["Maximum short-term GH stimulation is needed", "You are using it in a short cycle (2-4 weeks)", "You are experienced with peptide protocols"],
    chooseBIf: ["Long-term sustained GH optimization is the goal", "Minimal side effects are important", "You want a protocol you can maintain for months"],
    considerBothIf: undefined,
    relatedComparisons: ["ipamorelin-vs-ghrp-6", "ipamorelin-vs-ghrp-2", "ipamorelin-vs-cjc-1295"],
    faqItems: [
      { q: "Why is hexarelin not used more often despite being the most potent GHRP?", a: "Hexarelin causes rapid receptor desensitization, meaning its effectiveness diminishes quickly with continued use. Ipamorelin maintains its effectiveness over longer periods, making it more practical for sustained protocols." },
    ],
  },

  {
    slug: "tesamorelin-vs-sermorelin",
    peptideA: "Tesamorelin", peptideASlug: "tesamorelin",
    peptideB: "Sermorelin", peptideBSlug: "sermorelin",
    h1: "Tesamorelin vs Sermorelin: FDA-Approved vs Classic GHRH Analogue",
    metaDescription: "Tesamorelin vs sermorelin: comparing the FDA-approved GHRH analogue to the classic sermorelin. Visceral fat reduction, clinical data, and use cases. Vendor-neutral.",
    verdictSummary: "Tesamorelin has FDA approval for HIV-associated lipodystrophy and strong clinical data for visceral fat reduction. Sermorelin is more commonly used off-label for anti-aging and GH optimization with a longer track record in that context.",
    category: "Growth Hormone",
    atAGlance: [
      { dimension: "FDA Status", peptideA: "Approved (HIV lipodystrophy)", peptideB: "Approved (pediatric GH deficiency)" },
      { dimension: "Primary Use", peptideA: "Visceral fat reduction", peptideB: "GH optimization / anti-aging" },
      { dimension: "Half-Life", peptideA: "~30 minutes", peptideB: "~10-20 minutes" },
      { dimension: "Clinical Data", peptideA: "Strong (visceral fat)", peptideB: "Moderate (GH deficiency)" },
    ],
    deepDiveA: "Tesamorelin is a stabilized GHRH analogue with FDA approval for reducing visceral adipose tissue in HIV patients. Its clinical data for visceral fat reduction is among the strongest of any peptide, making it relevant for metabolic health protocols.",
    deepDiveB: "Sermorelin has been used off-label for adult GH optimization for decades. It produces physiological pulsatile GH release and is often considered the most natural GHRH analogue approach to GH support.",
    chooseAIf: ["Visceral fat reduction is a primary goal", "You want the strongest clinical data for metabolic effects", "You are working with a physician familiar with tesamorelin"],
    chooseBIf: ["General GH optimization is the goal", "Physiological pulsatile GH release is preferred", "Cost is a consideration"],
    considerBothIf: undefined,
    relatedComparisons: ["tesamorelin-vs-ipamorelin", "cjc-1295-vs-sermorelin", "ipamorelin-vs-sermorelin"],
    faqItems: [
      { q: "Is tesamorelin better than sermorelin for fat loss?", a: "For visceral fat specifically, tesamorelin has stronger clinical evidence. For general GH optimization and anti-aging, sermorelin's longer track record in that context makes it a common choice." },
    ],
  },

  {
    slug: "cjc-1295-dac-vs-no-dac",
    peptideA: "CJC-1295 with DAC", peptideASlug: "cjc-1295",
    peptideB: "CJC-1295 without DAC (Mod GRF 1-29)", peptideBSlug: "cjc-1295",
    h1: "CJC-1295 with DAC vs without DAC: Which Should You Use?",
    metaDescription: "CJC-1295 with DAC vs without DAC (Mod GRF 1-29): independent comparison. Half-life, GH pulse pattern, and which is right for your protocol. Vendor-neutral.",
    verdictSummary: "CJC-1295 with DAC provides sustained GH elevation with 1-2x weekly dosing. Without DAC (Mod GRF 1-29) produces pulsatile GH release requiring daily dosing. The choice depends on whether you want sustained or physiological pulsatile GH.",
    category: "Growth Hormone",
    atAGlance: [
      { dimension: "Half-Life", peptideA: "~6-8 days", peptideB: "~30 minutes" },
      { dimension: "GH Pattern", peptideA: "Sustained elevation", peptideB: "Pulsatile (physiological)" },
      { dimension: "Dosing Frequency", peptideA: "1-2x per week", peptideB: "Daily (2-3x daily for best results)" },
      { dimension: "IGF-1 Elevation", peptideA: "Sustained", peptideB: "Pulsatile" },
    ],
    deepDiveA: "The Drug Affinity Complex (DAC) modification allows CJC-1295 to bind to albumin, dramatically extending its half-life. This produces sustained GH and IGF-1 elevation, convenient for weekly dosing protocols.",
    deepDiveB: "CJC-1295 without DAC (also called Mod GRF 1-29) has a short half-life similar to natural GHRH. It produces pulsatile GH release when combined with a GHRP, more closely mimicking the body's natural GH secretion pattern.",
    chooseAIf: ["Convenience of 1-2x weekly dosing is important", "Sustained IGF-1 elevation is the goal", "You want a simpler protocol"],
    chooseBIf: ["Physiological pulsatile GH release is preferred", "You are combining with a GHRP for synergistic release", "Long-term receptor sensitivity is a concern"],
    considerBothIf: undefined,
    relatedComparisons: ["ipamorelin-vs-cjc-1295", "cjc-1295-vs-sermorelin", "cjc-1295-vs-ghrp-6"],
    faqItems: [
      { q: "Which is better, CJC-1295 with or without DAC?", a: "Neither is universally better. With DAC offers convenience and sustained elevation; without DAC offers more physiological pulsatile release. Many protocols use Mod GRF 1-29 (without DAC) combined with ipamorelin for the most natural GH stimulation pattern." },
    ],
  },

  {
    slug: "sermorelin-vs-hgh",
    peptideA: "Sermorelin", peptideASlug: "sermorelin",
    peptideB: "HGH (Synthetic)", peptideBSlug: "sermorelin",
    h1: "Sermorelin vs HGH: Natural GH Stimulation vs Direct Replacement",
    metaDescription: "Sermorelin vs HGH: independent comparison of GHRH analogue therapy vs synthetic human growth hormone. Safety, efficacy, cost, and legal status. Vendor-neutral.",
    verdictSummary: "Sermorelin stimulates the pituitary to produce GH naturally, preserving feedback mechanisms and costing significantly less than synthetic HGH. HGH provides direct GH replacement but bypasses natural regulation and carries higher risks.",
    category: "Growth Hormone",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "Stimulates natural GH production", peptideB: "Direct GH replacement" },
      { dimension: "Pituitary Feedback", peptideA: "Preserved (natural regulation)", peptideB: "Bypassed" },
      { dimension: "Cost", peptideA: "~$200-$400/month", peptideB: "~$500-$2,000+/month" },
      { dimension: "Legal Status", peptideA: "Prescription (off-label)", peptideB: "Prescription (FDA approved for deficiency)" },
      { dimension: "Side Effect Risk", peptideA: "Lower", peptideB: "Higher (acromegaly risk at supraphysiological doses)" },
    ],
    deepDiveA: "Sermorelin preserves the natural pituitary feedback loop, meaning GH production is regulated by somatostatin and other natural mechanisms. This reduces the risk of supraphysiological GH levels and maintains the body's own regulatory capacity.",
    deepDiveB: "Synthetic HGH provides direct GH replacement, bypassing the pituitary entirely. It is FDA approved for specific deficiency conditions and produces predictable, measurable GH levels. However, it is significantly more expensive and carries higher risks at non-physiological doses.",
    chooseAIf: ["You want to stimulate natural GH production", "Cost is a consideration", "You want to preserve pituitary function and feedback", "You are using it for anti-aging or optimization (not diagnosed deficiency)"],
    chooseBIf: ["You have diagnosed GH deficiency requiring direct replacement", "Precise, predictable GH levels are needed", "You are working with an endocrinologist for a specific medical indication"],
    considerBothIf: undefined,
    relatedComparisons: ["ipamorelin-vs-hgh", "sermorelin-vs-ipamorelin", "cjc-1295-vs-sermorelin"],
    faqItems: [
      { q: "Is sermorelin as effective as HGH?", a: "For anti-aging and optimization purposes, sermorelin can produce meaningful GH increases at lower cost and risk. For diagnosed GH deficiency requiring precise replacement, synthetic HGH is the standard of care." },
    ],
  },

  {
    slug: "ipamorelin-vs-hgh",
    peptideA: "Ipamorelin", peptideASlug: "ipamorelin",
    peptideB: "HGH (Synthetic)", peptideBSlug: "ipamorelin",
    h1: "Ipamorelin vs HGH: Peptide Secretagogue vs Direct GH Replacement",
    metaDescription: "Ipamorelin vs HGH: independent comparison. Ipamorelin stimulates natural GH pulses; HGH provides direct replacement. Cost, safety, and efficacy compared. Vendor-neutral.",
    verdictSummary: "Ipamorelin offers a safer, more affordable approach to GH optimization by stimulating natural pulsatile GH release. Synthetic HGH provides direct, predictable GH replacement but at significantly higher cost and risk.",
    category: "Growth Hormone",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "Stimulates pituitary GH release", peptideB: "Direct GH replacement" },
      { dimension: "GH Pattern", peptideA: "Natural pulsatile", peptideB: "Sustained (non-pulsatile)" },
      { dimension: "Cost", peptideA: "~$100-$300/month", peptideB: "~$500-$2,000+/month" },
      { dimension: "Cortisol/Prolactin", peptideA: "Minimal elevation", peptideB: "No direct effect" },
    ],
    deepDiveA: "Ipamorelin combined with a GHRH analogue (CJC-1295 or sermorelin) produces synergistic, pulsatile GH release that closely mimics natural GH secretion. This approach preserves pituitary function and natural feedback mechanisms.",
    deepDiveB: "Synthetic HGH provides direct, measurable GH replacement. It is the standard treatment for diagnosed GH deficiency but is frequently used off-label for anti-aging. Supraphysiological doses carry risks including insulin resistance and acromegaly.",
    chooseAIf: ["You want natural pulsatile GH stimulation", "Cost is a significant consideration", "You want to preserve pituitary function", "You are using peptides for optimization, not diagnosed deficiency"],
    chooseBIf: ["You have diagnosed GH deficiency", "Precise, measurable GH levels are required", "You are under endocrinologist supervision for a specific indication"],
    considerBothIf: undefined,
    relatedComparisons: ["sermorelin-vs-hgh", "ipamorelin-vs-cjc-1295", "ipamorelin-vs-sermorelin"],
    faqItems: [
      { q: "Is ipamorelin a substitute for HGH?", a: "For optimization purposes, ipamorelin (especially combined with CJC-1295) can produce meaningful GH increases at a fraction of the cost. It is not a substitute for diagnosed GH deficiency requiring direct replacement." },
    ],
  },

  {
    slug: "bpc-157-vs-ipamorelin",
    peptideA: "BPC-157", peptideASlug: "bpc-157",
    peptideB: "Ipamorelin", peptideBSlug: "ipamorelin",
    h1: "BPC-157 vs Ipamorelin: Healing Peptide vs GH Secretagogue",
    metaDescription: "BPC-157 vs ipamorelin: independent comparison of a healing peptide and a GH secretagogue. Different mechanisms, different goals. Which do you need? Vendor-neutral.",
    verdictSummary: "BPC-157 and ipamorelin serve fundamentally different purposes. BPC-157 is a healing and repair peptide; ipamorelin is a GH secretagogue for body composition and anti-aging. They are often combined rather than compared.",
    category: "Recovery",
    atAGlance: [
      { dimension: "Primary Purpose", peptideA: "Tissue healing and repair", peptideB: "GH stimulation" },
      { dimension: "Mechanism", peptideA: "Angiogenesis, growth factor upregulation", peptideB: "GHRP (ghrelin mimetic)" },
      { dimension: "Best For", peptideA: "Injuries, gut healing, inflammation", peptideB: "Body composition, anti-aging, sleep" },
      { dimension: "Stack Compatibility", peptideA: "Stacks well with ipamorelin", peptideB: "Stacks well with BPC-157" },
    ],
    deepDiveA: "BPC-157 promotes tissue healing through angiogenesis, growth factor upregulation, and anti-inflammatory mechanisms. It is most relevant for acute injuries, chronic pain, gut healing, and post-surgical recovery.",
    deepDiveB: "Ipamorelin stimulates pulsatile GH release, supporting body composition, sleep quality, and anti-aging. It works through a completely different pathway and is not primarily a healing peptide.",
    chooseAIf: ["You have an active injury, gut issue, or inflammatory condition", "Tissue repair is the primary goal", "You want the most researched healing peptide"],
    chooseBIf: ["Body composition and GH optimization are the goals", "Sleep quality improvement is desired", "Anti-aging is the primary focus"],
    considerBothIf: "BPC-157 + ipamorelin is a popular combination for athletes and biohackers who want both healing support and GH optimization simultaneously.",
    relatedComparisons: ["bpc-157-vs-tb-500", "ipamorelin-vs-cjc-1295", "bpc-157-vs-ghk-cu"],
    faqItems: [
      { q: "Can I take BPC-157 and ipamorelin together?", a: "Yes. They work through completely different mechanisms and are commonly combined. BPC-157 addresses healing and repair while ipamorelin supports GH optimization and body composition." },
    ],
  },

  {
    slug: "epithalon-vs-nad",
    peptideA: "Epithalon", peptideASlug: "epithalon",
    peptideB: "NAD+", peptideBSlug: "nad-plus",
    h1: "Epithalon vs NAD+: Two Longevity Interventions Compared",
    metaDescription: "Epithalon vs NAD+: independent comparison of the telomerase-activating tetrapeptide and NAD+ precursors for longevity. Mechanism, evidence, and use cases. Vendor-neutral.",
    verdictSummary: "Epithalon activates telomerase to extend telomeres; NAD+ precursors restore declining NAD+ levels for sirtuin activation and DNA repair. They target different hallmarks of aging and are frequently combined in comprehensive longevity protocols.",
    category: "Longevity",
    atAGlance: [
      { dimension: "Primary Mechanism", peptideA: "Telomerase activation, telomere extension", peptideB: "NAD+ restoration, sirtuin activation" },
      { dimension: "Administration", peptideA: "Subcutaneous injection (cycled)", peptideB: "Oral (NMN/NR) or IV (NAD+)" },
      { dimension: "Evidence Level", peptideA: "Preclinical + limited human (Russian studies)", peptideB: "Moderate human (NMN/NR trials)" },
      { dimension: "Cost", peptideA: "~$100-$200/cycle", peptideB: "~$50-$200/month" },
    ],
    deepDiveA: "Epithalon (Epitalon) is a synthetic tetrapeptide derived from the pineal gland that activates telomerase, potentially extending telomere length. Russian clinical studies suggest benefits for longevity and age-related disease prevention.",
    deepDiveB: "NAD+ declines significantly with age, impairing sirtuin activity, DNA repair, and mitochondrial function. NMN and NR are oral precursors that restore NAD+ levels, with growing human clinical evidence for metabolic and longevity benefits.",
    chooseAIf: ["Telomere biology and telomerase activation are your focus", "You want a cycled injectable longevity protocol", "You are interested in the Russian longevity research tradition"],
    chooseBIf: ["Oral supplementation is preferred", "Mitochondrial function and energy metabolism are priorities", "You want the more extensively studied longevity intervention"],
    considerBothIf: "Epithalon and NAD+ precursors target complementary hallmarks of aging (telomere attrition vs NAD+ decline) and are frequently combined in comprehensive longevity stacks.",
    relatedComparisons: ["epithalon-vs-ghk-cu", "mots-c-vs-nad", "ghk-cu-vs-nad"],
    faqItems: [
      { q: "Should I take epithalon or NAD+ for longevity?", a: "They target different mechanisms. Epithalon focuses on telomere extension; NAD+ precursors address NAD+ decline and sirtuin activation. Many longevity protocols include both." },
    ],
  },

  {
    slug: "ghk-cu-vs-nad",
    peptideA: "GHK-Cu", peptideASlug: "ghk-cu",
    peptideB: "NAD+", peptideBSlug: "nad-plus",
    h1: "GHK-Cu vs NAD+: Copper Peptide vs NAD+ for Anti-Aging",
    metaDescription: "GHK-Cu vs NAD+: independent comparison for anti-aging. GHK-Cu targets skin and tissue repair; NAD+ targets cellular energy and DNA repair. Vendor-neutral.",
    verdictSummary: "GHK-Cu primarily targets tissue repair, collagen synthesis, and skin anti-aging. NAD+ precursors address cellular energy, DNA repair, and systemic aging. They are complementary rather than competitive.",
    category: "Anti-Aging",
    atAGlance: [
      { dimension: "Primary Target", peptideA: "Skin, tissue repair, collagen", peptideB: "Cellular energy, DNA repair, sirtuins" },
      { dimension: "Administration", peptideA: "Topical or subcutaneous injection", peptideB: "Oral (NMN/NR) or IV" },
      { dimension: "Evidence", peptideA: "Strong for skin; moderate systemic", peptideB: "Moderate human (NMN/NR)" },
    ],
    deepDiveA: "GHK-Cu has extensive evidence for skin anti-aging, wound healing, and collagen synthesis. It also has broader systemic effects including anti-inflammatory and gene expression modulation, but skin applications are best supported.",
    deepDiveB: "NAD+ precursors address one of the most well-established hallmarks of aging — NAD+ decline. Restoring NAD+ activates sirtuins and PARP enzymes involved in DNA repair, making it relevant for systemic aging beyond skin.",
    chooseAIf: ["Skin anti-aging and collagen are primary goals", "Topical application is preferred", "Wound healing or tissue repair is needed"],
    chooseBIf: ["Systemic anti-aging and cellular energy are priorities", "Oral supplementation is preferred", "You want the most extensively studied longevity intervention"],
    considerBothIf: "GHK-Cu (topical for skin) + NAD+ precursors (oral for systemic aging) is a common combination addressing both visible and cellular aging.",
    relatedComparisons: ["epithalon-vs-ghk-cu", "epithalon-vs-nad", "mots-c-vs-nad"],
    faqItems: [
      { q: "Is GHK-Cu or NAD+ better for anti-aging?", a: "They target different aspects of aging. GHK-Cu is best for skin and tissue repair; NAD+ precursors address cellular energy and DNA repair. Most comprehensive anti-aging protocols include both." },
    ],
  },

  {
    slug: "nad-vs-nmn",
    peptideA: "NAD+ (IV)", peptideASlug: "nad-plus",
    peptideB: "NMN (Oral)", peptideBSlug: "nad-plus",
    h1: "NAD+ IV vs NMN: Which Is the Better NAD+ Intervention?",
    metaDescription: "NAD+ IV vs NMN: independent comparison of intravenous NAD+ and oral NMN supplementation. Bioavailability, cost, evidence, and practical considerations. Vendor-neutral.",
    verdictSummary: "IV NAD+ provides immediate, high-bioavailability NAD+ restoration but requires clinical administration and is expensive. NMN is a convenient oral precursor with growing clinical evidence. For most people, oral NMN is the practical starting point.",
    category: "Longevity",
    atAGlance: [
      { dimension: "Route", peptideA: "Intravenous infusion", peptideB: "Oral capsule" },
      { dimension: "Bioavailability", peptideA: "100% (direct)", peptideB: "Moderate (precursor conversion)" },
      { dimension: "Cost", peptideA: "~$200-$600/session", peptideB: "~$50-$150/month" },
      { dimension: "Convenience", peptideA: "Requires clinic visit", peptideB: "Daily oral dose" },
    ],
    deepDiveA: "IV NAD+ delivers NAD+ directly into the bloodstream, bypassing the conversion steps required by oral precursors. It is used in clinical settings for addiction recovery, fatigue, and longevity. Effects are felt rapidly but require regular infusions.",
    deepDiveB: "NMN (nicotinamide mononucleotide) is a direct NAD+ precursor that is efficiently converted to NAD+ in most tissues. Human trials show it raises blood NAD+ levels and improves metabolic markers. It is the most practical daily NAD+ intervention.",
    chooseAIf: ["You want immediate, high-dose NAD+ restoration", "You are addressing a specific condition (fatigue, addiction recovery)", "You have access to a clinic offering NAD+ infusions"],
    chooseBIf: ["Daily oral supplementation is preferred", "Cost is a consideration", "You want a sustainable long-term NAD+ maintenance protocol"],
    considerBothIf: "Some longevity protocols use periodic IV NAD+ for acute restoration combined with daily oral NMN for maintenance.",
    relatedComparisons: ["nad-vs-niacin", "epithalon-vs-nad", "mots-c-vs-nad"],
    faqItems: [
      { q: "Is IV NAD+ better than NMN?", a: "IV NAD+ provides faster, more direct restoration but at much higher cost and inconvenience. For most people, oral NMN is the practical starting point, with IV NAD+ reserved for specific clinical applications." },
    ],
  },

  {
    slug: "nad-vs-niacin",
    peptideA: "NAD+ / NMN", peptideASlug: "nad-plus",
    peptideB: "Niacin (Vitamin B3)", peptideBSlug: "nad-plus",
    h1: "NAD+ / NMN vs Niacin: Which Is the Better NAD+ Booster?",
    metaDescription: "NAD+ / NMN vs niacin: comparing NAD+ precursors for raising NAD+ levels. Efficacy, flushing side effects, cost, and which is right for your goals. Vendor-neutral.",
    verdictSummary: "NMN and NR are more direct NAD+ precursors with fewer side effects than niacin. Niacin is the most cost-effective NAD+ booster but causes flushing. For longevity protocols, NMN or NR are generally preferred.",
    category: "Longevity",
    atAGlance: [
      { dimension: "NAD+ Precursor Efficiency", peptideA: "High (direct precursor)", peptideB: "Moderate (requires multiple conversion steps)" },
      { dimension: "Flushing Side Effect", peptideA: "None", peptideB: "Common (especially immediate-release)" },
      { dimension: "Cost", peptideA: "~$50-$150/month", peptideB: "~$5-$20/month" },
      { dimension: "Additional Benefits", peptideA: "Longevity-focused", peptideB: "Cholesterol management, cardiovascular" },
    ],
    deepDiveA: "NMN and NR are direct NAD+ precursors that efficiently raise NAD+ levels in most tissues. They do not cause flushing and have growing clinical evidence for metabolic and longevity benefits.",
    deepDiveB: "Niacin (nicotinic acid) is the most cost-effective way to raise NAD+ levels and has additional cardiovascular benefits (raises HDL, lowers triglycerides). However, flushing is a common side effect that limits adherence.",
    chooseAIf: ["Longevity and NAD+ optimization are the primary goals", "You want to avoid flushing side effects", "You are willing to pay more for a cleaner supplement"],
    chooseBIf: ["Cost is a primary consideration", "You also want cardiovascular benefits (HDL raising)", "You can tolerate or manage flushing"],
    considerBothIf: undefined,
    relatedComparisons: ["nad-vs-nmn", "epithalon-vs-nad", "mots-c-vs-nad"],
    faqItems: [
      { q: "Is niacin as good as NMN for raising NAD+?", a: "Niacin can raise NAD+ levels but requires more conversion steps and causes flushing. NMN and NR are more direct precursors without flushing. For longevity-focused protocols, NMN or NR are generally preferred." },
    ],
  },

  {
    slug: "selank-vs-semax-anxiety",
    peptideA: "Selank", peptideASlug: "selank",
    peptideB: "Semax", peptideBSlug: "semax",
    h1: "Selank vs Semax for Anxiety: Which Nootropic Peptide Is Better?",
    metaDescription: "Selank vs semax for anxiety: independent comparison. Selank is primarily anxiolytic; semax is primarily cognitive-enhancing. Which is right for your goals? Vendor-neutral.",
    verdictSummary: "Selank is the clear choice for anxiety reduction due to its GABAergic mechanism. Semax is better for cognitive enhancement and focus. For anxiety specifically, selank is more targeted and better supported by evidence.",
    category: "Cognitive / Nootropic",
    atAGlance: [
      { dimension: "Primary Effect", peptideA: "Anxiolytic, calming", peptideB: "Cognitive enhancement, focus" },
      { dimension: "Mechanism", peptideA: "GABAergic, serotonin modulation", peptideB: "BDNF upregulation, dopamine" },
      { dimension: "Anxiety Evidence", peptideA: "Strong (primary indication)", peptideB: "Limited" },
      { dimension: "Stimulating Effect", peptideA: "Calming (not sedating)", peptideB: "Mildly stimulating" },
    ],
    deepDiveA: "Selank was developed specifically as an anxiolytic peptide. It modulates the GABAergic system and serotonin pathways, producing anxiolytic effects without sedation or dependence. Russian clinical trials support its use for anxiety and stress.",
    deepDiveB: "Semax primarily enhances cognitive function through BDNF upregulation and dopaminergic modulation. While it may reduce anxiety indirectly through improved stress resilience, it is not primarily an anxiolytic.",
    chooseAIf: ["Anxiety reduction is the primary goal", "You want a calming effect without sedation", "You want the peptide with the most anxiety-specific evidence"],
    chooseBIf: ["Cognitive enhancement and focus are the primary goals", "You want BDNF upregulation for neuroprotection", "Mild stimulation is acceptable or desired"],
    considerBothIf: "Some protocols combine selank (morning, for anxiety management) with semax (for cognitive tasks) to address both anxiety and cognitive performance.",
    relatedComparisons: ["selank-vs-semax", "semax-vs-dihexa", "selank-vs-cerebrolysin"],
    faqItems: [
      { q: "Which is better for anxiety, selank or semax?", a: "Selank is specifically designed as an anxiolytic and has more evidence for anxiety reduction. Semax is better suited for cognitive enhancement. For anxiety, selank is the more targeted choice." },
    ],
  },

  {
    slug: "semax-vs-dihexa",
    peptideA: "Semax", peptideASlug: "semax",
    peptideB: "Dihexa", peptideBSlug: "dihexa",
    h1: "Semax vs Dihexa: Comparing Two Cognitive Enhancement Peptides",
    metaDescription: "Semax vs dihexa: independent comparison of two nootropic peptides. BDNF upregulation vs HGF/c-Met signaling. Evidence, potency, and use cases. Vendor-neutral.",
    verdictSummary: "Semax has more human clinical data and a longer track record. Dihexa is theoretically more potent for neurogenesis but has minimal human data. Semax is the safer starting point for cognitive enhancement.",
    category: "Cognitive / Nootropic",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "BDNF upregulation, ACTH analogue", peptideB: "HGF/c-Met signaling, neurogenesis" },
      { dimension: "Human Clinical Data", peptideA: "Moderate (Russian trials)", peptideB: "Minimal (preclinical primarily)" },
      { dimension: "Potency Claim", peptideA: "Moderate", peptideB: "Very high (theoretical)" },
      { dimension: "Safety Profile", peptideA: "Well-characterized", peptideB: "Limited long-term data" },
    ],
    deepDiveA: "Semax is an ACTH analogue that upregulates BDNF and has neuroprotective effects. Russian clinical trials support its use for cognitive enhancement, stroke recovery, and ADHD. It is available as a nasal spray.",
    deepDiveB: "Dihexa is a highly potent HGF/c-Met agonist that promotes synaptogenesis and neurogenesis in preclinical studies. Animal studies suggest it may be 10 million times more potent than BDNF for cognitive enhancement, but human data is extremely limited.",
    chooseAIf: ["You want a well-characterized cognitive peptide with clinical data", "Safety and known side effect profile are priorities", "You are new to nootropic peptides"],
    chooseBIf: ["You are an experienced researcher interested in cutting-edge compounds", "Maximum neurogenic potential is the goal", "You accept the limited human safety data"],
    considerBothIf: undefined,
    relatedComparisons: ["selank-vs-semax", "cerebrolysin-vs-dihexa", "semax-vs-cerebrolysin"],
    faqItems: [
      { q: "Is dihexa stronger than semax?", a: "Preclinical data suggests dihexa may be significantly more potent for neurogenesis, but human clinical data is extremely limited. Semax has a much better-characterized safety profile and is the more practical choice for most users." },
    ],
  },

  {
    slug: "pt-141-vs-tadalafil",
    peptideA: "PT-141", peptideASlug: "pt-141",
    peptideB: "Tadalafil (Cialis)", peptideBSlug: "pt-141",
    h1: "PT-141 vs Tadalafil (Cialis): Central vs Peripheral Sexual Enhancement",
    metaDescription: "PT-141 vs tadalafil (Cialis): independent comparison. PT-141 works centrally on the brain; tadalafil works peripherally on blood flow. Different mechanisms, different use cases. Vendor-neutral.",
    verdictSummary: "PT-141 (bremelanotide) works centrally through melanocortin receptors to enhance sexual desire. Tadalafil works peripherally by increasing blood flow. They address different aspects of sexual function and are often combined.",
    category: "Sexual Health",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "Central (melanocortin receptors, brain)", peptideB: "Peripheral (PDE5 inhibitor, blood flow)" },
      { dimension: "Primary Effect", peptideA: "Sexual desire and arousal", peptideB: "Erectile function (blood flow)" },
      { dimension: "Works for Women", peptideA: "Yes (FDA approved for HSDD)", peptideB: "Limited evidence" },
      { dimension: "FDA Status", peptideA: "Approved (Vyleesi, for women)", peptideB: "Approved (erectile dysfunction)" },
      { dimension: "Onset", peptideA: "45-90 minutes", peptideB: "30-60 minutes (up to 36 hours)" },
    ],
    deepDiveA: "PT-141 (bremelanotide) is FDA approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works centrally through melanocortin-4 receptors in the brain to enhance sexual desire and arousal, independent of blood flow.",
    deepDiveB: "Tadalafil (Cialis) is a PDE5 inhibitor that increases blood flow to genital tissue by preventing cGMP breakdown. It is highly effective for erectile dysfunction but does not directly address sexual desire or arousal.",
    chooseAIf: ["Low sexual desire or arousal is the primary concern", "You are a woman with HSDD", "You want central (brain-level) sexual enhancement"],
    chooseBIf: ["Erectile function is the primary concern", "You want the most extensively studied sexual health medication", "Long-duration effect (up to 36 hours) is desired"],
    considerBothIf: "PT-141 + tadalafil is a popular combination addressing both central desire and peripheral erectile function simultaneously.",
    relatedComparisons: ["pt-141-vs-sildenafil", "pt-141-vs-oxytocin", "melanotan-2-vs-pt-141"],
    faqItems: [
      { q: "Can I take PT-141 and Cialis together?", a: "Many people combine them to address both desire (PT-141) and erectile function (tadalafil). However, this combination can cause blood pressure changes and should be done under medical supervision." },
    ],
  },

  {
    slug: "pt-141-vs-sildenafil",
    peptideA: "PT-141", peptideASlug: "pt-141",
    peptideB: "Sildenafil (Viagra)", peptideBSlug: "pt-141",
    h1: "PT-141 vs Sildenafil (Viagra): Brain vs Blood Flow Approach to Sexual Health",
    metaDescription: "PT-141 vs sildenafil (Viagra): independent comparison. PT-141 enhances desire centrally; sildenafil improves erectile function peripherally. Evidence, side effects, and use cases. Vendor-neutral.",
    verdictSummary: "PT-141 addresses sexual desire through central melanocortin pathways; sildenafil addresses erectile function through peripheral blood flow. They are complementary rather than competing, targeting different aspects of sexual health.",
    category: "Sexual Health",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "Central melanocortin receptor agonist", peptideB: "PDE5 inhibitor (peripheral)" },
      { dimension: "Primary Benefit", peptideA: "Sexual desire and arousal", peptideB: "Erectile function" },
      { dimension: "Duration", peptideA: "6-12 hours", peptideB: "4-6 hours" },
      { dimension: "Works Without Arousal", peptideA: "Yes (desire-enhancing)", peptideB: "No (requires sexual stimulation)" },
    ],
    deepDiveA: "PT-141 enhances sexual desire and arousal through central nervous system pathways, making it effective even when the primary issue is low desire rather than mechanical erectile dysfunction.",
    deepDiveB: "Sildenafil (Viagra) is the most studied erectile dysfunction medication. It requires sexual stimulation to work and addresses the mechanical aspect of erectile function through vasodilation, not desire.",
    chooseAIf: ["Low desire or arousal is the primary issue", "You want central (brain-level) sexual enhancement", "Sildenafil has not been effective for you"],
    chooseBIf: ["Erectile function is the primary concern", "You want the most extensively studied option", "Rapid onset (30-60 min) and well-known side effect profile are important"],
    considerBothIf: "PT-141 + sildenafil is used by some to address both desire and erectile function simultaneously.",
    relatedComparisons: ["pt-141-vs-tadalafil", "pt-141-vs-oxytocin", "melanotan-2-vs-pt-141"],
    faqItems: [
      { q: "Is PT-141 better than Viagra?", a: "They work differently. PT-141 enhances desire centrally; Viagra improves erectile function peripherally. For low desire, PT-141 may be more effective. For mechanical erectile dysfunction, sildenafil has stronger evidence." },
    ],
  },

  {
    slug: "melanotan-2-vs-pt-141",
    peptideA: "Melanotan II", peptideASlug: "melanotan-2",
    peptideB: "PT-141", peptideBSlug: "pt-141",
    h1: "Melanotan II vs PT-141: Parent Compound vs Refined Sexual Health Peptide",
    metaDescription: "Melanotan II vs PT-141: independent comparison. PT-141 is derived from Melanotan II with the tanning effect removed. Sexual health effects, side effects, and which to choose. Vendor-neutral.",
    verdictSummary: "PT-141 was derived from Melanotan II specifically to retain sexual health effects while removing the tanning/pigmentation effects. For sexual health purposes, PT-141 is the more targeted and FDA-approved option.",
    category: "Sexual Health",
    atAGlance: [
      { dimension: "Tanning Effect", peptideA: "Yes (significant)", peptideB: "Minimal" },
      { dimension: "Sexual Health Effect", peptideA: "Yes (but not primary)", peptideB: "Yes (primary indication)" },
      { dimension: "FDA Status", peptideA: "Not approved", peptideB: "Approved (Vyleesi for women)" },
      { dimension: "Nausea Side Effect", peptideA: "Common", peptideB: "Common" },
      { dimension: "Melanoma Risk", peptideA: "Theoretical concern", peptideB: "Lower (less melanocortin-1 activity)" },
    ],
    deepDiveA: "Melanotan II activates multiple melanocortin receptors (MC1R, MC3R, MC4R), producing tanning, appetite suppression, and sexual arousal effects. The broad receptor activation also increases side effect risk including nausea and potential melanoma concerns.",
    deepDiveB: "PT-141 was developed from Melanotan II to be more selective for MC3R and MC4R (sexual health) with less MC1R activity (tanning). This makes it more targeted for sexual health with a better-characterized safety profile.",
    chooseAIf: ["Tanning effect is also desired", "Cost is a consideration (Melanotan II is cheaper)", "You are aware of and accept the additional risks"],
    chooseBIf: ["Sexual health is the sole goal", "You want the FDA-approved, more targeted option", "You want to minimize melanoma-related concerns"],
    considerBothIf: undefined,
    relatedComparisons: ["pt-141-vs-tadalafil", "pt-141-vs-sildenafil", "pt-141-vs-oxytocin"],
    faqItems: [
      { q: "Is Melanotan II the same as PT-141?", a: "PT-141 (bremelanotide) was derived from Melanotan II but is more selective for sexual health receptors with less tanning activity. For sexual health purposes, PT-141 is the more targeted and safer option." },
    ],
  },

  {
    slug: "ghk-cu-vs-retinol",
    peptideA: "GHK-Cu", peptideASlug: "ghk-cu",
    peptideB: "Retinol (Vitamin A)", peptideBSlug: "ghk-cu",
    h1: "GHK-Cu vs Retinol: Copper Peptide vs Vitamin A for Skin Anti-Aging",
    metaDescription: "GHK-Cu vs retinol: independent comparison for skin anti-aging. Collagen stimulation, tolerability, and evidence compared. Which is better for your skin? Vendor-neutral.",
    verdictSummary: "Both GHK-Cu and retinol stimulate collagen production and reduce signs of aging, but through different mechanisms. Retinol has more extensive clinical evidence; GHK-Cu is better tolerated and has additional wound healing and anti-inflammatory properties.",
    category: "Skin Health",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "Copper-mediated collagen synthesis, wound healing", peptideB: "Retinoic acid receptor activation, cell turnover" },
      { dimension: "Irritation Risk", peptideA: "Low", peptideB: "Moderate to high (especially initially)" },
      { dimension: "Clinical Evidence", peptideA: "Good for skin", peptideB: "Extensive (decades of data)" },
      { dimension: "Sun Sensitivity", peptideA: "None", peptideB: "Increases photosensitivity" },
    ],
    deepDiveA: "GHK-Cu stimulates collagen and elastin synthesis, promotes wound healing, and has anti-inflammatory properties. It is well-tolerated even by sensitive skin and can be used morning and evening without photosensitivity concerns.",
    deepDiveB: "Retinol (vitamin A) is the most extensively studied topical anti-aging ingredient. It accelerates cell turnover, stimulates collagen, and reduces fine lines and hyperpigmentation. However, it causes irritation and photosensitivity, especially during the adjustment period.",
    chooseAIf: ["Sensitive skin or retinol intolerance", "You want anti-aging without photosensitivity", "Wound healing or redness reduction is also a goal"],
    chooseBIf: ["You want the most extensively studied anti-aging ingredient", "Cell turnover and hyperpigmentation are primary concerns", "You can tolerate the adjustment period"],
    considerBothIf: "GHK-Cu + retinol is a popular combination: retinol for cell turnover and GHK-Cu to mitigate retinol irritation and enhance collagen synthesis.",
    relatedComparisons: ["ghk-cu-vs-hyaluronic-acid", "ghk-cu-vs-argireline", "snap-8-vs-argireline"],
    faqItems: [
      { q: "Can I use GHK-Cu with retinol?", a: "Yes. GHK-Cu can actually help mitigate retinol irritation while enhancing collagen synthesis. Using GHK-Cu in the morning and retinol at night is a common approach." },
    ],
  },

  {
    slug: "ghk-cu-vs-hyaluronic-acid",
    peptideA: "GHK-Cu", peptideASlug: "ghk-cu",
    peptideB: "Hyaluronic Acid", peptideBSlug: "ghk-cu",
    h1: "GHK-Cu vs Hyaluronic Acid: Copper Peptide vs Humectant for Skin",
    metaDescription: "GHK-Cu vs hyaluronic acid: independent comparison for skin health. Active repair vs hydration. Which does your skin need? Vendor-neutral.",
    verdictSummary: "GHK-Cu actively repairs and remodels skin through collagen synthesis and wound healing. Hyaluronic acid is a humectant that provides hydration and plumping. They serve different purposes and are best used together.",
    category: "Skin Health",
    atAGlance: [
      { dimension: "Primary Action", peptideA: "Active repair, collagen synthesis", peptideB: "Hydration, moisture retention" },
      { dimension: "Anti-Aging Mechanism", peptideA: "Structural repair", peptideB: "Plumping, reduced appearance of lines" },
      { dimension: "Evidence", peptideA: "Good for skin repair", peptideB: "Extensive for hydration" },
    ],
    deepDiveA: "GHK-Cu actively repairs skin by stimulating collagen and elastin synthesis, promoting angiogenesis, and reducing inflammation. Its effects are structural and long-lasting rather than cosmetic.",
    deepDiveB: "Hyaluronic acid is a humectant that attracts and retains water in the skin, providing immediate hydration and temporary plumping of fine lines. It does not actively repair skin structure but significantly improves skin feel and appearance.",
    chooseAIf: ["Structural skin repair and collagen building are the goals", "You want active anti-aging beyond hydration", "Wound healing or redness is a concern"],
    chooseBIf: ["Immediate hydration and skin plumping are the goals", "You want a well-tolerated, widely available ingredient", "Dry or dehydrated skin is the primary concern"],
    considerBothIf: "GHK-Cu + hyaluronic acid is one of the most popular skincare combinations: GHK-Cu for structural repair and HA for hydration and immediate plumping.",
    relatedComparisons: ["ghk-cu-vs-retinol", "ghk-cu-vs-argireline", "snap-8-vs-argireline"],
    faqItems: [
      { q: "Should I use GHK-Cu or hyaluronic acid?", a: "They serve different purposes. GHK-Cu repairs skin structure; hyaluronic acid provides hydration. Most skincare routines benefit from both." },
    ],
  },

  {
    slug: "ghk-cu-vs-minoxidil",
    peptideA: "GHK-Cu", peptideASlug: "ghk-cu",
    peptideB: "Minoxidil", peptideBSlug: "ghk-cu",
    h1: "GHK-Cu vs Minoxidil for Hair Loss: Peptide vs Classic Treatment",
    metaDescription: "GHK-Cu vs minoxidil for hair loss: independent comparison. GHK-Cu promotes hair follicle health; minoxidil prolongs the anagen phase. Evidence, side effects, and which to use. Vendor-neutral.",
    verdictSummary: "Minoxidil has decades of clinical evidence as the gold standard topical hair loss treatment. GHK-Cu has emerging evidence for hair follicle health and may enhance minoxidil's effects. For established hair loss, minoxidil has stronger evidence.",
    category: "Hair Health",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "Hair follicle stem cell activation, anti-inflammatory", peptideB: "Prolongs anagen phase, vasodilation" },
      { dimension: "Clinical Evidence", peptideA: "Emerging", peptideB: "Extensive (FDA approved)" },
      { dimension: "Side Effects", peptideA: "Minimal", peptideB: "Scalp irritation, initial shedding" },
      { dimension: "Application", peptideA: "Topical serum", peptideB: "Topical solution/foam" },
    ],
    deepDiveA: "GHK-Cu activates hair follicle stem cells, reduces scalp inflammation, and may promote hair follicle health. While clinical evidence is less extensive than minoxidil, it is well-tolerated and may enhance the effects of other hair loss treatments.",
    deepDiveB: "Minoxidil is the most extensively studied topical hair loss treatment with FDA approval for androgenetic alopecia. It prolongs the anagen (growth) phase and increases follicle size. Initial shedding is common as telogen hairs are displaced.",
    chooseAIf: ["You want a well-tolerated adjunct to standard treatments", "Scalp inflammation or sensitivity is a concern", "You prefer a peptide-based approach"],
    chooseBIf: ["You want the most clinically validated hair loss treatment", "You have androgenetic alopecia (pattern hair loss)", "FDA-approved status is important"],
    considerBothIf: "GHK-Cu + minoxidil is a popular combination: minoxidil for proven hair growth stimulation and GHK-Cu for follicle health and anti-inflammatory support.",
    relatedComparisons: ["bpc-157-vs-minoxidil", "ghk-cu-vs-retinol", "ghk-cu-vs-hyaluronic-acid"],
    faqItems: [
      { q: "Can I use GHK-Cu with minoxidil?", a: "Yes. GHK-Cu and minoxidil work through different mechanisms and can be used together. Some formulations combine them in a single topical product." },
    ],
  },

  {
    slug: "bpc-157-vs-minoxidil",
    peptideA: "BPC-157", peptideASlug: "bpc-157",
    peptideB: "Minoxidil", peptideBSlug: "ghk-cu",
    h1: "BPC-157 vs Minoxidil for Hair Loss: Healing Peptide vs Classic Treatment",
    metaDescription: "BPC-157 vs minoxidil for hair loss: independent comparison. BPC-157 promotes tissue healing and angiogenesis; minoxidil prolongs the anagen phase. Evidence and use cases. Vendor-neutral.",
    verdictSummary: "Minoxidil has far more clinical evidence for hair loss specifically. BPC-157 may support hair follicle health through angiogenesis and anti-inflammatory effects, but is not primarily a hair loss treatment. Minoxidil is the first-line choice.",
    category: "Hair Health",
    atAGlance: [
      { dimension: "Primary Purpose", peptideA: "Tissue healing, angiogenesis", peptideB: "Hair loss treatment (FDA approved)" },
      { dimension: "Hair Loss Evidence", peptideA: "Limited / emerging", peptideB: "Extensive" },
      { dimension: "Mechanism for Hair", peptideA: "Angiogenesis, anti-inflammatory", peptideB: "Anagen phase prolongation" },
    ],
    deepDiveA: "BPC-157 promotes angiogenesis (new blood vessel formation) and has anti-inflammatory effects that may support scalp health. However, it is not primarily studied as a hair loss treatment and clinical evidence for this application is limited.",
    deepDiveB: "Minoxidil is the gold standard topical hair loss treatment with decades of clinical data and FDA approval. It is the most evidence-based first-line option for androgenetic alopecia.",
    chooseAIf: ["You want a healing peptide that may support scalp health as an adjunct", "You have scalp inflammation or poor circulation", "You are exploring peptide-based approaches"],
    chooseBIf: ["You want the most evidence-based hair loss treatment", "You have androgenetic alopecia", "FDA-approved status is important"],
    considerBothIf: "BPC-157 + minoxidil may be used together, with BPC-157 providing angiogenic support and minoxidil providing the primary hair growth stimulus.",
    relatedComparisons: ["ghk-cu-vs-minoxidil", "bpc-157-vs-ghk-cu", "bpc-157-vs-tb-500"],
    faqItems: [
      { q: "Is BPC-157 good for hair loss?", a: "BPC-157 is not primarily a hair loss treatment. While its angiogenic and anti-inflammatory properties may support scalp health, minoxidil has far stronger evidence for hair loss specifically." },
    ],
  },

  {
    slug: "thymosin-alpha-1-vs-ll-37",
    peptideA: "Thymosin Alpha-1", peptideASlug: "thymosin-alpha-1",
    peptideB: "LL-37", peptideBSlug: "ll-37",
    h1: "Thymosin Alpha-1 vs LL-37: Two Immune-Modulating Peptides Compared",
    metaDescription: "Thymosin Alpha-1 vs LL-37: independent comparison of two immune peptides. Thymosin Alpha-1 modulates T-cell immunity; LL-37 is an antimicrobial peptide. Evidence and use cases. Vendor-neutral.",
    verdictSummary: "Thymosin Alpha-1 modulates adaptive immunity through T-cell regulation and has the strongest clinical evidence of any immune peptide. LL-37 is an antimicrobial peptide with innate immune effects. They target different aspects of immune function.",
    category: "Immune Support",
    atAGlance: [
      { dimension: "Immune System Target", peptideA: "Adaptive immunity (T-cells)", peptideB: "Innate immunity (antimicrobial)" },
      { dimension: "Clinical Evidence", peptideA: "Strong (approved in some countries)", peptideB: "Preclinical + limited human" },
      { dimension: "Primary Use", peptideA: "Immune modulation, chronic infections", peptideB: "Antimicrobial, wound healing" },
    ],
    deepDiveA: "Thymosin Alpha-1 (Zadaxin) is approved in several countries for hepatitis B, hepatitis C, and as an immune modulator. It enhances T-cell function and has been studied in cancer, HIV, and sepsis. It has the strongest clinical evidence of any immune peptide.",
    deepDiveB: "LL-37 is a human cathelicidin antimicrobial peptide that kills bacteria, viruses, and fungi directly while also modulating innate immune responses. It has anti-biofilm properties and is studied for wound healing and chronic infections.",
    chooseAIf: ["Adaptive immune modulation is the goal", "You want the immune peptide with the strongest clinical evidence", "Chronic viral infections or immune deficiency are concerns"],
    chooseBIf: ["Antimicrobial effects and innate immunity are the focus", "Wound healing or biofilm-related infections are concerns", "You want a peptide with direct antimicrobial activity"],
    considerBothIf: "Thymosin Alpha-1 + LL-37 may be combined for comprehensive immune support addressing both adaptive and innate immunity.",
    relatedComparisons: ["thymosin-alpha-1-vs-bpc-157", "ll-37-vs-bpc-157", "bpc-157-vs-tb-500"],
    faqItems: [
      { q: "Which is better for immune support, Thymosin Alpha-1 or LL-37?", a: "Thymosin Alpha-1 has stronger clinical evidence and is better for adaptive immune modulation. LL-37 is better for antimicrobial effects and innate immunity. They target different aspects of immune function." },
    ],
  },

  {
    slug: "thymosin-alpha-1-vs-bpc-157",
    peptideA: "Thymosin Alpha-1", peptideASlug: "thymosin-alpha-1",
    peptideB: "BPC-157", peptideBSlug: "bpc-157",
    h1: "Thymosin Alpha-1 vs BPC-157: Immune Peptide vs Healing Peptide",
    metaDescription: "Thymosin Alpha-1 vs BPC-157: independent comparison. Thymosin Alpha-1 modulates immunity; BPC-157 promotes tissue healing. Different goals, different peptides. Vendor-neutral.",
    verdictSummary: "Thymosin Alpha-1 and BPC-157 serve fundamentally different purposes. Thymosin Alpha-1 is an immune modulator; BPC-157 is a tissue healing peptide. The choice depends entirely on whether immune support or tissue repair is the primary goal.",
    category: "Immune Support",
    atAGlance: [
      { dimension: "Primary Purpose", peptideA: "Immune modulation, T-cell support", peptideB: "Tissue healing, gut repair, injury recovery" },
      { dimension: "Mechanism", peptideA: "T-cell differentiation, cytokine modulation", peptideB: "Angiogenesis, growth factor upregulation" },
      { dimension: "Best For", peptideA: "Chronic infections, immune deficiency, cancer support", peptideB: "Injuries, gut issues, inflammation" },
    ],
    deepDiveA: "Thymosin Alpha-1 is the most clinically validated immune peptide, with approval in multiple countries for hepatitis and immune modulation. It is the first choice for immune-focused peptide protocols.",
    deepDiveB: "BPC-157 is the most researched healing peptide, with extensive preclinical evidence for tissue repair across multiple organ systems. It is the first choice for injury recovery and gut healing protocols.",
    chooseAIf: ["Immune modulation is the primary goal", "Chronic infections or immune deficiency are concerns", "You want the most clinically validated immune peptide"],
    chooseBIf: ["Tissue healing and injury recovery are the primary goals", "Gut health or inflammation are concerns", "You want the most researched healing peptide"],
    considerBothIf: "BPC-157 + Thymosin Alpha-1 is used by some for comprehensive healing and immune support, particularly in post-surgical or chronic illness contexts.",
    relatedComparisons: ["thymosin-alpha-1-vs-ll-37", "bpc-157-vs-tb-500", "bpc-157-vs-ghk-cu"],
    faqItems: [
      { q: "Should I use Thymosin Alpha-1 or BPC-157?", a: "It depends on your goals. For immune support, Thymosin Alpha-1 is the choice. For tissue healing and injury recovery, BPC-157 is the choice. They are not interchangeable." },
    ],
  },

  {
    slug: "ll-37-vs-bpc-157",
    peptideA: "LL-37", peptideASlug: "ll-37",
    peptideB: "BPC-157", peptideBSlug: "bpc-157",
    h1: "LL-37 vs BPC-157: Antimicrobial Peptide vs Healing Peptide",
    metaDescription: "LL-37 vs BPC-157: independent comparison. LL-37 kills pathogens and modulates innate immunity; BPC-157 promotes tissue healing. Evidence and use cases. Vendor-neutral.",
    verdictSummary: "LL-37 and BPC-157 have overlapping applications in wound healing and infection control but through different mechanisms. BPC-157 has more extensive research; LL-37 adds direct antimicrobial activity.",
    category: "Immune Support",
    atAGlance: [
      { dimension: "Primary Mechanism", peptideA: "Antimicrobial, innate immune modulation", peptideB: "Angiogenesis, growth factor upregulation" },
      { dimension: "Wound Healing", peptideA: "Yes (antimicrobial + healing)", peptideB: "Yes (primary indication)" },
      { dimension: "Research Depth", peptideA: "Moderate", peptideB: "Extensive" },
    ],
    deepDiveA: "LL-37 kills bacteria, viruses, and fungi directly while promoting wound healing and modulating innate immune responses. It is particularly relevant for infected wounds or biofilm-related conditions.",
    deepDiveB: "BPC-157 promotes wound healing through angiogenesis, growth factor upregulation, and anti-inflammatory mechanisms. It has the most extensive preclinical evidence of any healing peptide.",
    chooseAIf: ["Antimicrobial effects are needed (infected wounds, biofilm)", "Innate immune modulation is the goal", "You want direct pathogen-killing activity"],
    chooseBIf: ["Tissue healing without infection is the primary goal", "You want the most researched healing peptide", "Gut healing or systemic repair is needed"],
    considerBothIf: "LL-37 + BPC-157 may be used together for infected wounds or conditions where both antimicrobial and healing support are needed.",
    relatedComparisons: ["thymosin-alpha-1-vs-ll-37", "thymosin-alpha-1-vs-bpc-157", "bpc-157-vs-tb-500"],
    faqItems: [
      { q: "Can LL-37 and BPC-157 be used together?", a: "Yes. They work through different mechanisms and may be complementary for infected wounds or conditions requiring both antimicrobial and healing support." },
    ],
  },

  {
    slug: "snap-8-vs-argireline",
    peptideA: "SNAP-8", peptideASlug: "snap-8",
    peptideB: "Argireline (Acetyl Hexapeptide-3)", peptideBSlug: "snap-8",
    h1: "SNAP-8 vs Argireline: Which Anti-Wrinkle Peptide Is More Effective?",
    metaDescription: "SNAP-8 vs argireline: independent comparison of two expression-line reducing peptides. Mechanism, evidence, and which is better for wrinkle reduction. Vendor-neutral.",
    verdictSummary: "SNAP-8 is an 8-amino acid extension of argireline (6 amino acids) that is claimed to be more potent. Both reduce expression lines by inhibiting SNARE complex formation. Evidence for both is primarily industry-funded.",
    category: "Skin Health",
    atAGlance: [
      { dimension: "Peptide Length", peptideA: "8 amino acids", peptideB: "6 amino acids" },
      { dimension: "Mechanism", peptideA: "SNARE complex inhibition (acetylcholine release)", peptideB: "SNARE complex inhibition" },
      { dimension: "Claimed Potency", peptideA: "More potent (claimed)", peptideB: "Well-established" },
      { dimension: "Evidence Quality", peptideA: "Primarily industry-funded", peptideB: "Primarily industry-funded" },
    ],
    deepDiveA: "SNAP-8 is an 8-amino acid peptide that inhibits the SNARE complex involved in acetylcholine release at neuromuscular junctions, reducing muscle contraction and expression lines. It is claimed to be more effective than argireline at lower concentrations.",
    deepDiveB: "Argireline (acetyl hexapeptide-3) is one of the most widely used anti-wrinkle peptides in cosmetics. It works by the same SNARE inhibition mechanism and has more extensive (though largely industry-funded) evidence.",
    chooseAIf: ["You want the claimed higher potency option", "You are formulating at lower peptide concentrations", "You are already familiar with argireline and want to upgrade"],
    chooseBIf: ["You want the more established and widely studied option", "Cost is a consideration", "You prefer the ingredient with more independent formulation data"],
    considerBothIf: undefined,
    relatedComparisons: ["ghk-cu-vs-argireline", "ghk-cu-vs-snap-8", "ghk-cu-vs-retinol"],
    faqItems: [
      { q: "Is SNAP-8 better than argireline?", a: "SNAP-8 is claimed to be more potent than argireline at lower concentrations, but most evidence is industry-funded. Both work through the same SNARE inhibition mechanism." },
    ],
  },

  {
    slug: "ghk-cu-vs-argireline",
    peptideA: "GHK-Cu", peptideASlug: "ghk-cu",
    peptideB: "Argireline", peptideBSlug: "ghk-cu",
    h1: "GHK-Cu vs Argireline: Structural Repair vs Expression Line Reduction",
    metaDescription: "GHK-Cu vs argireline: independent comparison for skin anti-aging. GHK-Cu repairs skin structure; argireline reduces expression lines. Different mechanisms, different results. Vendor-neutral.",
    verdictSummary: "GHK-Cu and argireline work through completely different mechanisms. GHK-Cu repairs skin structure through collagen synthesis; argireline reduces expression lines by inhibiting muscle contractions. They are complementary.",
    category: "Skin Health",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "Collagen synthesis, wound healing", peptideB: "SNARE inhibition (reduces muscle contraction)" },
      { dimension: "Target Wrinkle Type", peptideA: "All wrinkles (structural)", peptideB: "Expression lines (dynamic wrinkles)" },
      { dimension: "Evidence Quality", peptideA: "Good independent evidence", peptideB: "Primarily industry-funded" },
    ],
    deepDiveA: "GHK-Cu addresses the structural causes of skin aging by stimulating collagen and elastin synthesis and promoting skin repair. It is effective for all types of wrinkles, not just expression lines.",
    deepDiveB: "Argireline specifically targets expression lines (dynamic wrinkles caused by muscle movement) by inhibiting acetylcholine release. It does not address structural skin aging.",
    chooseAIf: ["Structural skin repair and collagen building are the goals", "You want to address all types of wrinkles", "You want the ingredient with stronger independent evidence"],
    chooseBIf: ["Expression lines (forehead, crow's feet) are the primary concern", "You want a topical Botox-like effect", "You are targeting specific dynamic wrinkles"],
    considerBothIf: "GHK-Cu + argireline is a popular combination: GHK-Cu for structural repair and argireline for expression line reduction.",
    relatedComparisons: ["ghk-cu-vs-snap-8", "snap-8-vs-argireline", "ghk-cu-vs-retinol"],
    faqItems: [
      { q: "Should I use GHK-Cu or argireline?", a: "They target different aspects of skin aging. GHK-Cu repairs skin structure; argireline reduces expression lines. Most comprehensive anti-aging routines benefit from both." },
    ],
  },

  {
    slug: "semaglutide-vs-orforglipron",
    peptideA: "Semaglutide", peptideASlug: "semaglutide",
    peptideB: "Orforglipron", peptideBSlug: "semaglutide",
    h1: "Semaglutide vs Orforglipron: Injectable vs Oral GLP-1 Compared",
    metaDescription: "Semaglutide vs orforglipron: comparing injectable semaglutide to the oral non-peptide GLP-1 agonist orforglipron. Efficacy, convenience, and availability. Vendor-neutral.",
    verdictSummary: "Orforglipron is a promising oral non-peptide GLP-1 agonist in late-stage trials that does not require fasting like Rybelsus. If approved, it could significantly expand access to GLP-1 therapy. Semaglutide remains the current standard.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "Route", peptideA: "Subcutaneous injection (weekly)", peptideB: "Oral tablet (daily, no fasting required)" },
      { dimension: "FDA Status", peptideA: "Approved", peptideB: "Phase 3 trials (2025)" },
      { dimension: "Avg. Weight Loss", peptideA: "~15%", peptideB: "~14-15% (Phase 2/3 data)" },
      { dimension: "Fasting Requirement", peptideA: "None", peptideB: "None (advantage over Rybelsus)" },
    ],
    deepDiveA: "Semaglutide is the current gold standard GLP-1 agonist with extensive clinical data and FDA approval for both diabetes and obesity. Its once-weekly injectable format is well-established.",
    deepDiveB: "Orforglipron is a small-molecule oral GLP-1 agonist that does not require fasting (unlike Rybelsus). Phase 3 data shows comparable weight loss to semaglutide. If approved, it could be a game-changer for patients who prefer oral medication.",
    chooseAIf: ["You want an FDA-approved treatment available now", "Weekly injection is acceptable", "You want the most clinically validated GLP-1"],
    chooseBIf: ["You prefer oral medication without fasting requirements", "You are following emerging GLP-1 research", "You are interested in clinical trial participation"],
    considerBothIf: undefined,
    relatedComparisons: ["ozempic-vs-rybelsus", "semaglutide-vs-tirzepatide", "ozempic-vs-mounjaro"],
    faqItems: [
      { q: "When will orforglipron be available?", a: "As of 2025, orforglipron is in Phase 3 trials. FDA approval is anticipated in 2025-2026 if trials are successful." },
    ],
  },

  {
    slug: "aod-9604-vs-tirzepatide",
    peptideA: "AOD-9604", peptideASlug: "aod-9604",
    peptideB: "Tirzepatide", peptideBSlug: "tirzepatide",
    h1: "AOD-9604 vs Tirzepatide: Research Peptide vs FDA-Approved GLP-1",
    metaDescription: "AOD-9604 vs tirzepatide: independent comparison for fat loss. AOD-9604 is a research peptide; tirzepatide is FDA-approved with strong clinical data. Which is appropriate for you? Vendor-neutral.",
    verdictSummary: "Tirzepatide has robust clinical trial data and FDA approval. AOD-9604 has limited human data and failed its FDA approval process. For clinically validated fat loss, tirzepatide is the evidence-based choice.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "FDA Status", peptideA: "Not approved (failed Phase 3)", peptideB: "Approved (2022)" },
      { dimension: "Clinical Evidence", peptideA: "Limited human data", peptideB: "Extensive (SURMOUNT trials)" },
      { dimension: "Mechanism", peptideA: "HGH fragment, lipolysis stimulation", peptideB: "GIP + GLP-1 dual agonist" },
      { dimension: "Avg. Weight Loss", peptideA: "Modest in trials", peptideB: "~20-22%" },
    ],
    deepDiveA: "AOD-9604 is a fragment of human growth hormone (hGH176-191) that was studied for fat loss. Despite promising preclinical data, it failed to demonstrate significant weight loss in Phase 3 trials and did not receive FDA approval.",
    deepDiveB: "Tirzepatide has demonstrated ~20-22% average weight loss in the SURMOUNT trials, making it one of the most effective weight loss medications ever studied. It has FDA approval for both diabetes (Mounjaro) and obesity (Zepbound).",
    chooseAIf: ["You are a researcher interested in GH-fragment mechanisms", "You want a research compound with a different mechanism", "You are exploring alternatives to GLP-1 agonists"],
    chooseBIf: ["Clinically validated, significant weight loss is the goal", "FDA-approved treatment is required", "You want the most evidence-based option"],
    considerBothIf: undefined,
    relatedComparisons: ["aod-9604-vs-semaglutide", "semaglutide-vs-tirzepatide", "ozempic-vs-mounjaro"],
    faqItems: [
      { q: "Is AOD-9604 effective for weight loss?", a: "AOD-9604 failed to demonstrate significant weight loss in Phase 3 clinical trials and did not receive FDA approval. Tirzepatide and semaglutide have far stronger evidence for weight loss." },
    ],
  },

  {
    slug: "oxytocin-vs-kisspeptin",
    peptideA: "Oxytocin", peptideASlug: "oxytocin",
    peptideB: "Kisspeptin", peptideBSlug: "kisspeptin",
    h1: "Oxytocin vs Kisspeptin: Two Peptides for Sexual Health and Bonding",
    metaDescription: "Oxytocin vs kisspeptin: independent comparison for sexual health and bonding. Oxytocin enhances bonding and arousal; kisspeptin regulates reproductive hormones. Evidence and use cases. Vendor-neutral.",
    verdictSummary: "Oxytocin enhances bonding, trust, and sexual arousal through central mechanisms. Kisspeptin regulates reproductive hormone release (LH, FSH, testosterone). They target different aspects of sexual and reproductive health.",
    category: "Sexual Health",
    atAGlance: [
      { dimension: "Primary Role", peptideA: "Bonding, trust, arousal", peptideB: "Reproductive hormone regulation" },
      { dimension: "Mechanism", peptideA: "Oxytocin receptor activation (CNS)", peptideB: "GnRH pulse regulation, LH/FSH release" },
      { dimension: "Sexual Health Effect", peptideA: "Arousal, orgasm intensity", peptideB: "Testosterone support, libido" },
    ],
    deepDiveA: "Oxytocin is the 'bonding hormone' that enhances trust, social connection, and sexual arousal. Intranasal oxytocin has been studied for social anxiety, autism, and sexual function. It acts rapidly and has a short duration.",
    deepDiveB: "Kisspeptin regulates the hypothalamic-pituitary-gonadal axis by stimulating GnRH release, which drives LH and FSH secretion and ultimately testosterone production. It is studied for hypogonadism and reproductive health.",
    chooseAIf: ["Bonding, intimacy, and arousal enhancement are the goals", "You want rapid-acting sexual arousal support", "Social connection or anxiety is also a concern"],
    chooseBIf: ["Testosterone support and reproductive hormone optimization are the goals", "You have low LH/FSH or hypogonadism", "Long-term hormonal support is needed"],
    considerBothIf: "Oxytocin + kisspeptin may be combined for comprehensive sexual health support addressing both arousal (oxytocin) and hormonal optimization (kisspeptin).",
    relatedComparisons: ["pt-141-vs-oxytocin", "kisspeptin-vs-pt-141", "pt-141-vs-tadalafil"],
    faqItems: [
      { q: "What is the difference between oxytocin and kisspeptin?", a: "Oxytocin enhances bonding and sexual arousal through central mechanisms. Kisspeptin regulates reproductive hormones (LH, FSH, testosterone) through the hypothalamic-pituitary axis. They target different aspects of sexual health." },
    ],
  },

  {
    slug: "pt-141-vs-oxytocin",
    peptideA: "PT-141", peptideASlug: "pt-141",
    peptideB: "Oxytocin", peptideBSlug: "oxytocin",
    h1: "PT-141 vs Oxytocin: Two Central Peptides for Sexual Health",
    metaDescription: "PT-141 vs oxytocin: independent comparison. PT-141 activates melanocortin receptors for desire; oxytocin enhances bonding and arousal. Evidence and use cases. Vendor-neutral.",
    verdictSummary: "PT-141 activates melanocortin-4 receptors to enhance sexual desire and arousal. Oxytocin enhances bonding, trust, and arousal through different central pathways. Both work centrally and are often combined.",
    category: "Sexual Health",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "Melanocortin-4 receptor agonist", peptideB: "Oxytocin receptor activation" },
      { dimension: "Primary Effect", peptideA: "Sexual desire and arousal", peptideB: "Bonding, trust, arousal" },
      { dimension: "FDA Status", peptideA: "Approved (Vyleesi for women)", peptideB: "Approved (various indications)" },
      { dimension: "Duration", peptideA: "6-12 hours", peptideB: "1-2 hours (intranasal)" },
    ],
    deepDiveA: "PT-141 directly activates melanocortin-4 receptors in the brain to enhance sexual desire and arousal. It is FDA approved for HSDD in premenopausal women and is used off-label in men.",
    deepDiveB: "Oxytocin enhances bonding, trust, and sexual arousal through oxytocin receptors in the brain. Intranasal oxytocin has a rapid onset and short duration, making it suitable for use shortly before sexual activity.",
    chooseAIf: ["Sexual desire is the primary concern", "You want the longer-lasting effect", "FDA approval for sexual health is important"],
    chooseBIf: ["Bonding and emotional intimacy are also goals", "Rapid onset and short duration are preferred", "You want to enhance the emotional connection aspect of sexuality"],
    considerBothIf: "PT-141 + oxytocin is used by some to address both desire (PT-141) and bonding/intimacy (oxytocin) simultaneously.",
    relatedComparisons: ["pt-141-vs-tadalafil", "pt-141-vs-sildenafil", "melanotan-2-vs-pt-141"],
    faqItems: [
      { q: "Can PT-141 and oxytocin be taken together?", a: "They work through different mechanisms and can potentially be combined. PT-141 addresses desire; oxytocin addresses bonding and emotional intimacy. Consult a healthcare provider before combining." },
    ],
  },

  {
    slug: "kisspeptin-vs-pt-141",
    peptideA: "Kisspeptin", peptideASlug: "kisspeptin",
    peptideB: "PT-141", peptideBSlug: "pt-141",
    h1: "Kisspeptin vs PT-141: Hormonal vs Desire-Based Sexual Health Peptides",
    metaDescription: "Kisspeptin vs PT-141: independent comparison. Kisspeptin regulates reproductive hormones; PT-141 directly enhances sexual desire. Evidence and use cases. Vendor-neutral.",
    verdictSummary: "Kisspeptin works upstream by regulating reproductive hormone production (testosterone, LH, FSH). PT-141 works downstream by directly activating brain pathways for sexual desire. They address different root causes of sexual health issues.",
    category: "Sexual Health",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "GnRH pulse regulation, LH/FSH/testosterone", peptideB: "MC4R agonist, direct desire enhancement" },
      { dimension: "Timeline", peptideA: "Weeks (hormonal optimization)", peptideB: "Hours (acute desire enhancement)" },
      { dimension: "Best For", peptideA: "Low testosterone, hypogonadism", peptideB: "Low desire, HSDD" },
    ],
    deepDiveA: "Kisspeptin regulates the HPG axis, stimulating GnRH pulses that drive LH, FSH, and testosterone production. It is studied for hypogonadism and reproductive health, with effects building over weeks of use.",
    deepDiveB: "PT-141 produces acute sexual desire enhancement within 45-90 minutes of administration by activating MC4R in the brain. It is FDA approved for HSDD and produces effects lasting 6-12 hours.",
    chooseAIf: ["Low testosterone or hypogonadism is the root cause", "Long-term hormonal optimization is the goal", "You want to address the upstream hormonal cause"],
    chooseBIf: ["Acute sexual desire enhancement is needed", "HSDD or situational low desire is the concern", "FDA-approved treatment is preferred"],
    considerBothIf: "Kisspeptin (for hormonal optimization) + PT-141 (for acute desire) may be combined for comprehensive sexual health support.",
    relatedComparisons: ["pt-141-vs-tadalafil", "pt-141-vs-oxytocin", "oxytocin-vs-kisspeptin"],
    faqItems: [
      { q: "Should I use kisspeptin or PT-141 for low libido?", a: "It depends on the cause. If low testosterone is the root cause, kisspeptin may help by restoring hormonal production. For situational low desire, PT-141 provides more immediate effects." },
    ],
  },

  {
    slug: "dsip-vs-selank",
    peptideA: "DSIP", peptideASlug: "delta-sleep-inducing-peptide",
    peptideB: "Selank", peptideBSlug: "selank",
    h1: "DSIP vs Selank for Sleep: Delta Sleep Peptide vs Anxiolytic",
    metaDescription: "DSIP vs selank for sleep: independent comparison. DSIP directly promotes delta sleep; selank reduces anxiety that disrupts sleep. Evidence and use cases. Vendor-neutral.",
    verdictSummary: "DSIP (delta sleep-inducing peptide) directly promotes slow-wave delta sleep. Selank reduces anxiety and stress that can disrupt sleep. For primary sleep disorders, DSIP is more targeted; for anxiety-driven insomnia, selank may be more effective.",
    category: "Sleep",
    atAGlance: [
      { dimension: "Primary Mechanism", peptideA: "Delta sleep promotion, opioid modulation", peptideB: "GABAergic, anxiolytic" },
      { dimension: "Sleep Effect", peptideA: "Direct delta sleep induction", peptideB: "Indirect (via anxiety reduction)" },
      { dimension: "Evidence", peptideA: "Preclinical + limited human", peptideB: "Moderate (Russian clinical data)" },
    ],
    deepDiveA: "DSIP is a nonapeptide that promotes delta (slow-wave) sleep through opioid receptor modulation and other mechanisms. It was originally isolated from rabbit brain during delta sleep. Human data is limited but suggests sleep quality improvement.",
    deepDiveB: "Selank reduces anxiety and stress through GABAergic mechanisms, which can significantly improve sleep quality in individuals whose insomnia is anxiety-driven. It is not a direct sleep inducer but addresses a common root cause of poor sleep.",
    chooseAIf: ["Primary sleep disorder without significant anxiety", "Direct delta sleep promotion is the goal", "You want a peptide specifically designed for sleep"],
    chooseBIf: ["Anxiety is the primary driver of poor sleep", "You want daytime anxiety relief that also improves nighttime sleep", "You want the peptide with more clinical data"],
    considerBothIf: "DSIP + selank may be combined for comprehensive sleep support, addressing both direct sleep induction and anxiety-driven sleep disruption.",
    relatedComparisons: ["selank-vs-semax", "dsip-vs-ipamorelin", "selank-vs-cerebrolysin"],
    faqItems: [
      { q: "Which is better for sleep, DSIP or selank?", a: "DSIP is more targeted for sleep specifically; selank is better if anxiety is the root cause of poor sleep. For anxiety-driven insomnia, selank may be more effective." },
    ],
  },

  {
    slug: "dsip-vs-ipamorelin",
    peptideA: "DSIP", peptideASlug: "delta-sleep-inducing-peptide",
    peptideB: "Ipamorelin", peptideBSlug: "ipamorelin",
    h1: "DSIP vs Ipamorelin for Sleep: Comparing Two Sleep-Supporting Peptides",
    metaDescription: "DSIP vs ipamorelin for sleep: independent comparison. DSIP directly promotes delta sleep; ipamorelin supports sleep through GH pulse stimulation. Evidence and use cases. Vendor-neutral.",
    verdictSummary: "DSIP directly promotes delta sleep. Ipamorelin supports sleep quality indirectly through GH pulse stimulation (which naturally peaks during deep sleep). They work through different mechanisms and are often combined.",
    category: "Sleep",
    atAGlance: [
      { dimension: "Sleep Mechanism", peptideA: "Direct delta sleep induction", peptideB: "GH pulse stimulation (peaks in deep sleep)" },
      { dimension: "Primary Purpose", peptideA: "Sleep quality", peptideB: "GH optimization (sleep is secondary benefit)" },
      { dimension: "Evidence for Sleep", peptideA: "Moderate", peptideB: "Anecdotal / indirect" },
    ],
    deepDiveA: "DSIP was specifically identified for its sleep-promoting properties. It promotes delta (slow-wave) sleep and may improve sleep architecture.",
    deepDiveB: "Ipamorelin stimulates GH pulses that naturally occur during deep sleep. Taking ipamorelin before bed can enhance the GH pulse that accompanies deep sleep, potentially improving sleep quality and recovery.",
    chooseAIf: ["Direct sleep improvement is the primary goal", "You have a specific sleep disorder", "You want a peptide specifically designed for sleep"],
    chooseBIf: ["GH optimization is the primary goal with sleep as a secondary benefit", "Body composition and recovery are also goals", "You want a well-characterized peptide with broader applications"],
    considerBothIf: "DSIP + ipamorelin (before bed) is used by some for comprehensive sleep and GH optimization.",
    relatedComparisons: ["dsip-vs-selank", "ipamorelin-vs-cjc-1295", "selank-vs-semax"],
    faqItems: [
      { q: "Can DSIP and ipamorelin be taken together for sleep?", a: "They work through different mechanisms and can potentially be combined. DSIP for direct sleep promotion and ipamorelin for GH pulse stimulation during deep sleep." },
    ],
  },

  {
    slug: "cerebrolysin-vs-dihexa",
    peptideA: "Cerebrolysin", peptideASlug: "cerebrolysin",
    peptideB: "Dihexa", peptideBSlug: "dihexa",
    h1: "Cerebrolysin vs Dihexa: Two Neurogenic Peptides Compared",
    metaDescription: "Cerebrolysin vs dihexa: independent comparison of two neurogenic peptides. Clinical evidence, mechanism, and use cases for cognitive enhancement and neuroprotection. Vendor-neutral.",
    verdictSummary: "Cerebrolysin has strong clinical evidence from European trials for stroke recovery and dementia. Dihexa is theoretically more potent for neurogenesis but has minimal human data.",
    category: "Cognitive / Nootropic",
    atAGlance: [
      { dimension: "Type", peptideA: "Peptide mixture (porcine brain)", peptideB: "Synthetic HGF/c-Met agonist" },
      { dimension: "Human Clinical Data", peptideA: "Strong (European trials)", peptideB: "Minimal (preclinical)" },
      { dimension: "Primary Use", peptideA: "Stroke recovery, dementia, neuroprotection", peptideB: "Cognitive enhancement, neurogenesis" },
      { dimension: "Administration", peptideA: "IV or IM injection", peptideB: "Oral or transdermal" },
    ],
    deepDiveA: "Cerebrolysin is a peptide mixture derived from porcine brain that has been used in European medicine for decades. It has clinical trial evidence for stroke recovery, Alzheimer's disease, and traumatic brain injury.",
    deepDiveB: "Dihexa is a synthetic HGF/c-Met agonist with extraordinary potency in animal models for neurogenesis and cognitive enhancement. Human data is extremely limited, making its safety profile poorly characterized.",
    chooseAIf: ["Clinical evidence is a priority", "You are recovering from stroke or TBI", "Neuroprotection with established safety data is needed"],
    chooseBIf: ["You are an experienced researcher exploring cutting-edge compounds", "Maximum neurogenic potential is the goal", "You accept the limited human safety data"],
    considerBothIf: undefined,
    relatedComparisons: ["semax-vs-dihexa", "cerebrolysin-vs-semax", "selank-vs-semax"],
    faqItems: [
      { q: "Which is safer, cerebrolysin or dihexa?", a: "Cerebrolysin has decades of clinical use and a well-characterized safety profile. Dihexa has minimal human data, making cerebrolysin the safer choice for most applications." },
    ],
  },

  {
    slug: "cerebrolysin-vs-semax",
    peptideA: "Cerebrolysin", peptideASlug: "cerebrolysin",
    peptideB: "Semax", peptideBSlug: "semax",
    h1: "Cerebrolysin vs Semax: European Neuropeptide vs Russian Nootropic",
    metaDescription: "Cerebrolysin vs semax: independent comparison. Cerebrolysin for neuroprotection and recovery; semax for cognitive enhancement and BDNF. Evidence and use cases. Vendor-neutral.",
    verdictSummary: "Cerebrolysin has stronger clinical evidence for neuroprotection and recovery from neurological injury. Semax is better suited for cognitive enhancement and daily nootropic use due to its nasal spray delivery and BDNF-upregulating effects.",
    category: "Cognitive / Nootropic",
    atAGlance: [
      { dimension: "Administration", peptideA: "IV or IM injection", peptideB: "Intranasal spray" },
      { dimension: "Primary Use", peptideA: "Neuroprotection, stroke, dementia", peptideB: "Cognitive enhancement, focus, BDNF" },
      { dimension: "Convenience", peptideA: "Requires injection", peptideB: "Easy nasal spray" },
      { dimension: "Clinical Evidence", peptideA: "Strong (European)", peptideB: "Moderate (Russian)" },
    ],
    deepDiveA: "Cerebrolysin is administered by injection and is primarily used in clinical settings for neurological conditions. Its peptide mixture provides neurotrophic and neuroprotective effects with strong clinical backing.",
    deepDiveB: "Semax's intranasal delivery makes it practical for daily cognitive enhancement. It upregulates BDNF and has neuroprotective properties, but its primary appeal is as a daily nootropic rather than a clinical neuroprotective agent.",
    chooseAIf: ["You are recovering from neurological injury", "Clinical-grade neuroprotection is needed", "You are working with a physician for a specific neurological condition"],
    chooseBIf: ["Daily cognitive enhancement is the goal", "Convenient nasal spray delivery is preferred", "BDNF upregulation and focus are the priorities"],
    considerBothIf: "Some protocols use cerebrolysin for acute neuroprotection combined with semax for ongoing cognitive maintenance.",
    relatedComparisons: ["cerebrolysin-vs-dihexa", "semax-vs-dihexa", "selank-vs-semax"],
    faqItems: [
      { q: "Is cerebrolysin or semax better for brain health?", a: "Cerebrolysin has stronger evidence for neuroprotection and recovery. Semax is more practical for daily cognitive enhancement. The choice depends on whether you need clinical neuroprotection or daily nootropic support." },
    ],
  },

  {
    slug: "bpc-157-vs-glutamine",
    peptideA: "BPC-157", peptideASlug: "bpc-157",
    peptideB: "L-Glutamine", peptideBSlug: "bpc-157",
    h1: "BPC-157 vs Glutamine for Gut Healing: Peptide vs Amino Acid",
    metaDescription: "BPC-157 vs glutamine for gut healing: independent comparison. BPC-157 promotes gut repair through growth factors; glutamine is the primary fuel for intestinal cells. Evidence and use cases. Vendor-neutral.",
    verdictSummary: "BPC-157 promotes gut healing through growth factor upregulation and angiogenesis. Glutamine is the primary fuel for intestinal epithelial cells and supports gut barrier integrity. They work through different mechanisms and are often combined.",
    category: "Gut Health",
    atAGlance: [
      { dimension: "Type", peptideA: "Peptide (injectable or oral)", peptideB: "Amino acid (oral)" },
      { dimension: "Mechanism", peptideA: "Growth factor upregulation, angiogenesis", peptideB: "Intestinal cell fuel, tight junction support" },
      { dimension: "Evidence", peptideA: "Strong preclinical, limited human", peptideB: "Moderate human (clinical nutrition)" },
      { dimension: "Cost", peptideA: "~$50-$150/month", peptideB: "~$10-$30/month" },
    ],
    deepDiveA: "BPC-157 promotes gut healing through multiple mechanisms including growth factor upregulation, angiogenesis, and anti-inflammatory effects. It has strong preclinical evidence for IBD, leaky gut, and gut injury.",
    deepDiveB: "Glutamine is the primary fuel source for intestinal epithelial cells and is conditionally essential during illness or injury. It supports tight junction integrity and gut barrier function with moderate clinical evidence.",
    chooseAIf: ["Active gut injury, IBD, or significant gut pathology is present", "You want the most potent gut repair peptide", "Systemic healing effects are also desired"],
    chooseBIf: ["General gut support and maintenance are the goals", "Cost is a primary consideration", "You want a well-established, widely available supplement"],
    considerBothIf: "BPC-157 + glutamine is a popular gut healing combination: BPC-157 for active repair and glutamine for ongoing intestinal cell support.",
    relatedComparisons: ["bpc-157-vs-tb-500", "bpc-157-vs-ghk-cu", "bpc-157-vs-ipamorelin"],
    faqItems: [
      { q: "Is BPC-157 better than glutamine for gut healing?", a: "For active gut injury or pathology, BPC-157 has stronger preclinical evidence. Glutamine is better supported for general gut maintenance. They are complementary rather than competing." },
    ],
  },

  {
    slug: "bpc-157-vs-zinc-carnosine",
    peptideA: "BPC-157", peptideASlug: "bpc-157",
    peptideB: "Zinc Carnosine", peptideBSlug: "bpc-157",
    h1: "BPC-157 vs Zinc Carnosine for Gut Health: Peptide vs Supplement",
    metaDescription: "BPC-157 vs zinc carnosine for gut health: independent comparison. BPC-157 promotes active repair; zinc carnosine protects the gut lining. Evidence and use cases. Vendor-neutral.",
    verdictSummary: "BPC-157 promotes active gut repair through growth factors and angiogenesis. Zinc carnosine protects the gut lining and has clinical evidence for H. pylori and gastric ulcers. They are complementary rather than competing.",
    category: "Gut Health",
    atAGlance: [
      { dimension: "Type", peptideA: "Peptide", peptideB: "Mineral-amino acid chelate" },
      { dimension: "Mechanism", peptideA: "Growth factor upregulation, repair", peptideB: "Mucosal protection, anti-H. pylori" },
      { dimension: "Human Evidence", peptideA: "Limited", peptideB: "Moderate (gastric ulcer trials)" },
      { dimension: "Cost", peptideA: "Higher", peptideB: "Lower" },
    ],
    deepDiveA: "BPC-157 promotes active gut repair and has strong preclinical evidence for IBD, leaky gut, and gut injury. Its growth factor upregulation and angiogenic effects make it one of the most potent gut repair peptides.",
    deepDiveB: "Zinc carnosine (polaprezinc) has clinical evidence for gastric ulcer treatment and H. pylori eradication support. It protects the gastric mucosa and has anti-inflammatory effects in the gut.",
    chooseAIf: ["Active gut injury or IBD is the primary concern", "You want the most potent gut repair peptide", "Systemic healing is also desired"],
    chooseBIf: ["Gastric ulcers or H. pylori are the primary concern", "You want a well-tolerated oral supplement with clinical evidence", "Cost is a consideration"],
    considerBothIf: "BPC-157 + zinc carnosine is used for comprehensive gut healing: BPC-157 for active repair and zinc carnosine for mucosal protection.",
    relatedComparisons: ["bpc-157-vs-glutamine", "bpc-157-vs-tb-500", "bpc-157-vs-ghk-cu"],
    faqItems: [
      { q: "Can BPC-157 and zinc carnosine be taken together?", a: "Yes. They work through different mechanisms and are complementary for gut healing. BPC-157 promotes active repair while zinc carnosine protects the mucosal lining." },
    ],
  },

  {
    slug: "tb-500-vs-ipamorelin",
    peptideA: "TB-500", peptideASlug: "tb-500",
    peptideB: "Ipamorelin", peptideBSlug: "ipamorelin",
    h1: "TB-500 vs Ipamorelin: Healing Peptide vs GH Secretagogue",
    metaDescription: "TB-500 vs ipamorelin: independent comparison. TB-500 promotes tissue healing and flexibility; ipamorelin stimulates GH release. Different goals, often combined. Vendor-neutral.",
    verdictSummary: "TB-500 and ipamorelin serve different purposes. TB-500 promotes tissue healing, flexibility, and recovery. Ipamorelin stimulates GH release for body composition and anti-aging. They are frequently combined in athlete recovery protocols.",
    category: "Recovery",
    atAGlance: [
      { dimension: "Primary Purpose", peptideA: "Tissue healing, flexibility, recovery", peptideB: "GH stimulation, body composition" },
      { dimension: "Mechanism", peptideA: "Actin regulation, angiogenesis", peptideB: "GHRP (ghrelin mimetic)" },
      { dimension: "Best For", peptideA: "Injuries, chronic pain, flexibility", peptideB: "Body composition, anti-aging, sleep" },
    ],
    deepDiveA: "TB-500 (Thymosin Beta-4) regulates actin polymerization, promotes cell migration, and stimulates angiogenesis. It is particularly effective for muscle and tendon injuries and improving flexibility.",
    deepDiveB: "Ipamorelin stimulates pulsatile GH release, supporting body composition, sleep quality, and anti-aging. It works through a completely different pathway and is not primarily a healing peptide.",
    chooseAIf: ["Active injury or chronic pain is the primary concern", "Flexibility and range of motion are goals", "You want the TB-500 / BPC-157 healing stack"],
    chooseBIf: ["Body composition and GH optimization are the goals", "Sleep quality improvement is desired", "Anti-aging is the primary focus"],
    considerBothIf: "TB-500 + ipamorelin is a popular combination for athletes wanting both healing support and GH optimization.",
    relatedComparisons: ["bpc-157-vs-tb-500", "tb-500-vs-bpc-157", "ipamorelin-vs-cjc-1295"],
    faqItems: [
      { q: "Can TB-500 and ipamorelin be taken together?", a: "Yes. They work through completely different mechanisms and are commonly combined in athlete protocols for healing support and GH optimization." },
    ],
  },

  {
    slug: "semaglutide-vs-liraglutide",
    peptideA: "Semaglutide", peptideASlug: "semaglutide",
    peptideB: "Liraglutide", peptideBSlug: "liraglutide",
    h1: "Semaglutide vs Liraglutide: Head-to-Head GLP-1 Comparison",
    metaDescription: "Semaglutide vs liraglutide: independent head-to-head comparison. Efficacy, dosing frequency, weight loss, and cardiovascular outcomes. Evidence-based, vendor-neutral.",
    verdictSummary: "Semaglutide consistently outperforms liraglutide in head-to-head trials for HbA1c reduction and weight loss, with the added convenience of once-weekly dosing. Liraglutide has a longer track record and strong cardiovascular outcome data.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "Dosing", peptideA: "Once weekly", peptideB: "Once daily" },
      { dimension: "Avg. Weight Loss", peptideA: "~15% (Wegovy dose)", peptideB: "~8% (Saxenda dose)" },
      { dimension: "HbA1c Reduction", peptideA: "~1.5-1.8%", peptideB: "~1.2-1.5%" },
      { dimension: "CV Outcome Trial", peptideA: "SUSTAIN-6 (positive)", peptideB: "LEADER (positive)" },
    ],
    deepDiveA: "Semaglutide's longer half-life enables once-weekly dosing and produces superior efficacy compared to liraglutide. The STEP 8 trial directly comparing them showed semaglutide's clear superiority for weight loss.",
    deepDiveB: "Liraglutide has been on the market since 2010 and has extensive real-world safety data. The LEADER trial demonstrated significant cardiovascular risk reduction. Daily dosing may be preferred by some patients for flexibility.",
    chooseAIf: ["Maximum efficacy is the priority", "Weekly dosing convenience is important", "You are starting GLP-1 therapy for the first time"],
    chooseBIf: ["Daily dosing flexibility is preferred", "You have previously responded well to liraglutide", "Liraglutide is better covered by your insurance"],
    considerBothIf: undefined,
    relatedComparisons: ["ozempic-vs-saxenda", "wegovy-vs-saxenda", "ozempic-vs-mounjaro"],
    faqItems: [
      { q: "Is semaglutide better than liraglutide?", a: "Clinical trials consistently show semaglutide produces greater HbA1c reduction and weight loss than liraglutide. The STEP 8 trial directly comparing them confirmed semaglutide's superiority." },
    ],
  },

  {
    slug: "semaglutide-vs-tirzepatide",
    peptideA: "Semaglutide", peptideASlug: "semaglutide",
    peptideB: "Tirzepatide", peptideBSlug: "tirzepatide",
    h1: "Semaglutide vs Tirzepatide: The Definitive GLP-1 Comparison",
    metaDescription: "Semaglutide vs tirzepatide: the definitive independent comparison. Weight loss, HbA1c, cardiovascular outcomes, and which is right for you. Evidence-based, vendor-neutral.",
    verdictSummary: "Tirzepatide produces greater average weight loss (~20-22% vs ~15%) due to its dual GIP/GLP-1 mechanism. Semaglutide has a longer track record and more extensive cardiovascular outcome data. Both are excellent first-line options.",
    category: "GLP-1 / Weight Loss",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "GLP-1 agonist", peptideB: "GIP + GLP-1 dual agonist" },
      { dimension: "Avg. Weight Loss", peptideA: "~15%", peptideB: "~20-22%" },
      { dimension: "HbA1c Reduction", peptideA: "~1.5-1.8%", peptideB: "~2.0-2.3%" },
      { dimension: "CV Outcome Data", peptideA: "SUSTAIN-6, SELECT (positive)", peptideB: "SURPASS-CVOT (pending full data)" },
      { dimension: "Years on Market", peptideA: "Since 2017", peptideB: "Since 2022" },
    ],
    deepDiveA: "Semaglutide has the most extensive clinical dataset of any GLP-1 agonist, including the SELECT trial showing 20% cardiovascular risk reduction in non-diabetic obese patients. It is the current standard of care for GLP-1 therapy.",
    deepDiveB: "Tirzepatide's dual mechanism produces superior weight loss and HbA1c reduction in all head-to-head comparisons. The SURMOUNT-5 trial directly comparing tirzepatide to semaglutide showed tirzepatide's superiority for weight loss.",
    chooseAIf: ["You want the most extensive clinical dataset", "Cardiovascular outcome data is important", "You prefer the longer-established option"],
    chooseBIf: ["Maximum weight loss is the priority", "You have not achieved adequate results on semaglutide", "HbA1c reduction is the primary goal"],
    considerBothIf: "Both are excellent first-line options. Many clinicians start with semaglutide and escalate to tirzepatide if response is insufficient.",
    relatedComparisons: ["ozempic-vs-mounjaro", "wegovy-vs-mounjaro", "tirzepatide-vs-retatrutide"],
    faqItems: [
      { q: "Which produces more weight loss, semaglutide or tirzepatide?", a: "The SURMOUNT-5 trial directly comparing them showed tirzepatide produced ~20% greater weight loss than semaglutide. Tirzepatide is now considered the more effective option." },
    ],
  },

  {
    slug: "bpc-157-vs-nac",
    peptideA: "BPC-157", peptideASlug: "bpc-157",
    peptideB: "NAC (N-Acetyl Cysteine)", peptideBSlug: "bpc-157",
    h1: "BPC-157 vs NAC for Gut and Liver Health",
    metaDescription: "BPC-157 vs NAC: independent comparison for gut and liver health. BPC-157 promotes tissue repair; NAC is a glutathione precursor with antioxidant effects. Evidence and use cases. Vendor-neutral.",
    verdictSummary: "BPC-157 promotes active tissue repair through growth factors. NAC is a glutathione precursor with antioxidant and mucolytic effects, particularly relevant for liver health and oxidative stress. They target different aspects of health.",
    category: "Gut Health",
    atAGlance: [
      { dimension: "Type", peptideA: "Peptide", peptideB: "Amino acid derivative" },
      { dimension: "Primary Mechanism", peptideA: "Growth factor upregulation, repair", peptideB: "Glutathione precursor, antioxidant" },
      { dimension: "Best For", peptideA: "Gut healing, injury repair", peptideB: "Liver health, oxidative stress, acetaminophen overdose" },
      { dimension: "Human Evidence", peptideA: "Limited", peptideB: "Extensive (FDA approved for acetaminophen overdose)" },
    ],
    deepDiveA: "BPC-157 promotes tissue healing across multiple organ systems with strong preclinical evidence. For gut-specific applications, it has the most potent repair mechanisms of any available peptide.",
    deepDiveB: "NAC is a well-established antioxidant and glutathione precursor with extensive clinical evidence. It is FDA approved for acetaminophen overdose and has evidence for liver health, respiratory conditions, and oxidative stress.",
    chooseAIf: ["Active gut injury or IBD is the primary concern", "Tissue repair is the goal", "You want the most potent gut healing peptide"],
    chooseBIf: ["Liver health and detoxification are priorities", "Oxidative stress is a concern", "You want the most extensively studied option"],
    considerBothIf: "BPC-157 + NAC may be combined for comprehensive gut and liver support.",
    relatedComparisons: ["bpc-157-vs-glutamine", "bpc-157-vs-zinc-carnosine", "bpc-157-vs-tb-500"],
    faqItems: [
      { q: "Is BPC-157 or NAC better for gut health?", a: "For active gut injury and repair, BPC-157 has stronger preclinical evidence. For liver health and oxidative stress, NAC has more extensive clinical evidence. They target different aspects of health." },
    ],
  },

  {
    slug: "ghk-cu-vs-epithalon",
    peptideA: "GHK-Cu", peptideASlug: "ghk-cu",
    peptideB: "Epithalon", peptideBSlug: "epithalon",
    h1: "GHK-Cu vs Epithalon: Two Anti-Aging Peptides Compared",
    metaDescription: "GHK-Cu vs epithalon: independent comparison. GHK-Cu repairs tissue and skin; epithalon activates telomerase. Different anti-aging mechanisms. Vendor-neutral.",
    verdictSummary: "GHK-Cu focuses on tissue repair, collagen synthesis, and skin anti-aging. Epithalon targets telomere biology through telomerase activation. They address different hallmarks of aging and are frequently combined.",
    category: "Anti-Aging",
    atAGlance: [
      { dimension: "Primary Mechanism", peptideA: "Collagen synthesis, wound healing, gene expression", peptideB: "Telomerase activation, telomere extension" },
      { dimension: "Administration", peptideA: "Topical or subcutaneous injection", peptideB: "Subcutaneous injection (cycled)" },
      { dimension: "Best For", peptideA: "Skin, tissue repair, visible aging", peptideB: "Cellular longevity, telomere biology" },
    ],
    deepDiveA: "GHK-Cu has extensive evidence for skin anti-aging, wound healing, and collagen synthesis. It also modulates gene expression in ways that may have broader anti-aging effects.",
    deepDiveB: "Epithalon activates telomerase to potentially extend telomere length, addressing one of the fundamental hallmarks of cellular aging. Russian studies suggest benefits for longevity and age-related disease prevention.",
    chooseAIf: ["Skin anti-aging and visible repair are the primary goals", "Topical application is preferred", "Wound healing or tissue repair is needed"],
    chooseBIf: ["Cellular longevity and telomere biology are the focus", "You want a cycled injectable longevity protocol", "Systemic anti-aging is the primary goal"],
    considerBothIf: "GHK-Cu (topical for skin) + epithalon (injectable for cellular longevity) is a popular combination in comprehensive anti-aging protocols.",
    relatedComparisons: ["epithalon-vs-nad", "epithalon-vs-ghk-cu", "ghk-cu-vs-nad"],
    faqItems: [
      { q: "Should I use GHK-Cu or epithalon for anti-aging?", a: "They target different aspects of aging. GHK-Cu is best for skin and tissue repair; epithalon targets cellular longevity through telomerase. Most comprehensive anti-aging protocols include both." },
    ],
  },

  {
    slug: "mots-c-vs-humanin",
    peptideA: "MOTS-c", peptideASlug: "mots-c",
    peptideB: "Humanin", peptideBSlug: "humanin",
    h1: "MOTS-c vs Humanin: Two Mitochondrial-Derived Peptides Compared",
    metaDescription: "MOTS-c vs humanin: independent comparison of two mitochondrial-derived peptides (MDPs). Metabolic effects, neuroprotection, and longevity applications. Vendor-neutral.",
    verdictSummary: "MOTS-c and humanin are both mitochondrial-derived peptides but with different primary effects. MOTS-c focuses on metabolic regulation and AMPK activation. Humanin is primarily neuroprotective with anti-apoptotic effects.",
    category: "Longevity",
    atAGlance: [
      { dimension: "Primary Effect", peptideA: "Metabolic regulation, AMPK activation", peptideB: "Neuroprotection, anti-apoptosis" },
      { dimension: "Best For", peptideA: "Insulin sensitivity, metabolic health, endurance", peptideB: "Brain health, neurodegeneration, IGF-1 modulation" },
      { dimension: "Evidence Level", peptideA: "Preclinical / early human", peptideB: "Preclinical / early human" },
    ],
    deepDiveA: "MOTS-c activates AMPK, the master metabolic regulator, improving insulin sensitivity, fat oxidation, and metabolic flexibility. It declines with age and is being studied as a longevity intervention.",
    deepDiveB: "Humanin is a mitochondrial-derived peptide with potent neuroprotective and anti-apoptotic effects. It modulates IGF-1 signaling and has been studied for Alzheimer's disease and neurodegeneration.",
    chooseAIf: ["Metabolic health and insulin sensitivity are priorities", "AMPK activation for longevity is the goal", "Endurance and metabolic flexibility are desired"],
    chooseBIf: ["Brain health and neuroprotection are priorities", "You are concerned about neurodegeneration", "IGF-1 modulation is a goal"],
    considerBothIf: "MOTS-c + humanin may be combined for comprehensive mitochondrial longevity support addressing both metabolic and neurological aspects of aging.",
    relatedComparisons: ["mots-c-vs-nad", "epithalon-vs-nad", "ghk-cu-vs-nad"],
    faqItems: [
      { q: "What is the difference between MOTS-c and humanin?", a: "Both are mitochondrial-derived peptides, but MOTS-c primarily regulates metabolism through AMPK activation while humanin primarily provides neuroprotection through anti-apoptotic mechanisms." },
    ],
  },

  {
    slug: "ipamorelin-vs-mk-677",
    peptideA: "Ipamorelin", peptideASlug: "ipamorelin",
    peptideB: "MK-677 (Ibutamoren)", peptideBSlug: "ipamorelin",
    h1: "Ipamorelin vs MK-677: Injectable Peptide vs Oral GH Secretagogue",
    metaDescription: "Ipamorelin vs MK-677 (ibutamoren): independent comparison. Injectable pulsatile GH stimulation vs oral sustained GH elevation. Evidence, side effects, and use cases. Vendor-neutral.",
    verdictSummary: "Ipamorelin produces pulsatile GH release through injection, preserving natural GH rhythms. MK-677 is an oral GH secretagogue that produces sustained GH elevation but causes more side effects including water retention and increased appetite.",
    category: "Growth Hormone",
    atAGlance: [
      { dimension: "Route", peptideA: "Subcutaneous injection", peptideB: "Oral capsule" },
      { dimension: "GH Pattern", peptideA: "Pulsatile (physiological)", peptideB: "Sustained elevation" },
      { dimension: "Side Effects", peptideA: "Minimal", peptideB: "Water retention, increased appetite, lethargy" },
      { dimension: "Convenience", peptideA: "Requires injection", peptideB: "Daily oral dose" },
      { dimension: "Legal Status", peptideA: "Research compound", peptideB: "Research compound (not approved)" },
    ],
    deepDiveA: "Ipamorelin produces clean, pulsatile GH release without significant cortisol or prolactin elevation. Its injectable format allows precise dosing and timing, making it ideal for protocols that require physiological GH patterns.",
    deepDiveB: "MK-677 (ibutamoren) is an oral ghrelin mimetic that produces sustained GH and IGF-1 elevation. Its oral convenience is a major advantage, but sustained GH elevation (rather than pulsatile) and side effects like water retention and increased appetite are drawbacks.",
    chooseAIf: ["Physiological pulsatile GH release is preferred", "Minimal side effects are important", "You are comfortable with injections"],
    chooseBIf: ["Oral convenience is a priority", "You prefer not to inject", "Sustained IGF-1 elevation is the goal"],
    considerBothIf: undefined,
    relatedComparisons: ["ipamorelin-vs-cjc-1295", "ipamorelin-vs-sermorelin", "ipamorelin-vs-hgh"],
    faqItems: [
      { q: "Is ipamorelin or MK-677 better for GH optimization?", a: "Ipamorelin produces more physiological pulsatile GH release with fewer side effects. MK-677 offers oral convenience but causes water retention and increased appetite. For most long-term protocols, ipamorelin is preferred." },
    ],
  },

  {
    slug: "cjc-1295-vs-ghrp-6",
    peptideA: "CJC-1295", peptideASlug: "cjc-1295",
    peptideB: "GHRP-6", peptideBSlug: "ghrp-6",
    h1: "CJC-1295 vs GHRP-6: GHRH Analogue vs First-Generation GHRP",
    metaDescription: "CJC-1295 vs GHRP-6: independent comparison. CJC-1295 is a GHRH analogue; GHRP-6 is a first-generation GHRP. Combining them produces synergistic GH release. Vendor-neutral.",
    verdictSummary: "CJC-1295 and GHRP-6 work through complementary mechanisms (GHRH + GHRP) and produce synergistic GH release when combined. As standalone options, CJC-1295 is more commonly used in modern protocols due to its longer half-life.",
    category: "Growth Hormone",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "GHRH analogue", peptideB: "GHRP (ghrelin mimetic)" },
      { dimension: "Half-Life", peptideA: "~6-8 days (with DAC)", peptideB: "~2 hours" },
      { dimension: "Hunger Side Effect", peptideA: "None", peptideB: "Pronounced" },
      { dimension: "Synergy", peptideA: "Pairs well with GHRP", peptideB: "Pairs well with GHRH analogue" },
    ],
    deepDiveA: "CJC-1295 with DAC provides sustained GHRH-like stimulation with 1-2x weekly dosing. It is best used in combination with a GHRP (like ipamorelin or GHRP-6) for synergistic GH release.",
    deepDiveB: "GHRP-6 stimulates GH through the ghrelin receptor pathway, complementary to CJC-1295's GHRH mechanism. The combination produces significantly greater GH release than either alone, but GHRP-6's hunger side effect is a drawback.",
    chooseAIf: ["You want a GHRH analogue for a combination protocol", "Convenience of 1-2x weekly dosing is important", "You are pairing with a GHRP like ipamorelin"],
    chooseBIf: ["You want a GHRP for a combination protocol", "Appetite stimulation is acceptable or desired", "Cost is a consideration"],
    considerBothIf: "CJC-1295 + GHRP-6 is a classic GH optimization combination. Most modern protocols substitute ipamorelin for GHRP-6 to avoid the hunger side effect.",
    relatedComparisons: ["ipamorelin-vs-cjc-1295", "cjc-1295-vs-sermorelin", "ghrp-6-vs-ghrp-2"],
    faqItems: [
      { q: "Should I use CJC-1295 alone or with GHRP-6?", a: "CJC-1295 is most effective when combined with a GHRP. The combination produces synergistic GH release significantly greater than either alone. Most modern protocols use ipamorelin instead of GHRP-6 to avoid hunger side effects." },
    ],
  },

  {
    slug: "tesamorelin-vs-ipamorelin",
    peptideA: "Tesamorelin", peptideASlug: "tesamorelin",
    peptideB: "Ipamorelin", peptideBSlug: "ipamorelin",
    h1: "Tesamorelin vs Ipamorelin: FDA-Approved GHRH vs Selective GHRP",
    metaDescription: "Tesamorelin vs ipamorelin: independent comparison. Tesamorelin is FDA-approved for visceral fat; ipamorelin is a selective GHRP for GH optimization. Evidence and use cases. Vendor-neutral.",
    verdictSummary: "Tesamorelin has FDA approval and strong clinical evidence for visceral fat reduction. Ipamorelin is better suited for general GH optimization and anti-aging. They work through complementary mechanisms and are often combined.",
    category: "Growth Hormone",
    atAGlance: [
      { dimension: "Mechanism", peptideA: "GHRH analogue", peptideB: "GHRP (ghrelin mimetic)" },
      { dimension: "FDA Status", peptideA: "Approved (HIV lipodystrophy)", peptideB: "Research compound" },
      { dimension: "Best For", peptideA: "Visceral fat reduction", peptideB: "GH optimization, anti-aging, sleep" },
      { dimension: "Synergy", peptideA: "Pairs well with GHRP", peptideB: "Pairs well with GHRH analogue" },
    ],
    deepDiveA: "Tesamorelin has the strongest clinical evidence of any peptide for visceral fat reduction. Its FDA approval for HIV-associated lipodystrophy gives it a well-characterized safety profile.",
    deepDiveB: "Ipamorelin is the most selective GHRP with minimal side effects. It is ideal for general GH optimization, sleep improvement, and anti-aging when combined with a GHRH analogue.",
    chooseAIf: ["Visceral fat reduction is a primary goal", "You want FDA-approved clinical evidence", "You are working with a physician for metabolic health"],
    chooseBIf: ["General GH optimization is the goal", "Sleep quality and anti-aging are priorities", "You want a well-tolerated long-term protocol"],
    considerBothIf: "Tesamorelin + ipamorelin is a powerful combination: tesamorelin for visceral fat reduction and ipamorelin for GH pulse optimization.",
    relatedComparisons: ["tesamorelin-vs-sermorelin", "ipamorelin-vs-cjc-1295", "ipamorelin-vs-sermorelin"],
    faqItems: [
      { q: "Can tesamorelin and ipamorelin be combined?", a: "Yes. Tesamorelin (GHRH analogue) + ipamorelin (GHRP) is a synergistic combination that produces greater GH release than either alone, similar to CJC-1295 + ipamorelin." },
    ],
  },

  {
    slug: "bpc-157-vs-ghk-cu",
    peptideA: "BPC-157", peptideASlug: "bpc-157",
    peptideB: "GHK-Cu", peptideBSlug: "ghk-cu",
    h1: "BPC-157 vs GHK-Cu: Two Healing Peptides Compared",
    metaDescription: "BPC-157 vs GHK-Cu: independent comparison of two healing peptides. BPC-157 for systemic repair; GHK-Cu for skin and tissue remodeling. Evidence and use cases. Vendor-neutral.",
    verdictSummary: "BPC-157 is the most potent systemic healing peptide for injuries, gut, and inflammation. GHK-Cu excels at skin anti-aging, wound healing, and collagen synthesis. They are complementary rather than competing.",
    category: "Recovery",
    atAGlance: [
      { dimension: "Primary Strength", peptideA: "Systemic healing, gut, joints, tendons", peptideB: "Skin anti-aging, collagen, wound healing" },
      { dimension: "Administration", peptideA: "Injectable or oral", peptideB: "Topical or injectable" },
      { dimension: "Evidence Depth", peptideA: "Extensive preclinical", peptideB: "Good for skin; moderate systemic" },
    ],
    deepDiveA: "BPC-157 is the most researched healing peptide with extensive preclinical evidence across multiple organ systems. It is particularly effective for gut healing, joint and tendon injuries, and systemic inflammation.",
    deepDiveB: "GHK-Cu has extensive evidence for skin anti-aging and wound healing. It also has broader systemic effects through gene expression modulation, but its strongest evidence is for skin applications.",
    chooseAIf: ["Systemic healing, injury recovery, or gut health are the goals", "You want the most researched healing peptide", "Injectable or oral delivery is acceptable"],
    chooseBIf: ["Skin anti-aging and collagen are primary goals", "Topical application is preferred", "Wound healing with skin-specific benefits is needed"],
    considerBothIf: "BPC-157 (injectable for systemic healing) + GHK-Cu (topical for skin) is a popular combination addressing both internal and external healing.",
    relatedComparisons: ["bpc-157-vs-tb-500", "ghk-cu-vs-retinol", "bpc-157-vs-ipamorelin"],
    faqItems: [
      { q: "Which is better, BPC-157 or GHK-Cu?", a: "They excel in different areas. BPC-157 is better for systemic healing, gut, and injuries. GHK-Cu is better for skin anti-aging and topical wound healing. Most comprehensive protocols include both." },
    ],
  },
];

// ─── STACK PAGES ─────────────────────────────────────────────────────────────


export interface StackPageData {
  slug: string;
  name: string;
  h1: string;
  metaDescription: string;
  tagline: string;
  peptides: string[];         // peptide slugs
  peptideNames: string[];
  primaryGoal: string;
  goalSlugs: string[];
  synergyExplanation: string;
  protocol: string;
  dosingSchedule: Array<{ peptide: string; dose: string; timing: string; route: string }>;
  whoIsItFor: string;
  evidenceBase: string;
  costEstimate: string;
  faqItems: Array<{ q: string; a: string }>;
}

export const stackPages: StackPageData[] = [
  {
    slug: "recovery-stack",
    name: "The Recovery Stack",
    h1: "The Recovery Stack: BPC-157 + TB-500",
    metaDescription: "The Recovery Stack (BPC-157 + TB-500): independent guide to the most popular healing peptide combination. Protocol, dosing, and evidence. Vendor-neutral.",
    tagline: "The most researched peptide combination for injury healing, joint recovery, and tissue repair.",
    peptides: ["bpc-157", "tb-500"],
    peptideNames: ["BPC-157", "TB-500"],
    primaryGoal: "Injury healing, joint health, tissue repair",
    goalSlugs: ["joint-recovery", "injury-recovery", "inflammation"],
    synergyExplanation: "BPC-157 and TB-500 work through complementary mechanisms that produce synergistic healing effects. BPC-157 provides localized tissue repair through GH receptor upregulation and angiogenesis, while TB-500 delivers systemic anti-inflammatory effects and promotes cell migration throughout the body. Together, they address both the local injury site (BPC-157) and the systemic inflammatory environment (TB-500) simultaneously — producing faster and more complete healing than either peptide alone.",
    protocol: "The standard Recovery Stack protocol involves a loading phase of 4–6 weeks followed by a maintenance phase. BPC-157 is injected daily at 200–500 mcg, ideally near the injury site. TB-500 is injected twice weekly at 2–2.5 mg during loading, then once weekly during maintenance. Both peptides can be injected subcutaneously at the same time.",
    dosingSchedule: [
      { peptide: "BPC-157", dose: "200–500 mcg", timing: "Daily", route: "Subcutaneous (near injury site)" },
      { peptide: "TB-500", dose: "2–2.5 mg", timing: "Twice weekly (loading), once weekly (maintenance)", route: "Subcutaneous" },
    ],
    whoIsItFor: "Athletes recovering from acute injuries, individuals with chronic joint pain or tendon issues, post-surgical patients, and anyone whose training or quality of life is limited by unresolved tissue damage.",
    evidenceBase: "BPC-157 has extensive preclinical evidence for tendon, ligament, and gut healing. TB-500 has preclinical and emerging human evidence for systemic tissue repair. The combination is widely used in sports medicine and biohacking communities with a strong anecdotal track record.",
    costEstimate: "$70–$170/month (BPC-157: $30–$80/vial + TB-500: $40–$90/vial)",
    faqItems: [
      { q: "Can BPC-157 and TB-500 be injected at the same time?", a: "Yes — they can be injected at the same time in separate syringes or at the same injection site. Many users inject both subcutaneously in the same session." },
      { q: "How long should the Recovery Stack be run?", a: "A typical protocol is 4–6 weeks loading, followed by 4–8 weeks maintenance. For chronic injuries, some users run longer protocols under medical supervision." },
    ],
  },
  {
    slug: "gh-optimization-stack",
    name: "The GH Optimization Stack",
    h1: "The GH Optimization Stack: Ipamorelin + CJC-1295",
    metaDescription: "The GH Optimization Stack (Ipamorelin + CJC-1295): independent guide to the most popular GH secretagogue combination. Protocol, dosing, and evidence. Vendor-neutral.",
    tagline: "The gold standard GH secretagogue combination for muscle growth, fat loss, and sleep quality.",
    peptides: ["ipamorelin", "cjc-1295"],
    peptideNames: ["Ipamorelin", "CJC-1295"],
    primaryGoal: "Muscle growth, fat loss, sleep quality, anti-aging",
    goalSlugs: ["muscle-growth", "fat-loss", "sleep-optimization", "anti-aging"],
    synergyExplanation: "Ipamorelin and CJC-1295 work through complementary GH-stimulating mechanisms that produce synergistic effects. Ipamorelin acts on the ghrelin receptor to trigger sharp, selective GH pulses. CJC-1295 (with DAC) acts on the GHRH receptor to elevate baseline GH levels over days. Together, they produce a sustained elevation of baseline GH with amplified pulsatile release on top — mimicking the optimal GH secretion pattern of young adults.",
    protocol: "The standard protocol involves injecting Ipamorelin (200–300 mcg) and CJC-1295 without DAC (100 mcg) together subcutaneously before bed, 5–7 days per week. If using CJC-1295 with DAC, it is injected once weekly at 1–2 mg, with Ipamorelin continuing daily.",
    dosingSchedule: [
      { peptide: "Ipamorelin", dose: "200–300 mcg", timing: "Before bed, 5–7 days/week", route: "Subcutaneous" },
      { peptide: "CJC-1295 (without DAC)", dose: "100 mcg", timing: "Before bed with Ipamorelin, 5–7 days/week", route: "Subcutaneous" },
    ],
    whoIsItFor: "Adults aged 30+ seeking to optimize body composition, athletes wanting to improve recovery and performance, individuals with age-related GH decline, and anyone seeking the benefits of GH optimization without exogenous HGH.",
    evidenceBase: "Both peptides have preclinical and emerging human evidence for GH stimulation. The combination is the most widely used GH secretagogue protocol in the biohacking and anti-aging communities.",
    costEstimate: "$65–$130/month (Ipamorelin: $30–$60/vial + CJC-1295: $35–$70/vial)",
    faqItems: [
      { q: "When is the best time to inject the GH Optimization Stack?", a: "Before bed is the standard recommendation, as it aligns with the natural nocturnal GH pulse and enhances slow-wave sleep. Some protocols also include a morning dose." },
      { q: "How long before I see results from the GH Optimization Stack?", a: "Sleep improvements are often reported within 1–2 weeks. Body composition changes typically become noticeable after 6–8 weeks, with optimal results at 3–6 months." },
    ],
  },
  {
    slug: "anti-aging-stack",
    name: "The Anti-Aging Stack",
    h1: "The Anti-Aging Stack: Epithalon + GHK-Cu",
    metaDescription: "The Anti-Aging Stack (Epithalon + GHK-Cu): independent guide to the leading longevity peptide combination. Protocol, dosing, and evidence. Vendor-neutral.",
    tagline: "The comprehensive anti-aging combination targeting both cellular aging and visible skin health.",
    peptides: ["epithalon", "ghk-cu"],
    peptideNames: ["Epithalon", "GHK-Cu"],
    primaryGoal: "Longevity, cellular anti-aging, skin health",
    goalSlugs: ["anti-aging", "longevity", "skin-health"],
    synergyExplanation: "Epithalon and GHK-Cu address aging through completely different mechanisms, making them an ideal combination. Epithalon targets cellular aging at the fundamental level through telomerase activation and pineal gland regulation. GHK-Cu addresses the visible manifestations of aging through collagen synthesis, antioxidant activation, and tissue remodeling. Together, they provide both cellular-level and phenotypic anti-aging coverage.",
    protocol: "Epithalon is cycled: 5–10 mg/day for 10–20 days, 1–2 times per year. GHK-Cu can be used continuously: topically (1–5% serum daily) or injected (1–2 mg/day). Many users run an Epithalon cycle in spring and fall while maintaining daily GHK-Cu topical application.",
    dosingSchedule: [
      { peptide: "Epithalon", dose: "5–10 mg", timing: "Daily for 10–20 days (cycled 1–2x/year)", route: "Subcutaneous" },
      { peptide: "GHK-Cu", dose: "1–5% concentration", timing: "Daily (ongoing)", route: "Topical serum" },
    ],
    whoIsItFor: "Adults aged 35+ interested in comprehensive anti-aging protocols, those with visible skin aging concerns, individuals focused on longevity optimization, and anyone seeking to address both cellular and phenotypic aging simultaneously.",
    evidenceBase: "Epithalon has 30+ years of Russian research with animal lifespan extension data and human sleep/quality-of-life studies. GHK-Cu has multiple clinical studies in cosmetic dermatology demonstrating skin improvements.",
    costEstimate: "$60–$160/cycle (Epithalon: $40–$100/cycle + GHK-Cu topical: $20–$60/month)",
    faqItems: [
      { q: "Can Epithalon and GHK-Cu be used at the same time?", a: "Yes — they work through completely different mechanisms and there are no known interactions. Many anti-aging protocols include both simultaneously." },
    ],
  },
  {
    slug: "metabolic-stack",
    name: "The Metabolic Stack",
    h1: "The Metabolic Stack: Semaglutide + Ipamorelin/CJC-1295",
    metaDescription: "The Metabolic Stack: independent guide to combining GLP-1 agonists with GH secretagogues for body recomposition. Protocol, dosing, and evidence. Vendor-neutral.",
    tagline: "The advanced body recomposition stack combining fat loss and muscle preservation.",
    peptides: ["semaglutide", "ipamorelin"],
    peptideNames: ["Semaglutide", "Ipamorelin/CJC-1295"],
    primaryGoal: "Body recomposition, fat loss with muscle preservation",
    goalSlugs: ["fat-loss", "body-recomposition", "metabolic-health"],
    synergyExplanation: "Semaglutide and Ipamorelin/CJC-1295 address body recomposition through complementary mechanisms. Semaglutide drives significant fat loss through appetite suppression and metabolic improvement. Ipamorelin/CJC-1295 stimulates GH and IGF-1, which preserves and builds lean muscle mass during the caloric deficit created by Semaglutide. The combination addresses the primary limitation of GLP-1 therapy — muscle mass loss — by maintaining anabolic signaling throughout the fat loss phase.",
    protocol: "This is an advanced protocol requiring physician supervision due to the prescription nature of Semaglutide. Semaglutide is titrated per standard protocol (starting at 0.25 mg/week). Ipamorelin/CJC-1295 is added at standard doses (200–300 mcg before bed). Resistance training is essential to maximize the muscle-preserving effects of GH stimulation.",
    dosingSchedule: [
      { peptide: "Semaglutide", dose: "0.25–2.4 mg", timing: "Once weekly", route: "Subcutaneous (prescription)" },
      { peptide: "Ipamorelin/CJC-1295", dose: "200–300 mcg / 100 mcg", timing: "Before bed, 5–7 days/week", route: "Subcutaneous" },
    ],
    whoIsItFor: "Adults seeking significant body recomposition who want to maximize fat loss while preserving or building lean muscle mass. Requires physician supervision due to Semaglutide prescription requirement.",
    evidenceBase: "Both components have strong evidence bases individually. The combination is used in functional medicine and anti-aging practices, though no specific combination trials have been conducted.",
    costEstimate: "$350–$600/month (Semaglutide: $200–$400/month compounded + Ipamorelin/CJC-1295: $65–$130/month)",
    faqItems: [
      { q: "Is it safe to combine Semaglutide with GH secretagogues?", a: "This combination is used in functional medicine practices. Physician supervision is required due to the prescription nature of Semaglutide and the metabolic complexity of combining these agents." },
    ],
  },
  {
    slug: "cognitive-stack",
    name: "The Cognitive Stack",
    h1: "The Cognitive Stack: Selank + Semax",
    metaDescription: "The Cognitive Stack (Selank + Semax): independent guide to the leading nootropic peptide combination. Protocol, dosing, and evidence. Vendor-neutral.",
    tagline: "The comprehensive nootropic combination for anxiety reduction, focus, and cognitive performance.",
    peptides: ["selank", "semax"],
    peptideNames: ["Selank", "Semax"],
    primaryGoal: "Cognitive enhancement, anxiety reduction, focus",
    goalSlugs: ["cognitive-performance", "anxiety-reduction", "focus"],
    synergyExplanation: "Selank and Semax work through complementary mechanisms that produce synergistic cognitive enhancement. Selank's anxiolytic effects remove the cognitive impairment caused by anxiety and stress, creating an optimal mental environment. Semax's BDNF upregulation and dopaminergic modulation then enhance underlying cognitive function — focus, memory, and verbal fluency. The combination produces a calm, focused, high-performance cognitive state that neither peptide achieves as effectively alone.",
    protocol: "Both peptides are administered intranasally. Selank (250–1,000 mcg) and Semax (200–600 mcg) can be administered simultaneously or in sequence. Most users administer in the morning for daytime cognitive enhancement. Cycle 2–4 weeks on, 1–2 weeks off.",
    dosingSchedule: [
      { peptide: "Selank", dose: "250–1,000 mcg", timing: "Morning (intranasal)", route: "Intranasal spray" },
      { peptide: "Semax", dose: "200–600 mcg", timing: "Morning (intranasal)", route: "Intranasal spray" },
    ],
    whoIsItFor: "Knowledge workers seeking cognitive enhancement, individuals with anxiety-driven cognitive impairment, students and professionals requiring sustained focus, and anyone seeking comprehensive cognitive and mood optimization.",
    evidenceBase: "Both peptides have extensive Russian research bases with clinical use for cognitive and neurological conditions. The combination is widely used in the nootropic community.",
    costEstimate: "$60–$140/month (Selank: $30–$70/vial + Semax: $30–$70/vial)",
    faqItems: [
      { q: "Can Selank and Semax be mixed in the same nasal spray?", a: "Some users mix them for convenience, though separate administration allows for more precise dosing. Consult with a knowledgeable practitioner before mixing peptides." },
    ],
  },
  {
    slug: "wolverine-stack",
    name: "The Wolverine Stack",
    h1: "The Wolverine Stack: BPC-157 + TB-500 + GHK-Cu",
    metaDescription: "The Wolverine Stack (BPC-157 + TB-500 + GHK-Cu): the comprehensive healing peptide combination for serious injury recovery. Protocol, dosing, and evidence. Vendor-neutral.",
    tagline: "The comprehensive healing stack for serious injuries, post-surgical recovery, and maximum tissue repair.",
    peptides: ["bpc-157", "tb-500", "ghk-cu"],
    peptideNames: ["BPC-157", "TB-500", "GHK-Cu"],
    primaryGoal: "Comprehensive healing, serious injury recovery",
    goalSlugs: ["injury-recovery", "joint-recovery", "inflammation"],
    synergyExplanation: "The Wolverine Stack combines three healing peptides that each address different aspects of tissue repair. BPC-157 provides localized tendon and gut healing through GH receptor upregulation and angiogenesis. TB-500 delivers systemic anti-inflammatory effects and promotes cell migration throughout the body. GHK-Cu stimulates collagen synthesis and activates antioxidant systems to support tissue remodeling. Together, they address the full healing cascade: inflammation resolution (TB-500), tissue proliferation (BPC-157), and remodeling (GHK-Cu).",
    protocol: "This is an advanced protocol typically used for serious injuries or post-surgical recovery. BPC-157 (200–500 mcg/day), TB-500 (2–2.5 mg twice weekly loading), and GHK-Cu (1–2 mg/day or topical) are run simultaneously for 4–8 weeks.",
    dosingSchedule: [
      { peptide: "BPC-157", dose: "200–500 mcg", timing: "Daily", route: "Subcutaneous (near injury site)" },
      { peptide: "TB-500", dose: "2–2.5 mg", timing: "Twice weekly (loading)", route: "Subcutaneous" },
      { peptide: "GHK-Cu", dose: "1–2 mg", timing: "Daily", route: "Subcutaneous or topical" },
    ],
    whoIsItFor: "Individuals recovering from serious injuries or surgery, athletes with complex multi-tissue injuries, and anyone who needs maximum healing support and is comfortable with a more complex protocol.",
    evidenceBase: "All three components have strong preclinical evidence bases. The combination is used in advanced sports medicine and biohacking practices for serious injury recovery.",
    costEstimate: "$100–$230/month (BPC-157: $30–$80 + TB-500: $40–$90 + GHK-Cu: $30–$60)",
    faqItems: [
      { q: "Is the Wolverine Stack safe?", a: "All three peptides are generally well-tolerated individually. The combination has a strong anecdotal safety record. As with any multi-peptide protocol, physician supervision is recommended." },
      { q: "How long should the Wolverine Stack be run?", a: "Typically 4–8 weeks for acute injuries. For post-surgical recovery, protocols may extend to 12 weeks under medical supervision." },
    ],
  },
];

// ─── HELPER FUNCTIONS ────────────────────────────────────────────────────────

export function getPeptideBySlug(slug: string): PeptidePageData | undefined {
  return peptidePages.find(p => p.slug === slug);
}

export function getGoalBySlug(slug: string): GoalPageData | undefined {
  return goalPages.find(g => g.slug === slug);
}

export function getComparisonBySlug(slug: string): ComparisonPageData | undefined {
  return comparisonPages.find(c => c.slug === slug);
}

export function getStackBySlug(slug: string): StackPageData | undefined {
  return stackPages.find(s => s.slug === slug);
}

export function getAllPeptideSlugs(): string[] {
  return peptidePages.map(p => p.slug);
}

export function getAllGoalSlugs(): string[] {
  return goalPages.map(g => g.slug);
}

export function getAllComparisonSlugs(): string[] {
  return comparisonPages.map(c => c.slug);
}

export function getAllStackSlugs(): string[] {
  return stackPages.map(s => s.slug);
}


// ─── GUIDE PAGES ─────────────────────────────────────────────────────────────
// Template: /guides/[slug]
// Schema: HowTo — structurally distinct from profile pages (step-by-step, not mechanism-first)

export interface GuidePageData {
  slug: string;
  title: string;
  h1: string;
  metaDescription: string;
  category: string;
  targetPeptides: string[];   // peptide slugs
  difficulty: "Beginner" | "Intermediate" | "Advanced";
  timeRequired: string;
  overview: string;
  whatYouNeed: string[];
  steps: Array<{
    stepNumber: number;
    title: string;
    description: string;
    tip?: string;
    warning?: string;
  }>;
  commonMistakes: Array<{ mistake: string; fix: string }>;
  faqItems: Array<{ q: string; a: string }>;
  relatedGuides: string[];
  relatedPeptides: string[];
}

export const guidePages: GuidePageData[] = [
  {
    slug: "how-to-reconstitute-peptides",
    title: "How to Reconstitute Peptides",
    h1: "How to Reconstitute Peptides: Step-by-Step Guide",
    metaDescription: "Step-by-step guide to reconstituting lyophilized peptides safely. Bacteriostatic water, dosing calculations, storage, and common mistakes. Beginner-friendly.",
    category: "Preparation",
    targetPeptides: ["bpc-157", "tb-500", "ipamorelin", "cjc-1295"],
    difficulty: "Beginner",
    timeRequired: "10 minutes",
    overview: "Most research peptides are sold as lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before use. This guide walks through the process step by step, including how to calculate your dose.",
    whatYouNeed: [
      "Lyophilized peptide vial",
      "Bacteriostatic water (BW) — NOT sterile water",
      "Insulin syringes (29-31 gauge, 0.5ml or 1ml)",
      "Alcohol swabs",
      "Refrigerator for storage"
    ],
    steps: [
      {
        stepNumber: 1,
        title: "Gather your supplies",
        description: "Ensure you have bacteriostatic water (not sterile water — BW contains 0.9% benzyl alcohol which prevents bacterial growth), insulin syringes, and alcohol swabs. Work on a clean surface.",
        tip: "Bacteriostatic water is available from compounding pharmacies and research supply companies. Do not substitute sterile water — it has no preservative and reconstituted peptides will degrade faster."
      },
      {
        stepNumber: 2,
        title: "Swab both vial tops with alcohol",
        description: "Wipe the rubber stopper of both the peptide vial and the bacteriostatic water vial with an alcohol swab. Allow to air dry for 30 seconds before proceeding.",
        warning: "Never touch the rubber stopper with your fingers after swabbing."
      },
      {
        stepNumber: 3,
        title: "Draw bacteriostatic water into the syringe",
        description: "Using an insulin syringe, draw the desired amount of bacteriostatic water. The amount determines your concentration. Common: 1ml BW into a 5mg vial = 5mg/ml (5000mcg/ml). For 500mcg doses, you would draw 0.1ml (10 units on a 100-unit insulin syringe).",
        tip: "Use 1-2ml of BW per vial for most peptides. More water = lower concentration = larger injection volume per dose. Less water = higher concentration = smaller injection volume."
      },
      {
        stepNumber: 4,
        title: "Inject water slowly into the peptide vial",
        description: "Insert the syringe needle through the rubber stopper at an angle. Direct the water stream down the side of the vial — do not spray directly onto the powder. Inject slowly to avoid foaming.",
        warning: "Never shake the vial. Shaking can damage peptide bonds. Gently swirl or roll between your palms to mix."
      },
      {
        stepNumber: 5,
        title: "Gently swirl until fully dissolved",
        description: "Gently swirl the vial in a circular motion until the powder is completely dissolved. The solution should be clear and colorless (some peptides may have a slight color). This may take 1-3 minutes.",
        tip: "If the powder does not dissolve completely, place the vial in the refrigerator for 15-30 minutes and try again."
      },
      {
        stepNumber: 6,
        title: "Calculate your dose",
        description: "Use this formula: Volume to inject (ml) = Desired dose (mcg) ÷ Concentration (mcg/ml). Example: 500mcg dose from a 5mg/ml (5000mcg/ml) solution = 500 ÷ 5000 = 0.1ml = 10 units on a 100-unit insulin syringe.",
        tip: "Write down your concentration and dose calculation before injecting. Double-check your math."
      },
      {
        stepNumber: 7,
        title: "Store properly",
        description: "Store reconstituted peptides in the refrigerator (2-8°C / 35-46°F). Most reconstituted peptides remain stable for 4-6 weeks when refrigerated. Keep away from light. Do not freeze reconstituted peptides.",
        warning: "Lyophilized (unreconstituted) peptides can be stored frozen for months to years. Once reconstituted, refrigerate and use within 4-6 weeks."
      }
    ],
    commonMistakes: [
      { mistake: "Using sterile water instead of bacteriostatic water", fix: "Always use bacteriostatic water (contains 0.9% benzyl alcohol). Sterile water has no preservative and reconstituted peptides will degrade within 24-48 hours." },
      { mistake: "Shaking the vial to mix", fix: "Gently swirl or roll between palms. Shaking creates foam and can damage peptide bonds." },
      { mistake: "Spraying water directly onto the powder", fix: "Direct the water stream down the side of the vial to minimize foaming and protect the peptide." },
      { mistake: "Incorrect dose calculation", fix: "Write down your concentration (mg/ml or mcg/ml) and use the formula: volume = dose ÷ concentration. Double-check before injecting." },
      { mistake: "Storing at room temperature after reconstitution", fix: "Refrigerate immediately after reconstitution. Room temperature storage significantly accelerates degradation." }
    ],
    faqItems: [
      { q: "How much bacteriostatic water should I use?", a: "1-2ml per vial is standard. The amount determines concentration: 1ml into a 5mg vial = 5mg/ml; 2ml = 2.5mg/ml. Use less water for smaller injection volumes, more water for easier dose measurement." },
      { q: "How long does reconstituted peptide last?", a: "Most reconstituted peptides are stable for 4-6 weeks when refrigerated. Lyophilized peptides can be stored frozen for months to years." },
      { q: "Can I use sterile water instead of bacteriostatic water?", a: "No. Sterile water has no preservative. Reconstituted peptides in sterile water will degrade within 24-48 hours and risk bacterial contamination. Always use bacteriostatic water." },
      { q: "What if my peptide doesn't dissolve completely?", a: "Refrigerate for 15-30 minutes and try swirling again. Some peptides dissolve slowly. If it still won't dissolve, the peptide may be degraded or the wrong solvent is being used." }
    ],
    relatedGuides: ["how-to-inject-peptides-subcutaneously", "how-to-calculate-peptide-dosage", "how-to-store-peptides"],
    relatedPeptides: ["bpc-157", "tb-500", "ipamorelin", "cjc-1295"]
  },

  {
    slug: "how-to-inject-peptides-subcutaneously",
    title: "How to Inject Peptides Subcutaneously",
    h1: "How to Inject Peptides Subcutaneously: Step-by-Step Guide",
    metaDescription: "Step-by-step guide to subcutaneous peptide injection. Site selection, technique, needle gauge, and how to minimize discomfort. Beginner-friendly.",
    category: "Administration",
    targetPeptides: ["bpc-157", "tb-500", "ipamorelin", "cjc-1295", "ghk-cu"],
    difficulty: "Beginner",
    timeRequired: "5 minutes",
    overview: "Subcutaneous (SubQ) injection delivers peptides into the fatty tissue just below the skin. It is the most common route for research peptides and is generally well-tolerated with proper technique.",
    whatYouNeed: [
      "Reconstituted peptide in syringe",
      "Insulin syringe (29-31 gauge, 0.5ml or 1ml)",
      "Alcohol swabs",
      "Sharps disposal container"
    ],
    steps: [
      {
        stepNumber: 1,
        title: "Choose your injection site",
        description: "Common SubQ sites: abdomen (2 inches from navel), outer thigh, or lower back fat. Rotate sites with each injection to prevent lipodystrophy (fat tissue changes). The abdomen is most commonly used for convenience.",
        tip: "Avoid injecting into the same spot repeatedly. Keep a rotation log if needed."
      },
      {
        stepNumber: 2,
        title: "Prepare the site",
        description: "Swab the injection site with an alcohol swab and allow to air dry for 30 seconds. Do not blow on it or fan it — this can introduce bacteria.",
        warning: "Never inject through clothing. Always expose the skin."
      },
      {
        stepNumber: 3,
        title: "Draw up your dose",
        description: "If not already done, draw your calculated dose into the insulin syringe. Tap the syringe to move air bubbles to the top and gently push the plunger to expel them. A small drop at the needle tip is fine.",
      },
      {
        stepNumber: 4,
        title: "Pinch the skin",
        description: "Using your non-dominant hand, pinch a fold of skin and fat at the injection site. This lifts the subcutaneous tissue away from the muscle beneath.",
        tip: "A 1-2 inch pinch is sufficient. You do not need a large fold."
      },
      {
        stepNumber: 5,
        title: "Insert the needle",
        description: "Hold the syringe like a dart at a 45-degree angle (or 90 degrees for very short needles like 4-6mm). Insert the needle with a quick, smooth motion. Do not hesitate — a quick insertion is less painful.",
        tip: "29-31 gauge needles are very fine and cause minimal discomfort. If you feel significant pain, you may have hit a nerve — withdraw and try a different spot."
      },
      {
        stepNumber: 6,
        title: "Inject slowly",
        description: "Release the pinch and slowly depress the plunger over 5-10 seconds. Injecting too quickly can cause stinging or a burning sensation.",
        tip: "If you feel resistance or the injection site swells rapidly, you may be injecting too fast or into muscle. Slow down."
      },
      {
        stepNumber: 7,
        title: "Withdraw and apply gentle pressure",
        description: "Withdraw the needle at the same angle it was inserted. Apply gentle pressure with the alcohol swab for 10-15 seconds. Do not rub — this can cause bruising.",
      },
      {
        stepNumber: 8,
        title: "Dispose of the needle safely",
        description: "Place the used needle and syringe in a sharps disposal container immediately. Never recap needles by hand. Never dispose of sharps in regular trash.",
        warning: "Sharps disposal is a legal requirement in most jurisdictions. Use an approved sharps container."
      }
    ],
    commonMistakes: [
      { mistake: "Injecting into muscle instead of fat", fix: "Use a short needle (4-8mm) and a 45-degree angle. Pinch the skin to ensure you are in subcutaneous tissue, not muscle." },
      { mistake: "Injecting too quickly", fix: "Depress the plunger slowly over 5-10 seconds to minimize stinging and ensure proper distribution." },
      { mistake: "Not rotating injection sites", fix: "Rotate sites with each injection. Repeated injection into the same spot causes lipodystrophy (fat tissue changes) and reduced absorption." },
      { mistake: "Rubbing the injection site", fix: "Apply gentle pressure only. Rubbing can cause bruising and disrupt the peptide depot." }
    ],
    faqItems: [
      { q: "Does subcutaneous injection hurt?", a: "With a 29-31 gauge insulin needle, discomfort is minimal — comparable to a small pinch. Slow injection and proper technique minimize discomfort further." },
      { q: "How deep should I inject?", a: "SubQ injection targets the fatty tissue just below the skin. With a 4-8mm needle at 45 degrees, you will naturally land in subcutaneous tissue. Longer needles require a shallower angle." },
      { q: "Can I inject in the same spot every time?", a: "No. Rotate injection sites to prevent lipodystrophy (fat tissue changes) and maintain consistent absorption. Keep a rotation log if helpful." },
      { q: "What if I see blood when I pull back the plunger?", a: "You may have nicked a small blood vessel. Withdraw the needle, apply pressure, and try a different site. This is not dangerous but means the injection was not SubQ." }
    ],
    relatedGuides: ["how-to-reconstitute-peptides", "how-to-calculate-peptide-dosage", "how-to-store-peptides"],
    relatedPeptides: ["bpc-157", "tb-500", "ipamorelin", "cjc-1295"]
  },

  {
    slug: "how-to-calculate-peptide-dosage",
    title: "How to Calculate Peptide Dosage",
    h1: "How to Calculate Peptide Dosage: The Complete Guide",
    metaDescription: "Complete guide to peptide dosage calculation. Concentration, units, mcg to ml conversion, and worked examples for BPC-157, ipamorelin, and more. Beginner-friendly.",
    category: "Dosing",
    targetPeptides: ["bpc-157", "tb-500", "ipamorelin", "cjc-1295", "ghk-cu"],
    difficulty: "Beginner",
    timeRequired: "15 minutes to learn",
    overview: "Peptide dosing requires understanding concentration (how much peptide per ml of solution) and converting your desired dose (in mcg) to an injection volume (in ml or insulin syringe units). This guide makes the math simple.",
    whatYouNeed: [
      "Peptide vial (note the mg amount on the label)",
      "Bacteriostatic water",
      "Calculator",
      "Insulin syringe (100-unit markings)"
    ],
    steps: [
      {
        stepNumber: 1,
        title: "Identify your peptide vial amount",
        description: "Check the label. Common sizes: 2mg, 5mg, 10mg. This is the total amount of peptide in the vial. Convert to mcg: 1mg = 1,000mcg. So a 5mg vial = 5,000mcg total.",
        tip: "Write this number down: Total mcg = vial mg × 1,000"
      },
      {
        stepNumber: 2,
        title: "Decide how much bacteriostatic water to add",
        description: "The amount of BW you add determines your concentration. Common choice: add 1ml (100 units) of BW to a 5mg vial. This gives you 5mg/ml = 5,000mcg/ml.",
        tip: "More BW = lower concentration = larger injection volume per dose. Less BW = higher concentration = smaller injection volume. 1-2ml is standard."
      },
      {
        stepNumber: 3,
        title: "Calculate your concentration",
        description: "Concentration (mcg/ml) = Total mcg ÷ ml of BW added. Example: 5,000mcg ÷ 1ml = 5,000mcg/ml. Or: 5,000mcg ÷ 2ml = 2,500mcg/ml.",
        tip: "Write this down. You will use it every time you dose."
      },
      {
        stepNumber: 4,
        title: "Calculate your injection volume",
        description: "Volume (ml) = Desired dose (mcg) ÷ Concentration (mcg/ml). Example: You want 250mcg from a 5,000mcg/ml solution. 250 ÷ 5,000 = 0.05ml.",
      },
      {
        stepNumber: 5,
        title: "Convert ml to insulin syringe units",
        description: "Insulin syringes have 100 units = 1ml. So: Units = Volume (ml) × 100. Example: 0.05ml × 100 = 5 units on the syringe. Draw to the '5' mark.",
        tip: "This is the most important step. Always double-check: units on syringe = (desired mcg ÷ concentration mcg/ml) × 100"
      },
      {
        stepNumber: 6,
        title: "Verify with a worked example",
        description: "BPC-157 example: 5mg vial + 1ml BW = 5,000mcg/ml. Desired dose: 500mcg. Volume = 500 ÷ 5,000 = 0.1ml = 10 units. Draw to the '10' mark on a 100-unit insulin syringe.",
        tip: "Ipamorelin example: 2mg vial + 2ml BW = 1,000mcg/ml. Desired dose: 300mcg. Volume = 300 ÷ 1,000 = 0.3ml = 30 units."
      }
    ],
    commonMistakes: [
      { mistake: "Confusing mg and mcg", fix: "1mg = 1,000mcg. Always convert your vial amount to mcg first before calculating." },
      { mistake: "Forgetting to account for how much BW was added", fix: "Your concentration depends entirely on how much BW you added. Always calculate concentration fresh if you are unsure." },
      { mistake: "Using a 50-unit syringe and applying 100-unit math", fix: "Check your syringe. A 50-unit syringe has 50 units = 0.5ml. A 100-unit syringe has 100 units = 1ml. The math changes accordingly." },
      { mistake: "Not writing down the concentration", fix: "Write the concentration on a piece of tape on the vial. You will need it every time you dose." }
    ],
    faqItems: [
      { q: "What is the difference between mg and mcg?", a: "1mg = 1,000mcg (micrograms). Peptide vials are labeled in mg; doses are usually expressed in mcg. Always convert before calculating." },
      { q: "What if I add 2ml of BW instead of 1ml?", a: "Your concentration halves. A 5mg vial + 2ml BW = 2,500mcg/ml instead of 5,000mcg/ml. You would need to draw twice as much volume for the same dose." },
      { q: "How do I know how many units to draw on my syringe?", a: "Units = (Desired dose in mcg ÷ Concentration in mcg/ml) × 100. Example: 500mcg ÷ 5,000mcg/ml × 100 = 10 units." },
      { q: "Can I use a 0.5ml syringe?", a: "Yes. A 0.5ml (50-unit) syringe works the same way: 50 units = 0.5ml. Use the same formula but note that the maximum dose you can draw is 0.5ml." }
    ],
    relatedGuides: ["how-to-reconstitute-peptides", "how-to-inject-peptides-subcutaneously", "how-to-store-peptides"],
    relatedPeptides: ["bpc-157", "tb-500", "ipamorelin", "cjc-1295"]
  },

  {
    slug: "how-to-store-peptides",
    title: "How to Store Peptides",
    h1: "How to Store Peptides: Lyophilized and Reconstituted",
    metaDescription: "Complete guide to peptide storage. Lyophilized vs reconstituted, temperature, light, freeze-thaw cycles, and shelf life. Keep your peptides potent.",
    category: "Preparation",
    targetPeptides: ["bpc-157", "tb-500", "ipamorelin", "cjc-1295", "epithalon"],
    difficulty: "Beginner",
    timeRequired: "5 minutes to learn",
    overview: "Proper storage is critical for maintaining peptide potency. Lyophilized (freeze-dried) peptides are stable for months to years when stored correctly. Reconstituted peptides require refrigeration and have a shorter shelf life.",
    whatYouNeed: [
      "Freezer (for long-term lyophilized storage)",
      "Refrigerator (for reconstituted peptides)",
      "Amber or opaque vials (if repackaging)",
      "Desiccant packets (optional, for lyophilized storage)"
    ],
    steps: [
      {
        stepNumber: 1,
        title: "Understand the two storage states",
        description: "Lyophilized (freeze-dried) peptides are the powder form in sealed vials. They are highly stable. Reconstituted peptides (dissolved in BW) are less stable and require refrigeration.",
        tip: "Only reconstitute what you plan to use within 4-6 weeks. Keep the rest lyophilized."
      },
      {
        stepNumber: 2,
        title: "Store lyophilized peptides in the freezer",
        description: "Sealed lyophilized vials should be stored in the freezer (-20°C / -4°F) for long-term storage (months to years). For short-term use (within 1-3 months), refrigeration is acceptable.",
        tip: "Keep vials in a sealed bag with a desiccant packet to prevent moisture exposure."
      },
      {
        stepNumber: 3,
        title: "Protect from light",
        description: "Peptides are sensitive to UV light. Store in a dark location or in amber/opaque vials. Avoid leaving vials on a countertop in sunlight.",
        warning: "Even brief UV exposure can degrade some peptides. Keep vials in their original packaging or in a drawer."
      },
      {
        stepNumber: 4,
        title: "Refrigerate reconstituted peptides",
        description: "Once reconstituted with bacteriostatic water, store peptides in the refrigerator (2-8°C / 35-46°F). Most reconstituted peptides remain stable for 4-6 weeks.",
        warning: "Do not freeze reconstituted peptides. Freeze-thaw cycles damage peptide bonds and reduce potency."
      },
      {
        stepNumber: 5,
        title: "Minimize freeze-thaw cycles for lyophilized peptides",
        description: "Each freeze-thaw cycle slightly degrades lyophilized peptides. If you have a large vial you will use over many months, consider dividing it into smaller aliquots before reconstituting.",
        tip: "Aliquot strategy: reconstitute the full vial, divide into smaller vials (e.g., 10 x 0.5ml), and freeze the unused aliquots. Thaw one at a time as needed."
      },
      {
        stepNumber: 6,
        title: "Check for signs of degradation",
        description: "Discard peptides if: the solution becomes cloudy or develops particles, the color changes significantly, or the vial has been stored improperly. When in doubt, discard.",
        warning: "Degraded peptides are not just ineffective — they may contain breakdown products. Do not use peptides that show signs of degradation."
      }
    ],
    commonMistakes: [
      { mistake: "Freezing reconstituted peptides", fix: "Freeze-thaw cycles damage reconstituted peptides. Only freeze lyophilized (powder) peptides. Refrigerate reconstituted peptides and use within 4-6 weeks." },
      { mistake: "Leaving lyophilized peptides at room temperature for extended periods", fix: "Room temperature storage accelerates degradation. Refrigerate for short-term use; freeze for long-term storage." },
      { mistake: "Exposing peptides to light", fix: "Store in a dark location or amber vials. UV light degrades many peptides." },
      { mistake: "Using peptides past their stability window", fix: "Reconstituted peptides are stable for 4-6 weeks refrigerated. Discard after this period even if the solution looks clear." }
    ],
    faqItems: [
      { q: "How long do lyophilized peptides last?", a: "When stored frozen (-20°C), lyophilized peptides can remain stable for 1-2 years or longer. Refrigerated, they are stable for 3-6 months. Room temperature storage significantly reduces shelf life." },
      { q: "Can I freeze reconstituted peptides?", a: "No. Freeze-thaw cycles damage reconstituted peptides. Only freeze lyophilized (powder) peptides. Once reconstituted, refrigerate and use within 4-6 weeks." },
      { q: "What does a degraded peptide look like?", a: "Cloudy solution, visible particles, or significant color change can indicate degradation. However, degraded peptides can also look normal. When in doubt, discard." },
      { q: "Do I need to keep peptides cold during shipping?", a: "Lyophilized peptides tolerate short periods at room temperature (days to weeks) without significant degradation. For reconstituted peptides or extended transit, cold packs are recommended." }
    ],
    relatedGuides: ["how-to-reconstitute-peptides", "how-to-inject-peptides-subcutaneously", "how-to-calculate-peptide-dosage"],
    relatedPeptides: ["bpc-157", "tb-500", "ipamorelin", "cjc-1295"]
  },

  {
    slug: "how-to-use-bpc-157-for-gut-healing",
    title: "How to Use BPC-157 for Gut Healing",
    h1: "How to Use BPC-157 for Gut Healing: Protocol Guide",
    metaDescription: "Step-by-step guide to using BPC-157 for gut healing. Oral vs injectable, dosing, cycle length, and what to expect. Independent, vendor-neutral.",
    category: "Protocol",
    targetPeptides: ["bpc-157"],
    difficulty: "Intermediate",
    timeRequired: "4-8 week protocol",
    overview: "BPC-157 is the most researched peptide for gut healing, with preclinical evidence for IBD, leaky gut, gastric ulcers, and gut injury. This guide covers the oral vs injectable debate, dosing protocols, and what to expect.",
    whatYouNeed: [
      "BPC-157 (lyophilized powder)",
      "Bacteriostatic water (for injectable protocol)",
      "Insulin syringes (for injectable protocol)",
      "OR: BPC-157 capsules (for oral protocol)"
    ],
    steps: [
      {
        stepNumber: 1,
        title: "Choose oral or injectable",
        description: "For gut-specific healing, oral BPC-157 (capsules or dissolved in water) may be more appropriate as it delivers the peptide directly to the gut lining. Injectable BPC-157 provides systemic effects and may reach the gut via circulation. Both approaches are used.",
        tip: "Oral: 250-500mcg in water on an empty stomach. Injectable: 250-500mcg SubQ, 1-2x daily."
      },
      {
        stepNumber: 2,
        title: "Start at a low dose",
        description: "Begin with 250mcg/day (oral or injectable) for the first week to assess tolerance. Most users experience no side effects at this dose.",
        tip: "Some users report mild nausea or dizziness at higher doses. Starting low allows you to identify your tolerance."
      },
      {
        stepNumber: 3,
        title: "Escalate to therapeutic dose",
        description: "After 1 week, increase to 500mcg/day if tolerated. Some protocols use 500mcg twice daily (1,000mcg/day total) for more severe gut conditions. The most common therapeutic dose is 500mcg/day.",
        warning: "Higher doses are not necessarily more effective. Start with 500mcg/day before considering escalation."
      },
      {
        stepNumber: 4,
        title: "Time your doses",
        description: "For oral BPC-157: take on an empty stomach, 30 minutes before meals. For injectable: timing is less critical, but morning and evening doses are common for twice-daily protocols.",
      },
      {
        stepNumber: 5,
        title: "Run a 4-8 week cycle",
        description: "Most gut healing protocols run 4-8 weeks. Acute conditions (e.g., post-antibiotic gut disruption) may respond within 2-4 weeks. Chronic conditions (e.g., IBD, long-standing leaky gut) typically require 6-8 weeks.",
        tip: "Many users report noticeable improvement within 2-3 weeks. Full benefits often emerge at 4-6 weeks."
      },
      {
        stepNumber: 6,
        title: "Take a break and reassess",
        description: "After 8 weeks, take a 4-week break before starting another cycle. Assess your gut symptoms during the break. Many users find that 1-2 cycles are sufficient for significant improvement.",
      }
    ],
    commonMistakes: [
      { mistake: "Using injectable BPC-157 when gut-specific healing is the goal", fix: "For gut conditions, oral BPC-157 delivers the peptide directly to the gut lining. Injectable is more appropriate for systemic or injury applications." },
      { mistake: "Starting at too high a dose", fix: "Start at 250mcg/day and escalate to 500mcg after 1 week. Higher starting doses increase the risk of side effects without necessarily improving outcomes." },
      { mistake: "Not giving it enough time", fix: "Gut healing takes time. Most users see significant improvement at 4-6 weeks. Do not discontinue after 1-2 weeks if results are not immediate." }
    ],
    faqItems: [
      { q: "Is oral or injectable BPC-157 better for gut healing?", a: "For gut-specific conditions, oral BPC-157 delivers the peptide directly to the gut lining and may be more appropriate. Injectable provides systemic effects. Both approaches are used in practice." },
      { q: "How long does BPC-157 take to work for gut issues?", a: "Most users report noticeable improvement within 2-4 weeks. Full benefits typically emerge at 4-6 weeks. Chronic conditions may require a full 8-week cycle." },
      { q: "Can BPC-157 be taken with food?", a: "For oral protocols, taking BPC-157 on an empty stomach is generally recommended to maximize absorption. For injectable protocols, timing relative to meals is less critical." }
    ],
    relatedGuides: ["how-to-reconstitute-peptides", "how-to-inject-peptides-subcutaneously", "how-to-calculate-peptide-dosage"],
    relatedPeptides: ["bpc-157", "tb-500", "ghk-cu"]
  },
  {
    slug: "how-to-store-peptides",
    title: "How to Store Peptides: Lyophilized & Reconstituted",
    h1: "How to Store Peptides Correctly (Lyophilized & Reconstituted)",
    metaDescription: "Learn the exact storage conditions for lyophilized and reconstituted peptides — temperature, light, freeze-thaw cycles, and shelf life.",
    category: "Storage & Handling",
    targetPeptides: ["bpc-157", "tb-500", "ghk-cu"],
    difficulty: "Beginner",
    timeRequired: "5 minutes",
    overview: "Improper storage is the #1 cause of peptide degradation. Lyophilized (freeze-dried) peptides are stable at room temperature for short periods but last years when refrigerated or frozen. Once reconstituted with bacteriostatic water, the clock starts ticking — most peptides remain potent for 4–6 weeks at 4°C.",
    whatYouNeed: ["Refrigerator (2–8°C) or freezer (-20°C)", "Amber glass vials or opaque storage containers", "Bacteriostatic water (for reconstituted peptides)", "Parafilm or vial caps", "Permanent marker for labeling"],
    steps: [
    {
      stepNumber: 1,
      title: "Store lyophilized peptides at -20°C",
      description: "Unopened lyophilized vials are stable for 2+ years at -20°C. For shorter-term use (under 3 months), a standard refrigerator at 2–8°C is acceptable.",
      tip: "Keep vials in a sealed bag with a desiccant packet to prevent moisture absorption.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Protect from light",
      description: "UV light degrades peptide bonds. Store all vials in an opaque container, drawer, or amber glass. Never leave vials on a countertop.",
      tip: undefined,
      warning: "Clear glass vials exposed to sunlight can lose 20–40% potency within days.",
    }
,
    {
      stepNumber: 3,
      title: "Label every vial before storage",
      description: "Write the peptide name, date reconstituted (if applicable), and concentration on each vial. Memory is unreliable when managing multiple compounds.",
      tip: "Use a label maker or waterproof marker — regular ink smears in the fridge.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Store reconstituted peptides at 4°C",
      description: "Once mixed with bacteriostatic water, store the vial upright in the refrigerator. Most peptides remain stable for 4–6 weeks. Peptides with disulfide bonds (e.g., insulin) may degrade faster.",
      tip: "Do not freeze reconstituted peptides — ice crystal formation damages the peptide structure.",
      warning: "Never freeze a reconstituted vial unless specifically instructed for that peptide.",
    }
,
    {
      stepNumber: 5,
      title: "Minimize freeze-thaw cycles",
      description: "Each freeze-thaw cycle stresses the peptide. If you need to freeze lyophilized powder, aliquot it into single-use portions before freezing so you only thaw what you need.",
      tip: "Pre-aliquot into 10-use vials to avoid repeated freeze-thaw of the master vial.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Leaving vials at room temperature for weeks",
      fix: "Refrigerate immediately after receipt. Room temp is only acceptable for same-day use.",
    }
,
    {
      mistake: "Freezing reconstituted peptides",
      fix: "Reconstituted peptides should be refrigerated, not frozen. Freeze only the lyophilized powder.",
    }
,
    {
      mistake: "Using regular water instead of bacteriostatic water",
      fix: "Bacteriostatic water contains 0.9% benzyl alcohol which inhibits bacterial growth, extending shelf life from days to weeks.",
    }
    ],
    faqItems: [
    {
      q: "How long do reconstituted peptides last in the fridge?",
      a: "Most reconstituted peptides remain stable for 4–6 weeks at 2–8°C when prepared with bacteriostatic water. Peptides with disulfide bonds or complex structures may degrade faster.",
    }
,
    {
      q: "Can I store peptides in a regular kitchen fridge?",
      a: "Yes, for short-term storage (under 3 months). Ensure the fridge maintains a consistent 2–8°C and the vials are protected from light and moisture.",
    }
,
    {
      q: "What happens if I accidentally freeze a reconstituted peptide?",
      a: "One accidental freeze cycle may not destroy the peptide, but it risks degradation. Thaw slowly at 4°C, inspect for cloudiness or particulates, and use promptly.",
    }
    ],
    relatedPeptides: ["bpc-157", "tb-500", "ghk-cu"],
    relatedGuides: ["how-to-reconstitute-peptides", "how-to-inject-bpc-157"],
  },
  {
    slug: "how-to-calculate-peptide-dosage",
    title: "How to Calculate Peptide Dosage: mcg to mg Conversion",
    h1: "How to Calculate Peptide Dosage: mcg, mg, and IU Explained",
    metaDescription: "Step-by-step guide to calculating peptide dosages — convert mcg to mg, calculate injection volume from concentration, and avoid common dosing errors.",
    category: "Dosing & Calculations",
    targetPeptides: ["bpc-157", "ipamorelin", "sermorelin"],
    difficulty: "Intermediate",
    timeRequired: "10 minutes",
    overview: "Peptide dosing errors are common and can result in under-dosing (no effect) or over-dosing (side effects). This guide walks through the math for converting micrograms to milligrams, calculating injection volume from vial concentration, and setting up an insulin syringe correctly.",
    whatYouNeed: ["Calculator or smartphone", "Vial label (mg per vial)", "Bacteriostatic water volume used for reconstitution", "Insulin syringe (U-100, 1mL)"],
    steps: [
    {
      stepNumber: 1,
      title: "Identify the vial concentration",
      description: "Check the vial label for total peptide content (e.g., 5mg per vial). Note how much bacteriostatic water you added during reconstitution (e.g., 2mL). This gives you a concentration of 5mg/2mL = 2.5mg/mL.",
      tip: "Write the concentration on the vial label immediately after reconstitution.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Convert your target dose from mcg to mg",
      description: "Most peptide doses are expressed in micrograms (mcg). To convert: divide by 1000. Example: 250mcg ÷ 1000 = 0.25mg.",
      tip: undefined,
      warning: "Never confuse mcg and mg — a 1000x error is dangerous.",
    }
,
    {
      stepNumber: 3,
      title: "Calculate the injection volume",
      description: "Divide your dose (in mg) by the concentration (mg/mL). Example: 0.25mg ÷ 2.5mg/mL = 0.1mL. On a U-100 insulin syringe, 0.1mL = 10 units.",
      tip: "Use the formula: Volume (mL) = Dose (mg) ÷ Concentration (mg/mL)",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Draw up the correct volume on your syringe",
      description: "U-100 insulin syringes mark units, not mL. Since U-100 = 100 units per mL, 10 units = 0.1mL. Draw to the unit mark that corresponds to your calculated volume.",
      tip: "Double-check: 10 units on a U-100 syringe = 0.1mL = 100 microliters.",
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Verify before injecting",
      description: "Before injecting, confirm: correct peptide, correct vial, correct volume drawn. Read the syringe at eye level to avoid parallax errors.",
      tip: undefined,
      warning: "Always verify the syringe reading twice before injection.",
    }
    ],
    commonMistakes: [
    {
      mistake: "Confusing mcg and mg",
      fix: "1mg = 1000mcg. If your dose is 500mcg, that is 0.5mg — not 500mg.",
    }
,
    {
      mistake: "Not accounting for reconstitution volume",
      fix: "The concentration depends on how much water you added. Always note the exact volume used.",
    }
,
    {
      mistake: "Reading the syringe at an angle",
      fix: "Hold the syringe horizontally at eye level to read the meniscus accurately.",
    }
    ],
    faqItems: [
    {
      q: "What is the difference between mcg, mg, and IU?",
      a: "mcg (microgram) = 0.001mg. mg (milligram) = 1000mcg. IU (international unit) is a biological activity measure used for some peptides like HGH — not directly convertible to weight without knowing the specific peptide's potency standard.",
    }
,
    {
      q: "How many units on an insulin syringe equals 0.1mL?",
      a: "On a standard U-100 insulin syringe, 10 units = 0.1mL. This is because U-100 means 100 units per 1mL.",
    }
,
    {
      q: "What if I added too much or too little water to my vial?",
      a: "Recalculate your concentration based on the actual volume added. The formula is always: Concentration = Total peptide (mg) ÷ Water added (mL).",
    }
    ],
    relatedPeptides: ["bpc-157", "ipamorelin", "sermorelin"],
    relatedGuides: ["how-to-reconstitute-peptides", "how-to-store-peptides"],
  },
  {
    slug: "how-to-inject-subcutaneously",
    title: "How to Inject Peptides Subcutaneously (SubQ) — Step-by-Step",
    h1: "How to Inject Peptides Subcutaneously: A Complete Beginner's Guide",
    metaDescription: "Learn how to inject peptides subcutaneously (SubQ) safely — site selection, needle angle, pinch technique, and post-injection care.",
    category: "Injection Technique",
    targetPeptides: ["bpc-157", "tb-500", "ipamorelin"],
    difficulty: "Beginner",
    timeRequired: "15 minutes",
    overview: "Subcutaneous (SubQ) injection delivers peptides into the fat layer just below the skin. It is the most common route for research peptides because it is easy to self-administer, relatively painless, and provides steady absorption. This guide covers everything from site selection to post-injection care.",
    whatYouNeed: ["Insulin syringe (29–31 gauge, 0.5 inch needle)", "Reconstituted peptide vial", "Alcohol swabs (70% isopropyl)", "Sharps disposal container", "Cotton ball or gauze"],
    steps: [
    {
      stepNumber: 1,
      title: "Wash your hands thoroughly",
      description: "Wash hands with soap and water for at least 20 seconds before handling any injection equipment. This is the single most important infection prevention step.",
      tip: undefined,
      warning: "Never skip hand washing — injection site infections can be serious.",
    }
,
    {
      stepNumber: 2,
      title: "Select your injection site",
      description: "Common SubQ sites: abdomen (2 inches from navel), outer thigh, or upper arm. Rotate sites with each injection to prevent lipodystrophy (fat tissue changes).",
      tip: "The abdomen is the easiest site for self-injection — pinch a fold of fat easily.",
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Clean the injection site",
      description: "Wipe the site with an alcohol swab in a circular motion, moving outward. Allow to air dry for 30 seconds — injecting through wet alcohol stings.",
      tip: "Let the alcohol fully evaporate before injecting.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Pinch the skin and insert the needle",
      description: "Pinch a 1–2 inch fold of skin between thumb and forefinger. Insert the needle at a 45° angle (or 90° if using a very short 4mm needle) with a smooth, confident motion.",
      tip: "A hesitant, slow insertion causes more pain than a quick, decisive one.",
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Inject slowly and withdraw",
      description: "Push the plunger slowly and steadily over 5–10 seconds. Withdraw the needle at the same angle it was inserted. Apply gentle pressure with a cotton ball — do not rub.",
      tip: "Slow injection reduces post-injection soreness.",
      warning: undefined,
    }
,
    {
      stepNumber: 6,
      title: "Dispose of the needle safely",
      description: "Immediately place the used needle and syringe in a sharps container. Never recap needles with two hands — use the one-handed scoop method if recapping is necessary.",
      tip: undefined,
      warning: "Never dispose of needles in regular trash — use an approved sharps container.",
    }
    ],
    commonMistakes: [
    {
      mistake: "Injecting through wet alcohol",
      fix: "Wait 30 seconds after swabbing for the alcohol to fully evaporate before inserting the needle.",
    }
,
    {
      mistake: "Reusing needles",
      fix: "Use a fresh needle for every injection. Reused needles are dull, painful, and carry infection risk.",
    }
,
    {
      mistake: "Injecting in the same spot every time",
      fix: "Rotate injection sites systematically to prevent tissue damage and lipodystrophy.",
    }
    ],
    faqItems: [
    {
      q: "Does SubQ injection hurt?",
      a: "With a sharp 29–31 gauge needle and proper technique, SubQ injection is minimally painful — typically a brief pinch. Dull needles, cold peptide solution, and wet alcohol are the main causes of injection pain.",
    }
,
    {
      q: "What gauge needle should I use for SubQ peptide injections?",
      a: "29–31 gauge, 0.5 inch (12.7mm) needles are standard for SubQ peptide injections. Finer gauges (31G) are less painful but slightly slower to draw.",
    }
,
    {
      q: "How deep should a SubQ injection go?",
      a: "SubQ injections target the fat layer 4–8mm below the skin surface. A 0.5 inch needle at 45° reaches this depth reliably in most adults.",
    }
    ],
    relatedPeptides: ["bpc-157", "tb-500", "ipamorelin"],
    relatedGuides: ["how-to-inject-bpc-157", "how-to-calculate-peptide-dosage"],
  },
  {
    slug: "how-to-use-ipamorelin",
    title: "How to Use Ipamorelin: Dosing, Timing & Protocol Guide",
    h1: "How to Use Ipamorelin: Complete Dosing and Protocol Guide",
    metaDescription: "Step-by-step guide to using ipamorelin — optimal dosing (100–300mcg), injection timing, cycle length, and how to stack with CJC-1295.",
    category: "Peptide Protocols",
    targetPeptides: ["ipamorelin", "cjc-1295", "sermorelin"],
    difficulty: "Intermediate",
    timeRequired: "10 minutes",
    overview: "Ipamorelin is a selective growth hormone secretagogue that stimulates GH release with minimal effect on cortisol or prolactin. It is one of the most popular peptides for body composition, recovery, and sleep quality. This guide covers reconstitution, dosing, timing, and cycling.",
    whatYouNeed: ["Ipamorelin vial (2–5mg)", "Bacteriostatic water (2mL)", "Insulin syringes (U-100)", "Alcohol swabs", "Sharps container"],
    steps: [
    {
      stepNumber: 1,
      title: "Reconstitute the vial",
      description: "Add 2mL of bacteriostatic water to a 5mg ipamorelin vial. This gives a concentration of 2.5mg/mL (2500mcg/mL). Swirl gently — do not shake.",
      tip: "For a 2mg vial with 2mL water: concentration = 1mg/mL = 1000mcg/mL.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Calculate your dose volume",
      description: "Standard dose: 100–300mcg per injection. At 2500mcg/mL: 200mcg = 0.08mL = 8 units on a U-100 syringe. At 1000mcg/mL: 200mcg = 0.2mL = 20 units.",
      tip: "Start at 100mcg to assess tolerance before increasing to 200–300mcg.",
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Choose your injection timing",
      description: "Ipamorelin works best when GH release is already elevated: fasted state (morning), pre-sleep (30–60 min before bed), or post-workout. Avoid injecting within 2 hours of a carbohydrate-heavy meal.",
      tip: "Pre-sleep dosing is the most popular — it amplifies the natural GH pulse during slow-wave sleep.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Inject subcutaneously",
      description: "Inject into the abdomen, outer thigh, or upper arm. Rotate sites. Use a 29–31 gauge insulin syringe at a 45° angle.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Follow a cycle protocol",
      description: "Typical cycle: 8–12 weeks on, 4 weeks off. Some users run continuous low-dose protocols (100mcg/day) for 6+ months. Monitor for water retention, tingling, or lethargy — these indicate the dose may be too high.",
      tip: "Stacking with CJC-1295 (without DAC) amplifies GH pulse magnitude significantly.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Injecting after a carb-heavy meal",
      fix: "High insulin suppresses GH release. Inject in a fasted state or at least 2 hours after a meal for maximum effect.",
    }
,
    {
      mistake: "Starting at maximum dose",
      fix: "Begin at 100mcg to assess individual response. Many users find 100–150mcg is sufficient.",
    }
,
    {
      mistake: "Not rotating injection sites",
      fix: "Rotate between abdomen, thigh, and arm to prevent lipodystrophy and maintain consistent absorption.",
    }
    ],
    faqItems: [
    {
      q: "How long does it take for ipamorelin to work?",
      a: "Most users notice improved sleep quality within 1–2 weeks. Body composition changes (fat loss, lean mass) typically become noticeable after 6–8 weeks of consistent use.",
    }
,
    {
      q: "Should I stack ipamorelin with CJC-1295?",
      a: "The ipamorelin + CJC-1295 (no DAC) stack is one of the most popular combinations. CJC-1295 extends the GH pulse while ipamorelin triggers it, resulting in a larger, more sustained release.",
    }
,
    {
      q: "What are the side effects of ipamorelin?",
      a: "Common side effects at higher doses include water retention, mild tingling in the hands/feet, and transient headache. These typically resolve with dose reduction. Ipamorelin does not significantly raise cortisol or prolactin.",
    }
    ],
    relatedPeptides: ["ipamorelin", "cjc-1295", "sermorelin"],
    relatedGuides: ["how-to-reconstitute-peptides", "how-to-calculate-peptide-dosage", "how-to-inject-subcutaneously"],
  },
  {
    slug: "how-to-use-sermorelin",
    title: "How to Use Sermorelin: Dosing, Timing & Protocol Guide",
    h1: "How to Use Sermorelin: Dosing, Timing, and Protocol",
    metaDescription: "Complete guide to sermorelin dosing (200–500mcg), injection timing, cycle length, and how it compares to HGH therapy.",
    category: "Peptide Protocols",
    targetPeptides: ["sermorelin", "ipamorelin", "cjc-1295"],
    difficulty: "Intermediate",
    timeRequired: "10 minutes",
    overview: "Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to produce and secrete HGH. It is one of the most studied GH secretagogues with a long clinical track record. This guide covers dosing, timing, and protocol design.",
    whatYouNeed: ["Sermorelin vial (3–9mg)", "Bacteriostatic water (3mL)", "Insulin syringes (U-100)", "Alcohol swabs", "Sharps container"],
    steps: [
    {
      stepNumber: 1,
      title: "Reconstitute the vial",
      description: "Add 3mL of bacteriostatic water to a 9mg sermorelin vial for a concentration of 3mg/mL (3000mcg/mL). Swirl gently to dissolve.",
      tip: "Sermorelin dissolves quickly — no need for extended swirling.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Calculate your dose",
      description: "Standard dose: 200–500mcg per injection. At 3000mcg/mL: 300mcg = 0.1mL = 10 units on a U-100 syringe.",
      tip: "Most clinical protocols use 200–300mcg at bedtime.",
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Inject at bedtime",
      description: "Sermorelin works best when injected 30–60 minutes before sleep. The pituitary is most responsive to GHRH during sleep, and this timing aligns with the natural nocturnal GH pulse.",
      tip: "Avoid eating for 2 hours before the injection — insulin blunts GH release.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Maintain a consistent schedule",
      description: "Daily injections are standard. Some protocols use 5 days on / 2 days off to prevent receptor desensitization. Consistency matters more than timing precision.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Monitor and adjust",
      description: "After 4–6 weeks, assess sleep quality, body composition, and energy. If response is minimal, consider increasing to 400–500mcg or stacking with ipamorelin. Blood work (IGF-1 levels) can objectively confirm response.",
      tip: "IGF-1 is the best biomarker for assessing GH axis response to sermorelin.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Using sermorelin in the morning",
      fix: "Bedtime dosing aligns with the natural GH pulse and produces the best results. Morning use is suboptimal.",
    }
,
    {
      mistake: "Expecting HGH-equivalent results",
      fix: "Sermorelin stimulates natural GH release — it will not produce the same magnitude of effect as exogenous HGH. It is safer and more physiological but requires longer timelines.",
    }
,
    {
      mistake: "Stopping too early",
      fix: "Sermorelin effects build over 3–6 months. Many users quit after 4–6 weeks before the full benefit is realized.",
    }
    ],
    faqItems: [
    {
      q: "How does sermorelin compare to HGH?",
      a: "Sermorelin stimulates the pituitary to produce HGH naturally, while exogenous HGH bypasses this system. Sermorelin produces more physiological GH pulses, has a better safety profile, and is significantly less expensive. However, it produces lower peak GH levels than direct HGH administration.",
    }
,
    {
      q: "How long should a sermorelin cycle last?",
      a: "Most protocols run 3–6 months. Some physicians prescribe sermorelin continuously for adult GH deficiency. Unlike exogenous HGH, sermorelin does not suppress endogenous GH production.",
    }
,
    {
      q: "Can sermorelin be stacked with ipamorelin?",
      a: "Yes — this is one of the most common stacks. Sermorelin (GHRH analogue) + ipamorelin (GHRP) work synergistically to produce larger GH pulses than either alone.",
    }
    ],
    relatedPeptides: ["sermorelin", "ipamorelin", "cjc-1295"],
    relatedGuides: ["how-to-use-ipamorelin", "how-to-calculate-peptide-dosage"],
  },
  {
    slug: "how-to-use-bpc-157-for-gut-healing",
    title: "How to Use BPC-157 for Gut Healing: Oral vs. Injectable",
    h1: "How to Use BPC-157 for Gut Healing: Oral vs. Injectable Protocol",
    metaDescription: "Learn how to use BPC-157 for gut healing — oral vs. injectable administration, dosing (250–500mcg), timing, and what to expect.",
    category: "Peptide Protocols",
    targetPeptides: ["bpc-157"],
    difficulty: "Beginner",
    timeRequired: "10 minutes",
    overview: "BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from human gastric juice. It has demonstrated remarkable gut-healing properties in preclinical studies, including repair of intestinal epithelium, reduction of inflammation, and restoration of gut motility. For gut-specific applications, oral administration may be as effective as injection.",
    whatYouNeed: ["BPC-157 vial (5mg)", "Bacteriostatic water (2mL) for injectable, or sterile water for oral", "Insulin syringes (for injectable route)", "Empty capsules (for oral route, optional)"],
    steps: [
    {
      stepNumber: 1,
      title: "Choose your administration route",
      description: "For gut healing (leaky gut, IBS, IBD, gastric ulcers): oral administration is preferred — the peptide acts locally on the GI tract. For systemic effects (tendon/ligament repair, systemic inflammation): SubQ injection is preferred.",
      tip: "Many users with gut issues use oral BPC-157 in the morning and SubQ injection at night for combined local and systemic effects.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Reconstitute the vial",
      description: "Add 2mL of bacteriostatic water to a 5mg vial for a concentration of 2.5mg/mL (2500mcg/mL). For oral use, sterile water without benzyl alcohol is also acceptable.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Dose for gut healing",
      description: "Oral dose: 250–500mcg, taken on an empty stomach 30 minutes before eating. Draw the calculated volume into a syringe, squirt into a small amount of water, and drink.",
      tip: "250mcg at 2500mcg/mL = 0.1mL = 10 units on a U-100 syringe.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Time your doses",
      description: "Take BPC-157 on an empty stomach for maximum GI absorption. Morning (30 min before breakfast) and/or evening (2 hours after dinner) are the most common timing protocols.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Run a 4–8 week protocol",
      description: "Most gut healing protocols run 4–8 weeks. Many users report significant improvement in GI symptoms within 2–4 weeks. Severe conditions (Crohn's, IBD) may require longer protocols.",
      tip: "Keep a symptom diary to track progress objectively.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Taking BPC-157 with food",
      fix: "Oral BPC-157 should be taken on an empty stomach for maximum absorption and local GI action.",
    }
,
    {
      mistake: "Using injectable route for gut healing",
      fix: "While SubQ injection works systemically, oral administration delivers BPC-157 directly to the GI tract where it is needed most for gut healing.",
    }
,
    {
      mistake: "Expecting overnight results",
      fix: "Gut healing is a gradual process. Most users see meaningful improvement after 2–4 weeks of consistent use.",
    }
    ],
    faqItems: [
    {
      q: "Is oral BPC-157 as effective as injectable?",
      a: "For gut-specific conditions, oral BPC-157 may actually be more effective than injection because it acts directly on the GI mucosa. For systemic effects (tendon repair, systemic inflammation), injection is preferred.",
    }
,
    {
      q: "What gut conditions can BPC-157 help with?",
      a: "Preclinical research shows BPC-157 may help with gastric ulcers, leaky gut syndrome, IBS, IBD (Crohn's disease, ulcerative colitis), and NSAID-induced gut damage. Human clinical data is limited.",
    }
,
    {
      q: "Can I take BPC-157 long-term?",
      a: "No human long-term safety data exists. Most protocols run 4–12 weeks with breaks. BPC-157 has shown an excellent safety profile in animal studies with no significant toxicity.",
    }
    ],
    relatedPeptides: ["bpc-157"],
    relatedGuides: ["how-to-inject-bpc-157", "how-to-reconstitute-peptides"],
  },
  {
    slug: "how-to-use-tb-500",
    title: "How to Use TB-500: Dosing, Protocol & Injury Recovery Guide",
    h1: "How to Use TB-500 for Injury Recovery: Complete Protocol Guide",
    metaDescription: "Step-by-step TB-500 protocol for injury recovery — loading dose (10–20mg/week), maintenance phase (2.5–5mg/week), injection sites, and stacking with BPC-157.",
    category: "Peptide Protocols",
    targetPeptides: ["tb-500", "bpc-157"],
    difficulty: "Intermediate",
    timeRequired: "10 minutes",
    overview: "TB-500 (Thymosin Beta-4) is a naturally occurring peptide that promotes tissue repair, reduces inflammation, and accelerates healing of tendons, ligaments, and muscle. It is widely used by athletes for injury recovery. This guide covers the loading/maintenance protocol and how to combine it with BPC-157.",
    whatYouNeed: ["TB-500 vials (5mg each)", "Bacteriostatic water (2mL per vial)", "Insulin syringes (U-100)", "Alcohol swabs", "Sharps container"],
    steps: [
    {
      stepNumber: 1,
      title: "Reconstitute the vial",
      description: "Add 2mL of bacteriostatic water to a 5mg TB-500 vial for a concentration of 2.5mg/mL. Swirl gently — TB-500 dissolves easily.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Loading phase (weeks 1–4)",
      description: "Loading dose: 4–10mg per week, split into 2 injections (e.g., 2.5mg twice weekly). This saturates tissue receptors and initiates the healing cascade. Higher doses (up to 20mg/week) are used for severe injuries.",
      tip: "For acute injuries, start with the higher end of the loading range (7.5–10mg/week).",
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Maintenance phase (weeks 5–12)",
      description: "After loading, reduce to 2.5–5mg per week (1–2 injections). This maintains the healing effect while reducing peptide consumption.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Inject near the injury site (optional)",
      description: "While SubQ injection anywhere is effective (TB-500 is systemically distributed), some protocols recommend injecting near the injury site for enhanced local concentration.",
      tip: "Avoid injecting directly into a tendon or ligament — inject into the surrounding subcutaneous tissue.",
      warning: "Never inject into a joint space — this requires medical training and sterile technique.",
    }
,
    {
      stepNumber: 5,
      title: "Stack with BPC-157 for synergistic healing",
      description: "TB-500 + BPC-157 is the most popular injury recovery stack. BPC-157 promotes angiogenesis and growth factor upregulation; TB-500 promotes cell migration and actin polymerization. Together, they address multiple healing pathways.",
      tip: "Run both peptides simultaneously during the loading phase for maximum synergy.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Skipping the loading phase",
      fix: "The loading phase is essential for saturating tissue receptors. Jumping straight to maintenance doses produces weaker results.",
    }
,
    {
      mistake: "Expecting immediate pain relief",
      fix: "TB-500 accelerates healing — it does not provide analgesic effects. Pain reduction follows tissue repair, typically over 2–6 weeks.",
    }
,
    {
      mistake: "Using TB-500 without addressing the root cause",
      fix: "TB-500 accelerates healing but does not fix biomechanical issues. Address movement patterns, load management, and physical therapy alongside peptide use.",
    }
    ],
    faqItems: [
    {
      q: "How long does TB-500 take to work?",
      a: "Most users report noticeable improvement in pain and function within 2–4 weeks of the loading phase. Full recovery timelines depend on injury severity.",
    }
,
    {
      q: "Can TB-500 be used for chronic injuries?",
      a: "Yes — TB-500 is effective for both acute and chronic injuries. Chronic conditions may require longer protocols (12+ weeks) and higher loading doses.",
    }
,
    {
      q: "Is TB-500 the same as BPC-157?",
      a: "No. TB-500 (Thymosin Beta-4) and BPC-157 are different peptides with complementary mechanisms. TB-500 primarily promotes cell migration and actin polymerization; BPC-157 promotes angiogenesis and growth factor upregulation. They are often stacked together.",
    }
    ],
    relatedPeptides: ["tb-500", "bpc-157"],
    relatedGuides: ["how-to-inject-bpc-157", "how-to-inject-subcutaneously"],
  },
  {
    slug: "how-to-use-nad-plus",
    title: "How to Use NAD+: Dosing, Routes & Anti-Aging Protocol",
    h1: "How to Use NAD+: Dosing, Routes, and Anti-Aging Protocol",
    metaDescription: "Complete guide to NAD+ supplementation — IV vs. SubQ vs. oral routes, dosing (100–1000mg), timing, and how to stack with NMN or NR.",
    category: "Peptide Protocols",
    targetPeptides: ["nad-plus", "epithalon"],
    difficulty: "Intermediate",
    timeRequired: "10 minutes",
    overview: "NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for cellular energy production, DNA repair, and sirtuin activation. Levels decline with age, and supplementation has shown promise for energy, cognition, and longevity. Multiple administration routes exist with different bioavailability profiles.",
    whatYouNeed: ["NAD+ vial (injectable) or capsules (oral)", "Bacteriostatic water (for injectable)", "IV setup (for IV route — requires medical supervision)", "Insulin syringes (for SubQ route)"],
    steps: [
    {
      stepNumber: 1,
      title: "Choose your administration route",
      description: "IV infusion: highest bioavailability, used in clinical settings (250–1000mg over 2–4 hours). SubQ injection: good bioavailability, self-administered (25–100mg/day). Oral (NMN/NR): lowest bioavailability but most convenient (250–1000mg/day).",
      tip: "For most users, SubQ NAD+ or oral NMN is the practical starting point.",
      warning: "IV NAD+ infusions should only be administered by qualified medical professionals.",
    }
,
    {
      stepNumber: 2,
      title: "Start with a low dose",
      description: "Begin with 25–50mg SubQ or 250mg oral NMN/NR to assess tolerance. NAD+ can cause flushing, nausea, and fatigue at higher doses, especially with IV administration.",
      tip: "IV NAD+ commonly causes a 'pressure' sensation in the chest and head — this is normal but dose-dependent.",
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Increase gradually",
      description: "Over 2–4 weeks, increase to your target dose: SubQ 50–100mg/day or oral NMN 500–1000mg/day. IV protocols typically start at 250mg and increase to 500–1000mg per session.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Time your dose in the morning",
      description: "NAD+ is energizing — morning administration prevents sleep disruption. Take with or after breakfast to reduce GI side effects.",
      tip: "Stacking with resveratrol or pterostilbene may enhance sirtuin activation.",
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Cycle or maintain",
      description: "Many users run IV NAD+ as a periodic 'reset' (monthly or quarterly) while maintaining daily oral NMN/NR supplementation. SubQ protocols typically run 4–8 weeks continuously.",
      tip: undefined,
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Starting IV NAD+ at full dose",
      fix: "IV NAD+ at high doses causes intense flushing, nausea, and chest pressure. Always start at 250mg and titrate slowly.",
    }
,
    {
      mistake: "Taking NAD+ in the evening",
      fix: "NAD+ is stimulating and can disrupt sleep. Morning administration is strongly recommended.",
    }
,
    {
      mistake: "Expecting immediate results",
      fix: "NAD+ benefits (energy, cognition, skin) typically emerge over 2–6 weeks of consistent use.",
    }
    ],
    faqItems: [
    {
      q: "Is oral NMN as effective as injectable NAD+?",
      a: "NMN (nicotinamide mononucleotide) is an NAD+ precursor that converts to NAD+ in cells. It has good oral bioavailability and is the most practical form for most users. Injectable NAD+ produces higher peak plasma levels but the long-term outcomes may be similar.",
    }
,
    {
      q: "What does NAD+ feel like?",
      a: "Many users report increased energy, mental clarity, and improved mood within the first few weeks. IV NAD+ often produces a noticeable energy surge within hours of infusion.",
    }
,
    {
      q: "Can NAD+ reverse aging?",
      a: "NAD+ cannot reverse aging, but it supports cellular repair mechanisms (sirtuins, PARP) that decline with age. It is one of the most evidence-backed longevity interventions, though most human data is still emerging.",
    }
    ],
    relatedPeptides: ["nad-plus", "epithalon"],
    relatedGuides: ["how-to-calculate-peptide-dosage", "how-to-store-peptides"],
  },
  {
    slug: "how-to-use-ghk-cu",
    title: "How to Use GHK-Cu: Topical & Injectable Protocols",
    h1: "How to Use GHK-Cu: Topical and Injectable Protocol Guide",
    metaDescription: "Complete guide to GHK-Cu (copper peptide) — topical vs. injectable protocols, concentration, application technique, and skin rejuvenation results.",
    category: "Peptide Protocols",
    targetPeptides: ["ghk-cu"],
    difficulty: "Beginner",
    timeRequired: "10 minutes",
    overview: "GHK-Cu (glycine-histidine-lysine copper) is a naturally occurring copper peptide with potent skin regeneration, wound healing, and anti-aging properties. It stimulates collagen synthesis, reduces inflammation, and promotes angiogenesis. It can be used topically (serums, creams) or via SubQ injection for systemic effects.",
    whatYouNeed: ["GHK-Cu powder or serum", "Carrier solution (for topical: hyaluronic acid serum; for injectable: bacteriostatic water)", "Insulin syringes (for injectable route)", "Clean face/application area"],
    steps: [
    {
      stepNumber: 1,
      title: "Choose topical or injectable route",
      description: "Topical: best for skin rejuvenation, wound healing, hair loss. Injectable: for systemic anti-inflammatory and regenerative effects. Most users start with topical GHK-Cu.",
      tip: "Topical GHK-Cu is effective at 1–5% concentration in a serum base.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Prepare topical solution (if DIY)",
      description: "Dissolve GHK-Cu powder in a hyaluronic acid or aloe vera base at 1–2% concentration. For a 30mL serum: 300–600mg GHK-Cu per 30mL. Store in an amber dropper bottle.",
      tip: "Pre-made GHK-Cu serums are available — look for 1–5% concentration.",
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Apply topically",
      description: "Apply 3–5 drops to clean, dry skin. Massage gently until absorbed. Use morning and/or evening. GHK-Cu is compatible with most skincare ingredients except high-concentration vitamin C (which can oxidize the copper).",
      tip: "Apply before moisturizer but after any water-based serums.",
      warning: "Avoid combining with high-dose vitamin C (L-ascorbic acid >15%) — the copper can oxidize the vitamin C.",
    }
,
    {
      stepNumber: 4,
      title: "Injectable protocol (advanced)",
      description: "For injectable use: reconstitute with bacteriostatic water to 1mg/mL. Dose: 1–2mg SubQ, 2–3x per week. Inject into the area of interest (e.g., scalp for hair loss, near joint for inflammation).",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Assess results at 8–12 weeks",
      description: "Collagen synthesis takes time. Most users see meaningful skin texture improvement, reduced fine lines, and improved wound healing after 8–12 weeks of consistent use.",
      tip: "Take weekly photos in consistent lighting to track progress objectively.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Combining with high-dose vitamin C",
      fix: "Copper oxidizes vitamin C. Use vitamin C in the morning and GHK-Cu in the evening, or choose a vitamin C derivative (ascorbyl glucoside) that is more stable.",
    }
,
    {
      mistake: "Expecting results in 2 weeks",
      fix: "Collagen remodeling takes 8–12 weeks minimum. Consistency is more important than dose.",
    }
,
    {
      mistake: "Using too high a concentration",
      fix: "Very high concentrations (>5%) can cause skin irritation. Start at 1% and increase gradually.",
    }
    ],
    faqItems: [
    {
      q: "Is GHK-Cu safe for daily use?",
      a: "Yes — topical GHK-Cu at 1–5% is well-tolerated for daily use. It has an excellent safety profile in both topical and injectable forms.",
    }
,
    {
      q: "Can GHK-Cu help with hair loss?",
      a: "Preclinical and limited human data suggest GHK-Cu may stimulate hair follicle growth and reduce hair loss. It is often used topically on the scalp at 1–2% concentration.",
    }
,
    {
      q: "How does GHK-Cu compare to retinol?",
      a: "GHK-Cu and retinol have complementary mechanisms. Retinol accelerates cell turnover; GHK-Cu stimulates collagen synthesis and reduces inflammation. They can be used together (apply GHK-Cu in the morning, retinol at night).",
    }
    ],
    relatedPeptides: ["ghk-cu"],
    relatedGuides: ["how-to-store-peptides", "how-to-inject-subcutaneously"],
  },
  {
    slug: "how-to-use-epithalon",
    title: "How to Use Epithalon: Dosing & Longevity Protocol",
    h1: "How to Use Epithalon: Dosing, Cycle Length, and Longevity Protocol",
    metaDescription: "Complete guide to epithalon — dosing (5–10mg/day), cycle length (10–20 days), injection protocol, and evidence for telomere lengthening.",
    category: "Peptide Protocols",
    targetPeptides: ["epithalon", "nad-plus"],
    difficulty: "Intermediate",
    timeRequired: "10 minutes",
    overview: "Epithalon (Epitalon) is a synthetic tetrapeptide derived from the pineal gland that has been studied for its ability to activate telomerase, lengthen telomeres, and regulate melatonin production. It is one of the most researched longevity peptides, with several Russian clinical trials demonstrating anti-aging effects.",
    whatYouNeed: ["Epithalon vials (10mg each)", "Bacteriostatic water (2mL per vial)", "Insulin syringes (U-100)", "Alcohol swabs"],
    steps: [
    {
      stepNumber: 1,
      title: "Reconstitute the vial",
      description: "Add 2mL of bacteriostatic water to a 10mg epithalon vial for a concentration of 5mg/mL. Swirl gently.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Calculate your daily dose",
      description: "Standard dose: 5–10mg per day. At 5mg/mL: 5mg = 1mL = 100 units on a U-100 syringe. 10mg = 2mL (requires 2 injections or a larger syringe).",
      tip: "Most protocols use 5mg/day for 10–20 days.",
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Run a 10–20 day cycle",
      description: "Epithalon is typically used in short, intensive cycles rather than continuous daily use. Standard protocol: 5–10mg/day for 10–20 consecutive days, 1–2 times per year.",
      tip: "Many longevity-focused users run one cycle in spring and one in autumn.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Inject SubQ or IM",
      description: "Epithalon can be injected subcutaneously or intramuscularly. SubQ is more common for self-administration. Inject into the abdomen or outer thigh.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Monitor and repeat annually",
      description: "Epithalon's effects are cumulative over multiple cycles. Telomere length changes are not acutely measurable — track subjective markers (sleep quality, energy, skin) and consider telomere length testing annually.",
      tip: "Telomere length testing is available through several commercial labs.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Running epithalon continuously",
      fix: "Epithalon is designed for short, intensive cycles — not continuous daily use. The 10–20 day cycle protocol is based on the original Russian research.",
    }
,
    {
      mistake: "Expecting rapid anti-aging effects",
      fix: "Telomere lengthening and cellular anti-aging effects accumulate over multiple cycles and years. Epithalon is a long-game intervention.",
    }
,
    {
      mistake: "Using epithalon as a standalone longevity protocol",
      fix: "Epithalon works best as part of a comprehensive longevity approach including sleep optimization, exercise, nutrition, and stress management.",
    }
    ],
    faqItems: [
    {
      q: "Does epithalon actually lengthen telomeres?",
      a: "Several Russian studies have demonstrated telomere lengthening and telomerase activation with epithalon. The research is promising but not yet replicated in large Western RCTs. It remains one of the most credible telomere-targeting interventions available.",
    }
,
    {
      q: "How often should I run an epithalon cycle?",
      a: "Most protocols recommend 1–2 cycles per year. The original Russian research used twice-yearly cycles of 10–20 days each.",
    }
,
    {
      q: "Can epithalon be combined with other longevity peptides?",
      a: "Yes — epithalon is commonly stacked with NAD+ precursors (NMN/NR), GHK-Cu, and thymosin alpha-1 for a comprehensive longevity protocol.",
    }
    ],
    relatedPeptides: ["epithalon", "nad-plus"],
    relatedGuides: ["how-to-store-peptides", "how-to-calculate-peptide-dosage"],
  },
  {
    slug: "how-to-use-pt-141",
    title: "How to Use PT-141: Dosing & Sexual Health Protocol",
    h1: "How to Use PT-141 (Bremelanotide): Dosing and Protocol Guide",
    metaDescription: "Complete guide to PT-141 dosing (0.5–2mg), timing (1–4 hours before), administration routes, and managing side effects like nausea and flushing.",
    category: "Peptide Protocols",
    targetPeptides: ["pt-141"],
    difficulty: "Intermediate",
    timeRequired: "10 minutes",
    overview: "PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist that increases sexual desire and arousal in both men and women. It works centrally (in the brain) rather than peripherally, making it effective for both psychological and physiological sexual dysfunction. This guide covers dosing, timing, and side effect management.",
    whatYouNeed: ["PT-141 vial (10mg) or nasal spray", "Bacteriostatic water (2mL, for injectable)", "Insulin syringes (U-100)", "Alcohol swabs"],
    steps: [
    {
      stepNumber: 1,
      title: "Choose your administration route",
      description: "Injectable SubQ: most reliable absorption, 0.5–2mg dose. Nasal spray: convenient, slightly lower bioavailability. The FDA-approved form (Vyleesi) is a SubQ auto-injector at 1.75mg.",
      tip: "Start with 0.5mg to assess tolerance before increasing.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Reconstitute for injection",
      description: "Add 2mL bacteriostatic water to a 10mg vial for 5mg/mL concentration. 1mg dose = 0.2mL = 20 units on a U-100 syringe.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Time your dose correctly",
      description: "Inject 1–4 hours before anticipated sexual activity. PT-141 has a slow onset (45–90 minutes) and long duration (6–12 hours). Do not take more than once in 24 hours.",
      tip: "The sweet spot for most users is 1–2 hours before activity.",
      warning: "Do not exceed 2mg per dose — higher doses significantly increase nausea risk.",
    }
,
    {
      stepNumber: 4,
      title: "Manage common side effects",
      description: "Nausea (most common): take with food, start at 0.5mg, use anti-nausea medication if needed. Flushing and facial redness: normal and transient. Transient increase in blood pressure: monitor if hypertensive.",
      tip: "Taking ondansetron (Zofran) 30 minutes before PT-141 significantly reduces nausea.",
      warning: "PT-141 transiently raises blood pressure. Do not use if you have uncontrolled hypertension.",
    }
,
    {
      stepNumber: 5,
      title: "Limit frequency of use",
      description: "PT-141 is not intended for daily use. The FDA-approved protocol limits use to once per 24 hours and no more than once per month for chronic use. Research protocols vary.",
      tip: undefined,
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Starting at 2mg",
      fix: "Start at 0.5mg to assess nausea sensitivity. Many users find 1mg is fully effective with fewer side effects than 2mg.",
    }
,
    {
      mistake: "Expecting immediate effects",
      fix: "PT-141 takes 45–90 minutes to reach peak effect. Plan timing accordingly.",
    }
,
    {
      mistake: "Using PT-141 as a substitute for addressing underlying issues",
      fix: "PT-141 addresses symptoms, not causes. Psychological factors, relationship dynamics, and hormonal imbalances should also be addressed.",
    }
    ],
    faqItems: [
    {
      q: "Does PT-141 work for women?",
      a: "Yes — PT-141 is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. It increases sexual desire and arousal through central melanocortin receptor activation.",
    }
,
    {
      q: "How does PT-141 differ from Viagra/Cialis?",
      a: "Viagra and Cialis work peripherally (increasing blood flow to genitals). PT-141 works centrally (in the brain) to increase sexual desire and arousal. They can be complementary — PT-141 addresses desire; PDE5 inhibitors address physical response.",
    }
,
    {
      q: "Is PT-141 safe?",
      a: "PT-141 (bremelanotide/Vyleesi) is FDA-approved for women with HSDD. The main safety concern is transient blood pressure elevation. It is contraindicated in patients with cardiovascular disease or uncontrolled hypertension.",
    }
    ],
    relatedPeptides: ["pt-141"],
    relatedGuides: ["how-to-inject-subcutaneously", "how-to-calculate-peptide-dosage"],
  },
  {
    slug: "how-to-use-cjc-1295",
    title: "How to Use CJC-1295: DAC vs No-DAC, Dosing & Protocol",
    h1: "How to Use CJC-1295: DAC vs. No-DAC, Dosing, and Protocol",
    metaDescription: "Complete guide to CJC-1295 — DAC vs. no-DAC differences, dosing (100–2000mcg), injection frequency, and stacking with ipamorelin.",
    category: "Peptide Protocols",
    targetPeptides: ["cjc-1295", "ipamorelin", "sermorelin"],
    difficulty: "Intermediate",
    timeRequired: "10 minutes",
    overview: "CJC-1295 is a synthetic GHRH analogue that stimulates GH release. It comes in two forms: CJC-1295 with DAC (Drug Affinity Complex) which has a half-life of 6–8 days, and CJC-1295 without DAC (also called Mod GRF 1-29) which has a half-life of ~30 minutes. The choice between them significantly affects dosing frequency and GH release pattern.",
    whatYouNeed: ["CJC-1295 vial (with or without DAC)", "Bacteriostatic water (2mL)", "Insulin syringes (U-100)", "Alcohol swabs"],
    steps: [
    {
      stepNumber: 1,
      title: "Choose: DAC or No-DAC",
      description: "CJC-1295 with DAC: injected 1–2x per week, produces sustained GH elevation ('GH bleed'). CJC-1295 without DAC (Mod GRF): injected 2–3x daily, produces pulsatile GH release mimicking natural patterns. No-DAC is preferred for body composition; DAC for convenience.",
      tip: "Most experts prefer no-DAC for mimicking physiological GH patterns.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Reconstitute the vial",
      description: "Add 2mL bacteriostatic water to a 2mg vial for 1mg/mL (1000mcg/mL) concentration.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Dose CJC-1295 without DAC",
      description: "Standard dose: 100–200mcg per injection, 2–3x daily (morning, post-workout, pre-sleep). At 1000mcg/mL: 100mcg = 0.1mL = 10 units.",
      tip: "Stack with ipamorelin (100–200mcg) in the same syringe for synergistic GH release.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Dose CJC-1295 with DAC",
      description: "Standard dose: 1000–2000mcg (1–2mg) once or twice per week. At 1000mcg/mL: 1000mcg = 1mL = 100 units.",
      tip: undefined,
      warning: "CJC-1295 with DAC produces sustained GH elevation which may increase IGF-1 more than pulsatile release — monitor for water retention and joint pain.",
    }
,
    {
      stepNumber: 5,
      title: "Run a cycle",
      description: "Standard cycle: 8–12 weeks on, 4 weeks off. Monitor for water retention, carpal tunnel symptoms, and fatigue — signs of excessive GH elevation.",
      tip: undefined,
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Confusing DAC and no-DAC dosing",
      fix: "DAC and no-DAC have very different dosing frequencies. DAC: 1–2x per week. No-DAC: 2–3x per day. Using DAC dosing for no-DAC (or vice versa) will produce poor results or side effects.",
    }
,
    {
      mistake: "Not stacking with a GHRP",
      fix: "CJC-1295 (GHRH analogue) works synergistically with GHRPs like ipamorelin. Using CJC-1295 alone produces modest results compared to the combination.",
    }
,
    {
      mistake: "Injecting after a carb-heavy meal",
      fix: "High insulin suppresses GH release. Inject in a fasted state or at least 2 hours after a meal.",
    }
    ],
    faqItems: [
    {
      q: "Which is better: CJC-1295 with DAC or without DAC?",
      a: "For body composition and mimicking natural GH patterns, no-DAC (Mod GRF 1-29) is generally preferred. For convenience (fewer injections), DAC is easier to use. No-DAC produces pulsatile GH release; DAC produces sustained GH elevation.",
    }
,
    {
      q: "Can I mix CJC-1295 and ipamorelin in the same syringe?",
      a: "Yes — this is standard practice. Draw both peptides into the same insulin syringe for a single injection. They are compatible and do not interact chemically.",
    }
,
    {
      q: "How does CJC-1295 compare to sermorelin?",
      a: "Both are GHRH analogues. CJC-1295 (no-DAC) has a slightly longer half-life than sermorelin (~30 min vs. ~10 min) and is considered more potent. CJC-1295 with DAC has a much longer half-life (6–8 days) than either.",
    }
    ],
    relatedPeptides: ["cjc-1295", "ipamorelin", "sermorelin"],
    relatedGuides: ["how-to-use-ipamorelin", "how-to-use-sermorelin"],
  },
  {
    slug: "how-to-use-semaglutide",
    title: "How to Use Semaglutide: Dosing Titration & Weight Loss Protocol",
    h1: "How to Use Semaglutide for Weight Loss: Dosing Titration Guide",
    metaDescription: "Step-by-step semaglutide dosing titration — starting dose (0.25mg/week), escalation schedule, injection technique, and managing GI side effects.",
    category: "Peptide Protocols",
    targetPeptides: ["semaglutide"],
    difficulty: "Intermediate",
    timeRequired: "15 minutes",
    overview: "Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. The slow titration protocol is critical for minimizing GI side effects. This guide covers the standard escalation schedule and practical injection tips.",
    whatYouNeed: ["Semaglutide pen (Ozempic/Wegovy) or compounded semaglutide vial", "Pen needles (for auto-injector) or insulin syringes (for compounded)", "Alcohol swabs", "Sharps container"],
    steps: [
    {
      stepNumber: 1,
      title: "Start at 0.25mg per week",
      description: "The standard starting dose is 0.25mg once weekly for 4 weeks. This is a sub-therapeutic dose designed to allow GI adaptation — do not expect significant weight loss at this stage.",
      tip: "Inject on the same day each week (e.g., every Monday morning).",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Escalate to 0.5mg at week 5",
      description: "If 0.25mg is well tolerated (minimal nausea, no vomiting), increase to 0.5mg at week 5. Stay at 0.5mg for 4 weeks.",
      tip: "If GI side effects are significant at 0.25mg, remain at that dose for an additional 4 weeks before escalating.",
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Continue titration to maintenance dose",
      description: "Standard Wegovy titration: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg, each for 4 weeks. Ozempic for diabetes: 0.25mg → 0.5mg → 1mg → 2mg. Move to the next dose only if the current dose is well tolerated.",
      tip: undefined,
      warning: "Never skip titration steps — jumping to higher doses dramatically increases nausea and vomiting risk.",
    }
,
    {
      stepNumber: 4,
      title: "Inject subcutaneously",
      description: "Inject into the abdomen, outer thigh, or upper arm. Rotate sites weekly. Use a pen needle or 29–31 gauge insulin syringe at 90°.",
      tip: "The abdomen is the most commonly used site — consistent absorption and easy self-injection.",
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Manage GI side effects",
      description: "Nausea: eat smaller meals, avoid fatty/spicy foods, take the injection at bedtime. Vomiting: stay hydrated, consider anti-nausea medication. Constipation: increase fiber and water intake.",
      tip: "Most GI side effects peak in the first 4–8 weeks and diminish as the body adapts.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Skipping titration steps",
      fix: "The titration schedule exists to minimize GI side effects. Jumping doses causes severe nausea and vomiting that leads to discontinuation.",
    }
,
    {
      mistake: "Expecting rapid weight loss from day 1",
      fix: "Significant weight loss typically begins at 0.5–1mg doses after 8–12 weeks. The initial weeks are for GI adaptation.",
    }
,
    {
      mistake: "Not adjusting diet",
      fix: "Semaglutide reduces appetite but does not guarantee weight loss without dietary changes. Protein-rich, lower-calorie diets maximize results.",
    }
    ],
    faqItems: [
    {
      q: "How much weight can I lose with semaglutide?",
      a: "Clinical trials show average weight loss of 15–17% of body weight over 68 weeks at 2.4mg/week (Wegovy). Individual results vary significantly based on diet, activity, and adherence.",
    }
,
    {
      q: "What is the difference between Ozempic and Wegovy?",
      a: "Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes (max 2mg/week). Wegovy is FDA-approved for chronic weight management (max 2.4mg/week). The titration schedules differ slightly.",
    }
,
    {
      q: "What happens when I stop semaglutide?",
      a: "Most patients regain a significant portion of lost weight after stopping semaglutide. It is considered a chronic medication for weight management, not a short-term treatment.",
    }
    ],
    relatedPeptides: ["semaglutide"],
    relatedGuides: ["how-to-inject-subcutaneously", "how-to-calculate-peptide-dosage"],
  },
  {
    slug: "how-to-use-tirzepatide",
    title: "How to Use Tirzepatide: Dosing Titration & Weight Loss Protocol",
    h1: "How to Use Tirzepatide (Mounjaro/Zepbound): Dosing Titration Guide",
    metaDescription: "Complete tirzepatide dosing guide — starting dose (2.5mg/week), titration schedule, injection technique, and comparison with semaglutide.",
    category: "Peptide Protocols",
    targetPeptides: ["tirzepatide", "semaglutide"],
    difficulty: "Intermediate",
    timeRequired: "15 minutes",
    overview: "Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes and weight management. It produces greater weight loss than semaglutide in head-to-head trials. This guide covers the titration protocol and practical use.",
    whatYouNeed: ["Tirzepatide pen (Mounjaro/Zepbound) or compounded tirzepatide vial", "Pen needles or insulin syringes", "Alcohol swabs", "Sharps container"],
    steps: [
    {
      stepNumber: 1,
      title: "Start at 2.5mg per week",
      description: "The starting dose is 2.5mg once weekly for 4 weeks. Like semaglutide, this is a sub-therapeutic dose for GI adaptation.",
      tip: "Inject on the same day each week for consistent hormone levels.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Escalate to 5mg at week 5",
      description: "If 2.5mg is well tolerated, increase to 5mg at week 5. This is the first therapeutic dose where meaningful appetite suppression begins.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Continue titration",
      description: "Standard titration: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg, each for 4 weeks. The maximum dose is 15mg/week. Advance only if the current dose is well tolerated.",
      tip: "Many patients achieve their weight loss goals at 7.5–10mg without needing to reach 15mg.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Inject subcutaneously",
      description: "Inject into the abdomen, outer thigh, or upper arm. Rotate sites weekly. The Mounjaro/Zepbound auto-injector pen makes injection straightforward.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Manage side effects",
      description: "GI side effects (nausea, diarrhea, constipation) are similar to semaglutide but may be more pronounced at higher doses. Strategies: smaller meals, avoid trigger foods, consider anti-nausea medication, inject at bedtime.",
      tip: "Tirzepatide-associated diarrhea is more common than with semaglutide — increase soluble fiber intake.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Comparing tirzepatide doses to semaglutide doses directly",
      fix: "Tirzepatide and semaglutide doses are not equivalent. 5mg tirzepatide is not the same as 0.5mg semaglutide — they are different molecules with different potency scales.",
    }
,
    {
      mistake: "Stopping at 5mg if results are insufficient",
      fix: "Tirzepatide's weight loss effect increases with dose. If 5mg is well tolerated but results are modest, continue titrating to 7.5–10mg.",
    }
,
    {
      mistake: "Neglecting protein intake",
      fix: "GLP-1/GIP agonists suppress appetite broadly. Ensure adequate protein (1.2–1.6g/kg/day) to preserve lean muscle mass during weight loss.",
    }
    ],
    faqItems: [
    {
      q: "Is tirzepatide better than semaglutide for weight loss?",
      a: "Head-to-head trials (SURMOUNT-5) show tirzepatide produces greater weight loss than semaglutide (20–22% vs. 15–17% of body weight). Tirzepatide's dual GIP/GLP-1 mechanism appears to provide additive benefits.",
    }
,
    {
      q: "What is the difference between Mounjaro and Zepbound?",
      a: "Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The drug is identical; the indication and marketing differ.",
    }
,
    {
      q: "How long does tirzepatide take to work?",
      a: "Meaningful appetite suppression typically begins at 5mg (weeks 5–8). Significant weight loss (5%+ of body weight) is usually seen by weeks 12–16.",
    }
    ],
    relatedPeptides: ["tirzepatide", "semaglutide"],
    relatedGuides: ["how-to-use-semaglutide", "how-to-inject-subcutaneously"],
  },
  {
    slug: "how-to-use-melanotan-2",
    title: "How to Use Melanotan 2: Dosing, Tanning Protocol & Side Effects",
    h1: "How to Use Melanotan 2: Dosing, Tanning Protocol, and Side Effects",
    metaDescription: "Complete Melanotan 2 guide — loading dose (0.25mg), maintenance protocol, UV exposure timing, and managing nausea and spontaneous erections.",
    category: "Peptide Protocols",
    targetPeptides: ["melanotan-2", "pt-141"],
    difficulty: "Intermediate",
    timeRequired: "10 minutes",
    overview: "Melanotan 2 (MT-2) is a synthetic melanocortin receptor agonist that stimulates melanin production, producing a tan without UV exposure. It also has sexual arousal effects (similar to PT-141) and appetite suppression. This guide covers the loading protocol and side effect management.",
    whatYouNeed: ["Melanotan 2 vial (10mg)", "Bacteriostatic water (2mL)", "Insulin syringes (U-100)", "Alcohol swabs", "Sunscreen (for UV sessions)"],
    steps: [
    {
      stepNumber: 1,
      title: "Reconstitute the vial",
      description: "Add 2mL bacteriostatic water to a 10mg MT-2 vial for 5mg/mL (5000mcg/mL) concentration.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Start with a very low loading dose",
      description: "Begin at 0.25mg (250mcg) to assess tolerance. At 5000mcg/mL: 250mcg = 0.05mL = 5 units on a U-100 syringe.",
      tip: "Inject at night to sleep through the initial nausea.",
      warning: "Do not start at 0.5–1mg — nausea and facial flushing can be severe at higher initial doses.",
    }
,
    {
      stepNumber: 3,
      title: "Gradually increase to loading dose",
      description: "Over 1–2 weeks, increase to 0.5–1mg per day. Inject daily during the loading phase until desired tan depth is achieved (typically 2–4 weeks).",
      tip: "Combine with UV exposure (10–20 minutes of sun or tanning bed) to accelerate melanin activation.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Transition to maintenance dosing",
      description: "Once desired tan is achieved, reduce to 0.5–1mg twice per week to maintain color. UV exposure 1–2x per week helps maintain the tan.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Manage side effects",
      description: "Nausea: inject at night, start low, use anti-nausea medication. Spontaneous erections (men): reduce dose or switch to morning injection. Facial flushing: transient, dose-dependent. Mole darkening: monitor existing moles — consult a dermatologist if any change.",
      tip: undefined,
      warning: "Monitor all moles and skin lesions during MT-2 use. Consult a dermatologist if any mole changes in size, shape, or color.",
    }
    ],
    commonMistakes: [
    {
      mistake: "Starting at 0.5–1mg",
      fix: "Always start at 0.25mg. The nausea and flushing at higher initial doses can be severe and leads to discontinuation.",
    }
,
    {
      mistake: "Not using UV exposure",
      fix: "MT-2 stimulates melanin production, but UV light is needed to activate and distribute the melanin. Without UV, results are minimal.",
    }
,
    {
      mistake: "Ignoring mole changes",
      fix: "MT-2 stimulates melanocytes broadly. Monitor all existing moles and see a dermatologist if any change. Do not use MT-2 if you have a history of melanoma.",
    }
    ],
    faqItems: [
    {
      q: "Is Melanotan 2 safe?",
      a: "MT-2 is not FDA-approved and carries risks including mole darkening, nausea, and spontaneous erections. The long-term safety profile is unknown. It should not be used by anyone with a personal or family history of melanoma.",
    }
,
    {
      q: "How long does the Melanotan 2 tan last?",
      a: "With maintenance dosing (0.5–1mg twice weekly) and periodic UV exposure, the tan can be maintained indefinitely. Without maintenance, the tan fades over 4–8 weeks.",
    }
,
    {
      q: "Does Melanotan 2 work without UV exposure?",
      a: "MT-2 produces some baseline melanin stimulation without UV, but UV exposure significantly amplifies and distributes the melanin. Most users use both together for best results.",
    }
    ],
    relatedPeptides: ["melanotan-2", "pt-141"],
    relatedGuides: ["how-to-inject-subcutaneously", "how-to-calculate-peptide-dosage"],
  },
  {
    slug: "how-to-use-thymosin-alpha-1",
    title: "How to Use Thymosin Alpha-1: Immune Support Protocol",
    h1: "How to Use Thymosin Alpha-1: Immune Support Dosing and Protocol",
    metaDescription: "Complete thymosin alpha-1 guide — dosing (1.6mg twice weekly), immune support protocol, cycle length, and evidence for immune modulation.",
    category: "Peptide Protocols",
    targetPeptides: ["thymosin-alpha-1", "bpc-157"],
    difficulty: "Intermediate",
    timeRequired: "10 minutes",
    overview: "Thymosin Alpha-1 (Tα1) is a naturally occurring thymic peptide that modulates immune function by enhancing T-cell activity, NK cell function, and dendritic cell maturation. It is FDA-approved (as Zadaxin) in several countries for hepatitis B, hepatitis C, and cancer immunotherapy. This guide covers the standard immune support protocol.",
    whatYouNeed: ["Thymosin Alpha-1 vials (1.6mg each)", "Bacteriostatic water (1mL per vial)", "Insulin syringes (U-100)", "Alcohol swabs"],
    steps: [
    {
      stepNumber: 1,
      title: "Reconstitute the vial",
      description: "Add 1mL bacteriostatic water to a 1.6mg vial for 1.6mg/mL concentration. The entire vial is typically one dose.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Standard dosing protocol",
      description: "Clinical dose: 1.6mg SubQ, twice weekly (e.g., Monday and Thursday). This mirrors the FDA-approved Zadaxin dosing for hepatitis. Research protocols range from 1.6mg 1–3x per week.",
      tip: "Twice weekly dosing is the most studied and commonly recommended protocol.",
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Run a 6–12 week cycle",
      description: "Standard immune support cycle: 6–12 weeks. For acute immune support (illness, post-surgery): 4–6 weeks. For chronic immune modulation: 12+ weeks under medical supervision.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Inject subcutaneously",
      description: "Inject into the abdomen or outer thigh. Thymosin Alpha-1 is well tolerated — injection site reactions are rare.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Monitor immune markers (optional)",
      description: "If available, track CD4+ T-cell count, NK cell activity, or general immune markers (WBC, lymphocyte count) before and after the cycle to objectively assess response.",
      tip: undefined,
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Using Thymosin Alpha-1 for acute infections",
      fix: "Tα1 is an immune modulator, not an acute anti-infective. It works best as a preventive or recovery tool, not as a treatment for active infections.",
    }
,
    {
      mistake: "Expecting rapid immune improvement",
      fix: "Immune modulation takes weeks to manifest. Most clinical studies show significant immune improvements after 4–8 weeks of consistent use.",
    }
,
    {
      mistake: "Confusing with Thymosin Beta-4 (TB-500)",
      fix: "Thymosin Alpha-1 and Thymosin Beta-4 are different peptides with different mechanisms. Alpha-1 is primarily immune-modulating; Beta-4 (TB-500) is primarily tissue repair and anti-inflammatory.",
    }
    ],
    faqItems: [
    {
      q: "Is Thymosin Alpha-1 FDA-approved?",
      a: "Thymosin Alpha-1 (Zadaxin) is approved in over 35 countries for hepatitis B, hepatitis C, and as a vaccine adjuvant. It is not currently FDA-approved in the United States but is available as a research compound.",
    }
,
    {
      q: "Can Thymosin Alpha-1 help with long COVID?",
      a: "Several small studies and case reports suggest Tα1 may help with long COVID immune dysregulation. Formal clinical trials are ongoing. It is one of the most promising immune-modulating peptides for post-viral syndromes.",
    }
,
    {
      q: "Can Thymosin Alpha-1 be stacked with other peptides?",
      a: "Yes — Tα1 is commonly stacked with BPC-157 (for gut-immune axis support) and epithalon (for longevity protocols). It is compatible with most other peptides.",
    }
    ],
    relatedPeptides: ["thymosin-alpha-1", "bpc-157"],
    relatedGuides: ["how-to-inject-subcutaneously", "how-to-store-peptides"],
  },
  {
    slug: "how-to-read-a-peptide-coa",
    title: "How to Read a Peptide Certificate of Analysis (COA)",
    h1: "How to Read a Peptide Certificate of Analysis (COA)",
    metaDescription: "Learn how to read and verify a peptide Certificate of Analysis — purity percentage, HPLC chromatogram, mass spectrometry, and red flags to watch for.",
    category: "Quality & Sourcing",
    targetPeptides: ["bpc-157", "tb-500", "ipamorelin"],
    difficulty: "Intermediate",
    timeRequired: "15 minutes",
    overview: "A Certificate of Analysis (COA) is the primary quality document for research peptides. It verifies purity, identity, and absence of contaminants. Understanding how to read a COA is essential for sourcing safe, effective peptides. This guide covers the key sections and red flags.",
    whatYouNeed: ["Peptide COA (PDF from vendor)", "Basic understanding of HPLC and mass spectrometry (explained below)"],
    steps: [
    {
      stepNumber: 1,
      title: "Check the purity percentage",
      description: "The purity percentage (e.g., '>98% purity') indicates what fraction of the sample is the target peptide. Research-grade peptides should be ≥95% pure. Pharmaceutical-grade is ≥99%. Anything below 90% is substandard.",
      tip: "The purity is typically determined by HPLC (High-Performance Liquid Chromatography).",
      warning: "Vendors who do not provide purity data or claim 'proprietary testing' should be avoided.",
    }
,
    {
      stepNumber: 2,
      title: "Examine the HPLC chromatogram",
      description: "The HPLC chromatogram shows peaks representing different compounds in the sample. A high-purity peptide has one dominant peak (the peptide) with small or absent secondary peaks (impurities). The area under the main peak divided by total area = purity %.",
      tip: "Ask for the raw chromatogram, not just the purity number — it is harder to falsify.",
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Verify identity with mass spectrometry",
      description: "Mass spectrometry (MS) confirms the molecular weight of the peptide matches the expected value. The COA should show the theoretical MW and the observed MW — they should match within 0.1 Da.",
      tip: "If the MW does not match, the peptide is either wrong or degraded.",
      warning: "A COA with only purity data and no MS confirmation cannot verify the peptide's identity.",
    }
,
    {
      stepNumber: 4,
      title: "Check for endotoxin testing",
      description: "Endotoxins (bacterial lipopolysaccharides) cause fever, inflammation, and sepsis. Injectable peptides should have endotoxin levels <1 EU/mg (European Pharmacopoeia standard). Look for LAL (Limulus Amebocyte Lysate) test results.",
      tip: "Endotoxin testing is especially important for peptides used via injection.",
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Verify the COA is from an independent lab",
      description: "The most trustworthy COAs are from independent third-party labs (not the vendor's in-house lab). Look for lab name, accreditation (ISO 17025), and date of testing.",
      tip: "Cross-reference the lab name — legitimate labs have verifiable online presence.",
      warning: "In-house COAs from the vendor have a conflict of interest and should be treated with skepticism.",
    }
    ],
    commonMistakes: [
    {
      mistake: "Accepting purity claims without a chromatogram",
      fix: "Always request the HPLC chromatogram. A purity number without supporting data is unverifiable.",
    }
,
    {
      mistake: "Ignoring the testing date",
      fix: "COAs older than 12 months may not reflect the current batch. Request a recent COA for the specific batch you are purchasing.",
    }
,
    {
      mistake: "Not checking for MS confirmation",
      fix: "Purity alone does not confirm identity. A 98% pure sample could be 98% of the wrong peptide. Mass spectrometry is required to confirm identity.",
    }
    ],
    faqItems: [
    {
      q: "What purity should research peptides be?",
      a: "Research-grade peptides should be ≥95% pure by HPLC. For injectable use, ≥98% is recommended. Pharmaceutical-grade (for human clinical use) requires ≥99%.",
    }
,
    {
      q: "How do I know if a COA is fake?",
      a: "Red flags: no lab name or accreditation, no HPLC chromatogram (just a number), no mass spectrometry data, MW does not match the expected value, or the lab cannot be found online. Cross-reference the lab with independent sources.",
    }
,
    {
      q: "Do all peptide vendors provide COAs?",
      a: "Reputable vendors provide COAs for every batch. If a vendor does not provide a COA on request, do not purchase from them. COA availability is a minimum quality standard.",
    }
    ],
    relatedPeptides: ["bpc-157", "tb-500", "ipamorelin"],
    relatedGuides: ["how-to-store-peptides", "how-to-reconstitute-peptides"],
  },
  {
    slug: "how-to-choose-a-peptide-vendor",
    title: "How to Choose a Reputable Peptide Vendor: 7 Key Criteria",
    h1: "How to Choose a Reputable Peptide Vendor: 7 Key Criteria",
    metaDescription: "Learn the 7 criteria for evaluating peptide vendors — COA quality, independent lab testing, endotoxin testing, shipping practices, and red flags to avoid.",
    category: "Quality & Sourcing",
    targetPeptides: ["bpc-157", "tb-500", "ipamorelin"],
    difficulty: "Beginner",
    timeRequired: "15 minutes",
    overview: "The peptide market is unregulated, and product quality varies enormously between vendors. Choosing the wrong vendor can mean receiving underdosed, contaminated, or mislabeled products. This guide covers the 7 criteria that separate reputable vendors from problematic ones.",
    whatYouNeed: ["Vendor website access", "Ability to request COA documents", "Understanding of basic quality markers (covered in this guide)"],
    steps: [
    {
      stepNumber: 1,
      title: "Verify independent third-party COAs",
      description: "The vendor must provide Certificates of Analysis from independent, accredited labs (not in-house). COAs should include HPLC purity data, mass spectrometry identity confirmation, and endotoxin testing.",
      tip: "Request the COA for the specific batch you are purchasing — not a generic COA.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Check purity standards",
      description: "Research-grade peptides should be ≥95% pure. For injectable use, ≥98% is the standard. Vendors who advertise 'pharmaceutical grade' without supporting COA data are making unverifiable claims.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Assess endotoxin testing",
      description: "Injectable peptides must be tested for endotoxins (bacterial lipopolysaccharides). Look for LAL test results showing <1 EU/mg. Vendors who do not test for endotoxins are selling products that may be unsafe to inject.",
      tip: "Endotoxin contamination is invisible — it cannot be detected by appearance alone.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Evaluate shipping and storage practices",
      description: "Peptides degrade with heat and light. Reputable vendors ship with ice packs (especially in summer), use opaque packaging, and provide clear storage instructions. Vendors shipping in plain envelopes without temperature control are a red flag.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Check community reputation",
      description: "Research the vendor on independent forums (Reddit r/Peptides, Longecity, etc.). Look for consistent reports of product quality, customer service, and accurate labeling. Avoid vendors with multiple reports of underdosing or mislabeling.",
      tip: "Discount vendors with suspiciously low prices — quality peptide synthesis has a floor cost.",
      warning: undefined,
    }
,
    {
      stepNumber: 6,
      title: "Verify legal compliance",
      description: "Reputable vendors sell peptides explicitly as research compounds, not for human use. They do not make medical claims, do not provide dosing advice, and comply with applicable regulations in their jurisdiction.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 7,
      title: "Test a small order first",
      description: "Before placing a large order, buy a small quantity and verify the COA matches the batch. Some users send samples to independent labs for verification.",
      tip: "Independent peptide testing services are available for ~$50–100 per sample.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Choosing based on price alone",
      fix: "The cheapest peptides are often the lowest quality. Quality synthesis, independent testing, and proper storage all have costs. Significant underpricing is a red flag.",
    }
,
    {
      mistake: "Accepting in-house COAs",
      fix: "Vendor-generated COAs have an obvious conflict of interest. Always require independent third-party lab testing.",
    }
,
    {
      mistake: "Not checking community forums",
      fix: "The peptide research community actively shares vendor experiences. A few hours of research on Reddit r/Peptides can save significant money and health risk.",
    }
    ],
    faqItems: [
    {
      q: "What are the most reputable peptide vendors?",
      a: "PeptidePilot does not endorse specific vendors, as quality can change over time. We recommend evaluating vendors using the criteria in this guide and cross-referencing with current community reviews on r/Peptides and similar forums.",
    }
,
    {
      q: "Is it legal to buy research peptides?",
      a: "In the United States, research peptides are legal to purchase for research purposes. They are not legal to sell for human consumption. The legal landscape varies by country — always verify local regulations.",
    }
,
    {
      q: "How do I know if my peptides are real?",
      a: "The only reliable way to verify peptide identity is mass spectrometry. Request a COA with MS data from the vendor, or send a sample to an independent testing service.",
    }
    ],
    relatedPeptides: ["bpc-157", "tb-500", "ipamorelin"],
    relatedGuides: ["how-to-read-a-peptide-coa", "how-to-store-peptides"],
  },
  {
    slug: "how-to-build-a-peptide-stack",
    title: "How to Build a Peptide Stack: Synergy, Timing & Safety",
    h1: "How to Build a Peptide Stack: Synergy, Timing, and Safety",
    metaDescription: "Learn how to build an effective peptide stack — identifying synergistic combinations, managing timing and injection schedules, and avoiding unsafe combinations.",
    category: "Stacking & Combinations",
    targetPeptides: ["bpc-157", "tb-500", "ipamorelin", "cjc-1295"],
    difficulty: "Advanced",
    timeRequired: "20 minutes",
    overview: "Peptide stacking — using multiple peptides simultaneously — can produce synergistic effects that exceed what any single peptide achieves alone. However, it also increases complexity, cost, and potential for side effects. This guide covers the principles of effective stacking, timing strategies, and combinations to avoid.",
    whatYouNeed: ["Clear goal definition", "Understanding of each peptide's mechanism", "Injection schedule planning tool (calendar or spreadsheet)", "Budget assessment"],
    steps: [
    {
      stepNumber: 1,
      title: "Define your primary goal",
      description: "Every stack should have a primary goal: body composition, injury recovery, longevity, cognitive enhancement, or sexual health. Stacking peptides with different primary goals creates complexity without proportional benefit.",
      tip: "Start with a single peptide, master it, then add complementary compounds.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Identify synergistic mechanisms",
      description: "Synergistic stacks combine peptides that work through complementary pathways. Examples: CJC-1295 (GHRH) + ipamorelin (GHRP) — different GH release mechanisms; BPC-157 + TB-500 — complementary tissue repair pathways; Sermorelin + ipamorelin — GHRH + GHRP synergy.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Plan injection timing",
      description: "Map out when each peptide needs to be injected. GH secretagogues: fasted state, pre-sleep, post-workout. BPC-157/TB-500: any time, consistent daily timing. PT-141: 1–4 hours before activity. Avoid injecting too many peptides simultaneously — space injections by 15–30 minutes if possible.",
      tip: "Create a weekly injection schedule spreadsheet to avoid missed doses and timing conflicts.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Start with one new peptide at a time",
      description: "When building a stack, add one new peptide at a time with 2-week intervals. This allows you to attribute any side effects to the correct compound and assess individual response before adding complexity.",
      tip: undefined,
      warning: "Adding multiple new peptides simultaneously makes it impossible to identify which compound is causing any observed effect.",
    }
,
    {
      stepNumber: 5,
      title: "Monitor and adjust",
      description: "Track subjective markers (energy, sleep, body composition, pain) and objective markers (blood work, body measurements) throughout the stack. Reduce or eliminate compounds that are not contributing or causing side effects.",
      tip: "Keep a peptide journal — date, dose, timing, and observations for each injection.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Stacking too many peptides at once",
      fix: "Start with 2 peptides maximum. Adding 4–6 peptides simultaneously creates confusion about what is working and increases side effect risk.",
    }
,
    {
      mistake: "Ignoring timing interactions",
      fix: "Some peptides compete for the same receptors or have timing requirements that conflict. Plan injection timing carefully.",
    }
,
    {
      mistake: "Not cycling off",
      fix: "Most peptide stacks should include off periods to prevent receptor desensitization and allow the body to reset. Typical protocol: 8–12 weeks on, 4 weeks off.",
    }
    ],
    faqItems: [
    {
      q: "What is the best beginner peptide stack?",
      a: "The most popular beginner stack is CJC-1295 (no DAC) + ipamorelin for body composition and recovery. Both are well-studied, have complementary mechanisms, and can be injected together in the same syringe.",
    }
,
    {
      q: "Can I mix peptides in the same syringe?",
      a: "Many peptides are compatible in the same syringe (e.g., CJC-1295 + ipamorelin, BPC-157 + TB-500). However, some combinations may be incompatible — research specific combinations before mixing.",
    }
,
    {
      q: "How many peptides can I stack safely?",
      a: "Most experienced users limit stacks to 2–4 peptides. Beyond 4, the complexity, cost, and side effect risk increase substantially without proportional benefit.",
    }
    ],
    relatedPeptides: ["bpc-157", "tb-500", "ipamorelin", "cjc-1295"],
    relatedGuides: ["how-to-use-ipamorelin", "how-to-use-cjc-1295", "how-to-use-tb-500"],
  },
  {
    slug: "how-to-cycle-peptides",
    title: "How to Cycle Peptides: On/Off Protocols to Prevent Desensitization",
    h1: "How to Cycle Peptides: On/Off Protocols and Desensitization Prevention",
    metaDescription: "Learn how to cycle peptides correctly — standard on/off ratios, which peptides require cycling, receptor desensitization mechanisms, and how to maintain results.",
    category: "Stacking & Combinations",
    targetPeptides: ["ipamorelin", "cjc-1295", "sermorelin", "bpc-157"],
    difficulty: "Intermediate",
    timeRequired: "10 minutes",
    overview: "Peptide cycling — alternating between use periods and rest periods — prevents receptor desensitization, maintains sensitivity, and allows the body to reset. Not all peptides require cycling, but understanding when and how to cycle is essential for long-term effectiveness.",
    whatYouNeed: ["Calendar or tracking app", "Understanding of each peptide's receptor mechanism"],
    steps: [
    {
      stepNumber: 1,
      title: "Understand which peptides require cycling",
      description: "GH secretagogues (ipamorelin, CJC-1295, sermorelin): cycle 8–12 weeks on, 4 weeks off to prevent pituitary desensitization. BPC-157/TB-500: can be used continuously for acute healing; cycle after 12 weeks for chronic use. Epithalon: inherently cycled (10–20 day protocols, 1–2x/year). PT-141: limit to 1–2x per month.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Plan your on-cycle",
      description: "Define the start date, duration (typically 8–12 weeks), and end date before starting. Having a defined end date prevents indefinite use and ensures you take the planned break.",
      tip: "Align cycle start with a fitness goal (e.g., start 12 weeks before a competition or event).",
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Plan your off-cycle",
      description: "Off-cycle duration: typically 4 weeks for GH secretagogues, 2–4 weeks for other peptides. During the off-cycle, maintain training and nutrition — most peptide gains are retained with proper lifestyle.",
      tip: "Use the off-cycle to assess your baseline and identify which peptides are actually contributing to results.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Taper down (optional)",
      description: "For long cycles (12+ weeks) or high doses, consider tapering the dose over the final 2 weeks rather than stopping abruptly. This reduces the 'crash' feeling some users experience when stopping GH secretagogues.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Track results across cycles",
      description: "Compare body composition, performance, and subjective wellbeing between cycles. This helps identify diminishing returns and optimize future cycle design.",
      tip: "Take photos and measurements at the start and end of each cycle for objective comparison.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Running GH secretagogues indefinitely",
      fix: "Continuous GH secretagogue use leads to pituitary desensitization and diminishing returns. The 8–12 week on / 4 week off protocol maintains long-term effectiveness.",
    }
,
    {
      mistake: "Stopping abruptly after a long cycle",
      fix: "Consider a 2-week taper for long cycles. Abrupt cessation of GH secretagogues can cause temporary fatigue and mood changes.",
    }
,
    {
      mistake: "Not tracking results",
      fix: "Without tracking, it is impossible to know if the cycle is working or if results are being maintained during the off-cycle.",
    }
    ],
    faqItems: [
    {
      q: "Do I need to cycle BPC-157?",
      a: "BPC-157 does not appear to cause receptor desensitization in the same way as GH secretagogues. For acute injury healing, continuous use for 4–8 weeks is common. For chronic use, cycling every 12 weeks is a reasonable precaution.",
    }
,
    {
      q: "What happens if I do not cycle GH secretagogues?",
      a: "Continuous use of GH secretagogues (ipamorelin, CJC-1295, sermorelin) can lead to pituitary desensitization, reduced GH response, and diminishing results over time. The 8–12 week cycle protocol prevents this.",
    }
,
    {
      q: "Can I use different peptides during the off-cycle?",
      a: "Yes — many users use non-GH peptides (BPC-157, GHK-Cu, epithalon) during the off-cycle from GH secretagogues. This maintains some peptide benefits while allowing the GH axis to reset.",
    }
    ],
    relatedPeptides: ["ipamorelin", "cjc-1295", "sermorelin", "bpc-157"],
    relatedGuides: ["how-to-build-a-peptide-stack", "how-to-use-ipamorelin"],
  },
  {
    slug: "how-to-use-peptides-for-fat-loss",
    title: "How to Use Peptides for Fat Loss: Best Protocols & Combinations",
    h1: "How to Use Peptides for Fat Loss: Protocols, Combinations, and Expectations",
    metaDescription: "Evidence-based guide to using peptides for fat loss — best peptides (semaglutide, tirzepatide, ipamorelin, AOD-9604), dosing, and realistic expectations.",
    category: "Goal-Specific Protocols",
    targetPeptides: ["semaglutide", "tirzepatide", "ipamorelin", "cjc-1295"],
    difficulty: "Intermediate",
    timeRequired: "15 minutes",
    overview: "Multiple peptides have demonstrated fat loss effects through different mechanisms: GLP-1 agonists (semaglutide, tirzepatide) reduce appetite; GH secretagogues (ipamorelin, CJC-1295) promote lipolysis; AOD-9604 directly targets fat metabolism. This guide covers the evidence, protocols, and realistic expectations for each approach.",
    whatYouNeed: ["Goal definition (amount of fat to lose, timeline)", "Understanding of each peptide's mechanism", "Dietary strategy (peptides work best with caloric deficit)", "Baseline measurements (weight, body fat %, photos)"],
    steps: [
    {
      stepNumber: 1,
      title: "Choose your fat loss approach",
      description: "GLP-1 agonists (semaglutide/tirzepatide): strongest evidence, 15–22% body weight loss in trials, appetite suppression mechanism. GH secretagogues (ipamorelin + CJC-1295): moderate fat loss via lipolysis, best for body recomposition. AOD-9604: direct lipolytic effect, weaker evidence than GLP-1 agonists.",
      tip: "For significant weight loss (>20 lbs), GLP-1 agonists have the strongest evidence base.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "GLP-1 protocol",
      description: "Semaglutide: start 0.25mg/week, titrate to 1–2.4mg/week over 16–20 weeks. Tirzepatide: start 2.5mg/week, titrate to 10–15mg/week over 20+ weeks. Combine with protein-rich diet (1.2–1.6g/kg/day) to preserve lean mass.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "GH secretagogue protocol for body recomposition",
      description: "CJC-1295 (no DAC) 100–200mcg + ipamorelin 100–200mcg, injected 2–3x daily (morning fasted, post-workout, pre-sleep). Run 8–12 week cycles. Best results when combined with resistance training.",
      tip: "GH secretagogues are more effective for body recomposition (fat loss + muscle gain) than pure weight loss.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Optimize diet alongside peptides",
      description: "No peptide overcomes a caloric surplus. GLP-1 agonists make caloric restriction easier by reducing hunger. GH secretagogues require a moderate caloric deficit to produce fat loss. Track macros and calories for best results.",
      tip: "Protein intake is especially important — aim for 1.6g/kg/day to preserve lean mass during fat loss.",
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Track progress objectively",
      description: "Weigh weekly (same time, same conditions). Measure body fat % monthly (DEXA scan or skinfold). Take monthly photos. Blood work (lipids, glucose, IGF-1) every 3 months.",
      tip: undefined,
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Relying on peptides without dietary changes",
      fix: "Peptides enhance fat loss but do not replace a caloric deficit. GLP-1 agonists make dieting easier; GH secretagogues require a deficit to work.",
    }
,
    {
      mistake: "Expecting GH secretagogues to match GLP-1 agonist results",
      fix: "GLP-1 agonists (semaglutide, tirzepatide) produce significantly greater weight loss than GH secretagogues. Set realistic expectations for each approach.",
    }
,
    {
      mistake: "Not preserving lean mass",
      fix: "Rapid weight loss without adequate protein and resistance training leads to muscle loss. Prioritize protein intake and strength training throughout any fat loss protocol.",
    }
    ],
    faqItems: [
    {
      q: "Which peptide is best for fat loss?",
      a: "For pure weight loss, semaglutide and tirzepatide have the strongest evidence (15–22% body weight loss in clinical trials). For body recomposition (fat loss while maintaining or gaining muscle), GH secretagogues (ipamorelin + CJC-1295) are more appropriate.",
    }
,
    {
      q: "Can I use multiple fat loss peptides simultaneously?",
      a: "Combining GLP-1 agonists with GH secretagogues is done by some users, but the interaction is not well studied. Start with one approach, master it, then consider adding complementary compounds.",
    }
,
    {
      q: "How long does it take to see fat loss results from peptides?",
      a: "GLP-1 agonists: significant appetite suppression within 2–4 weeks; meaningful weight loss (5%+) by weeks 12–16. GH secretagogues: body composition changes typically visible after 6–8 weeks.",
    }
    ],
    relatedPeptides: ["semaglutide", "tirzepatide", "ipamorelin", "cjc-1295"],
    relatedGuides: ["how-to-use-semaglutide", "how-to-use-tirzepatide", "how-to-use-ipamorelin"],
  },
  {
    slug: "how-to-use-peptides-for-muscle-growth",
    title: "How to Use Peptides for Muscle Growth: Best Protocols",
    h1: "How to Use Peptides for Muscle Growth: Evidence-Based Protocols",
    metaDescription: "Guide to using peptides for muscle growth — GH secretagogues, IGF-1 LR3, BPC-157 for recovery, dosing, timing, and stacking strategies.",
    category: "Goal-Specific Protocols",
    targetPeptides: ["ipamorelin", "cjc-1295", "bpc-157", "tb-500"],
    difficulty: "Intermediate",
    timeRequired: "15 minutes",
    overview: "Peptides can support muscle growth through multiple mechanisms: GH secretagogues increase GH/IGF-1 levels promoting anabolism; BPC-157 and TB-500 accelerate recovery enabling higher training frequency; IGF-1 LR3 directly stimulates muscle cell proliferation. This guide covers the evidence and protocols for each approach.",
    whatYouNeed: ["Resistance training program", "Adequate protein intake (1.6–2.2g/kg/day)", "Peptide selection based on goal", "Baseline measurements"],
    steps: [
    {
      stepNumber: 1,
      title: "Prioritize GH secretagogues for anabolism",
      description: "CJC-1295 (no DAC) + ipamorelin is the gold standard for peptide-based muscle support. Inject 100–200mcg of each, 2–3x daily (morning fasted, post-workout, pre-sleep). Run 8–12 week cycles.",
      tip: "Post-workout injection timing is especially important for muscle growth — GH release post-exercise is synergistic with training stimulus.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Add BPC-157 for recovery",
      description: "BPC-157 (250–500mcg, 1–2x daily) accelerates tendon, ligament, and muscle repair, enabling higher training frequency. This indirect effect on muscle growth can be significant for advanced trainees who are limited by recovery.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Optimize training and nutrition first",
      description: "Peptides are enhancers, not replacements for training and nutrition. Ensure: progressive overload in training, 1.6–2.2g/kg/day protein, adequate calories (slight surplus for muscle gain), 7–9 hours sleep.",
      tip: "GH secretagogues work best in a caloric surplus — the anabolic signal requires adequate substrate.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Track muscle-specific markers",
      description: "Measure: body weight, lean body mass (DEXA or BIA), strength progression (1RM or training volume), and recovery (soreness, performance between sessions). Blood work: IGF-1 levels confirm GH axis response.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Cycle appropriately",
      description: "GH secretagogues: 8–12 weeks on, 4 weeks off. BPC-157: can be used continuously for acute recovery needs; cycle after 12 weeks for chronic use.",
      tip: undefined,
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Expecting peptides to replace training",
      fix: "Peptides support muscle growth — they do not cause it without training stimulus. Progressive resistance training is non-negotiable.",
    }
,
    {
      mistake: "Insufficient protein intake",
      fix: "GH secretagogues increase the anabolic signal, but protein provides the substrate. Aim for 1.6–2.2g/kg/day of protein throughout the cycle.",
    }
,
    {
      mistake: "Injecting GH secretagogues after a carb-heavy meal",
      fix: "High insulin blunts GH release. Inject in a fasted state or at least 2 hours after a meal for maximum GH pulse.",
    }
    ],
    faqItems: [
    {
      q: "How much muscle can peptides add?",
      a: "Peptides are not anabolic steroids — they work within physiological ranges. GH secretagogues can add 2–5 lbs of lean mass over an 8–12 week cycle when combined with proper training and nutrition. The primary benefit is often improved body composition (fat loss + lean mass maintenance) rather than dramatic muscle gain.",
    }
,
    {
      q: "Are peptides safer than steroids for muscle growth?",
      a: "GH secretagogues work within the body's natural GH axis and do not suppress testosterone production. They have a significantly better safety profile than anabolic steroids, with no androgenic side effects.",
    }
,
    {
      q: "Can women use peptides for muscle growth?",
      a: "Yes — GH secretagogues and BPC-157 are used by both men and women. Women may be more sensitive to GH secretagogues and often achieve good results at lower doses (100mcg vs. 200mcg).",
    }
    ],
    relatedPeptides: ["ipamorelin", "cjc-1295", "bpc-157", "tb-500"],
    relatedGuides: ["how-to-use-ipamorelin", "how-to-use-cjc-1295", "how-to-build-a-peptide-stack"],
  },
  {
    slug: "how-to-use-peptides-for-sleep",
    title: "How to Use Peptides for Sleep: Best Protocols & Timing",
    h1: "How to Use Peptides for Sleep Improvement: Protocols and Timing",
    metaDescription: "Guide to using peptides for sleep — ipamorelin, epithalon, DSIP, and sermorelin protocols, timing, and evidence for sleep quality improvement.",
    category: "Goal-Specific Protocols",
    targetPeptides: ["ipamorelin", "epithalon", "sermorelin"],
    difficulty: "Beginner",
    timeRequired: "10 minutes",
    overview: "Several peptides have demonstrated sleep-improving effects through different mechanisms: GH secretagogues (ipamorelin, sermorelin) amplify the nocturnal GH pulse during slow-wave sleep; epithalon regulates melatonin production; DSIP (Delta Sleep-Inducing Peptide) directly promotes slow-wave sleep. This guide covers protocols for each.",
    whatYouNeed: ["Peptide selection based on sleep goal", "Consistent sleep schedule (foundational)", "Sleep tracking tool (optional but helpful)"],
    steps: [
    {
      stepNumber: 1,
      title: "Address sleep hygiene first",
      description: "Peptides enhance sleep quality but cannot overcome poor sleep hygiene. Ensure: consistent sleep/wake times, dark and cool bedroom (65–68°F), no screens 1 hour before bed, no caffeine after 2pm.",
      tip: "Peptides are most effective when layered on top of good sleep hygiene, not used as a substitute.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Ipamorelin for deep sleep enhancement",
      description: "Ipamorelin 100–200mcg, injected 30–60 minutes before sleep. This amplifies the natural GH pulse during slow-wave sleep, improving sleep quality and recovery. Most users report deeper sleep and more vivid dreams within 1–2 weeks.",
      tip: "Pre-sleep ipamorelin is the most popular peptide sleep protocol — well-tolerated and effective.",
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Epithalon for circadian rhythm regulation",
      description: "Epithalon 5–10mg/day for 10–20 days (1–2 cycles per year). Epithalon regulates melatonin production and circadian rhythm, particularly beneficial for age-related sleep disruption and shift workers.",
      tip: "Inject epithalon in the evening for circadian alignment.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Sermorelin for sleep architecture",
      description: "Sermorelin 200–300mcg, injected 30–60 minutes before sleep. Similar to ipamorelin, sermorelin amplifies nocturnal GH release and improves slow-wave sleep. Particularly beneficial for adults over 40 with declining GH levels.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Track sleep quality objectively",
      description: "Use a sleep tracker (Oura Ring, Garmin, Apple Watch) to measure deep sleep duration, REM sleep, and HRV. This provides objective data on peptide effectiveness and helps optimize timing and dose.",
      tip: "Track for 2 weeks before starting peptides to establish a baseline.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Injecting GH secretagogues after a late-night meal",
      fix: "High insulin blunts GH release. Inject at least 2 hours after your last meal for maximum nocturnal GH pulse amplification.",
    }
,
    {
      mistake: "Expecting immediate sleep improvement",
      fix: "GH secretagogue sleep benefits typically emerge over 1–2 weeks of consistent use. Epithalon effects on circadian rhythm may take 2–4 weeks.",
    }
,
    {
      mistake: "Using sleep peptides without addressing sleep hygiene",
      fix: "Peptides cannot overcome chronic sleep deprivation, irregular schedules, or poor sleep environment. Address foundational sleep hygiene first.",
    }
    ],
    faqItems: [
    {
      q: "Which peptide is best for sleep?",
      a: "For most users, pre-sleep ipamorelin (100–200mcg) is the best starting point — well-studied, well-tolerated, and produces noticeable sleep quality improvement within 1–2 weeks. Epithalon is better for circadian rhythm issues and age-related sleep disruption.",
    }
,
    {
      q: "Can peptides help with insomnia?",
      a: "Peptides like ipamorelin and epithalon improve sleep quality and depth, but they are not sleep medications. For clinical insomnia, consult a physician. Peptides work best for subclinical sleep issues (poor sleep quality, insufficient deep sleep, disrupted circadian rhythm).",
    }
,
    {
      q: "Will GH secretagogues cause vivid dreams?",
      a: "Yes — many users report more vivid, memorable dreams with pre-sleep GH secretagogues. This is a normal consequence of enhanced slow-wave and REM sleep and is generally considered a positive sign of effect.",
    }
    ],
    relatedPeptides: ["ipamorelin", "epithalon", "sermorelin"],
    relatedGuides: ["how-to-use-ipamorelin", "how-to-use-epithalon", "how-to-use-sermorelin"],
  },
  {
    slug: "how-to-use-peptides-for-anti-aging",
    title: "How to Use Peptides for Anti-Aging: Longevity Protocol Guide",
    h1: "How to Use Peptides for Anti-Aging: A Comprehensive Longevity Protocol",
    metaDescription: "Evidence-based guide to anti-aging peptides — epithalon, GHK-Cu, NAD+, thymosin alpha-1, dosing protocols, and how to build a longevity stack.",
    category: "Goal-Specific Protocols",
    targetPeptides: ["epithalon", "nad-plus", "ghk-cu", "thymosin-alpha-1"],
    difficulty: "Advanced",
    timeRequired: "20 minutes",
    overview: "Anti-aging peptide protocols target multiple hallmarks of aging simultaneously: telomere shortening (epithalon), cellular energy decline (NAD+), collagen loss (GHK-Cu), immune senescence (thymosin alpha-1), and GH axis decline (sermorelin). This guide covers the evidence and protocols for each target.",
    whatYouNeed: ["Baseline bloodwork (IGF-1, telomere length optional, NAD+ levels optional)", "Clear longevity goals", "Budget assessment (longevity protocols can be expensive)", "Physician oversight (recommended)"],
    steps: [
    {
      stepNumber: 1,
      title: "Establish your baseline",
      description: "Before starting any anti-aging protocol, get baseline bloodwork: IGF-1, testosterone, DHEA-S, cortisol, inflammatory markers (CRP, IL-6), metabolic panel, and CBC. Optional: telomere length testing, NAD+ levels. This allows objective assessment of protocol effectiveness.",
      tip: "Repeat bloodwork every 6 months to track changes.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Epithalon for telomere support",
      description: "Epithalon 5–10mg/day for 10–20 days, 1–2 cycles per year. This is the most studied telomere-targeting peptide with multiple Russian clinical trials demonstrating telomerase activation and telomere lengthening.",
      tip: "Run epithalon cycles in spring and autumn for circadian alignment.",
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "NAD+ for cellular energy",
      description: "NMN or NR 500–1000mg/day orally (most practical), or SubQ NAD+ 25–100mg/day, or periodic IV NAD+ infusions (250–1000mg). NAD+ supports mitochondrial function, DNA repair, and sirtuin activation.",
      tip: "Take in the morning — NAD+ is energizing and can disrupt sleep if taken late.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "GHK-Cu for skin and tissue rejuvenation",
      description: "Topical GHK-Cu 1–5% serum, applied morning and/or evening. Optional: SubQ injection 1–2mg, 2–3x per week. GHK-Cu stimulates collagen synthesis, reduces inflammation, and promotes tissue repair.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Thymosin Alpha-1 for immune support",
      description: "Thymosin Alpha-1 1.6mg SubQ, twice weekly for 6–12 weeks, 1–2 cycles per year. Supports T-cell function, NK cell activity, and immune surveillance — addressing immune senescence.",
      tip: "Stack with epithalon during the same cycle for comprehensive longevity support.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Starting a complex longevity stack without baseline testing",
      fix: "Baseline bloodwork is essential for measuring protocol effectiveness. Without it, you cannot know if the protocol is working.",
    }
,
    {
      mistake: "Expecting rapid anti-aging effects",
      fix: "Anti-aging interventions work on timescales of months to years. Telomere lengthening, immune rejuvenation, and cellular repair are gradual processes.",
    }
,
    {
      mistake: "Neglecting lifestyle foundations",
      fix: "No peptide protocol overcomes poor sleep, sedentary lifestyle, poor nutrition, or chronic stress. Peptides are amplifiers of a healthy lifestyle, not substitutes.",
    }
    ],
    faqItems: [
    {
      q: "What is the best anti-aging peptide stack?",
      a: "A comprehensive longevity stack includes: epithalon (telomere support), NAD+ precursors (cellular energy), GHK-Cu (tissue rejuvenation), and thymosin alpha-1 (immune support). This addresses four distinct hallmarks of aging simultaneously.",
    }
,
    {
      q: "How long before anti-aging peptides show results?",
      a: "Subjective improvements (energy, skin quality, sleep) may be noticeable within 4–8 weeks. Objective markers (telomere length, immune function, IGF-1) change over months to years. Anti-aging is a long-term commitment.",
    }
,
    {
      q: "Is physician oversight necessary for anti-aging peptide protocols?",
      a: "Strongly recommended. Anti-aging protocols involve multiple compounds, potential drug interactions, and require interpretation of bloodwork. A physician familiar with peptide therapy can optimize the protocol and monitor for adverse effects.",
    }
    ],
    relatedPeptides: ["epithalon", "nad-plus", "ghk-cu", "thymosin-alpha-1"],
    relatedGuides: ["how-to-use-epithalon", "how-to-use-nad-plus", "how-to-use-ghk-cu"],
  },
  {
    slug: "how-to-use-peptides-for-injury-recovery",
    title: "How to Use Peptides for Injury Recovery: Complete Protocol",
    h1: "How to Use Peptides for Injury Recovery: BPC-157, TB-500, and Beyond",
    metaDescription: "Complete guide to peptides for injury recovery — BPC-157 + TB-500 stack, dosing, injection sites, timeline expectations, and which injuries respond best.",
    category: "Goal-Specific Protocols",
    targetPeptides: ["bpc-157", "tb-500"],
    difficulty: "Intermediate",
    timeRequired: "15 minutes",
    overview: "BPC-157 and TB-500 are the two most studied peptides for injury recovery. BPC-157 promotes angiogenesis, growth factor upregulation, and gut-brain axis repair. TB-500 promotes cell migration, actin polymerization, and systemic tissue repair. Together, they address multiple healing pathways and are commonly stacked for synergistic effect.",
    whatYouNeed: ["BPC-157 vials (5mg each)", "TB-500 vials (5mg each)", "Bacteriostatic water (2mL per vial)", "Insulin syringes (U-100)", "Alcohol swabs", "Injury assessment (type, severity, location)"],
    steps: [
    {
      stepNumber: 1,
      title: "Assess the injury type",
      description: "BPC-157 is most effective for: tendon/ligament injuries, gut injuries, nerve damage, muscle tears. TB-500 is most effective for: systemic tissue repair, muscle injuries, cardiac tissue, corneal healing. Both are effective for most musculoskeletal injuries.",
      tip: "For tendon/ligament injuries specifically, BPC-157 has stronger evidence. For systemic or diffuse injuries, TB-500 may be more appropriate.",
      warning: undefined,
    }
,
    {
      stepNumber: 2,
      title: "Reconstitute both vials",
      description: "BPC-157: add 2mL bacteriostatic water to 5mg vial → 2.5mg/mL (2500mcg/mL). TB-500: add 2mL bacteriostatic water to 5mg vial → 2.5mg/mL.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 3,
      title: "Loading phase (weeks 1–4)",
      description: "BPC-157: 250–500mcg SubQ, twice daily (morning and evening). TB-500: 5–10mg per week, split into 2 injections. Inject both near the injury site when possible (SubQ, not into the joint).",
      tip: "Many users mix BPC-157 and TB-500 in the same syringe for convenience — they are compatible.",
      warning: undefined,
    }
,
    {
      stepNumber: 4,
      title: "Maintenance phase (weeks 5–12)",
      description: "BPC-157: reduce to 250mcg once daily. TB-500: reduce to 2.5–5mg per week. Continue until healing is complete or 12 weeks, whichever comes first.",
      tip: undefined,
      warning: undefined,
    }
,
    {
      stepNumber: 5,
      title: "Combine with physical therapy",
      description: "Peptides accelerate healing but do not address biomechanical dysfunction. Combine with appropriate physical therapy, load management, and movement correction for complete recovery.",
      tip: "Start gentle range-of-motion exercises as soon as pain allows — peptides support active recovery better than complete rest.",
      warning: undefined,
    }
    ],
    commonMistakes: [
    {
      mistake: "Using peptides as a substitute for medical evaluation",
      fix: "Serious injuries (fractures, complete tendon ruptures, nerve injuries) require medical evaluation and may need surgical intervention. Peptides are adjuncts to, not replacements for, appropriate medical care.",
    }
,
    {
      mistake: "Expecting complete pain relief",
      fix: "Peptides accelerate tissue healing — they do not provide analgesic effects. Pain reduction follows tissue repair, typically over 2–6 weeks.",
    }
,
    {
      mistake: "Stopping too early",
      fix: "Tissue healing takes time. Most users see significant improvement in 4–6 weeks but complete healing may require 8–12 weeks of consistent peptide use.",
    }
    ],
    faqItems: [
    {
      q: "Which injuries respond best to BPC-157 and TB-500?",
      a: "Tendon and ligament injuries show the strongest response to BPC-157. Muscle injuries and systemic tissue damage respond well to TB-500. Both are effective for most musculoskeletal injuries, and the combination covers the widest range of injury types.",
    }
,
    {
      q: "Can I inject BPC-157 directly into the injured area?",
      a: "Injecting near (not into) the injured area is common practice. Inject into the subcutaneous tissue surrounding the injury, not into tendons, ligaments, or joint spaces. Intra-articular injection requires medical training and sterile technique.",
    }
,
    {
      q: "How does the BPC-157 + TB-500 stack compare to using either alone?",
      a: "The combination is generally considered more effective than either alone because they work through complementary mechanisms. BPC-157 promotes angiogenesis and growth factor upregulation; TB-500 promotes cell migration and actin polymerization. Together, they address the healing cascade more comprehensively.",
    }
    ],
    relatedPeptides: ["bpc-157", "tb-500"],
    relatedGuides: ["how-to-use-bpc-157-for-gut-healing", "how-to-use-tb-500", "how-to-build-a-peptide-stack"],
  }
];

// ─── FOR-CONDITION PAGES ──────────────────────────────────────────────────────
// Template: /for/[slug]
// Schema: MedicalCondition — symptom-first layout, distinct from profile pages

export interface ForConditionPageData {
  slug: string;
  condition: string;
  h1: string;
  metaDescription: string;
  category: string;
  icdCode?: string;
  prevalence?: string;
  conditionOverview: string;
  symptoms: string[];
  conventionalTreatments: string[];
  howPeptidesHelp: string;
  topPeptides: Array<{
    peptideSlug: string;
    peptideName: string;
    mechanism: string;
    evidenceLevel: string;
    typicalDose: string;
    rank: number;
  }>;
  protocolSuggestion: string;
  importantCaveats: string;
  faqItems: Array<{ q: string; a: string }>;
   relatedConditions: string[];
}
export const forConditionPages: ForConditionPageData[] = [
  {
    slug: "leaky-gut",
    condition: "Leaky Gut (Intestinal Permeability)",
    h1: "Best Peptides for Leaky Gut: Evidence-Based Guide",
    metaDescription: "Independent guide to peptides for leaky gut (intestinal permeability). BPC-157, glutamine, and zinc carnosine compared. Evidence, dosing, and protocols. Vendor-neutral.",
    category: "Gut Health",
    prevalence: "Estimated to affect 10-15% of the general population; higher in those with IBD, IBS, or autoimmune conditions",
    conditionOverview: "Leaky gut (intestinal hyperpermeability) occurs when tight junctions between intestinal epithelial cells become compromised, allowing bacteria, toxins, and undigested food particles to enter the bloodstream. It is associated with IBD, IBS, autoimmune conditions, and systemic inflammation.",
    symptoms: [
      "Bloating and gas after meals",
      "Food sensitivities and intolerances",
      "Chronic fatigue",
      "Brain fog",
      "Joint pain",
      "Skin issues (eczema, acne, rosacea)",
      "Autoimmune flares"
    ],
    conventionalTreatments: [
      "Elimination diets (gluten-free, low-FODMAP)",
      "Probiotics and prebiotics",
      "L-glutamine supplementation",
      "Zinc supplementation",
      "Anti-inflammatory diet",
      "Stress reduction"
    ],
    howPeptidesHelp: "Several peptides have demonstrated the ability to repair intestinal tight junctions, reduce gut inflammation, and promote epithelial cell regeneration. BPC-157 has the most extensive preclinical evidence for gut healing, with demonstrated effects on tight junction repair and mucosal regeneration.",
    topPeptides: [
      {
        peptideSlug: "bpc-157",
        peptideName: "BPC-157",
        mechanism: "Upregulates growth factors (EGF, VEGF), promotes angiogenesis, repairs tight junctions, reduces gut inflammation",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "250-500mcg/day oral or injectable",
        rank: 1
      },
      {
        peptideSlug: "ghk-cu",
        peptideName: "GHK-Cu",
        mechanism: "Anti-inflammatory, promotes tissue repair and collagen synthesis in gut lining",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "1-2mg/day injectable",
        rank: 2
      },
      {
        peptideSlug: "tb-500",
        peptideName: "TB-500",
        mechanism: "Promotes cell migration and tissue repair, anti-inflammatory",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "2-5mg 2x/week injectable",
        rank: 3
      }
    ],
    protocolSuggestion: "Most practitioners start with BPC-157 500mcg/day (oral for gut-specific application) for 6-8 weeks. Some add zinc carnosine (75mg twice daily) as a well-tolerated adjunct with clinical evidence for gut mucosal protection.",
    importantCaveats: "Leaky gut is not a recognized diagnosis in conventional medicine, though intestinal permeability is a measurable phenomenon. Peptide evidence for this condition is primarily preclinical. Work with a healthcare provider to identify and address underlying causes (diet, stress, medications).",
    faqItems: [
      { q: "Which peptide is best for leaky gut?", a: "BPC-157 has the most extensive preclinical evidence for gut healing and tight junction repair. It is the most commonly used peptide for leaky gut protocols." },
      { q: "How long does it take for peptides to heal leaky gut?", a: "Most users report improvement within 2-4 weeks, with full benefits at 6-8 weeks. Chronic or severe cases may require longer protocols." },
      { q: "Is oral or injectable BPC-157 better for leaky gut?", a: "For gut-specific conditions, oral BPC-157 delivers the peptide directly to the gut lining and is generally preferred. Injectable provides systemic effects." }
    ],
    relatedConditions: ["ibs", "crohns-disease", "ulcerative-colitis", "sibo"]
  },

  {
    slug: "joint-pain",
    condition: "Joint Pain and Osteoarthritis",
    h1: "Best Peptides for Joint Pain: Evidence-Based Guide",
    metaDescription: "Independent guide to peptides for joint pain and osteoarthritis. BPC-157, TB-500, and collagen peptides compared. Evidence, dosing, and protocols. Vendor-neutral.",
    category: "Joint Health",
    prevalence: "Osteoarthritis affects over 32.5 million adults in the US; joint pain is one of the most common complaints in adults over 40",
    conditionOverview: "Joint pain can result from osteoarthritis (cartilage degradation), inflammatory arthritis (rheumatoid, psoriatic), tendinopathy, bursitis, or acute injury. Conventional treatments focus on symptom management; peptides may address underlying tissue repair mechanisms.",
    symptoms: [
      "Joint stiffness, especially in the morning",
      "Pain with movement or weight-bearing",
      "Swelling and inflammation around the joint",
      "Reduced range of motion",
      "Crepitus (grinding or clicking sounds)",
      "Muscle weakness around the affected joint"
    ],
    conventionalTreatments: [
      "NSAIDs (ibuprofen, naproxen)",
      "Corticosteroid injections",
      "Physical therapy",
      "Hyaluronic acid injections",
      "Glucosamine and chondroitin",
      "Joint replacement surgery (severe cases)"
    ],
    howPeptidesHelp: "BPC-157 and TB-500 have demonstrated the ability to promote tendon, ligament, and cartilage repair in preclinical studies. They work through complementary mechanisms: BPC-157 through growth factor upregulation and angiogenesis; TB-500 through actin regulation and cell migration.",
    topPeptides: [
      {
        peptideSlug: "bpc-157",
        peptideName: "BPC-157",
        mechanism: "Upregulates growth factors, promotes angiogenesis in joint tissue, reduces inflammation, accelerates tendon and ligament healing",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "250-500mcg/day injectable (local or systemic)",
        rank: 1
      },
      {
        peptideSlug: "tb-500",
        peptideName: "TB-500",
        mechanism: "Promotes cell migration, reduces inflammation, improves flexibility and range of motion",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "2-5mg 2x/week injectable",
        rank: 2
      },
      {
        peptideSlug: "ghk-cu",
        peptideName: "GHK-Cu",
        mechanism: "Anti-inflammatory, promotes collagen synthesis and tissue remodeling",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "1-2mg/day injectable",
        rank: 3
      }
    ],
    protocolSuggestion: "The most common protocol for joint pain is BPC-157 (500mcg/day) + TB-500 (2.5mg 2x/week) for 6-8 weeks — known as the 'Recovery Stack.' Some practitioners inject BPC-157 locally near the affected joint for more targeted effects.",
    importantCaveats: "Peptide evidence for joint pain is primarily preclinical. Human clinical trials are limited. Peptides are not a substitute for conventional treatment of inflammatory arthritis. Always rule out serious pathology (fracture, infection, autoimmune disease) before pursuing peptide protocols.",
    faqItems: [
      { q: "Which peptide is best for joint pain?", a: "BPC-157 has the most extensive preclinical evidence for joint and tendon healing. The BPC-157 + TB-500 combination (Recovery Stack) is the most commonly used protocol for joint pain." },
      { q: "Can peptides help with osteoarthritis?", a: "Preclinical studies suggest BPC-157 and TB-500 may promote cartilage repair and reduce joint inflammation. Human clinical evidence is limited, but anecdotal reports are encouraging." },
      { q: "How long does it take for peptides to work for joint pain?", a: "Most users report improvement within 2-4 weeks, with significant benefit at 6-8 weeks. Chronic joint conditions may require longer protocols or repeat cycles." }
    ],
    relatedConditions: ["tendinopathy", "sports-injury", "back-pain", "muscle-recovery"]
  },

  {
    slug: "low-testosterone",
    condition: "Low Testosterone (Hypogonadism)",
    h1: "Best Peptides for Low Testosterone: Evidence-Based Guide",
    metaDescription: "Independent guide to peptides for low testosterone. Kisspeptin, gonadorelin, and PT-141 compared. Evidence, dosing, and how peptides support testosterone. Vendor-neutral.",
    category: "Hormonal Health",
    prevalence: "Affects approximately 2-4% of men; subclinical low testosterone is more common, especially in men over 40",
    conditionOverview: "Low testosterone (hypogonadism) can be primary (testicular failure) or secondary (hypothalamic-pituitary dysfunction). Symptoms include fatigue, low libido, muscle loss, fat gain, depression, and cognitive decline. Peptides can support testosterone production through the HPG axis.",
    symptoms: [
      "Low libido and sexual dysfunction",
      "Fatigue and low energy",
      "Loss of muscle mass",
      "Increased body fat (especially abdominal)",
      "Depression and mood changes",
      "Cognitive decline and brain fog",
      "Poor sleep quality"
    ],
    conventionalTreatments: [
      "Testosterone replacement therapy (TRT)",
      "Clomiphene citrate (for secondary hypogonadism)",
      "hCG therapy",
      "Lifestyle modifications (exercise, sleep, diet)",
      "Addressing underlying causes (obesity, sleep apnea)"
    ],
    howPeptidesHelp: "Several peptides support testosterone production through the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin stimulates GnRH release, driving LH and FSH production. Gonadorelin is a GnRH analogue that directly stimulates pituitary LH/FSH release. These approaches preserve natural testosterone production rather than replacing it.",
    topPeptides: [
      {
        peptideSlug: "ipamorelin",
        peptideName: "Ipamorelin + CJC-1295",
        mechanism: "GH optimization indirectly supports testosterone through improved body composition and metabolic health",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "300mcg ipamorelin + 100mcg CJC-1295 before bed",
        rank: 1
      },
      {
        peptideSlug: "pt-141",
        peptideName: "PT-141",
        mechanism: "Central melanocortin receptor activation for sexual desire (not testosterone-raising)",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "1.75mg SubQ 45-90 min before activity",
        rank: 2
      },
      {
        peptideSlug: "epithalon",
        peptideName: "Epithalon",
        mechanism: "Pineal gland regulation, may support hormonal balance through telomerase and anti-aging mechanisms",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "5-10mg/day for 10-20 day cycles",
        rank: 3
      }
    ],
    protocolSuggestion: "For low testosterone, the most evidence-based approach is working with an endocrinologist or men's health physician for TRT or clomiphene. Peptides like ipamorelin/CJC-1295 may support overall hormonal health and body composition as adjuncts. PT-141 addresses sexual desire directly without raising testosterone.",
    importantCaveats: "Low testosterone requires proper diagnosis (blood tests, clinical evaluation). Peptides are not a substitute for TRT in clinically diagnosed hypogonadism. Kisspeptin and gonadorelin require physician supervision. Self-treating low testosterone without diagnosis is not recommended.",
    faqItems: [
      { q: "Can peptides raise testosterone?", a: "Some peptides (kisspeptin, gonadorelin) can stimulate LH/FSH release and support natural testosterone production. However, they are not as effective as TRT for clinically diagnosed hypogonadism." },
      { q: "What is the best peptide for low libido?", a: "PT-141 (bremelanotide) is FDA approved for sexual desire disorders and directly enhances libido through central melanocortin receptors. It does not raise testosterone but addresses desire directly." },
      { q: "Should I use peptides instead of TRT?", a: "For clinically diagnosed hypogonadism, TRT is the evidence-based standard of care. Peptides may be appropriate as adjuncts or for subclinical cases. Discuss with your physician." }
    ],
    relatedConditions: ["sexual-dysfunction", "muscle-loss", "fatigue", "body-composition"]
  },

  {
    slug: "anxiety",
    condition: "Anxiety and Stress",
    h1: "Best Peptides for Anxiety: Evidence-Based Guide",
    metaDescription: "Independent guide to peptides for anxiety and stress. Selank, semax, and BPC-157 compared. Mechanism, evidence, and protocols. Vendor-neutral.",
    category: "Mental Health",
    prevalence: "Anxiety disorders affect approximately 19% of US adults annually; generalized anxiety is the most common",
    conditionOverview: "Anxiety disorders include generalized anxiety disorder (GAD), social anxiety, panic disorder, and PTSD. They involve dysregulation of the stress response, GABAergic and serotonergic systems, and HPA axis. Peptides offer novel mechanisms distinct from conventional anxiolytics.",
    symptoms: [
      "Persistent worry and rumination",
      "Physical tension and muscle tightness",
      "Sleep disruption",
      "Avoidance behaviors",
      "Rapid heartbeat and shortness of breath",
      "Difficulty concentrating",
      "Irritability"
    ],
    conventionalTreatments: [
      "SSRIs and SNRIs (first-line)",
      "Benzodiazepines (short-term)",
      "Buspirone",
      "Cognitive behavioral therapy (CBT)",
      "Mindfulness and meditation",
      "Beta-blockers (for situational anxiety)"
    ],
    howPeptidesHelp: "Selank was specifically developed as an anxiolytic peptide and has the most direct evidence for anxiety reduction. It modulates GABAergic and serotonergic systems without causing sedation or dependence. Semax may reduce anxiety indirectly through BDNF upregulation and stress resilience.",
    topPeptides: [
      {
        peptideSlug: "selank",
        peptideName: "Selank",
        mechanism: "GABAergic modulation, serotonin regulation, anxiolytic without sedation",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "250-500mcg intranasal, 1-3x daily",
        rank: 1
      },
      {
        peptideSlug: "semax",
        peptideName: "Semax",
        mechanism: "BDNF upregulation, stress resilience, indirect anxiolytic",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "200-600mcg intranasal, 1-2x daily",
        rank: 2
      },
      {
        peptideSlug: "bpc-157",
        peptideName: "BPC-157",
        mechanism: "Dopamine and serotonin system modulation, anti-inflammatory effects on CNS",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "250-500mcg/day injectable",
        rank: 3
      }
    ],
    protocolSuggestion: "For anxiety, selank (250-500mcg intranasal, 1-3x daily) is the most targeted peptide option. It can be used as needed or on a daily basis. Semax may be added for cognitive support and stress resilience. Both are available as nasal sprays, making them convenient for daily use.",
    importantCaveats: "Peptides for anxiety have primarily been studied in Russian clinical trials with limited independent replication. They should not replace evidence-based treatments (SSRIs, CBT) for diagnosed anxiety disorders. Do not discontinue prescribed medications without physician guidance.",
    faqItems: [
      { q: "Which peptide is best for anxiety?", a: "Selank has the most direct evidence for anxiety reduction. It was specifically developed as an anxiolytic and modulates GABAergic and serotonergic systems without sedation." },
      { q: "Is selank addictive?", a: "Selank does not appear to cause dependence or withdrawal. Unlike benzodiazepines, it does not downregulate GABA receptors with continued use. However, long-term human data is limited." },
      { q: "Can peptides replace SSRIs for anxiety?", a: "Peptides should not replace prescribed medications without physician guidance. They may be useful as adjuncts or for subclinical anxiety, but SSRIs with CBT remain the evidence-based standard for diagnosed anxiety disorders." }
    ],
    relatedConditions: ["depression", "sleep-disorders", "ptsd", "social-anxiety"]
  },

  {
    slug: "poor-sleep",
    condition: "Poor Sleep and Insomnia",
    h1: "Best Peptides for Sleep: Evidence-Based Guide",
    metaDescription: "Independent guide to peptides for sleep improvement. Ipamorelin, DSIP, and selank compared. Mechanism, evidence, and protocols. Vendor-neutral.",
    category: "Sleep",
    prevalence: "Approximately 30% of adults report insomnia symptoms; 10% have chronic insomnia disorder",
    conditionOverview: "Poor sleep can result from insomnia, sleep apnea, circadian rhythm disruption, anxiety, or hormonal imbalances. Chronic poor sleep is associated with increased risk of cardiovascular disease, metabolic disorders, and cognitive decline. Peptides offer novel approaches to sleep quality improvement.",
    symptoms: [
      "Difficulty falling asleep",
      "Frequent nighttime waking",
      "Non-restorative sleep",
      "Daytime fatigue and sleepiness",
      "Difficulty concentrating",
      "Mood disturbances",
      "Reliance on sleep aids"
    ],
    conventionalTreatments: [
      "Cognitive behavioral therapy for insomnia (CBT-I)",
      "Sleep hygiene optimization",
      "Melatonin",
      "Prescription sleep aids (zolpidem, eszopiclone)",
      "Treating underlying conditions (anxiety, sleep apnea)"
    ],
    howPeptidesHelp: "Ipamorelin stimulates GH pulses that naturally occur during deep sleep, potentially enhancing sleep quality and recovery. DSIP (delta sleep-inducing peptide) directly promotes slow-wave delta sleep. Selank reduces anxiety that commonly disrupts sleep.",
    topPeptides: [
      {
        peptideSlug: "ipamorelin",
        peptideName: "Ipamorelin",
        mechanism: "GH pulse stimulation during deep sleep, enhances sleep quality and recovery",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "200-300mcg SubQ before bed",
        rank: 1
      },
      {
        peptideSlug: "selank",
        peptideName: "Selank",
        mechanism: "Anxiolytic, reduces anxiety-driven sleep disruption",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "250-500mcg intranasal before bed",
        rank: 2
      },
      {
        peptideSlug: "epithalon",
        peptideName: "Epithalon",
        mechanism: "Pineal gland regulation, melatonin support, circadian rhythm normalization",
            evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "5-10mg/day for 10-20 day cycles",
        rank: 3
      }
    ],
    protocolSuggestion: "Ipamorelin (200-300mcg SubQ before bed) is the most commonly used peptide for sleep quality improvement. It enhances the natural GH pulse during deep sleep. For anxiety-driven insomnia, selank (250-500mcg intranasal) before bed may be more appropriate.",
    importantCaveats: "Peptide evidence for sleep is primarily preclinical or anecdotal. CBT-I remains the gold standard for chronic insomnia. Rule out sleep apnea and other treatable causes before pursuing peptide protocols. Do not combine peptide sleep protocols with prescription sleep aids without physician guidance.",
    faqItems: [
      { q: "Which peptide is best for sleep?", a: "Ipamorelin is the most commonly used peptide for sleep quality improvement. It enhances GH pulses during deep sleep and is well-tolerated. For anxiety-driven insomnia, selank may be more appropriate." },
      { q: "When should I take ipamorelin for sleep?", a: "Take ipamorelin 30-60 minutes before bed on an empty stomach (no food for 2 hours before). This timing aligns with the natural GH pulse that occurs during early deep sleep." },
      { q: "Can peptides cure insomnia?", a: "Peptides are not a cure for insomnia. They may improve sleep quality as part of a comprehensive approach. CBT-I and addressing underlying causes remain the most evidence-based treatments." }
    ],
    relatedConditions: ["anxiety", "fatigue", "hormonal-imbalance", "recovery"]
  },
  {
    slug: "tendinopathy",
    condition: "Tendinopathy (Tendon Injury)",
    h1: "Best Peptides for Tendinopathy: Evidence-Based Guide",
    metaDescription: "Independent guide to peptides for tendinopathy and tendon injuries. BPC-157 and TB-500 compared with evidence, dosing, and protocols.",
    category: "Musculoskeletal",
    icdCode: "M77.9",
    prevalence: "Affects approximately 30% of active adults; one of the most common sports injuries",
    conditionOverview: "Tendinopathy encompasses a spectrum of tendon disorders including tendinitis (acute inflammation) and tendinosis (chronic degeneration). Common sites include the Achilles, patellar, rotator cuff, and lateral epicondyle tendons. Standard treatment includes rest, physical therapy, NSAIDs, and corticosteroid injections — but outcomes are often incomplete, driving interest in regenerative approaches.",
    symptoms: ["Localized tendon pain, especially with loading", "Morning stiffness that improves with activity", "Tendon thickening or nodularity", "Reduced strength and range of motion", "Pain that worsens with repetitive activity"],
    conventionalTreatments: ["Rest and activity modification", "Eccentric exercise protocols", "NSAIDs (short-term)", "Corticosteroid injections (short-term relief)", "Platelet-rich plasma (PRP) injections", "Surgery (severe cases)"],
    howPeptidesHelp: "BPC-157 has demonstrated direct tendon healing effects in multiple animal studies, including upregulation of growth factor receptors (VEGFR2, FGFR2), promotion of angiogenesis, and acceleration of tendon-to-bone healing. TB-500 promotes cell migration and actin polymerization, supporting the repair of tendon fibers. Together, they address the vascular and structural components of tendon healing.",
    topPeptides: [
    {
      peptideSlug: "bpc-157",
      peptideName: "BPC-157",
      mechanism: "Upregulates growth factor receptors, promotes angiogenesis, accelerates tendon-to-bone healing",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "250-500mcg SubQ near injury site, twice daily",
      rank: 1,
    },    {
      peptideSlug: "tb-500",
      peptideName: "TB-500",
      mechanism: "Promotes cell migration and actin polymerization; systemic tissue repair",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "5-10mg/week loading, 2.5-5mg/week maintenance",
      rank: 2,
    }
    ],
    protocolSuggestion: "Loading phase (weeks 1-4): BPC-157 500mcg twice daily + TB-500 5mg twice weekly. Maintenance (weeks 5-12): BPC-157 250mcg once daily + TB-500 2.5mg twice weekly. Combine with eccentric exercise protocol.",
    importantCaveats: "Peptide research for tendinopathy is primarily preclinical (animal studies). Human clinical trials are limited. These compounds are research chemicals, not FDA-approved treatments. Consult a sports medicine physician for severe tendon injuries.",
    faqItems: [
    {
      q: "How long does BPC-157 take to heal tendons?",
      a: "Most users report noticeable pain reduction and functional improvement within 2-4 weeks of the loading phase. Complete tendon healing typically takes 8-12 weeks of consistent use combined with appropriate physical therapy.",
    },    {
      q: "Can I inject BPC-157 directly into the tendon?",
      a: "Inject into the subcutaneous tissue near the tendon, not directly into the tendon itself. Intra-tendinous injection requires medical training and carries risk of tendon rupture.",
    },    {
      q: "Is BPC-157 better than PRP for tendinopathy?",
      a: "No direct comparison studies exist. PRP has more human clinical evidence; BPC-157 has stronger preclinical mechanistic data. Some practitioners use both together.",
    }
    ],
    relatedConditions: ["sports-injury", "muscle-recovery", "back-pain", "rotator-cuff"],
  },
  {
    slug: "chronic-fatigue",
    condition: "Chronic Fatigue Syndrome (ME/CFS)",
    h1: "Best Peptides for Chronic Fatigue: Evidence-Based Guide",
    metaDescription: "Guide to peptides for chronic fatigue syndrome — NAD+, thymosin alpha-1, BPC-157, and sermorelin with evidence, dosing, and protocols.",
    category: "Metabolic & Energy",
    icdCode: "G93.3",
    prevalence: "Affects approximately 0.4% of the global population; 2.5 million Americans",
    conditionOverview: "Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, multisystem illness characterized by profound fatigue not relieved by rest, post-exertional malaise, cognitive impairment, and sleep disturbances. The pathophysiology involves mitochondrial dysfunction, immune dysregulation, autonomic nervous system abnormalities, and neuroinflammation.",
    symptoms: ["Profound fatigue lasting 6+ months", "Post-exertional malaise (PEM)", "Cognitive impairment ('brain fog')", "Unrefreshing sleep", "Orthostatic intolerance", "Widespread pain"],
    conventionalTreatments: ["Pacing and energy management", "Cognitive behavioral therapy (limited evidence)", "Graded exercise therapy (controversial)", "Symptom management (sleep aids, pain management)", "Low-dose naltrexone (off-label)"],
    howPeptidesHelp: "NAD+ addresses mitochondrial dysfunction and energy metabolism deficits common in ME/CFS. Thymosin Alpha-1 modulates immune dysfunction and may address the immune activation component. BPC-157 supports gut-brain axis integrity, which is increasingly recognized as important in ME/CFS. Sermorelin may help with the GH axis dysregulation seen in some ME/CFS patients.",
    topPeptides: [
    {
      peptideSlug: "nad-plus",
      peptideName: "NAD+",
      mechanism: "Restores mitochondrial function, supports cellular energy production, activates sirtuins",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "500-1000mg/day oral NMN/NR, or 25-100mg/day SubQ NAD+",
      rank: 1,
    },    {
      peptideSlug: "thymosin-alpha-1",
      peptideName: "Thymosin Alpha-1",
      mechanism: "Immune modulation, T-cell activation, reduction of immune dysregulation",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "1.6mg SubQ twice weekly for 6-12 weeks",
      rank: 2,
    },    {
      peptideSlug: "bpc-157",
      peptideName: "BPC-157",
      mechanism: "Gut-brain axis support, anti-inflammatory, autonomic nervous system modulation",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "250-500mcg oral or SubQ daily",
      rank: 3,
    }
    ],
    protocolSuggestion: "Start with NAD+ (NMN 500mg/day orally) for 4 weeks to assess tolerance and energy response. Add Thymosin Alpha-1 (1.6mg twice weekly) in week 5. Add BPC-157 (250mcg oral daily) in week 9 if gut symptoms are present. Pace activity carefully — avoid post-exertional malaise triggers.",
    importantCaveats: "ME/CFS is a complex illness with heterogeneous presentations. No peptide protocol has been validated in ME/CFS clinical trials. Start low and go slow — post-exertional malaise can be triggered by overexertion, including the stress of new interventions. Work with a physician familiar with ME/CFS.",
    faqItems: [
    {
      q: "Can peptides cure ME/CFS?",
      a: "No peptide has been shown to cure ME/CFS. Peptides may address specific pathophysiological components (mitochondrial dysfunction, immune dysregulation) and improve quality of life, but ME/CFS is a complex condition requiring comprehensive management.",
    },    {
      q: "Is NAD+ safe for ME/CFS patients?",
      a: "NAD+ precursors (NMN, NR) are generally well-tolerated. Start at a low dose (250mg/day) and increase slowly. Some ME/CFS patients are sensitive to stimulating interventions — monitor for post-exertional malaise.",
    },    {
      q: "What is the best peptide for brain fog in ME/CFS?",
      a: "NAD+ has the most evidence for cognitive symptoms in ME/CFS, supporting mitochondrial function in neurons. BPC-157 may help via gut-brain axis modulation. Thymosin Alpha-1 may reduce neuroinflammation.",
    }
    ],
    relatedConditions: ["long-covid", "fibromyalgia", "sleep-disorders", "cognitive-decline"],
  },
  {
    slug: "anxiety",
    condition: "Anxiety Disorders",
    h1: "Best Peptides for Anxiety: Evidence-Based Guide",
    metaDescription: "Guide to peptides for anxiety — selank, BPC-157, and thymosin alpha-1 with evidence, dosing, and protocols for anxiety management.",
    category: "Mental Health",
    icdCode: "F41.9",
    prevalence: "Affects 284 million people worldwide; most common mental health disorder",
    conditionOverview: "Anxiety disorders encompass generalized anxiety disorder (GAD), social anxiety, panic disorder, and PTSD. They involve dysregulation of the HPA axis, GABAergic and serotonergic neurotransmission, and neuroinflammation. Standard treatments include SSRIs, SNRIs, benzodiazepines, and cognitive behavioral therapy.",
    symptoms: ["Persistent worry and apprehension", "Physical tension and restlessness", "Sleep disturbances", "Difficulty concentrating", "Avoidance behaviors", "Panic attacks (in panic disorder)"],
    conventionalTreatments: ["SSRIs and SNRIs (first-line)", "Benzodiazepines (short-term)", "Cognitive behavioral therapy (CBT)", "Buspirone", "Beta-blockers (situational anxiety)"],
    howPeptidesHelp: "Selank is a synthetic analogue of tuftsin with anxiolytic properties demonstrated in Russian clinical trials — it modulates GABA-A receptors and reduces anxiety without sedation or dependence. BPC-157 has shown anxiolytic effects in animal models, possibly through dopaminergic and serotonergic modulation. Thymosin Alpha-1 may help by reducing neuroinflammation, which is increasingly linked to anxiety disorders.",
    topPeptides: [
    {
      peptideSlug: "selank",
      peptideName: "Selank",
      mechanism: "GABA-A modulation, anxiolytic without sedation, reduces stress response",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "250-500mcg intranasal or SubQ, 1-2x daily",
      rank: 1,
    },    {
      peptideSlug: "bpc-157",
      peptideName: "BPC-157",
      mechanism: "Dopaminergic and serotonergic modulation, gut-brain axis support",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "250-500mcg SubQ or oral daily",
      rank: 2,
    }
    ],
    protocolSuggestion: "Selank 250mcg intranasal or SubQ, twice daily for 4-8 weeks. Can be combined with BPC-157 250mcg oral daily for gut-brain axis support. These are adjuncts to, not replacements for, evidence-based anxiety treatments (CBT, SSRIs).",
    importantCaveats: "Selank has limited Western clinical trial data — most evidence is from Russian studies. Do not discontinue prescribed anxiety medications without physician guidance. Peptides for anxiety are experimental and should be used under medical supervision.",
    faqItems: [
    {
      q: "Is selank safe?",
      a: "Selank has a good safety profile in Russian clinical trials with no significant adverse effects reported. It does not cause sedation, dependence, or withdrawal — key advantages over benzodiazepines.",
    },    {
      q: "How quickly does selank work for anxiety?",
      a: "Many users report anxiolytic effects within 30-60 minutes of intranasal administration. Consistent daily use over 2-4 weeks appears to produce cumulative benefits.",
    },    {
      q: "Can peptides replace SSRIs for anxiety?",
      a: "No. Peptides are experimental adjuncts, not replacements for evidence-based anxiety treatments. Never discontinue prescribed medications without physician guidance.",
    }
    ],
    relatedConditions: ["depression", "ptsd", "sleep-disorders", "chronic-fatigue"],
  },
  {
    slug: "depression",
    condition: "Depression (Major Depressive Disorder)",
    h1: "Best Peptides for Depression: Evidence-Based Guide",
    metaDescription: "Guide to peptides for depression — selank, semax, BPC-157, and NAD+ with evidence, dosing, and protocols for mood support.",
    category: "Mental Health",
    icdCode: "F32.9",
    prevalence: "Affects 280 million people worldwide; leading cause of disability globally",
    conditionOverview: "Major depressive disorder (MDD) involves persistent low mood, anhedonia, cognitive impairment, and neurobiological changes including reduced neuroplasticity, HPA axis dysregulation, and neuroinflammation. Standard treatments include SSRIs, SNRIs, tricyclics, MAOIs, and psychotherapy.",
    symptoms: ["Persistent low mood or sadness", "Loss of interest or pleasure (anhedonia)", "Fatigue and low energy", "Cognitive impairment and poor concentration", "Sleep disturbances", "Feelings of worthlessness or guilt"],
    conventionalTreatments: ["SSRIs and SNRIs (first-line)", "Tricyclic antidepressants", "MAOIs", "Cognitive behavioral therapy (CBT)", "Electroconvulsive therapy (ECT)", "Ketamine/esketamine (treatment-resistant)"],
    howPeptidesHelp: "Semax is a synthetic ACTH analogue that increases BDNF (brain-derived neurotrophic factor), promoting neuroplasticity — a key mechanism in antidepressant action. Selank has shown mood-stabilizing and anxiolytic effects. BPC-157 may support the gut-brain axis, which is increasingly implicated in depression. NAD+ addresses mitochondrial dysfunction and energy deficits common in depression.",
    topPeptides: [
    {
      peptideSlug: "semax",
      peptideName: "Semax",
      mechanism: "Increases BDNF, promotes neuroplasticity, modulates dopamine and serotonin systems",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "200-600mcg intranasal daily",
      rank: 1,
    },    {
      peptideSlug: "selank",
      peptideName: "Selank",
      mechanism: "Anxiolytic, mood stabilization, GABA modulation",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "250-500mcg intranasal or SubQ daily",
      rank: 2,
    },    {
      peptideSlug: "nad-plus",
      peptideName: "NAD+",
      mechanism: "Mitochondrial support, energy metabolism, sirtuin activation",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "500-1000mg/day oral NMN/NR",
      rank: 3,
    }
    ],
    protocolSuggestion: "Semax 200-400mcg intranasal daily for 4-8 weeks. Can be combined with Selank for combined anxiolytic/mood support. These are experimental adjuncts — do not replace evidence-based depression treatments.",
    importantCaveats: "Depression is a serious medical condition. Never discontinue prescribed antidepressants without physician guidance. Peptides for depression are experimental with limited Western clinical data. Seek professional mental health support.",
    faqItems: [
    {
      q: "Does semax help with depression?",
      a: "Semax increases BDNF and promotes neuroplasticity — mechanisms shared with effective antidepressants. Russian clinical trials show mood-improving effects. Western clinical trial data is limited.",
    },    {
      q: "Can peptides be combined with antidepressants?",
      a: "Potential interactions between peptides and antidepressants are not well studied. Consult a physician before combining peptides with any psychiatric medications.",
    },    {
      q: "How long does semax take to work for mood?",
      a: "Some users report mood improvements within 1-2 weeks of intranasal semax. Neuroplasticity changes (BDNF upregulation) take longer — 4-8 weeks of consistent use.",
    }
    ],
    relatedConditions: ["anxiety", "chronic-fatigue", "sleep-disorders", "cognitive-decline"],
  },
  {
    slug: "osteoporosis",
    condition: "Osteoporosis",
    h1: "Best Peptides for Osteoporosis: Evidence-Based Guide",
    metaDescription: "Guide to peptides for osteoporosis — PTH analogues, GH secretagogues, and GHK-Cu with evidence, dosing, and bone density protocols.",
    category: "Bone Health",
    icdCode: "M81.0",
    prevalence: "Affects 200 million people worldwide; 1 in 3 women and 1 in 5 men over 50",
    conditionOverview: "Osteoporosis is characterized by reduced bone mineral density (BMD) and deterioration of bone microarchitecture, increasing fracture risk. It results from an imbalance between osteoblast (bone formation) and osteoclast (bone resorption) activity. Standard treatments include bisphosphonates, denosumab, teriparatide (PTH analogue), and calcium/vitamin D supplementation.",
    symptoms: ["Often asymptomatic until fracture", "Height loss over time", "Stooped posture (kyphosis)", "Back pain from vertebral fractures", "Fractures from minimal trauma"],
    conventionalTreatments: ["Bisphosphonates (alendronate, zoledronic acid)", "Denosumab (RANKL inhibitor)", "Teriparatide (PTH analogue — anabolic)", "Romosozumab (sclerostin inhibitor)", "Calcium and vitamin D supplementation", "Weight-bearing exercise"],
    howPeptidesHelp: "GH secretagogues (ipamorelin, sermorelin) increase GH/IGF-1, which promotes osteoblast activity and bone formation. GHK-Cu stimulates collagen synthesis and may support bone matrix quality. Thymosin Beta-4 (TB-500) has shown bone regeneration properties in preclinical studies. These are adjuncts to, not replacements for, FDA-approved osteoporosis treatments.",
    topPeptides: [
    {
      peptideSlug: "ipamorelin",
      peptideName: "Ipamorelin",
      mechanism: "Increases GH/IGF-1, promotes osteoblast activity and bone formation",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "200-300mcg SubQ, 2-3x daily",
      rank: 1,
    },    {
      peptideSlug: "ghk-cu",
      peptideName: "GHK-Cu",
      mechanism: "Stimulates collagen synthesis, supports bone matrix quality",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "1-2mg SubQ 2-3x weekly",
      rank: 2,
    }
    ],
    protocolSuggestion: "Ipamorelin 200mcg SubQ twice daily (morning and pre-sleep) for 12 weeks, combined with resistance training and adequate calcium/vitamin D. GHK-Cu 1mg SubQ twice weekly as an adjunct. These are experimental adjuncts — FDA-approved osteoporosis medications should be the primary treatment.",
    importantCaveats: "Osteoporosis is a serious condition with significant fracture risk. FDA-approved treatments (bisphosphonates, teriparatide) have strong clinical evidence. Peptides are experimental adjuncts. DEXA scan monitoring of BMD is essential. Work with an endocrinologist or rheumatologist.",
    faqItems: [
    {
      q: "Can peptides reverse osteoporosis?",
      a: "No peptide has been proven to reverse osteoporosis in clinical trials. GH secretagogues may support bone formation, but FDA-approved treatments (especially teriparatide) have much stronger evidence for increasing BMD.",
    },    {
      q: "Is ipamorelin safe for osteoporosis patients?",
      a: "GH secretagogues are generally well-tolerated. However, they should be used cautiously in patients with active malignancy (GH can stimulate tumor growth). Consult an endocrinologist.",
    },    {
      q: "What is the best exercise for osteoporosis?",
      a: "Weight-bearing and resistance exercise are the most effective non-pharmacological interventions for osteoporosis. They stimulate osteoblast activity and improve bone density. Combine with peptide protocols for synergistic effect.",
    }
    ],
    relatedConditions: ["muscle-loss", "hormonal-imbalance", "sports-injury", "recovery"],
  },
  {
    slug: "erectile-dysfunction",
    condition: "Erectile Dysfunction",
    h1: "Best Peptides for Erectile Dysfunction: Evidence-Based Guide",
    metaDescription: "Guide to peptides for erectile dysfunction — PT-141, BPC-157, and sermorelin with evidence, dosing, and protocols.",
    category: "Sexual Health",
    icdCode: "N52.9",
    prevalence: "Affects approximately 30 million men in the United States; prevalence increases with age",
    conditionOverview: "Erectile dysfunction (ED) involves the inability to achieve or maintain an erection sufficient for satisfactory sexual activity. It has vascular (endothelial dysfunction), neurological, hormonal (low testosterone), and psychological components. Standard treatments include PDE5 inhibitors (sildenafil, tadalafil), testosterone replacement, and vacuum erection devices.",
    symptoms: ["Difficulty achieving erection", "Difficulty maintaining erection", "Reduced sexual desire", "Anxiety about sexual performance"],
    conventionalTreatments: ["PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis)", "Testosterone replacement therapy (if hypogonadal)", "Vacuum erection devices", "Penile injections (alprostadil)", "Penile implants (severe cases)", "Psychotherapy (psychological ED)"],
    howPeptidesHelp: "PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in women and works centrally to increase sexual desire and arousal in men. BPC-157 may support endothelial function and penile vascular health. Sermorelin/ipamorelin may help by addressing GH axis decline, which is associated with reduced sexual function.",
    topPeptides: [
    {
      peptideSlug: "pt-141",
      peptideName: "PT-141",
      mechanism: "Central melanocortin receptor agonist; increases sexual desire and arousal centrally",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "0.5-2mg SubQ, 1-4 hours before activity",
      rank: 1,
    },    {
      peptideSlug: "bpc-157",
      peptideName: "BPC-157",
      mechanism: "Endothelial support, vascular health, nitric oxide modulation",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "250-500mcg SubQ daily",
      rank: 2,
    }
    ],
    protocolSuggestion: "PT-141 0.5-1mg SubQ, 1-2 hours before sexual activity. Start at 0.5mg to assess nausea tolerance. Can be combined with PDE5 inhibitors (complementary mechanisms). BPC-157 250mcg daily as a vascular support adjunct.",
    importantCaveats: "PT-141 transiently raises blood pressure — contraindicated in uncontrolled hypertension or cardiovascular disease. ED can be a sign of underlying cardiovascular disease — medical evaluation is important. Peptides are adjuncts to, not replacements for, FDA-approved ED treatments.",
    faqItems: [
    {
      q: "Can PT-141 be combined with Viagra?",
      a: "PT-141 works centrally (desire/arousal) while PDE5 inhibitors work peripherally (blood flow). They are complementary and can be combined, but consult a physician — both can affect blood pressure.",
    },    {
      q: "How does PT-141 differ from Viagra for ED?",
      a: "Viagra increases blood flow to the penis (peripheral mechanism). PT-141 increases sexual desire and arousal in the brain (central mechanism). PT-141 is more effective for desire/libido issues; Viagra is more effective for vascular/physical ED.",
    },    {
      q: "Is PT-141 safe for men?",
      a: "PT-141 is FDA-approved for women with HSDD. In men, clinical trial data shows it is generally well-tolerated. Main concerns are nausea and transient blood pressure elevation. Avoid if you have cardiovascular disease.",
    }
    ],
    relatedConditions: ["sexual-dysfunction", "hormonal-imbalance", "depression", "anxiety"],
  },
  {
    slug: "hair-loss",
    condition: "Hair Loss (Androgenetic Alopecia)",
    h1: "Best Peptides for Hair Loss: Evidence-Based Guide",
    metaDescription: "Guide to peptides for hair loss — GHK-Cu, PTD-DBM, and thymosin beta-4 with evidence, dosing, and topical protocols.",
    category: "Dermatology",
    icdCode: "L64.9",
    prevalence: "Affects 50% of men by age 50 and 25% of women by age 50",
    conditionOverview: "Androgenetic alopecia (AGA) is the most common form of hair loss, driven by DHT (dihydrotestosterone) sensitivity in genetically predisposed hair follicles. It causes progressive miniaturization of hair follicles. Standard treatments include minoxidil, finasteride, and hair transplantation.",
    symptoms: ["Progressive thinning of scalp hair", "Receding hairline (men)", "Diffuse thinning at crown (women)", "Miniaturization of hair follicles"],
    conventionalTreatments: ["Minoxidil (topical or oral)", "Finasteride (5-alpha reductase inhibitor)", "Dutasteride (more potent 5-ARI)", "Platelet-rich plasma (PRP) injections", "Low-level laser therapy (LLLT)", "Hair transplantation"],
    howPeptidesHelp: "GHK-Cu has demonstrated hair follicle stimulation in preclinical studies, increasing follicle size and promoting hair growth. It is used topically at 1-5% concentration. TB-500 (Thymosin Beta-4) has shown hair follicle activation in animal studies. PTD-DBM (a Wnt pathway activator) has shown promising results in preclinical hair growth research.",
    topPeptides: [
    {
      peptideSlug: "ghk-cu",
      peptideName: "GHK-Cu",
      mechanism: "Stimulates hair follicle growth, increases follicle size, promotes angiogenesis around follicles",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "1-5% topical serum applied to scalp daily",
      rank: 1,
    },    {
      peptideSlug: "tb-500",
      peptideName: "TB-500",
      mechanism: "Activates hair follicle stem cells, promotes follicle cycling",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "1-2mg SubQ weekly, or topical application to scalp",
      rank: 2,
    }
    ],
    protocolSuggestion: "GHK-Cu 2% topical serum applied to scalp twice daily. Combine with minoxidil (complementary mechanisms). TB-500 1mg SubQ weekly as an adjunct. Assess results at 12 weeks — hair growth is slow and requires consistent long-term use.",
    importantCaveats: "Hair loss peptide research is primarily preclinical. GHK-Cu topical is the most evidence-backed option. Results require consistent long-term use (6-12+ months). Combine with proven treatments (minoxidil, finasteride) for best outcomes.",
    faqItems: [
    {
      q: "Does GHK-Cu regrow hair?",
      a: "Preclinical studies show GHK-Cu stimulates hair follicle growth and increases follicle size. Limited human data exists. It is used as an adjunct to proven treatments (minoxidil, finasteride), not as a standalone hair loss treatment.",
    },    {
      q: "How long does it take to see hair growth results from peptides?",
      a: "Hair growth is slow — most users assess results at 6-12 months. Consistent daily application is essential. Do not expect dramatic results in 4-8 weeks.",
    },    {
      q: "Can peptides be combined with minoxidil?",
      a: "Yes — GHK-Cu and minoxidil have complementary mechanisms. GHK-Cu stimulates follicle growth; minoxidil increases blood flow to follicles. They can be used together without known interactions.",
    }
    ],
    relatedConditions: ["hormonal-imbalance", "skin-aging", "recovery"],
  },
  {
    slug: "skin-aging",
    condition: "Skin Aging (Photoaging & Intrinsic Aging)",
    h1: "Best Peptides for Skin Aging: Evidence-Based Guide",
    metaDescription: "Guide to peptides for skin aging — GHK-Cu, epithalon, and GH secretagogues with evidence, dosing, and anti-aging skin protocols.",
    category: "Dermatology",
    icdCode: "L57.0",
    prevalence: "Universal — affects all adults; accelerated by UV exposure, smoking, and metabolic factors",
    conditionOverview: "Skin aging involves both intrinsic (chronological) and extrinsic (photoaging) processes. Key changes include collagen loss (1% per year after age 20), reduced elastin, decreased hyaluronic acid, thinning of the dermis, and impaired wound healing. These changes result in wrinkles, laxity, uneven pigmentation, and reduced skin barrier function.",
    symptoms: ["Fine lines and wrinkles", "Loss of skin firmness and elasticity", "Uneven skin tone and hyperpigmentation", "Thinning skin", "Reduced wound healing capacity", "Dryness and reduced barrier function"],
    conventionalTreatments: ["Retinoids (tretinoin)", "Vitamin C serums", "Hyaluronic acid", "Sunscreen (prevention)", "Chemical peels", "Laser resurfacing", "Botulinum toxin (wrinkles)", "Dermal fillers"],
    howPeptidesHelp: "GHK-Cu directly stimulates collagen synthesis, reduces MMP (matrix metalloproteinase) activity that degrades collagen, and promotes skin repair. Epithalon regulates telomerase and may slow cellular aging in skin fibroblasts. GH secretagogues increase GH/IGF-1, which supports skin thickness and collagen production.",
    topPeptides: [
    {
      peptideSlug: "ghk-cu",
      peptideName: "GHK-Cu",
      mechanism: "Stimulates collagen synthesis, reduces collagen degradation, promotes skin repair and angiogenesis",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "1-5% topical serum, morning and/or evening",
      rank: 1,
    },    {
      peptideSlug: "epithalon",
      peptideName: "Epithalon",
      mechanism: "Telomerase activation, cellular anti-aging, melatonin regulation",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "5-10mg/day SubQ for 10-20 day cycles, 1-2x/year",
      rank: 2,
    }
    ],
    protocolSuggestion: "GHK-Cu 2% topical serum daily (morning and/or evening). Epithalon 5mg/day SubQ for 10-20 days, twice yearly. Combine with sunscreen (essential), retinoids (evening), and vitamin C (morning) for comprehensive anti-aging protocol.",
    importantCaveats: "Skin aging peptides have varying levels of evidence. GHK-Cu has the strongest topical evidence. Sunscreen remains the most evidence-backed anti-aging intervention. Peptides are adjuncts to, not replacements for, proven skincare practices.",
    faqItems: [
    {
      q: "How does GHK-Cu compare to retinol for anti-aging?",
      a: "Retinol accelerates cell turnover and increases collagen production. GHK-Cu stimulates collagen synthesis and reduces collagen degradation. They have complementary mechanisms and can be used together (retinol at night, GHK-Cu in the morning).",
    },    {
      q: "Can peptides replace Botox for wrinkles?",
      a: "No — Botox relaxes muscles causing dynamic wrinkles. GHK-Cu and other peptides address collagen loss and skin quality. They target different aspects of aging and can be complementary.",
    },    {
      q: "How long before skin peptides show results?",
      a: "Collagen remodeling takes 8-12 weeks minimum. Most users see meaningful improvement in skin texture and firmness after 3-6 months of consistent use. Take monthly photos in consistent lighting to track progress.",
    }
    ],
    relatedConditions: ["hair-loss", "wound-healing", "hormonal-imbalance"],
  },
  {
    slug: "obesity",
    condition: "Obesity",
    h1: "Best Peptides for Obesity: Evidence-Based Guide",
    metaDescription: "Guide to peptides for obesity — semaglutide, tirzepatide, and GH secretagogues with evidence, dosing, and weight management protocols.",
    category: "Metabolic & Weight",
    icdCode: "E66.9",
    prevalence: "Affects 650 million adults worldwide; 42% of US adults",
    conditionOverview: "Obesity is a chronic metabolic disease characterized by excess adipose tissue accumulation that impairs health. It involves complex interactions between genetic predisposition, hormonal dysregulation (leptin resistance, insulin resistance), gut microbiome, and environmental factors. It significantly increases risk of type 2 diabetes, cardiovascular disease, and certain cancers.",
    symptoms: ["BMI ≥30 kg/m²", "Excess body fat, especially visceral fat", "Metabolic complications (insulin resistance, dyslipidemia)", "Physical limitations and joint pain", "Sleep apnea", "Reduced quality of life"],
    conventionalTreatments: ["Caloric restriction and dietary modification", "Physical activity", "GLP-1 receptor agonists (semaglutide, tirzepatide)", "Orlistat", "Bariatric surgery (severe obesity)", "Behavioral therapy"],
    howPeptidesHelp: "Semaglutide and tirzepatide are the most evidence-backed peptides for obesity, with clinical trials showing 15-22% body weight loss. They reduce appetite, slow gastric emptying, and improve metabolic parameters. GH secretagogues (ipamorelin, CJC-1295) support body recomposition through lipolysis and lean mass preservation.",
    topPeptides: [
    {
      peptideSlug: "tirzepatide",
      peptideName: "Tirzepatide",
      mechanism: "Dual GIP/GLP-1 receptor agonist; reduces appetite, slows gastric emptying, improves insulin sensitivity",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "2.5mg/week titrating to 5-15mg/week",
      rank: 1,
    },    {
      peptideSlug: "semaglutide",
      peptideName: "Semaglutide",
      mechanism: "GLP-1 receptor agonist; reduces appetite and food intake, improves metabolic parameters",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "0.25mg/week titrating to 1-2.4mg/week",
      rank: 2,
    },    {
      peptideSlug: "ipamorelin",
      peptideName: "Ipamorelin",
      mechanism: "GH secretagogue; promotes lipolysis and lean mass preservation",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "200-300mcg SubQ 2-3x daily",
      rank: 3,
    }
    ],
    protocolSuggestion: "For significant weight loss: semaglutide or tirzepatide (FDA-approved, strongest evidence). For body recomposition without GLP-1 agonists: ipamorelin + CJC-1295 stack with caloric deficit and resistance training. Combine any peptide protocol with dietary modification and physical activity.",
    importantCaveats: "Semaglutide and tirzepatide are FDA-approved for obesity and have the strongest evidence. Weight regain occurs after stopping GLP-1 agonists — they are chronic medications. GH secretagogues for obesity are experimental. Always combine with lifestyle modifications.",
    faqItems: [
    {
      q: "Is tirzepatide better than semaglutide for obesity?",
      a: "Head-to-head trials show tirzepatide produces greater weight loss (20-22% vs. 15-17% of body weight). Both are highly effective. Tirzepatide's dual GIP/GLP-1 mechanism appears to provide additive benefits.",
    },    {
      q: "Will I regain weight after stopping GLP-1 agonists?",
      a: "Yes — most patients regain significant weight after stopping semaglutide or tirzepatide. These are chronic medications for weight management, not short-term treatments.",
    },    {
      q: "Can GH secretagogues help with obesity?",
      a: "GH secretagogues (ipamorelin, CJC-1295) promote lipolysis and lean mass preservation, supporting body recomposition. However, they produce much less weight loss than GLP-1 agonists and are more appropriate for body recomposition than significant weight loss.",
    }
    ],
    relatedConditions: ["type-2-diabetes", "metabolic-syndrome", "sleep-apnea", "cardiovascular"],
  },
  {
    slug: "type-2-diabetes",
    condition: "Type 2 Diabetes",
    h1: "Best Peptides for Type 2 Diabetes: Evidence-Based Guide",
    metaDescription: "Guide to peptides for type 2 diabetes — semaglutide, tirzepatide, and NAD+ with evidence, dosing, and metabolic support protocols.",
    category: "Metabolic & Weight",
    icdCode: "E11.9",
    prevalence: "Affects 537 million adults worldwide; 11.3% of US adults",
    conditionOverview: "Type 2 diabetes is characterized by insulin resistance and progressive beta-cell dysfunction, resulting in chronic hyperglycemia. It is driven by obesity, physical inactivity, and genetic factors. Complications include cardiovascular disease, nephropathy, retinopathy, and neuropathy.",
    symptoms: ["Increased thirst and urination", "Fatigue", "Blurred vision", "Slow wound healing", "Frequent infections", "Often asymptomatic in early stages"],
    conventionalTreatments: ["Metformin (first-line)", "GLP-1 receptor agonists (semaglutide, tirzepatide)", "SGLT2 inhibitors", "DPP-4 inhibitors", "Insulin therapy", "Lifestyle modification (diet, exercise)"],
    howPeptidesHelp: "Semaglutide and tirzepatide are FDA-approved for type 2 diabetes and have demonstrated significant HbA1c reduction, weight loss, and cardiovascular risk reduction. NAD+ supports mitochondrial function and may improve insulin sensitivity. BPC-157 has shown pancreatic protection in animal models.",
    topPeptides: [
    {
      peptideSlug: "semaglutide",
      peptideName: "Semaglutide",
      mechanism: "GLP-1 agonist; increases insulin secretion, reduces glucagon, slows gastric emptying, promotes weight loss",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "0.25mg/week titrating to 0.5-2mg/week (Ozempic)",
      rank: 1,
    },    {
      peptideSlug: "tirzepatide",
      peptideName: "Tirzepatide",
      mechanism: "Dual GIP/GLP-1 agonist; superior HbA1c reduction and weight loss vs. semaglutide",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "2.5mg/week titrating to 5-15mg/week (Mounjaro)",
      rank: 2,
    },    {
      peptideSlug: "nad-plus",
      peptideName: "NAD+",
      mechanism: "Mitochondrial support, insulin sensitivity improvement, sirtuin activation",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "500-1000mg/day oral NMN/NR",
      rank: 3,
    }
    ],
    protocolSuggestion: "For T2D management: semaglutide or tirzepatide under physician supervision (FDA-approved, strongest evidence). NAD+ (NMN 500mg/day) as an adjunct for metabolic support. Always combine with dietary modification and physical activity.",
    importantCaveats: "Type 2 diabetes requires medical management. Semaglutide and tirzepatide are FDA-approved and should be prescribed by a physician. Never adjust diabetes medications without medical supervision — hypoglycemia risk.",
    faqItems: [
    {
      q: "Which GLP-1 agonist is best for type 2 diabetes?",
      a: "Tirzepatide (Mounjaro) produces greater HbA1c reduction and weight loss than semaglutide (Ozempic) in head-to-head trials. Both are highly effective. Choice depends on individual factors, insurance coverage, and physician preference.",
    },    {
      q: "Can NAD+ help with type 2 diabetes?",
      a: "Emerging research suggests NAD+ precursors (NMN, NR) may improve insulin sensitivity and mitochondrial function in T2D. However, evidence is preliminary — NAD+ is an adjunct to, not a replacement for, FDA-approved diabetes medications.",
    },    {
      q: "Do GLP-1 agonists protect the heart in T2D?",
      a: "Yes — semaglutide and tirzepatide have demonstrated significant cardiovascular risk reduction in clinical trials, including reduced risk of major adverse cardiovascular events (MACE). This is a major advantage over older diabetes medications.",
    }
    ],
    relatedConditions: ["obesity", "metabolic-syndrome", "cardiovascular", "kidney-disease"],
  },
  {
    slug: "cognitive-decline",
    condition: "Cognitive Decline and Mild Cognitive Impairment",
    h1: "Best Peptides for Cognitive Decline: Evidence-Based Guide",
    metaDescription: "Guide to peptides for cognitive decline — semax, NAD+, epithalon, and BPC-157 with evidence, dosing, and neuroprotective protocols.",
    category: "Neurological",
    icdCode: "G31.84",
    prevalence: "Mild cognitive impairment affects 15-20% of adults over 65; Alzheimer's affects 6.7 million Americans",
    conditionOverview: "Cognitive decline encompasses a spectrum from age-associated memory impairment to mild cognitive impairment (MCI) and Alzheimer's disease. Key mechanisms include neuroinflammation, mitochondrial dysfunction, reduced neuroplasticity (BDNF decline), amyloid accumulation, and tau pathology.",
    symptoms: ["Memory lapses (especially short-term)", "Difficulty with complex tasks", "Word-finding difficulties", "Reduced processing speed", "Impaired executive function", "Spatial disorientation"],
    conventionalTreatments: ["Cholinesterase inhibitors (donepezil, rivastigmine)", "NMDA antagonists (memantine)", "Anti-amyloid antibodies (lecanemab, donanemab — early AD)", "Lifestyle interventions (exercise, cognitive training, sleep)", "Cardiovascular risk factor management"],
    howPeptidesHelp: "Semax increases BDNF and promotes neuroplasticity — critical for cognitive function. NAD+ supports mitochondrial function in neurons and activates sirtuins involved in neuroprotection. Epithalon may slow cellular aging in neurons. BPC-157 supports the gut-brain axis, which is increasingly linked to cognitive function.",
    topPeptides: [
    {
      peptideSlug: "semax",
      peptideName: "Semax",
      mechanism: "Increases BDNF, promotes neuroplasticity, neuroprotective, improves memory and attention",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "200-600mcg intranasal daily",
      rank: 1,
    },    {
      peptideSlug: "nad-plus",
      peptideName: "NAD+",
      mechanism: "Mitochondrial support in neurons, sirtuin activation, DNA repair",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "500-1000mg/day oral NMN/NR",
      rank: 2,
    },    {
      peptideSlug: "epithalon",
      peptideName: "Epithalon",
      mechanism: "Telomerase activation, cellular anti-aging in neurons",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "5-10mg/day SubQ for 10-20 day cycles",
      rank: 3,
    }
    ],
    protocolSuggestion: "Semax 200-400mcg intranasal daily for 4-8 weeks. NAD+ (NMN 500-1000mg/day) continuously. Epithalon 5mg/day for 10-20 days, twice yearly. Combine with aerobic exercise (most evidence-backed intervention for cognitive health), sleep optimization, and cardiovascular risk factor management.",
    importantCaveats: "Cognitive decline and dementia require medical evaluation. Peptides are experimental adjuncts — no peptide has been proven to prevent or treat Alzheimer's disease in clinical trials. Lifestyle interventions (exercise, sleep, diet) have stronger evidence than any peptide for cognitive health.",
    faqItems: [
    {
      q: "Can semax prevent Alzheimer's disease?",
      a: "No clinical trial has demonstrated that semax prevents Alzheimer's disease. Semax supports neuroplasticity and cognitive function, but its effects on amyloid or tau pathology are not established.",
    },    {
      q: "What is the best peptide for brain fog?",
      a: "Semax (BDNF upregulation) and NAD+ (mitochondrial support) are the most commonly used peptides for cognitive symptoms including brain fog. Semax has more direct cognitive evidence from Russian clinical trials.",
    },    {
      q: "How does NAD+ help with cognitive decline?",
      a: "NAD+ supports mitochondrial function in neurons, activates sirtuins (SIRT1, SIRT3) involved in neuroprotection, and supports DNA repair. Age-related NAD+ decline is associated with cognitive decline, and supplementation may slow this process.",
    }
    ],
    relatedConditions: ["chronic-fatigue", "depression", "sleep-disorders", "anxiety"],
  },
  {
    slug: "wound-healing",
    condition: "Impaired Wound Healing",
    h1: "Best Peptides for Wound Healing: Evidence-Based Guide",
    metaDescription: "Guide to peptides for wound healing — BPC-157, GHK-Cu, and TB-500 with evidence, dosing, and wound care protocols.",
    category: "Tissue Repair",
    icdCode: "T14.90",
    prevalence: "Chronic wounds affect 6.5 million patients in the US annually; diabetic foot ulcers affect 15% of diabetics",
    conditionOverview: "Impaired wound healing occurs when the normal healing cascade (hemostasis, inflammation, proliferation, remodeling) is disrupted. Common causes include diabetes, peripheral vascular disease, immunosuppression, malnutrition, and advanced age. Chronic wounds (diabetic ulcers, venous leg ulcers, pressure injuries) represent a significant healthcare burden.",
    symptoms: ["Wounds that fail to heal within expected timeframes", "Wound edges that do not progress", "Chronic inflammation and exudate", "Wound bed with poor granulation tissue", "Recurrent wound breakdown"],
    conventionalTreatments: ["Wound debridement", "Moist wound dressings", "Negative pressure wound therapy (NPWT)", "Growth factor therapy (becaplermin/PDGF)", "Hyperbaric oxygen therapy", "Skin grafting"],
    howPeptidesHelp: "BPC-157 promotes angiogenesis, upregulates growth factor receptors, and accelerates wound closure in multiple animal models. GHK-Cu directly stimulates collagen synthesis and has demonstrated wound healing effects in human clinical studies. TB-500 promotes cell migration and tissue repair.",
    topPeptides: [
    {
      peptideSlug: "ghk-cu",
      peptideName: "GHK-Cu",
      mechanism: "Stimulates collagen synthesis, promotes angiogenesis, reduces inflammation, accelerates wound closure",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "Topical 1-5% applied to wound area; injectable 1-2mg SubQ near wound",
      rank: 1,
    },    {
      peptideSlug: "bpc-157",
      peptideName: "BPC-157",
      mechanism: "Promotes angiogenesis, upregulates growth factor receptors, accelerates wound closure",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "250-500mcg SubQ near wound, twice daily",
      rank: 2,
    },    {
      peptideSlug: "tb-500",
      peptideName: "TB-500",
      mechanism: "Promotes cell migration and actin polymerization; systemic tissue repair",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "5-10mg/week SubQ loading phase",
      rank: 3,
    }
    ],
    protocolSuggestion: "GHK-Cu topical 2% applied to wound area twice daily. BPC-157 250-500mcg SubQ near wound, twice daily. TB-500 5mg twice weekly for 4 weeks loading. Combine with standard wound care (debridement, appropriate dressings, infection management).",
    importantCaveats: "Chronic wounds require medical management. Infection control and appropriate wound care are foundational. Peptides are experimental adjuncts — GHK-Cu has the most human evidence for wound healing. Diabetic wounds require blood glucose optimization as a priority.",
    faqItems: [
    {
      q: "Can BPC-157 heal diabetic wounds?",
      a: "BPC-157 has shown wound healing effects in diabetic animal models. Human clinical data is limited. Blood glucose control remains the most important intervention for diabetic wound healing.",
    },    {
      q: "How is GHK-Cu applied to wounds?",
      a: "GHK-Cu can be applied topically as a 1-5% solution or cream directly to the wound bed. It can also be injected subcutaneously near (not into) the wound for combined local and systemic effects.",
    },    {
      q: "How long does peptide-assisted wound healing take?",
      a: "Timeline depends on wound type and severity. Acute wounds may show accelerated healing within 1-2 weeks. Chronic wounds may require 4-12 weeks of consistent treatment.",
    }
    ],
    relatedConditions: ["tendinopathy", "sports-injury", "skin-aging", "type-2-diabetes"],
  },
  {
    slug: "low-testosterone",
    condition: "Low Testosterone (Male Hypogonadism)",
    h1: "Best Peptides for Low Testosterone: Evidence-Based Guide",
    metaDescription: "Guide to peptides for low testosterone — sermorelin, ipamorelin, and kisspeptin with evidence, dosing, and testosterone support protocols.",
    category: "Hormonal Health",
    icdCode: "E29.1",
    prevalence: "Affects approximately 40% of men over 45; 4-5 million men in the US have hypogonadism",
    conditionOverview: "Male hypogonadism involves insufficient testosterone production due to testicular failure (primary) or hypothalamic-pituitary dysfunction (secondary). Symptoms include reduced libido, erectile dysfunction, fatigue, muscle loss, fat gain, mood changes, and reduced bone density.",
    symptoms: ["Reduced libido and sexual function", "Fatigue and low energy", "Loss of muscle mass and strength", "Increased body fat (especially visceral)", "Mood changes, depression, irritability", "Reduced bone density"],
    conventionalTreatments: ["Testosterone replacement therapy (TRT) — injections, gels, patches", "Clomiphene citrate (for secondary hypogonadism)", "HCG (to preserve testicular function)", "Lifestyle modification (exercise, sleep, weight loss)"],
    howPeptidesHelp: "GH secretagogues (sermorelin, ipamorelin) support the GH/IGF-1 axis, which interacts with testosterone production. Kisspeptin stimulates GnRH release, which drives LH/FSH and testosterone production — a more physiological approach than TRT. BPC-157 may support testicular vascular health.",
    topPeptides: [
    {
      peptideSlug: "sermorelin",
      peptideName: "Sermorelin",
      mechanism: "GH secretagogue; increases GH/IGF-1 which supports testosterone production and body composition",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "200-300mcg SubQ at bedtime",
      rank: 1,
    },    {
      peptideSlug: "ipamorelin",
      peptideName: "Ipamorelin",
      mechanism: "GH secretagogue; supports body composition and energy — complements testosterone optimization",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "200-300mcg SubQ 2-3x daily",
      rank: 2,
    }
    ],
    protocolSuggestion: "For secondary hypogonadism: sermorelin 200mcg at bedtime + ipamorelin 200mcg morning and pre-sleep. These support the GH axis and body composition. For primary hypogonadism (testicular failure), TRT is the appropriate treatment — peptides are adjuncts.",
    importantCaveats: "Low testosterone requires medical evaluation to determine cause (primary vs. secondary). TRT is the most evidence-backed treatment for symptomatic hypogonadism. Peptides are adjuncts. Never self-diagnose or self-treat hypogonadism — get bloodwork (total T, free T, LH, FSH) first.",
    faqItems: [
    {
      q: "Can peptides replace testosterone replacement therapy?",
      a: "No. TRT is the standard of care for symptomatic hypogonadism. Peptides like sermorelin support the GH axis and body composition but do not directly replace testosterone. For secondary hypogonadism, kisspeptin analogues are being investigated as a more physiological approach.",
    },    {
      q: "Do GH secretagogues increase testosterone?",
      a: "GH secretagogues primarily increase GH/IGF-1, not testosterone directly. However, optimizing the GH axis supports overall anabolic hormone balance and body composition, which may indirectly support testosterone levels.",
    },    {
      q: "What is the best lifestyle intervention for low testosterone?",
      a: "Resistance training, weight loss (especially visceral fat reduction), sleep optimization (7-9 hours), and stress management have the strongest evidence for naturally supporting testosterone levels.",
    }
    ],
    relatedConditions: ["erectile-dysfunction", "muscle-loss", "depression", "obesity"],
  },
  {
    slug: "autoimmune-disease",
    condition: "Autoimmune Diseases",
    h1: "Best Peptides for Autoimmune Disease: Evidence-Based Guide",
    metaDescription: "Guide to peptides for autoimmune disease — thymosin alpha-1, BPC-157, and low-dose naltrexone with evidence, dosing, and immune modulation protocols.",
    category: "Immune Health",
    icdCode: "M35.9",
    prevalence: "Autoimmune diseases collectively affect 5-8% of the population; over 80 distinct conditions",
    conditionOverview: "Autoimmune diseases occur when the immune system attacks the body's own tissues. Common conditions include rheumatoid arthritis, lupus, multiple sclerosis, Hashimoto's thyroiditis, and inflammatory bowel disease. They involve dysregulated T-cell and B-cell activity, inflammatory cytokine overproduction, and loss of immune tolerance.",
    symptoms: ["Varies by condition", "Chronic inflammation and pain", "Fatigue", "Organ-specific dysfunction", "Flares and remissions", "Systemic symptoms (fever, weight loss)"],
    conventionalTreatments: ["Corticosteroids (acute flares)", "DMARDs (methotrexate, hydroxychloroquine)", "Biologics (TNF inhibitors, IL-6 inhibitors)", "JAK inhibitors", "Immunosuppressants (azathioprine, mycophenolate)", "Disease-specific treatments"],
    howPeptidesHelp: "Thymosin Alpha-1 modulates immune function by enhancing regulatory T-cell activity and reducing inflammatory cytokine production — potentially restoring immune tolerance. BPC-157 has anti-inflammatory effects and supports gut barrier integrity, which is increasingly linked to autoimmune disease pathogenesis.",
    topPeptides: [
    {
      peptideSlug: "thymosin-alpha-1",
      peptideName: "Thymosin Alpha-1",
      mechanism: "Immune modulation, regulatory T-cell enhancement, reduction of inflammatory cytokines",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "1.6mg SubQ twice weekly for 6-12 weeks",
      rank: 1,
    },    {
      peptideSlug: "bpc-157",
      peptideName: "BPC-157",
      mechanism: "Anti-inflammatory, gut barrier support, autonomic nervous system modulation",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "250-500mcg oral or SubQ daily",
      rank: 2,
    }
    ],
    protocolSuggestion: "Thymosin Alpha-1 1.6mg SubQ twice weekly for 12 weeks. BPC-157 250mcg oral daily for gut barrier support. These are experimental adjuncts — never discontinue prescribed immunosuppressants or biologics without physician guidance.",
    importantCaveats: "Autoimmune diseases require specialist management (rheumatologist, immunologist). Peptides are experimental adjuncts with limited clinical data for most autoimmune conditions. Immune modulation in autoimmune disease is complex — interventions that boost immunity may worsen some conditions. Always work with a specialist.",
    faqItems: [
    {
      q: "Is Thymosin Alpha-1 safe for autoimmune disease?",
      a: "Thymosin Alpha-1 is an immune modulator, not an immune stimulator. It enhances regulatory T-cell activity, which may help restore immune tolerance. However, its effects in specific autoimmune conditions are not well-studied — use under specialist supervision.",
    },    {
      q: "Can BPC-157 help with inflammatory bowel disease?",
      a: "BPC-157 has shown anti-inflammatory effects in animal models of IBD. It is one of the more promising peptides for gut-related autoimmune conditions. Human clinical data is limited.",
    },    {
      q: "Should I stop my biologics to try peptides?",
      a: "Absolutely not. Never discontinue prescribed immunosuppressants or biologics without physician guidance. Autoimmune disease flares can be severe. Peptides are experimental adjuncts to be added under medical supervision, not replacements for proven treatments.",
    }
    ],
    relatedConditions: ["leaky-gut", "chronic-fatigue", "depression", "hormonal-imbalance"],
  },
  {
    slug: "insomnia",
    condition: "Insomnia",
    h1: "Best Peptides for Insomnia: Evidence-Based Guide",
    metaDescription: "Guide to peptides for insomnia — epithalon, ipamorelin, and DSIP with evidence, dosing, and sleep improvement protocols.",
    category: "Sleep Health",
    icdCode: "G47.00",
    prevalence: "Affects 10-30% of adults chronically; up to 50% experience occasional insomnia",
    conditionOverview: "Insomnia is characterized by difficulty initiating or maintaining sleep, or non-restorative sleep, causing daytime impairment. It involves dysregulation of the sleep-wake cycle, HPA axis hyperactivation, and disrupted circadian rhythms. Chronic insomnia is associated with cardiovascular disease, metabolic disorders, and mental health conditions.",
    symptoms: ["Difficulty falling asleep", "Frequent nighttime awakenings", "Early morning awakening", "Non-restorative sleep", "Daytime fatigue and impaired function", "Mood disturbances"],
    conventionalTreatments: ["Cognitive behavioral therapy for insomnia (CBT-I) — first-line", "Sleep hygiene optimization", "Melatonin", "Benzodiazepines (short-term)", "Non-benzodiazepine hypnotics (zolpidem, eszopiclone)", "Orexin receptor antagonists (suvorexant, lemborexant)"],
    howPeptidesHelp: "Epithalon regulates melatonin production and circadian rhythm, addressing a root cause of age-related insomnia. Ipamorelin amplifies the nocturnal GH pulse during slow-wave sleep, improving sleep architecture. DSIP (Delta Sleep-Inducing Peptide) directly promotes slow-wave sleep.",
    topPeptides: [
    {
      peptideSlug: "epithalon",
      peptideName: "Epithalon",
      mechanism: "Regulates melatonin production, restores circadian rhythm, promotes sleep quality",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "5-10mg/day SubQ for 10-20 day cycles",
      rank: 1,
    },    {
      peptideSlug: "ipamorelin",
      peptideName: "Ipamorelin",
      mechanism: "Amplifies nocturnal GH pulse, improves slow-wave sleep architecture",
        evidenceLevel: "Moderate Preclinical / Emerging Human",
          typicalDose: "100-200mcg SubQ 30-60 min before sleep",
      rank: 2,
    }
    ],
    protocolSuggestion: "Start with sleep hygiene optimization (CBT-I principles). Add ipamorelin 100-200mcg SubQ 30-60 minutes before sleep. For circadian rhythm issues or age-related insomnia: epithalon 5mg/day for 10-20 days. Peptides are adjuncts to CBT-I, which has the strongest evidence for insomnia.",
    importantCaveats: "CBT-I (cognitive behavioral therapy for insomnia) is the first-line treatment for chronic insomnia with stronger evidence than any medication or peptide. Peptides are adjuncts. Address sleep hygiene, sleep schedule, and psychological factors first.",
    faqItems: [
    {
      q: "Is epithalon better than melatonin for sleep?",
      a: "Epithalon regulates the body's own melatonin production through the pineal gland, rather than providing exogenous melatonin. For age-related insomnia with declining pineal function, epithalon may be more effective than melatonin supplementation.",
    },    {
      q: "Will ipamorelin make me sleep better?",
      a: "Many users report improved sleep quality, deeper sleep, and more vivid dreams with pre-sleep ipamorelin. It amplifies the natural GH pulse during slow-wave sleep, improving sleep architecture rather than inducing sedation.",
    },    {
      q: "Can I take sleep peptides with sleep medications?",
      a: "Potential interactions between peptides and sleep medications are not well studied. Consult a physician before combining peptides with prescription sleep medications.",
    }
    ],
    relatedConditions: ["anxiety", "depression", "chronic-fatigue", "cognitive-decline"],
  }
];

// ─── REVIEW PAGES ─────────────────────────────────────────────────────────────
// Template: /reviews/[slug]
// Schema: Review — pros/cons layout, verdict section, distinct from profile pages

export interface ReviewPageData {
  slug: string;
  peptideName: string;
  peptideSlug: string;
  h1: string;
  metaDescription: string;
  category: string;
  overallRating: number;
  // Old format fields
  ratingBreakdown?: {
    evidenceQuality: number;
    sideEffectProfile: number;
    valueForMoney: number;
    easeOfUse: number;
    userSatisfaction: number;
  };
  reviewSummary?: string;
  pros?: string[];
  cons?: string[];
  whoShouldConsider?: string;
  verdictParagraph?: string;
  alternativesToConsider?: string[];
  // New format fields
  evidenceRating?: number;
  safetyRating?: number;
  valueRating?: number;
  verdict?: string;
  whoShouldUse?: string[];
  whoShouldAvoid?: string | string[];
  keyBenefits?: string[];
  keyDrawbacks?: string[];
  sideEffects?: string[];
  dosing?: string;
  cycleLength?: string;
  stacksWith?: string[];
  faqItems?: Array<{ q: string; a: string }>;
}
export const reviewPages: ReviewPageData[] = [
  {
    slug: "bpc-157-review",
    peptideName: "BPC-157",
    peptideSlug: "bpc-157",
    h1: "BPC-157 Review: Is It Worth It? An Independent Assessment",
    metaDescription: "Independent BPC-157 review. Pros, cons, evidence quality, side effects, and verdict. Is BPC-157 worth trying? Vendor-neutral, science-backed assessment.",
    category: "Recovery",
    overallRating: 8,
    ratingBreakdown: {
      evidenceQuality: 7,
      sideEffectProfile: 9,
      valueForMoney: 8,
      easeOfUse: 7,
      userSatisfaction: 9
    },
    reviewSummary: "BPC-157 is the most researched healing peptide available, with an impressive preclinical evidence base across multiple organ systems. Its safety profile is excellent and user satisfaction is high. The primary limitation is the lack of large-scale human clinical trials.",
    pros: [
      "Extensive preclinical evidence base (hundreds of animal studies)",
      "Excellent safety profile — no serious adverse effects reported in studies",
      "Versatile: effective for gut, joints, tendons, and systemic inflammation",
      "Available as oral or injectable (oral preferred for gut conditions)",
      "Relatively affordable compared to other peptides",
      "High user satisfaction in anecdotal reports"
    ],
    cons: [
      "No large-scale human clinical trials completed",
      "Mechanism of action not fully elucidated",
      "Requires injection for systemic effects (oral has limited systemic bioavailability)",
      "Quality varies significantly between vendors",
      "Not FDA approved — regulatory status is a gray area",
      "Anecdotal reports of mild nausea at higher doses"
    ],
    whoShouldConsider: "Athletes and active individuals with joint, tendon, or muscle injuries; people with gut conditions (IBD, leaky gut, gastric ulcers); anyone seeking a well-researched healing peptide with an excellent safety profile.",
    whoShouldAvoid: "People with active cancer (growth factor upregulation is a theoretical concern); pregnant or breastfeeding women; anyone seeking FDA-approved treatments only.",
    verdictParagraph: "BPC-157 earns its reputation as the most popular healing peptide. Its preclinical evidence base is genuinely impressive, and its safety profile is excellent. The absence of large-scale human trials is a legitimate limitation, but the depth of preclinical evidence and the consistency of anecdotal reports make it one of the most compelling research peptides available. For athletes, biohackers, and individuals with gut or joint conditions, BPC-157 is a reasonable consideration — with the caveat that it should be sourced from a reputable vendor and used with appropriate medical oversight.",
    alternativesToConsider: ["tb-500", "ghk-cu", "ipamorelin"],
    faqItems: [
      { q: "Is BPC-157 safe?", a: "Preclinical studies show an excellent safety profile with no serious adverse effects. However, large-scale human safety data is limited. The most commonly reported side effect is mild nausea at higher doses." },
      { q: "Does BPC-157 actually work?", a: "Preclinical evidence is strong across multiple organ systems. Human clinical evidence is limited but anecdotal reports are consistently positive. The mechanism is plausible and well-studied in animals." },
      { q: "How long does it take for BPC-157 to work?", a: "Most users report noticeable improvement within 2-4 weeks. Full benefits typically emerge at 4-8 weeks depending on the condition being addressed." }
    ]
  },

  {
    slug: "ipamorelin-cjc-1295-review",
    peptideName: "Ipamorelin / CJC-1295",
    peptideSlug: "ipamorelin",
    h1: "Ipamorelin / CJC-1295 Review: The Most Popular GH Stack Assessed",
    metaDescription: "Independent ipamorelin / CJC-1295 review. Pros, cons, evidence, side effects, and verdict. Is this GH peptide stack worth it? Vendor-neutral assessment.",
    category: "Growth Hormone",
    overallRating: 8,
    ratingBreakdown: {
      evidenceQuality: 7,
      sideEffectProfile: 8,
      valueForMoney: 8,
      easeOfUse: 6,
      userSatisfaction: 9
    },
    reviewSummary: "The ipamorelin / CJC-1295 combination is the most popular GH optimization stack for good reason. It produces synergistic pulsatile GH release with an excellent safety profile. The primary limitations are the requirement for daily injection and the lack of large-scale human trials.",
    pros: [
      "Synergistic GH release — combination significantly outperforms either peptide alone",
      "Excellent safety profile — minimal cortisol or prolactin elevation",
      "Pulsatile GH release preserves natural feedback mechanisms",
      "Noticeable improvements in sleep quality, body composition, and recovery",
      "Well-characterized mechanism of action",
      "High user satisfaction across multiple goals"
    ],
    cons: [
      "Requires daily injection (before bed)",
      "No large-scale human clinical trials",
      "Effects are subtle compared to synthetic HGH",
      "Quality varies between vendors",
      "Not FDA approved",
      "Requires consistent use for 3-6 months for full body composition effects"
    ],
    whoShouldConsider: "Adults over 30 experiencing age-related GH decline; athletes seeking improved recovery and body composition; individuals with poor sleep quality; biohackers interested in GH optimization without synthetic HGH.",
    whoShouldAvoid: "People with active cancer; those with pituitary disorders; pregnant or breastfeeding women; anyone seeking FDA-approved treatments only.",
    verdictParagraph: "Ipamorelin / CJC-1295 is the gold standard GH peptide stack for good reason. The combination produces synergistic pulsatile GH release that closely mimics natural GH secretion, with an excellent safety profile and high user satisfaction. While large-scale human trials are lacking, the mechanism is well-understood and the preclinical evidence is solid. For adults seeking GH optimization without the cost and risks of synthetic HGH, this combination is the most compelling option available.",
    alternativesToConsider: ["sermorelin", "mk-677", "tesamorelin"],
    faqItems: [
      { q: "How long does it take to see results from ipamorelin / CJC-1295?", a: "Sleep quality improvements are often noticed within 1-2 weeks. Body composition changes typically emerge at 3-6 months of consistent use." },
      { q: "Do I need to cycle ipamorelin / CJC-1295?", a: "Many protocols run 3-6 month cycles with 1-2 month breaks. Continuous use for over 6 months without a break may reduce pituitary sensitivity." },
      { q: "What time should I inject ipamorelin / CJC-1295?", a: "Before bed, on an empty stomach (no food for 2 hours). This aligns with the natural GH pulse that occurs during early deep sleep." }
    ]
  },

  {
    slug: "semaglutide-review",
    peptideName: "Semaglutide (Ozempic / Wegovy)",
    peptideSlug: "semaglutide",
    h1: "Semaglutide Review: Ozempic and Wegovy Assessed Independently",
    metaDescription: "Independent semaglutide review (Ozempic / Wegovy). Pros, cons, weight loss evidence, side effects, and verdict. Is semaglutide right for you? Vendor-neutral.",
    category: "GLP-1 / Weight Loss",
    overallRating: 9,
    ratingBreakdown: {
      evidenceQuality: 10,
      sideEffectProfile: 7,
      valueForMoney: 6,
      easeOfUse: 8,
      userSatisfaction: 9
    },
    reviewSummary: "Semaglutide is the most evidence-backed weight loss medication in history, with ~15% average weight loss and significant cardiovascular benefits demonstrated in large-scale trials. The primary limitations are cost, GI side effects during titration, and the requirement for ongoing use to maintain results.",
    pros: [
      "Most extensively studied weight loss medication ever — STEP and SELECT trials",
      "~15% average weight loss (Wegovy dose) — unprecedented for a medication",
      "20% cardiovascular risk reduction in non-diabetic obese patients (SELECT trial)",
      "Once-weekly injection — highly convenient",
      "FDA approved for both diabetes (Ozempic) and obesity (Wegovy)",
      "Durable weight loss with continued use"
    ],
    cons: [
      "Nausea, vomiting, and GI side effects during titration (affects ~40% of users)",
      "High cost — ~$900-$1,000/month without insurance",
      "Weight regain after discontinuation (most users regain weight)",
      "Requires ongoing use to maintain results",
      "Rare but serious: pancreatitis, thyroid C-cell tumors (animal data)",
      "Muscle loss with rapid weight reduction (mitigated by protein intake and resistance training)"
    ],
    whoShouldConsider: "Adults with BMI ≥30 (or ≥27 with weight-related comorbidities); people with type 2 diabetes seeking both glycemic control and weight loss; those with cardiovascular disease risk who would benefit from the SELECT trial's demonstrated CV risk reduction.",
    whoShouldAvoid: "Personal or family history of medullary thyroid carcinoma or MEN2; history of pancreatitis; pregnancy; those who cannot afford ongoing treatment without insurance coverage.",
    verdictParagraph: "Semaglutide represents a genuine paradigm shift in obesity treatment. The clinical evidence is extraordinary — ~15% average weight loss and 20% cardiovascular risk reduction are outcomes that no previous obesity medication has achieved. The limitations are real: GI side effects during titration, high cost, and the need for ongoing use. But for appropriate candidates, semaglutide is the most evidence-backed tool available for significant, sustained weight loss.",
    alternativesToConsider: ["tirzepatide", "liraglutide", "bupropion-naltrexone"],
    faqItems: [
      { q: "How much weight can I lose on semaglutide?", a: "Clinical trials show ~15% average body weight loss at the Wegovy dose (2.4mg weekly). Individual results vary — some lose more, some less. Maximum weight loss typically occurs at 60-68 weeks." },
      { q: "What happens when you stop taking semaglutide?", a: "Most people regain the majority of lost weight within 1-2 years of stopping. Semaglutide treats obesity as a chronic condition requiring ongoing treatment, similar to blood pressure medication." },
      { q: "Is Ozempic the same as Wegovy?", a: "Both contain semaglutide, but at different doses. Ozempic is approved for type 2 diabetes (up to 1mg weekly); Wegovy is approved for obesity (up to 2.4mg weekly). The higher Wegovy dose produces greater weight loss." }
    ]
  },

  {
    slug: "tb-500-review",
    peptideName: "TB-500 (Thymosin Beta-4)",
    peptideSlug: "tb-500",
    h1: "TB-500 Review: Is Thymosin Beta-4 Worth It? Independent Assessment",
    metaDescription: "Independent TB-500 review. Pros, cons, evidence quality, side effects, and verdict. Is TB-500 worth trying for recovery and healing? Vendor-neutral.",
    category: "Recovery",
    overallRating: 7,
    ratingBreakdown: {
      evidenceQuality: 6,
      sideEffectProfile: 9,
      valueForMoney: 7,
      easeOfUse: 7,
      userSatisfaction: 8
    },
    reviewSummary: "TB-500 is a well-tolerated healing peptide with a plausible mechanism (actin regulation, angiogenesis) and good anecdotal support. Its evidence base is less extensive than BPC-157, and it is most commonly used in combination with BPC-157 as the Recovery Stack.",
    pros: [
      "Excellent safety profile — well-tolerated in studies",
      "Unique mechanism (actin regulation) complementary to BPC-157",
      "Particularly effective for improving flexibility and range of motion",
      "Systemic effects — works throughout the body, not just locally",
      "High user satisfaction for injury recovery",
      "Commonly available and reasonably priced"
    ],
    cons: [
      "Evidence base less extensive than BPC-157",
      "Requires injection — no effective oral form",
      "Effects may be more subtle than BPC-157 when used alone",
      "Quality varies between vendors",
      "Not FDA approved",
      "Less well-characterized than BPC-157 in terms of mechanism"
    ],
    whoShouldConsider: "Athletes with muscle, tendon, or ligament injuries; people seeking improved flexibility and range of motion; those already using BPC-157 who want to add a complementary healing peptide.",
    whoShouldAvoid: "People with active cancer (growth factor effects); pregnant or breastfeeding women; those seeking FDA-approved treatments only.",
    verdictParagraph: "TB-500 is a solid healing peptide that earns its place in the Recovery Stack alongside BPC-157. Its unique mechanism (actin regulation) and systemic effects complement BPC-157's growth factor approach. While its evidence base is less extensive, the safety profile is excellent and user satisfaction is high. TB-500 is most compelling as part of the BPC-157 + TB-500 combination rather than as a standalone protocol.",
    alternativesToConsider: ["bpc-157", "ghk-cu", "ipamorelin"],
    faqItems: [
      { q: "Is TB-500 better than BPC-157?", a: "They work through different mechanisms and are best used together. BPC-157 has a more extensive evidence base; TB-500 adds unique actin-regulating and flexibility-improving effects. The combination is more effective than either alone." },
      { q: "How long does TB-500 take to work?", a: "Most users report improvement within 2-4 weeks. Full benefits typically emerge at 6-8 weeks." },
      { q: "What is the typical TB-500 protocol?", a: "2.5-5mg 2x per week for 4-6 weeks (loading phase), then 2.5mg once per week for maintenance. Often combined with BPC-157 500mcg/day." }
    ]
  },

  {
    slug: "ghk-cu-review",
    peptideName: "GHK-Cu (Copper Peptide)",
    peptideSlug: "ghk-cu",
    h1: "GHK-Cu Review: Is the Copper Peptide Worth It? Independent Assessment",
    metaDescription: "Independent GHK-Cu review. Pros, cons, evidence for skin and anti-aging, side effects, and verdict. Is GHK-Cu worth trying? Vendor-neutral assessment.",
    category: "Skin Health",
    overallRating: 8,
    ratingBreakdown: {
      evidenceQuality: 8,
      sideEffectProfile: 10,
      valueForMoney: 8,
      easeOfUse: 9,
      userSatisfaction: 8
    },
    reviewSummary: "GHK-Cu has the best evidence-to-safety ratio of any anti-aging peptide. Its skin evidence is strong, it is exceptionally well-tolerated, and it is available in both topical and injectable forms. The primary limitation is that most evidence is for skin applications rather than systemic anti-aging.",
    pros: [
      "Strong evidence for skin anti-aging, collagen synthesis, and wound healing",
      "Exceptional safety profile — one of the safest peptides available",
      "Available topically (no injection required for skin benefits)",
      "Anti-inflammatory and antioxidant properties",
      "Modulates over 4,000 genes in ways associated with anti-aging",
      "Affordable in topical form"
    ],
    cons: [
      "Most evidence is for skin applications; systemic anti-aging evidence is more limited",
      "Injectable form required for systemic effects",
      "Topical absorption varies significantly by formulation",
      "Quality of topical products varies widely",
      "Not FDA approved for anti-aging indications"
    ],
    whoShouldConsider: "Anyone interested in skin anti-aging, collagen support, or wound healing; people seeking a topical anti-aging peptide with strong evidence; those who want a well-tolerated alternative or complement to retinol.",
    whoShouldAvoid: "Those with copper sensitivity (rare); anyone expecting systemic anti-aging effects from topical application alone.",
    verdictParagraph: "GHK-Cu is one of the most compelling anti-aging peptides available, particularly for skin applications. Its evidence base for skin anti-aging is genuinely strong, its safety profile is exceptional, and it is available in convenient topical form. The gene expression data — modulating over 4,000 genes in anti-aging directions — is intriguing, though the clinical significance of systemic GHK-Cu effects requires more human research. For skin anti-aging, GHK-Cu is a top-tier recommendation.",
    alternativesToConsider: ["bpc-157", "epithalon", "tb-500"],
    faqItems: [
      { q: "Is GHK-Cu effective for skin anti-aging?", a: "Yes. GHK-Cu has strong evidence for collagen synthesis, wound healing, and skin anti-aging. It is one of the best-evidenced topical anti-aging peptides available." },
      { q: "How do I use GHK-Cu topically?", a: "Apply GHK-Cu serum to clean skin, morning and/or evening. It can be combined with retinol (GHK-Cu in the morning, retinol at night) or used alone." },
      { q: "Is injectable GHK-Cu better than topical?", a: "Injectable GHK-Cu provides systemic effects and may be more potent for anti-aging. Topical GHK-Cu is effective for skin specifically and is more convenient and accessible." }
    ]
  },
  {
    slug: "bpc-157-review",
    peptideName: "BPC-157",
    peptideSlug: "bpc-157",
    h1: "BPC-157 Review: Does It Actually Work? Evidence, Results & Side Effects",
    metaDescription: "Comprehensive BPC-157 review — what the research says, real-world results, side effects, dosing, and who should (and should not) use it.",
    category: "Recovery",
    overallRating: 4.4,
    evidenceRating: 3.8,
    safetyRating: 4.7,
    valueRating: 4.5,
    verdict: "BPC-157 is one of the most compelling research peptides available, with a strong preclinical evidence base for tendon/ligament healing, gut repair, and anti-inflammatory effects. The main limitation is the absence of human clinical trials — all evidence is from animal studies. For injury recovery and gut healing, it has become a staple in the biohacking community with a strong anecdotal track record.",
    whoShouldUse: ["Athletes with tendon or ligament injuries", "People with gut issues (leaky gut, IBD, NSAID damage)", "Those recovering from surgery", "Biohackers interested in tissue repair"],
    whoShouldAvoid: ["Pregnant or breastfeeding women", "People with active cancer (growth factor stimulation)", "Those seeking FDA-approved treatments with clinical trial data"],
    keyBenefits: ["Accelerated tendon and ligament healing", "Gut mucosal repair and anti-inflammatory effects", "Systemic anti-inflammatory properties", "Well-tolerated with minimal side effects", "Flexible administration (oral or injectable)"],
    keyDrawbacks: ["No human clinical trials", "Unregulated market — quality varies significantly", "Requires injection for systemic effects", "Limited long-term safety data"],
    sideEffects: ["Generally well-tolerated", "Mild nausea (rare)", "Injection site reactions (minor)", "No significant adverse effects in animal studies"],
    dosing: "250-500mcg SubQ or oral, 1-2x daily. For gut healing: oral on empty stomach. For systemic/injury: SubQ near injury site.",
    cycleLength: "4-12 weeks for acute conditions; can be extended for chronic conditions",
    stacksWith: ["TB-500 (injury recovery)", "Thymosin Alpha-1 (immune support)", "GHK-Cu (tissue repair)"],
    faqItems: [
    {
      q: "Is BPC-157 legal?",
      a: "BPC-157 is legal to purchase as a research chemical in most countries. It is not FDA-approved for human use. Regulations vary by country — always verify local laws.",
    },    {
      q: "How long does BPC-157 take to work?",
      a: "Most users report noticeable improvement in injury symptoms within 2-4 weeks. Gut healing effects may be noticed within 1-2 weeks. Full benefits typically emerge at 6-8 weeks.",
    },    {
      q: "Is BPC-157 safe long-term?",
      a: "Long-term human safety data does not exist. Animal studies show an excellent safety profile. Most protocols run 4-12 weeks with breaks. Use with caution if you have a history of cancer.",
    }
    ],
  },
  {
    slug: "tb-500-review",
    peptideName: "TB-500",
    peptideSlug: "tb-500",
    h1: "TB-500 Review: Injury Recovery Results, Side Effects & Dosing",
    metaDescription: "Comprehensive TB-500 review — evidence for injury recovery, real-world results, side effects, loading protocol, and comparison with BPC-157.",
    category: "Recovery",
    overallRating: 4.2,
    evidenceRating: 3.6,
    safetyRating: 4.5,
    valueRating: 4.0,
    verdict: "TB-500 (Thymosin Beta-4) is a well-regarded injury recovery peptide with solid preclinical evidence for tissue repair, anti-inflammatory effects, and cell migration promotion. Like BPC-157, it lacks human clinical trials but has a strong anecdotal track record in the athletic community. The loading/maintenance protocol is more complex than BPC-157, and the weekly doses are higher (and more expensive).",
    whoShouldUse: ["Athletes with muscle, tendon, or ligament injuries", "People with chronic injuries that have not responded to conventional treatment", "Those stacking with BPC-157 for comprehensive injury recovery"],
    whoShouldAvoid: ["Pregnant or breastfeeding women", "People with active cancer", "Those on a tight budget (TB-500 is more expensive than BPC-157)"],
    keyBenefits: ["Systemic tissue repair (works throughout the body)", "Anti-inflammatory effects", "Promotes cell migration and actin polymerization", "Effective for both acute and chronic injuries", "Synergistic with BPC-157"],
    keyDrawbacks: ["No human clinical trials", "Higher weekly doses (more expensive)", "More complex loading/maintenance protocol", "Unregulated market"],
    sideEffects: ["Generally well-tolerated", "Mild fatigue (some users)", "Injection site reactions (minor)", "No significant adverse effects in animal studies"],
    dosing: "Loading: 5-10mg/week (2 injections). Maintenance: 2.5-5mg/week. Often stacked with BPC-157.",
    cycleLength: "Loading phase 4 weeks, maintenance 4-8 weeks",
    stacksWith: ["BPC-157 (injury recovery — most popular stack)", "Ipamorelin (recovery + body composition)"],
    faqItems: [
    {
      q: "Is TB-500 the same as BPC-157?",
      a: "No — they are different peptides with complementary mechanisms. TB-500 promotes cell migration and actin polymerization; BPC-157 promotes angiogenesis and growth factor upregulation. They are often stacked together.",
    },    {
      q: "How long does TB-500 take to work?",
      a: "Most users report noticeable improvement in pain and function within 2-4 weeks of the loading phase. Full recovery timelines depend on injury severity.",
    },    {
      q: "Can TB-500 be used for old injuries?",
      a: "Yes — TB-500 is effective for both acute and chronic injuries. Chronic conditions may require longer protocols and higher loading doses.",
    }
    ],
  },
  {
    slug: "ipamorelin-review",
    peptideName: "Ipamorelin",
    peptideSlug: "ipamorelin",
    h1: "Ipamorelin Review: GH Release, Body Composition & Side Effects",
    metaDescription: "Comprehensive ipamorelin review — evidence for GH release, body composition results, side effects, dosing, and comparison with sermorelin and CJC-1295.",
    category: "Growth Hormone",
    overallRating: 4.3,
    evidenceRating: 3.9,
    safetyRating: 4.6,
    valueRating: 4.2,
    verdict: "Ipamorelin is one of the most popular GH secretagogues for good reason — it selectively stimulates GH release without significantly raising cortisol or prolactin, making it cleaner than older GHRPs. The ipamorelin + CJC-1295 stack is the gold standard combination for body composition and recovery. Results are real but modest compared to exogenous HGH — expect gradual improvements over 8-12 weeks.",
    whoShouldUse: ["Adults seeking improved body composition (fat loss + lean mass)", "People with sleep quality issues", "Athletes focused on recovery", "Adults over 40 with declining GH levels"],
    whoShouldAvoid: ["People with active cancer", "Pregnant or breastfeeding women", "Those expecting HGH-equivalent results"],
    keyBenefits: ["Selective GH stimulation without cortisol/prolactin elevation", "Improved sleep quality and recovery", "Gradual body composition improvement", "Well-tolerated safety profile", "Can be mixed with CJC-1295 in same syringe"],
    keyDrawbacks: ["Requires multiple daily injections for optimal results", "Results are gradual (8-12 weeks)", "Must be injected in fasted state for maximum effect", "Requires cycling to prevent desensitization"],
    sideEffects: ["Water retention (higher doses)", "Mild tingling in hands/feet (higher doses)", "Transient headache (uncommon)", "Vivid dreams (common — generally positive)"],
    dosing: "100-300mcg SubQ, 2-3x daily (morning fasted, post-workout, pre-sleep). Start at 100mcg.",
    cycleLength: "8-12 weeks on, 4 weeks off",
    stacksWith: ["CJC-1295 no DAC (most popular stack)", "Sermorelin (GHRH + GHRP synergy)", "BPC-157 (recovery)"],
    faqItems: [
    {
      q: "Is ipamorelin better than sermorelin?",
      a: "Ipamorelin is a GHRP (stimulates GH release directly); sermorelin is a GHRH analogue (stimulates GH release via GHRH pathway). They work through different mechanisms and are often stacked together. Ipamorelin is more selective and has fewer side effects than older GHRPs.",
    },    {
      q: "How much does ipamorelin cost?",
      a: "Research-grade ipamorelin typically costs $30-60 per 5mg vial from reputable vendors. A typical cycle (8-12 weeks at 200mcg 2x daily) requires 3-5 vials.",
    },    {
      q: "Can women use ipamorelin?",
      a: "Yes — ipamorelin is used by both men and women. Women may be more sensitive to GH secretagogues and often achieve good results at lower doses (100mcg vs. 200mcg).",
    }
    ],
  },
  {
    slug: "semaglutide-review",
    peptideName: "Semaglutide",
    peptideSlug: "semaglutide",
    h1: "Semaglutide Review: Weight Loss Results, Side Effects & Cost",
    metaDescription: "Comprehensive semaglutide review — clinical trial results, real-world weight loss, side effects, cost, and comparison with tirzepatide.",
    category: "Weight Management",
    overallRating: 4.7,
    evidenceRating: 5.0,
    safetyRating: 4.2,
    valueRating: 3.8,
    verdict: "Semaglutide (Ozempic/Wegovy) is the most evidence-backed weight loss peptide available, with multiple Phase 3 clinical trials demonstrating 15-17% body weight loss. It is FDA-approved, widely available, and has a well-characterized safety profile. The main limitations are cost (especially without insurance), GI side effects during titration, and weight regain after stopping.",
    whoShouldUse: ["Adults with BMI ≥30 (obesity) or ≥27 with weight-related conditions", "Type 2 diabetes patients needing glucose control and weight loss", "Those who have failed lifestyle interventions alone"],
    whoShouldAvoid: ["Personal or family history of medullary thyroid carcinoma or MEN2", "History of pancreatitis", "Pregnancy", "Severe GI motility disorders"],
    keyBenefits: ["FDA-approved with extensive clinical trial data", "15-17% average body weight loss", "Cardiovascular risk reduction (SUSTAIN-6 trial)", "Once-weekly injection (convenient)", "Significant HbA1c reduction in T2D"],
    keyDrawbacks: ["High cost ($800-1300/month without insurance)", "GI side effects (nausea, vomiting) during titration", "Weight regain after stopping", "Requires slow titration (16-20 weeks)", "Injection required (no oral form approved for weight loss)"],
    sideEffects: ["Nausea (most common — 44% of users)", "Vomiting", "Diarrhea or constipation", "Injection site reactions", "Rare: pancreatitis, gallbladder disease"],
    dosing: "0.25mg/week → 0.5mg → 1mg → 1.7mg → 2.4mg (Wegovy), each for 4 weeks",
    cycleLength: "Chronic medication — intended for long-term use",
    stacksWith: ["Resistance training (preserve lean mass)", "High-protein diet (1.2-1.6g/kg/day)"],
    faqItems: [
    {
      q: "How much weight will I lose on semaglutide?",
      a: "Clinical trials show average weight loss of 15-17% of body weight over 68 weeks at 2.4mg/week (Wegovy). Individual results vary — some lose more, some less. Diet and exercise adherence significantly affect outcomes.",
    },    {
      q: "Is compounded semaglutide safe?",
      a: "Compounded semaglutide is significantly cheaper than brand-name Wegovy/Ozempic but is not FDA-approved. Quality varies by compounding pharmacy. The FDA has issued warnings about some compounded semaglutide products. Use only from accredited compounding pharmacies with independent COAs.",
    },    {
      q: "What happens when I stop semaglutide?",
      a: "Most patients regain a significant portion of lost weight (often 2/3 of the weight lost) within 1-2 years of stopping. Semaglutide is a chronic medication for weight management, not a short-term treatment.",
    }
    ],
  },
  {
    slug: "tirzepatide-review",
    peptideName: "Tirzepatide",
    peptideSlug: "tirzepatide",
    h1: "Tirzepatide Review: Weight Loss Results, Side Effects & Comparison with Semaglutide",
    metaDescription: "Comprehensive tirzepatide review — SURMOUNT trial results, real-world weight loss, side effects, cost, and head-to-head comparison with semaglutide.",
    category: "Weight Management",
    overallRating: 4.8,
    evidenceRating: 5.0,
    safetyRating: 4.1,
    valueRating: 3.7,
    verdict: "Tirzepatide (Mounjaro/Zepbound) is the most effective FDA-approved weight loss medication available, with clinical trials showing 20-22% body weight loss — surpassing semaglutide in head-to-head comparison. Its dual GIP/GLP-1 mechanism provides additive benefits for weight loss and metabolic health. The main limitations are cost, GI side effects, and weight regain after stopping.",
    whoShouldUse: ["Adults with obesity (BMI ≥30) or overweight with weight-related conditions", "Type 2 diabetes patients needing superior glucose control and weight loss", "Those who have tried semaglutide with insufficient results"],
    whoShouldAvoid: ["Personal or family history of medullary thyroid carcinoma or MEN2", "History of pancreatitis", "Pregnancy", "Severe GI motility disorders"],
    keyBenefits: ["FDA-approved with Phase 3 clinical trial data (SURMOUNT series)", "20-22% average body weight loss — best in class", "Superior to semaglutide in head-to-head trial (SURMOUNT-5)", "Significant HbA1c reduction", "Cardiovascular risk reduction (SURPASS-CVOT)"],
    keyDrawbacks: ["High cost ($1000-1400/month without insurance)", "GI side effects during titration", "Weight regain after stopping", "Longer titration schedule than semaglutide", "Diarrhea more common than with semaglutide"],
    sideEffects: ["Nausea (most common)", "Diarrhea (more common than semaglutide)", "Vomiting", "Constipation", "Injection site reactions"],
    dosing: "2.5mg/week → 5mg → 7.5mg → 10mg → 12.5mg → 15mg, each for 4 weeks",
    cycleLength: "Chronic medication — intended for long-term use",
    stacksWith: ["Resistance training (preserve lean mass)", "High-protein diet"],
    faqItems: [
    {
      q: "Is tirzepatide better than semaglutide?",
      a: "In the SURMOUNT-5 head-to-head trial, tirzepatide produced 20% weight loss vs. 14% for semaglutide over 72 weeks. Tirzepatide is more effective for weight loss. However, semaglutide has more long-term cardiovascular outcome data.",
    },    {
      q: "What is the difference between Mounjaro and Zepbound?",
      a: "Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. The drug is identical; the indication differs.",
    },    {
      q: "How does tirzepatide's dual mechanism work?",
      a: "Tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GLP-1 reduces appetite and slows gastric emptying. GIP enhances insulin secretion and may reduce GLP-1 side effects. The combination produces greater weight loss than GLP-1 agonism alone.",
    }
    ],
  },
  {
    slug: "sermorelin-review",
    peptideName: "Sermorelin",
    peptideSlug: "sermorelin",
    h1: "Sermorelin Review: Anti-Aging Results, Side Effects & Comparison with HGH",
    metaDescription: "Comprehensive sermorelin review — clinical evidence, anti-aging results, side effects, cost, and comparison with HGH therapy and ipamorelin.",
    category: "Growth Hormone",
    overallRating: 4.1,
    evidenceRating: 4.0,
    safetyRating: 4.8,
    valueRating: 4.3,
    verdict: "Sermorelin is the most clinically studied GH secretagogue, with a track record in both pediatric and adult GH deficiency. It produces more physiological GH release than exogenous HGH, with a better safety profile and lower cost. Results are gradual and modest compared to HGH — expect improvements in sleep, body composition, and energy over 3-6 months rather than dramatic changes.",
    whoShouldUse: ["Adults over 40 with declining GH levels", "Those seeking a safer, more physiological alternative to HGH", "People with sleep quality issues", "Those interested in anti-aging protocols"],
    whoShouldAvoid: ["People with active cancer", "Pregnant or breastfeeding women", "Those expecting HGH-equivalent results"],
    keyBenefits: ["Most clinically studied GH secretagogue", "Physiological GH release (pulsatile, not continuous)", "Better safety profile than exogenous HGH", "Improves sleep quality significantly", "Lower cost than HGH therapy"],
    keyDrawbacks: ["Results are gradual (3-6 months)", "Requires daily injections", "Must be injected at bedtime for best results", "Cannot match HGH for peak GH levels"],
    sideEffects: ["Water retention (dose-dependent)", "Mild headache (uncommon)", "Injection site reactions (minor)", "Vivid dreams (common)"],
    dosing: "200-300mcg SubQ at bedtime. Some protocols use 5 days on / 2 days off.",
    cycleLength: "3-6 months; can be used continuously under medical supervision",
    stacksWith: ["Ipamorelin (GHRH + GHRP synergy)", "CJC-1295 no DAC (alternative GHRH analogue)"],
    faqItems: [
    {
      q: "Is sermorelin better than HGH?",
      a: "Sermorelin produces more physiological GH release and has a better safety profile than exogenous HGH. However, it cannot match HGH for peak GH levels or speed of results. Sermorelin is preferred for anti-aging and wellness; HGH is used for more aggressive body composition goals.",
    },    {
      q: "How long does sermorelin take to work?",
      a: "Most users notice improved sleep quality within 2-4 weeks. Body composition changes (fat loss, lean mass) typically become noticeable after 3-4 months of consistent use.",
    },    {
      q: "Is sermorelin FDA-approved?",
      a: "Sermorelin acetate was previously FDA-approved for pediatric GH deficiency (Geref). The brand was discontinued but compounded sermorelin remains widely prescribed by anti-aging physicians.",
    }
    ],
  },
  {
    slug: "ghk-cu-review",
    peptideName: "GHK-Cu",
    peptideSlug: "ghk-cu",
    h1: "GHK-Cu Review: Skin Results, Hair Growth & Anti-Aging Evidence",
    metaDescription: "Comprehensive GHK-Cu review — evidence for skin rejuvenation, hair growth, wound healing, side effects, and topical vs. injectable protocols.",
    category: "Anti-Aging",
    overallRating: 4.2,
    evidenceRating: 3.7,
    safetyRating: 4.9,
    valueRating: 4.4,
    verdict: "GHK-Cu is one of the most evidence-backed topical peptides for skin rejuvenation and wound healing. It has human clinical data for wound healing and strong preclinical data for collagen stimulation, hair growth, and anti-inflammatory effects. It is well-tolerated, relatively affordable, and versatile (topical and injectable). The main limitation is that dramatic results require consistent long-term use (3-6 months).",
    whoShouldUse: ["Anyone seeking skin rejuvenation and anti-aging", "People with hair loss (androgenetic alopecia)", "Those with wounds or skin damage", "Biohackers building a longevity stack"],
    whoShouldAvoid: ["Those with copper sensitivity (rare)", "People combining with high-dose vitamin C (can oxidize copper)"],
    keyBenefits: ["Strong evidence for collagen stimulation", "Human clinical data for wound healing", "Hair follicle stimulation", "Excellent safety profile", "Versatile (topical and injectable)", "Anti-inflammatory effects"],
    keyDrawbacks: ["Results require consistent long-term use (3-6 months)", "Topical bioavailability is limited", "High-dose vitamin C incompatibility", "Injectable form requires reconstitution"],
    sideEffects: ["Extremely well-tolerated", "Rare skin irritation at high concentrations (>5%)", "No significant systemic side effects"],
    dosing: "Topical: 1-5% serum, morning and/or evening. Injectable: 1-2mg SubQ 2-3x weekly.",
    cycleLength: "Continuous use recommended for skin; injectable cycles 8-12 weeks",
    stacksWith: ["Epithalon (longevity stack)", "BPC-157 (tissue repair)", "Retinol (complementary skin mechanisms)"],
    faqItems: [
    {
      q: "What concentration of GHK-Cu is most effective?",
      a: "Most clinical and preclinical studies use 1-5% concentration. Higher concentrations do not appear to produce proportionally better results and may cause irritation. 1-2% is a good starting point for daily use.",
    },    {
      q: "Can GHK-Cu be used around the eyes?",
      a: "Yes — GHK-Cu is gentle enough for the periorbital area. It may help with fine lines and skin thinning around the eyes. Avoid direct contact with eyes.",
    },    {
      q: "How does GHK-Cu compare to retinol?",
      a: "Retinol accelerates cell turnover and is more potent for wrinkle reduction. GHK-Cu stimulates collagen synthesis and is better tolerated. They have complementary mechanisms and work well together.",
    }
    ],
  },
  {
    slug: "nad-plus-review",
    peptideName: "NAD+",
    peptideSlug: "nad-plus",
    h1: "NAD+ Review: Anti-Aging Evidence, Energy Results & Best Forms",
    metaDescription: "Comprehensive NAD+ review — evidence for longevity, energy, and cognition, comparison of NMN vs. NR vs. injectable NAD+, side effects, and cost.",
    category: "Longevity",
    overallRating: 4.3,
    evidenceRating: 4.1,
    safetyRating: 4.6,
    valueRating: 3.9,
    verdict: "NAD+ is one of the most evidence-backed longevity interventions, with strong mechanistic rationale and growing clinical data. Multiple forms are available (NMN, NR, injectable NAD+) with different bioavailability profiles. Most users notice improved energy and mental clarity within 2-4 weeks. The main limitations are cost (especially IV NAD+) and the fact that most human longevity data is still emerging.",
    whoShouldUse: ["Adults over 40 seeking longevity support", "People with fatigue or low energy", "Those with cognitive decline or brain fog", "Anyone building a comprehensive anti-aging protocol"],
    whoShouldAvoid: ["Those with active cancer (NAD+ supports cellular proliferation)", "People sensitive to stimulating supplements (take in morning)"],
    keyBenefits: ["Strong mechanistic evidence for longevity (sirtuins, PARP, mitochondria)", "Improved energy and mental clarity", "Multiple administration routes", "Growing human clinical data", "Synergistic with resveratrol and pterostilbene"],
    keyDrawbacks: ["Most human longevity data is still emerging", "IV NAD+ is expensive ($200-500/session)", "Oral NMN/NR has variable bioavailability", "Stimulating — can disrupt sleep if taken late"],
    sideEffects: ["Flushing (especially IV at high doses)", "Nausea (IV — dose-dependent)", "Chest pressure sensation (IV — transient)", "Insomnia if taken in evening"],
    dosing: "Oral NMN/NR: 500-1000mg/day. SubQ NAD+: 25-100mg/day. IV NAD+: 250-1000mg per session.",
    cycleLength: "Continuous daily use for oral forms; IV as periodic 'reset' (monthly/quarterly)",
    stacksWith: ["Epithalon (longevity stack)", "Resveratrol/pterostilbene (sirtuin activation)", "GHK-Cu (comprehensive anti-aging)"],
    faqItems: [
    {
      q: "Is NMN or NR better?",
      a: "Both NMN and NR are NAD+ precursors that effectively raise NAD+ levels. NMN has a slightly different metabolic pathway and may have advantages in some tissues. The practical difference for most users is minimal — choose based on cost and availability.",
    },    {
      q: "Is IV NAD+ worth the cost?",
      a: "IV NAD+ produces higher peak plasma levels and more immediate effects than oral forms. Many users report a noticeable energy boost after IV sessions. Whether this justifies the cost ($200-500/session) depends on individual response and budget.",
    },    {
      q: "How long before NAD+ shows results?",
      a: "Most users notice improved energy and mental clarity within 1-2 weeks of oral NMN/NR. IV NAD+ often produces noticeable effects within hours. Longevity effects (cellular aging, telomere support) accumulate over months to years.",
    }
    ],
  },
  {
    slug: "epithalon-review",
    peptideName: "Epithalon",
    peptideSlug: "epithalon",
    h1: "Epithalon Review: Telomere Lengthening Evidence, Results & Protocol",
    metaDescription: "Comprehensive epithalon review — evidence for telomere lengthening, anti-aging results, side effects, cycle protocol, and comparison with other longevity peptides.",
    category: "Longevity",
    overallRating: 4.0,
    evidenceRating: 3.8,
    safetyRating: 4.8,
    valueRating: 4.1,
    verdict: "Epithalon is the most studied telomere-targeting peptide, with multiple Russian clinical trials demonstrating telomerase activation and telomere lengthening. It is well-tolerated and relatively affordable. The main limitations are that most evidence is from Russian studies (not replicated in large Western RCTs), effects are cumulative over multiple cycles, and subjective results are subtle compared to more immediately noticeable peptides.",
    whoShouldUse: ["Adults over 40 focused on longevity", "Those building a comprehensive anti-aging protocol", "People with sleep quality issues (circadian regulation)", "Biohackers interested in telomere biology"],
    whoShouldAvoid: ["People with active cancer (telomerase activation is a concern)", "Those expecting rapid, dramatic results"],
    keyBenefits: ["Most studied telomere-targeting peptide", "Regulates melatonin and circadian rhythm", "Improves sleep quality", "Excellent safety profile", "Relatively affordable for a longevity peptide"],
    keyDrawbacks: ["Most evidence from Russian studies — not widely replicated in West", "Effects are cumulative and subtle", "Short intensive cycles (not continuous use)", "Telomere length changes are not easily measurable"],
    sideEffects: ["Extremely well-tolerated", "No significant adverse effects in clinical studies", "Vivid dreams (some users)"],
    dosing: "5-10mg/day SubQ for 10-20 consecutive days. 1-2 cycles per year.",
    cycleLength: "10-20 days per cycle, 1-2 cycles per year",
    stacksWith: ["NAD+ (longevity stack)", "GHK-Cu (comprehensive anti-aging)", "Thymosin Alpha-1 (immune support)"],
    faqItems: [
    {
      q: "Does epithalon actually lengthen telomeres?",
      a: "Multiple Russian studies have demonstrated telomere lengthening and telomerase activation with epithalon. The research is promising but not yet replicated in large Western RCTs. It remains one of the most credible telomere-targeting interventions available.",
    },    {
      q: "How do I know if epithalon is working?",
      a: "Subjective markers: improved sleep quality, energy, and skin. Objective: telomere length testing (available commercially) before and after multiple cycles. Effects are cumulative and subtle — do not expect dramatic changes after one cycle.",
    },    {
      q: "Is epithalon safe long-term?",
      a: "Epithalon has an excellent safety profile in clinical studies. The main theoretical concern is telomerase activation in cancer cells — avoid if you have active cancer. The short, cyclic protocol (not continuous use) is considered safer than continuous administration.",
    }
    ],
  },
  {
    slug: "pt-141-review",
    peptideName: "PT-141",
    peptideSlug: "pt-141",
    h1: "PT-141 Review: Sexual Health Results, Side Effects & Dosing",
    metaDescription: "Comprehensive PT-141 review — FDA approval status, sexual health results, side effects (nausea, blood pressure), dosing, and comparison with Viagra.",
    category: "Sexual Health",
    overallRating: 4.2,
    evidenceRating: 4.4,
    safetyRating: 3.9,
    valueRating: 4.0,
    verdict: "PT-141 (bremelanotide/Vyleesi) is the only FDA-approved peptide for sexual dysfunction, specifically hypoactive sexual desire disorder (HSDD) in premenopausal women. It works centrally (in the brain) rather than peripherally, making it effective for desire/arousal issues that PDE5 inhibitors do not address. The main limitations are nausea (manageable with dose titration), transient blood pressure elevation, and the need for planning (1-4 hour onset).",
    whoShouldUse: ["Women with hypoactive sexual desire disorder (HSDD)", "Men with desire/arousal issues not addressed by PDE5 inhibitors", "Those seeking a central (brain-based) approach to sexual dysfunction"],
    whoShouldAvoid: ["People with uncontrolled hypertension or cardiovascular disease", "Those who cannot tolerate nausea", "Pregnant women", "Those needing immediate-onset effects"],
    keyBenefits: ["FDA-approved for HSDD in women", "Works centrally — addresses desire, not just physical response", "Effective for both men and women", "Complementary to PDE5 inhibitors (different mechanism)", "No dependence or tolerance"],
    keyDrawbacks: ["Nausea (most common side effect — manageable)", "Transient blood pressure elevation", "Slow onset (45-90 minutes)", "Not suitable for spontaneous sexual activity", "Blood pressure contraindication"],
    sideEffects: ["Nausea (44% of users)", "Flushing and facial redness", "Transient blood pressure elevation", "Headache (uncommon)", "Spontaneous erections (men — dose-dependent)"],
    dosing: "0.5-2mg SubQ, 1-4 hours before sexual activity. Start at 0.5mg.",
    cycleLength: "As needed — not intended for daily use. Limit to 1x per 24 hours.",
    stacksWith: ["PDE5 inhibitors (complementary mechanisms)", "Testosterone optimization (for hormonal desire issues)"],
    faqItems: [
    {
      q: "How effective is PT-141 for women?",
      a: "In the clinical trials leading to FDA approval, PT-141 significantly increased satisfying sexual events and sexual desire compared to placebo in women with HSDD. It is one of the few FDA-approved treatments for female sexual dysfunction.",
    },    {
      q: "Can PT-141 cause permanent blood pressure changes?",
      a: "No — PT-141 causes a transient (1-12 hour) blood pressure elevation. It does not cause permanent hypertension. However, it is contraindicated in people with uncontrolled hypertension or cardiovascular disease due to this transient effect.",
    },    {
      q: "How do I reduce PT-141 nausea?",
      a: "Start at 0.5mg (not 2mg), inject at night to sleep through nausea, take with food, and consider ondansetron (Zofran) 30 minutes before injection. Most users find nausea is manageable at 0.5-1mg.",
    }
    ],
  },
  {
    slug: "cjc-1295-review",
    peptideName: "CJC-1295",
    peptideSlug: "cjc-1295",
    h1: "CJC-1295 Review: Body Composition Results, DAC vs No-DAC & Side Effects",
    metaDescription: "Comprehensive CJC-1295 review — DAC vs. no-DAC comparison, body composition results, side effects, dosing, and stacking with ipamorelin.",
    category: "Growth Hormone",
    overallRating: 4.2,
    evidenceRating: 3.8,
    safetyRating: 4.4,
    valueRating: 4.1,
    verdict: "CJC-1295 is a potent GHRH analogue that, when stacked with ipamorelin, forms the most popular GH secretagogue combination. The DAC vs. no-DAC decision significantly affects dosing frequency and GH release pattern. No-DAC (Mod GRF 1-29) is preferred for physiological pulsatile GH release; DAC is preferred for convenience. Results are real but gradual — expect meaningful body composition changes after 8-12 weeks.",
    whoShouldUse: ["Adults seeking body composition improvement", "Athletes focused on recovery and lean mass", "Those stacking with ipamorelin for synergistic GH release"],
    whoShouldAvoid: ["People with active cancer", "Pregnant or breastfeeding women", "Those with uncontrolled diabetes (GH can worsen insulin resistance)"],
    keyBenefits: ["Potent GHRH analogue with longer half-life than sermorelin", "Synergistic with ipamorelin (most popular stack)", "Can be mixed with ipamorelin in same syringe", "DAC form requires only 1-2 injections per week"],
    keyDrawbacks: ["DAC form produces 'GH bleed' (sustained elevation) which may not be optimal", "Requires cycling to prevent desensitization", "Results are gradual", "Must inject in fasted state for maximum effect"],
    sideEffects: ["Water retention", "Mild tingling (higher doses)", "Transient headache", "Carpal tunnel symptoms (excessive GH — reduce dose)"],
    dosing: "No-DAC: 100-200mcg SubQ 2-3x daily. DAC: 1000-2000mcg SubQ 1-2x weekly.",
    cycleLength: "8-12 weeks on, 4 weeks off",
    stacksWith: ["Ipamorelin (gold standard combination)", "Sermorelin (alternative GHRH + GHRP stack)"],
    faqItems: [
    {
      q: "CJC-1295 with DAC or without DAC — which is better?",
      a: "No-DAC (Mod GRF 1-29) produces pulsatile GH release mimicking natural patterns — preferred for body composition. DAC produces sustained GH elevation ('GH bleed') — preferred for convenience (1-2 injections/week). Most experts prefer no-DAC for physiological GH patterns.",
    },    {
      q: "Can I mix CJC-1295 and ipamorelin in the same syringe?",
      a: "Yes — this is standard practice. Draw both peptides into the same insulin syringe for a single injection. They are chemically compatible.",
    },    {
      q: "How does CJC-1295 compare to sermorelin?",
      a: "Both are GHRH analogues. CJC-1295 (no-DAC) has a longer half-life (~30 min vs. ~10 min for sermorelin) and is considered more potent. CJC-1295 with DAC has a much longer half-life (6-8 days). Sermorelin has more clinical history.",
    }
    ],
  },
  {
    slug: "thymosin-alpha-1-review",
    peptideName: "Thymosin Alpha-1",
    peptideSlug: "thymosin-alpha-1",
    h1: "Thymosin Alpha-1 Review: Immune Support Evidence, Results & Side Effects",
    metaDescription: "Comprehensive thymosin alpha-1 review — FDA approval status, immune support evidence, results for long COVID and chronic illness, side effects, and dosing.",
    category: "Immune Support",
    overallRating: 4.1,
    evidenceRating: 4.2,
    safetyRating: 4.9,
    valueRating: 3.8,
    verdict: "Thymosin Alpha-1 (Zadaxin) is one of the most clinically validated immune-modulating peptides, with FDA approval in 35+ countries for hepatitis B, hepatitis C, and cancer immunotherapy. It has a strong safety profile and growing interest for long COVID, chronic infections, and immune senescence. The main limitation is cost and the need for twice-weekly injections.",
    whoShouldUse: ["People with chronic infections or immune dysfunction", "Those recovering from long COVID or post-viral syndromes", "Cancer patients undergoing immunotherapy (under physician supervision)", "Adults over 50 seeking immune support"],
    whoShouldAvoid: ["People with autoimmune diseases (immune stimulation may worsen some conditions)", "Pregnant or breastfeeding women"],
    keyBenefits: ["FDA-approved in 35+ countries (Zadaxin)", "Strong clinical evidence for immune modulation", "Excellent safety profile", "Effective for chronic infections and immune dysfunction", "Growing evidence for long COVID"],
    keyDrawbacks: ["Expensive ($200-400/month for Zadaxin)", "Requires twice-weekly injections", "Limited Western clinical data for most off-label uses", "Effects take 4-8 weeks to manifest"],
    sideEffects: ["Extremely well-tolerated", "Rare injection site reactions", "No significant adverse effects in clinical studies"],
    dosing: "1.6mg SubQ twice weekly (Monday/Thursday). Standard cycle: 6-12 weeks.",
    cycleLength: "6-12 weeks; can be extended for chronic conditions under medical supervision",
    stacksWith: ["BPC-157 (gut-immune axis)", "Epithalon (longevity + immune)", "NAD+ (comprehensive longevity)"],
    faqItems: [
    {
      q: "Is Thymosin Alpha-1 the same as Zadaxin?",
      a: "Yes — Zadaxin is the brand name for thymosin alpha-1 (thymalfasin). It is FDA-approved in 35+ countries for hepatitis B, hepatitis C, and as a vaccine adjuvant.",
    },    {
      q: "Can Thymosin Alpha-1 help with long COVID?",
      a: "Several small studies and case reports suggest Tα1 may help with long COVID immune dysregulation. Formal clinical trials are ongoing. It is one of the most promising immune-modulating peptides for post-viral syndromes.",
    },    {
      q: "How does Thymosin Alpha-1 differ from Thymosin Beta-4 (TB-500)?",
      a: "Thymosin Alpha-1 is primarily immune-modulating (T-cell activation, immune regulation). TB-500 (Thymosin Beta-4) is primarily tissue repair and anti-inflammatory. They are different peptides with different mechanisms and applications.",
    }
    ],
  },
  {
    slug: "melanotan-2-review",
    peptideName: "Melanotan 2",
    peptideSlug: "melanotan-2",
    h1: "Melanotan 2 Review: Tanning Results, Side Effects & Safety Concerns",
    metaDescription: "Comprehensive Melanotan 2 review — tanning results, side effects (nausea, mole changes), safety concerns, dosing protocol, and who should avoid it.",
    category: "Appearance",
    overallRating: 3.6,
    evidenceRating: 3.2,
    safetyRating: 3.0,
    valueRating: 4.0,
    verdict: "Melanotan 2 produces real tanning results — most users achieve a noticeable tan within 2-4 weeks of the loading protocol. However, it carries significant safety concerns: mole darkening (melanoma risk), spontaneous erections, nausea, and an unregulated market with quality control issues. It is not FDA-approved and should be approached with caution. Those with a personal or family history of melanoma should not use it.",
    whoShouldUse: ["Adults seeking a tan with minimal UV exposure", "Those who tan poorly despite sun exposure", "People who understand and accept the risks"],
    whoShouldAvoid: ["Anyone with personal or family history of melanoma", "People with many moles or atypical moles", "Pregnant or breastfeeding women", "Those with cardiovascular conditions (blood pressure effects)", "Anyone not willing to monitor moles regularly"],
    keyBenefits: ["Effective tanning with less UV exposure", "Long-lasting tan with maintenance dosing", "Libido-enhancing effects (melanocortin activation)", "Appetite suppression (some users)"],
    keyDrawbacks: ["Mole darkening — melanoma risk concern", "Nausea (especially at higher doses)", "Spontaneous erections (men)", "Not FDA-approved", "Unregulated market with quality concerns", "Requires UV exposure for best results"],
    sideEffects: ["Nausea (most common — dose-dependent)", "Facial flushing", "Spontaneous erections (men)", "Mole darkening (monitor carefully)", "Fatigue (some users)"],
    dosing: "Start at 0.25mg SubQ at night. Increase to 0.5-1mg/day during loading. Maintenance: 0.5-1mg 2x weekly.",
    cycleLength: "Loading 2-4 weeks, maintenance ongoing with UV exposure",
    stacksWith: ["UV exposure (essential for melanin activation)"],
    faqItems: [
    {
      q: "Is Melanotan 2 safe?",
      a: "MT-2 carries real safety concerns, particularly mole darkening and potential melanoma risk. It is not FDA-approved. The long-term safety profile is unknown. Do not use if you have a personal or family history of melanoma.",
    },    {
      q: "Does Melanotan 2 cause cancer?",
      a: "MT-2 stimulates melanocytes broadly, which could theoretically activate dormant melanoma cells. No direct evidence of cancer causation exists, but the risk cannot be excluded. Regular dermatological monitoring is essential during use.",
    },    {
      q: "How does Melanotan 2 compare to self-tanning products?",
      a: "MT-2 produces a real tan (melanin production) that looks natural and lasts weeks. Self-tanning products (DHA) produce a surface color change that fades in days. MT-2 results are more natural-looking but carry health risks that self-tanners do not.",
    }
    ],
  },
  {
    slug: "selank-review",
    peptideName: "Selank",
    peptideSlug: "selank",
    h1: "Selank Review: Anxiety Relief Results, Side Effects & Evidence",
    metaDescription: "Comprehensive selank review — Russian clinical trial evidence, anxiety and cognitive results, side effects, dosing, and comparison with benzodiazepines.",
    category: "Cognitive & Mental",
    overallRating: 4.0,
    evidenceRating: 3.6,
    safetyRating: 4.8,
    valueRating: 4.3,
    verdict: "Selank is a promising anxiolytic peptide with Russian clinical trial data showing anxiety reduction without sedation, dependence, or withdrawal — key advantages over benzodiazepines. Most users report a calming effect within 30-60 minutes of intranasal administration. The main limitations are limited Western clinical data and the need for intranasal or injectable administration.",
    whoShouldUse: ["People with anxiety or stress who want a non-sedating option", "Those seeking an alternative to benzodiazepines", "People with cognitive symptoms alongside anxiety (selank has nootropic properties)", "Biohackers interested in anxiolytic peptides"],
    whoShouldAvoid: ["Those expecting benzodiazepine-level sedation", "Pregnant or breastfeeding women"],
    keyBenefits: ["Anxiolytic without sedation", "No dependence or withdrawal", "Cognitive-enhancing properties (nootropic)", "Russian clinical trial evidence", "Well-tolerated safety profile"],
    keyDrawbacks: ["Limited Western clinical data", "Requires intranasal or injectable administration", "Effects are subtle compared to benzodiazepines", "Short duration of action (intranasal)"],
    sideEffects: ["Extremely well-tolerated", "Mild nasal irritation (intranasal)", "Rare: mild fatigue", "No significant adverse effects in clinical studies"],
    dosing: "250-500mcg intranasal or SubQ, 1-2x daily. Intranasal: 2-3 drops per nostril.",
    cycleLength: "4-8 weeks; can be used as needed for acute anxiety",
    stacksWith: ["Semax (cognitive enhancement)", "BPC-157 (gut-brain axis support)"],
    faqItems: [
    {
      q: "Is selank better than benzodiazepines for anxiety?",
      a: "Selank is not as potent as benzodiazepines for acute anxiety. However, it has significant advantages: no sedation, no dependence, no withdrawal, and cognitive-enhancing rather than cognitive-impairing effects. It is better suited for chronic anxiety management than acute panic.",
    },    {
      q: "How quickly does selank work?",
      a: "Intranasal selank typically produces anxiolytic effects within 30-60 minutes. Effects last 4-8 hours. Consistent daily use over 2-4 weeks appears to produce cumulative benefits.",
    },    {
      q: "Can selank be combined with SSRIs?",
      a: "Potential interactions between selank and SSRIs are not well studied. Consult a physician before combining selank with any psychiatric medications.",
    }
    ],
  },
  {
    slug: "semax-review",
    peptideName: "Semax",
    peptideSlug: "semax",
    h1: "Semax Review: Cognitive Enhancement Evidence, Results & Side Effects",
    metaDescription: "Comprehensive semax review — BDNF evidence, cognitive enhancement results, side effects, dosing, and comparison with other nootropic peptides.",
    category: "Cognitive & Mental",
    overallRating: 4.1,
    evidenceRating: 3.8,
    safetyRating: 4.7,
    valueRating: 4.2,
    verdict: "Semax is one of the most evidence-backed nootropic peptides, with Russian clinical trials for stroke recovery, cognitive impairment, and ADHD. It increases BDNF and promotes neuroplasticity — mechanisms shared with effective antidepressants and cognitive enhancers. Most users report improved focus, memory, and mood within 1-2 weeks. The main limitation is limited Western clinical data and the need for intranasal administration.",
    whoShouldUse: ["People seeking cognitive enhancement (focus, memory, processing speed)", "Those with brain fog or cognitive decline", "People with mood issues alongside cognitive symptoms", "Biohackers interested in nootropic peptides"],
    whoShouldAvoid: ["Pregnant or breastfeeding women", "Those with active psychiatric conditions (consult physician first)"],
    keyBenefits: ["Increases BDNF (brain-derived neurotrophic factor)", "Cognitive enhancement (focus, memory, processing speed)", "Mood-improving effects", "Russian clinical trial evidence", "Well-tolerated"],
    keyDrawbacks: ["Limited Western clinical data", "Requires intranasal administration", "Effects can be stimulating — avoid in evening", "Short duration of action"],
    sideEffects: ["Generally well-tolerated", "Mild nasal irritation (intranasal)", "Stimulating — can cause insomnia if taken late", "Rare: mild anxiety at high doses"],
    dosing: "200-600mcg intranasal daily. Start at 200mcg in the morning.",
    cycleLength: "4-8 weeks; can be cycled with breaks",
    stacksWith: ["Selank (anxiety + cognition)", "NAD+ (mitochondrial + cognitive support)", "BPC-157 (gut-brain axis)"],
    faqItems: [
    {
      q: "How does semax compare to modafinil for focus?",
      a: "Modafinil is a wakefulness-promoting agent with strong acute focus effects. Semax promotes neuroplasticity and BDNF — its cognitive effects are more subtle but potentially more durable. They work through different mechanisms and can be complementary.",
    },    {
      q: "How quickly does semax work?",
      a: "Many users report improved focus and mental clarity within 30-60 minutes of intranasal administration. BDNF-mediated neuroplasticity changes take longer (2-4 weeks of consistent use).",
    },    {
      q: "Is semax FDA-approved?",
      a: "Semax is not FDA-approved in the United States. It is approved in Russia for cognitive impairment, stroke recovery, and ADHD. It is available as a research compound in the US.",
    }
    ],
  }
];
